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Abstract 
 
Mutations in proteolipid protein 1 (PLP1), an X-linked gene causes Pelizaeus-Merzbacher 
disease (PMD) in humans. The most frequent cause of PMD is the duplication of PLP1, 
which encodes the major myelin membrane protein of the human CNS. The #66 transgenic 
mice with extra copies of the wild type Plp1 gene are a valid model of PMD caused by 
increased gene dosage (Readhead et al., 1994). These mice develop dysmyelinating or 
demyelinating phenotypes dependant on the gene dosage. This study investigated the 
effects of both low and high increased Plp1 gene dosage on various different selected 
aspects of myelin, including morphology, message and protein levels of PLP/DM20 and 
other representative myelin proteins and PLP/DM20 dynamics.  
Early in development mice with low increased gene dosage (hemizygous) are 
indistinguishable at the protein and myelin levels from their wild type littermates. During 
myelination these animals display elevated levels of PLP/DM20 in the oligodendrocyte 
cell body and alterations in other myelin protein levels and to the structure of myelin but 
these are transitory effects. These transient changes suggest the oligodendrocytes at low 
gene dosage retain the ability to regulate expression, production and incorporation of 
proteins into myelin thus maintaining the normal process of myelination.  
At high increased gene dosage (homozygous), oligodendrocytes in culture, pre and early 
myelinating oligodendrocytes in vivo and oligodendrocytes in vivo during peak 
myelination all exhibit elevated levels of PLP/DM20 in the their cell bodies. The protein is 
sequestered into autophagic vacuoles and late endosomes/lysosomes (LE/Ls), while the 
levels in myelin are reduced compared to wild type and hemizygous cells. Synthesis, 
partitioning with lipids and incorporation of PLP/DM20 are all also affected in the 
homozygous animals. The increased Plp1 gene dosage does affect other myelin proteins, in 
particular MBP, which showed a consistent and dramatic reduction in oligodendrocytes 
and myelin. 
These results indicate the heterogeneity of phenotypes and underlying changes caused by 
low and high increased Plp1 gene dosage. The cause of the dysmyelination observed in 
#66 mice and patients with PMD does not appear to be due to one single change in 
myelinogenesis. Each alteration observed in #66 transgenic mice could be a contributing 
factor. Importantly, the perturbation of MBP expression, in the light of this gene’s pivotal 
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role in myelination, highlights that the relationship between Plp1 and Mbp expression is 
implicated in the pathogenesis of dysmyelination.  
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1 Introduction 
1.1 Background 
Myelin disorders account for a small group of incapacitating diseases in humans. 
Fortunately, there are many spontaneously occurring animal models of myelin disorders 
allowing for the study of mechanism and pathology of disease. Over the years one focus of 
research has been the proteolipid protein (PLP1) gene.  The PLP1 gene encodes the most 
abundant protein found in central nervous system (CNS) myelin making up 50% of all 
myelin protein. The gene is highly conserved across species and regulation of the gene is 
also very highly controlled. A wide spectrum of myelin disorders is caused by mutations in 
this gene or alterations in its expression level through changes in gene copy number 
including Pelizaeus-Merzbacher disease (PMD) and X-linked Spastic Paraplegia type 2 
(SPG2). However, the functions of the gene and how mutations of it lead to disease is still 
incompletely understood.  
The main cause of PMD in humans is duplication of the region of the X chromosome 
containing the PLP1 gene. The conservation of the gene across species makes animals such 
as mice and rats a valid model to study disease mechanisms. Although, there are 
spontaneous animal mutants of known human point mutations of the PLP1 gene that cause 
PMD and SPG2 there are no naturally occurring animal models representing altered gene 
copy number. Transgenic animals have been generated by several groups to combat lack of 
suitable models and allow for the study of the mechanisms of how copy number perturbs 
gene function leading to the disease process. One transgenic line of mice that has been 
engineered with extra copies of the murine Plp1 gene is the line #66 (Readhead et al., 
1994). This thesis describes the effects that extra copies of the wild type Plp1 gene have on 
multiple aspects of the myelination process in the mouse CNS in these mice. The 
introduction to this thesis summarises the current knowledge of the Plp1 gene, other 
myelin genes investigated in this thesis, background on PMD and the animal models 
available to allow investigation in disease mechanisms.  
1.2 CNS structure and Function 
The CNS consists of neurons and glial cells and can be divided into gray and white matter. 
Neurons constitute about half the volume of the CNS making up the gray matter and glial 
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cells along with neuronal processes known as axons make up the remainder. The 
relationship and interactions in the CNS between glial cells and neurons are highly 
complex and specialised. Glial cells provide support and protection for neurons. They are 
thus known as the "supporting cells" of the nervous system. The four main functions of 
glial cells are: to surround neurons and hold them in place, to supply nutrients and oxygen 
to neurons, to insulate one neuron from another, and to destroy and remove the remains of 
dead neurons. The three types of CNS supporting cells are oligodendrocytes (from the 
Greek literally meaning few tree cells), astrocytes and microglia. In the peripheral nervous 
system (PNS) the supporting cells are Schwann cells, enteric glial cells and satellite cells 
(Jessen 2004).  
In the CNS myelination occurs after birth in rodents and happens at different times in 
different regions (Morell and Norton 1980). In the developing brain, neurons are formed a 
long way from their final resting place requiring a great amount of migration in which the 
glial cells are also involved. In humans the process of myelination starts in the third 
trimester of pregnancy and continues to up the third decade of life. Peak myelination 
occurs in the first year of life (Baumann and Pham-Dinh 2001).  
1.2.1 Oligodendrocytes 
The oligodendrocyte is the extremely specialised CNS-specific glial cell that is responsible 
for the production of myelin (1.2.2 Myelin) and axonal ensheathment. Each 
oligodendrocyte can myelinate multiple axons with the number varying depending on 
calibre of axon whereas Schwann cells can ensheath only one internode (one myelin/axon 
subunit) (Figure 1). In certain areas of the CNS oligodendrocytes myelinate up to 40 
internodes, many on different axons (Morell and Norton 1980). In areas with larger 
myelinated fibres oligodendrocytes make fewer sheaths whereas in tracts with smaller 
fibres oligodendrocytes make more sheaths. The interaction between oligodendrocytes and 
axons appears to be determined by the diameter of axons in contact with the 
oligodendrocyte. In size, oligodendrocytes are smaller than another CNS cell, the 
astrocytes (Baumann and Pham-Dinh 2001). 
Oligodendrocytes are derived from an oligodendrocyte progenitor cell (OPC) that 
originates in specialised areas of the ventral subventricular zone of the neural tube (Trapp 
et al., 2004). In mature CNS, OPCs account for 5-8% of the glial cell populations 
(Vouyiouklis 2003). These cells migrate, divide and populate the CNS during early 
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development. These early OPCs go on to differentiate into late OPCs or oligodendroblasts 
that are committed to oligodendrogenesis (Trapp et al., 2004). Late OPCs are post 
migratory and differentiate into oligodendrocytes in a temporal and spatial sequence that 
precedes myelination by a few days (Trapp et al., 1997). Numbers of immature 
oligodendrocytes are greater than are finally required by the CNS triggering apoptosis 
pathways to reduce the numbers of cells (Barres et al., 1992). 
The cells known as premyelinating oligodendrocytes can be characterised by distinct 
criteria. Some of the myelin proteins such as DM20, myelin associated glycoprotein 
(MAG), and 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP) are expressed and are 
evenly distributed throughout the cell. These cells also extend multiple processes called 
membrane sheets, radially and symmetrically. The differentiation from a premyelinating to 
myelinating oligodendrocyte is again characterised by morphological and molecular 
changes. The most important change is from a non-polarised cell to a polarised cell with 
the oligodendrocyte targeting myelin proteins to specific membrane domains. PLP/DM20 
is targeted to compact myelin, CNP to non-compact myelin of the internode, MAG to 
periaxonal membranes and myelin basic protein (MBP) mRNA along processes (Trapp et 
al., 2004). 
Findings put forward by Spassky et al., (2000) showing Plp/Dm20 progenitor cells and 
platlet-derived growth factor receptor alpha (PDGFRα) expressing progenitors highlight 
the possibility of more than one oligodendrocyte lineage in the CNS. This research is 
supported by findings from Le Bras and colleagues (2005) that Plp/Dm20 progenitors 
generate OPCs independent of PDGFRα OPCs. Richardson et al., (2006) reviewed the 
evidence for site(s) of origin of oligodendrocytes concluding that both dorsal and ventral 
sources are involved and each is active at different times during development of the CNS. 
Oligodendrocytes require neurons as they produce certain factors essential for formation 
and maintainence of myelin in the CNS. OPCs can differentiate as normal in axon-free 
culture and express myelin components but later oligodendrocytes become dependant on 
axonal signals. One such extrinsic signal is platelet-derived growth factor-AA (PDGF-
AA), which is a major mitogen in rodents (reviewed by Rogister et al., 1999). The release 
of adenosine triphosphate (ATP) from electrically active neurons, which is then hydrolysed 
to adenosine, causes the inhibition of OPC proliferation and stimulates differentiation 
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(Stevens et al., 2002).  Unlike Schwann cells, oligodendrocytes do not have a basal lamina 
or microvilla.   
In cultured oligodendrocytes, PLP is a latecomer, being expressed after MAG and MBP 
(Dubois-Dalcq et al., 1997). PLP is translated and modified in the ER and Golgi apparatus 
then transported to the site of incorporation whereas MBP is actually translated at its site of 
incorporation into myelin. MAG and CNP are also translated in the oligodendrocyte cell 
body rather than their sites of incorporation. The presence of PLP is a sign of a mature 
myelin-forming oligodendrocyte. Oligodendrocytes express some of the same molecular 
components as Schwann cells in the PNS; however, two proteins expressed only by 
oligodendrocytes are myelin-oligodendrocyte glycoprotein (MOG) on their outer cell 
membrane and myelin-associated oligodendrocytic basic protein (MOBP) in the major 
dense line (MDL) of compact myelin (Arroyo and Scherer 2000). 
Jung-Testas and co-workers (1994) have shown that oligodendrocytes synthesise 
pregnanolone, progesterone and their sulfated metabolites. These hormones appear to 
activate the synthesis of specific proteins. The production of such hormones in females 
may have an influence on myelination. This effect is observed in Multiple Sclerosis               
(MS) when in pregnancy estrogen and progesterone levels are high and improvements in 
disease status are seen. In animals the difference is more notable in older animals during 
remyelination (Li et al., 2006). Cahill (2006) reviewed how sex influences the 
development of the brain, its anatomy and function in humans highlighting the importance 
of understanding there is a difference between male and females brains. This can affect any 
results obtained from female animals therefore all studies in this thesis were carried out on 
male mice. Another factor in this decision was the fact that PMD mainly affects males.  
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Figure 1. Drawing of an oligodendrocyte and axons also showing the myelin sheaths, 
internodes and nodes of Ranvier and myelin. Obtained from 
http://members.tripod.com/blustein/Oligodendrocytes/oligodendrocytes.htm. 
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1.2.2 Myelin 
In man, more than 40% of an area of a brain section may consist of white matter (Morell 
and Norton 1980). This white matter is a fatty coating of axons known as myelin. Myelin 
derived from the Greek word for marrow (myelos), was first described by a German 
pathologist Rudolf Virchow in 1864. The main reason there is so much white matter or 
myelin in the brain is that it is essential for the speedy conduction of electrical signals 
along the axon length. To double the conduction velocity of signal on a bare fibre would 
require a four times increase in diameter whereas with a myelinated fibre a doubling only 
requires a two times increase in diameter thus saving on space and energy needed (Morell 
and Norton 1980). Myelination in the CNS is dependant on a balance between positive and 
negative axonal signals received by the myelinating cell (Colman et al., 2005).  
Myelination is the process of ensheathing axons with myelin extending from certain glial 
cells in the CNS and PNS. The myelin is formed by vast extensions of membranes of glial 
cells, oligodendrocytes in the CNS and Schwann cells in the PNS. Formation of myelin 
follows a set pattern after contact between the glial cell and the axon is made. The initial 
area to myelinate is the cervical spinal cord and from this region myelination spreads 
caudally along the spinal cord and rostrally through the brain. Small diameter fibre tracts 
myelinate after large diameter fibre tracts and the optic nerve myelinates later than the 
spinal cord. The myelin sheath forms after the plasma membrane of the glial cell process 
wraps around the axon and then compacts, squeezing out all the cytoplasm (Figure 2A) 
(Sherman and Brophy 2005). As it wraps, two different membrane appositions are 
generated, the intracellular or major dense line (MDL) and the extracellular or intraperiod 
line (IPL) (Figure 2B) (Lemke 1988). The basic ultrastructure of CNS and PNS myelin is 
similar although the proteins involved vary between the two. In the CNS periodicity of the 
IPL is maintained by PLP whereas is the PNS the regularity of IPL is determined by the P0 
glycoprotein (Giese et al., 1992). The structure and myelin membrane orientation of the 
proteins, MAG, MBP, PLP and P0 are shown in Figure 2C. As the process of myelination 
continues the link between the oligodendrocyte cell body and compacted membrane 
becomes less apparent and is less visible by electron microscopy (Deber and Reynolds 
1991).  
Most myelinated axons in any given animal have the same g ratio (ratio of axon diameter 
to fibre diameter) and this value is normally between 0.6 and 0.7 (Sherman and Brophy 
2005). Neuregulin 1 (NRG1) type III protein was shown to be active in regulating myelin 
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thickness in the PNS thus influencing g ratios (Michailov et al., 2004, Sherman and 
Brophy 2005). Whether NRG1 type III has a role in the regulation of g ratios in the CNS is 
unknown and if it is not, the factors involved have yet to be identified. g ratio is the precise 
relation between axon diameter and myelin sheath thickness but the mechanism by which 
the myelinating cell determines the number of wraps to produce is still a matter of 
investigation. Transplantation of oligodendrocytes into nerve tracts demonstrated that 
axons, and not the glial cells, determine the number of myelin wraps (ffrench-Constant et 
al., 2004). Myelin periodicity in the CNS is 14nm as viewed by electron microscopy and 
18nm in fresh nerves by X-ray diffraction (Arroyo and Scherer 2000). The myelin sheath is 
divided into two parts, compact and non-compact myelin, which contains non-overlapping 
groups of proteins. The bulk of myelin is compact with non-compact myelin found at the 
paranodes and the oligodendrocyte inner tongue.  
There is little or no cytoplasm left between adjacent wraps in myelin. At the lateral 
margins of every wrap a membrane loop forms containing some cytoplasm known as a 
paranodal loop. These make up part of the non-compacted myelin and each paranodal loop 
forms a highly specialised cell junction with the axon called the axoglial apparatus (Boiko 
and Winckler 2006). The paranodal loops flank the nodes of Ranvier. All these structures 
contain different molecular components (Arroyo and Scherer 2000). 
CNS myelin has a distinct structure as well as composition. One of the structural 
differences between CNS and PNS myelin is that CNS myelin has a radial component, 
which is a series of radially arranged intralamellar strands that span the sheath normally in 
a single strand (Arroyo and Scherer 2000). The radial component consists of a series of 
interlamellar tight junctions containing the protein claudin 11 (also known as 
oligodendrocyte-specific protein (OSP)); other components of the radial component are 
MOBP and MBP. Myelin is different from other cell membranes in that it has a high lipid 
to protein ratio (Figure 2D) (Morell and Norton 1980). This enables myelin to function as 
an insulator. Although other profiles of the myelin sheath have been observed the most 
generally accepted theory is that of spiral wrapping by a single cell process whether from 
an oligodendrocyte or Schwann cell (Hirano and Dembitzer 1967).  
Myelin once produced by the oligodendrocyte to ensheath axons is not a stable static 
membrane. It is constantly renewed and replaced by the cell throughout its life span as are 
components of myelin. However this process occurs more slowly than for components of 
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other membranes in the CNS.  The half-life of the lipids in myelin can be as long as several 
months and the same is true for most of the PLP/DM20 and MBP present (Morell and 
Norton 1980). 
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Figure 2. Myelin in wild type mice.  
A) Electron micrograph of wild type myelin ensheathing axons. Bar = 2μm. B) Higher 
magnification EM of myelin ultrastructure showing the IPL (white arrow) and MDL (black 
arrow). Bar = 0.05μm. 
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Figure 2 (continued). 
C) Diagram of myelin showing MDLs and IPLs, and location of some myelin proteins 
within these structures. D) Diagram showing proportion of protein and lipids in myelin 
(adapted from Morell and Norton 1980). 
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1.2.3 Axons 
The axon is the main process of neurons and conducts signals away from the cell body. 
Neurons are typically composed of a soma, or cell body, a dendritic tree and an axon and 
can vary in size. The majority of vertebrate neurons receive input on the cell body and 
dendritic tree, and transmit output via the axon. Axons larger than 1µm in diameter in mice 
are ensheathed by myelin. The membrane that forms the surface of the axon, the 
axolemma, maintains a difference in voltage between the inside and outside of the cell 
(Morell and Norton 1980). The membrane does this by concentrating potassium ions 
within the cell and keeping sodium ions outside with the sodium ions only getting into the 
cell under special circumstances. The nerve impulse or signal is the depolarization of the 
membrane down the length of the axon due to an influx of sodium ions. This is then 
followed by a decreased out-flowing of potassium ions restoring the voltage difference.  
Axons are wrapped many times by the sheet-like membrane extensions to form the mature 
internodal myelin sheath. Some internodes can be as long as 1mm in length and are 
separated from the next by a very short gap of less 1µm known as the node of Ranvier 
(ffrench-Constant et al., 2004). In myelinated axons the membrane is depolarized at a node 
of Ranvier and it activates the membrane at the next node, thus, jumping along the axon 
from node to node increasing the speed of the impulse (Morell and Norton 1980). This is 
called saltatory conduction. Action potentials can reach speeds of more than 100m/s in the 
fastest fibres (Aldskogius 2005). The action potentials jump from node to node due to the 
concentration of voltage dependant sodium channels at the node and the high electrical 
resistance of the myelin sheath.  
The node of Ranier has a distribution of highly specialised proteins to allow saltatory 
conduction to occur. Voltage-dependant Na+ channels are highly concentrated in the 
axolemma at the node in both CNS and PNS. Molecules located at the axolemma at the 
node include ankyrinG 480/270 kDa, neurofascin and Nr-cell adhesion molecule (Nr-
CAM). Neurofascin is essential for the clustering of Na+ channels at the node (Sherman et 
al., 2005). Two proteins appear at the node of Ranier before ankyrinG 480/270 kDa or 
voltage-dependant Na+ channels (Arroyo and Scherer 2000). One, an intrinsic membrane 
protein called Caspr, is located at the axonal paranodal membranes in both the CNS and 
PNS. A binding site for protein 4.1, which binds the actin cytoskeleton, is contained in the 
cytoplasmic domain of Caspr (Arroyo and Scherer 2000). Caspr also binds with 
F3/contactin (Faivre-Sarrailh et al., 2000, Rios et al., 2000). Other specialized proteins are 
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present at the juxtaparanode, Caspr2, a homologue of Caspr, and Kv1.1/1.2/β2 K+ channels 
subunits (reviewed by Schafer and Rasband 2006, Rasband 2006).  
Axons are very long and unable to produce the components they need to survive. 
Therefore, neuron cell bodies produce the majority of the components required and 
transport them down the length of the axon. A peripheral layer of actin microfilaments is 
located just beneath the axolemma which supports the axolemma and anchors the 
cytoskeleton to it. The shape and size of the axon is determined by the neurofilament 
cytoskeleton. Fast axonal transport mechanisms that move membrane-bound organelles 
such as mitochondria along the axon are contained within microtubular domains. The fast 
axonal transport mechanisms have high energy requirements utilising translocators such as 
kinesin for anterograde transport and dynein for retrograde transport (Edgar et al., 2004). 
Golgi-derived vesicles are transported anterogradely away from the cell body (perikaryon), 
lysosomal-derived vesicles are transported retrogradely towards the cell body whereas 
organelles such as mitochondria move in both directions along the axon. 
Although axons are not necessary for oligodendrocyte production they do play a role in 
regulating and modulating oligodendrocyte numbers (Trapp et al., 2004). In the CNS, the 
generation of adenosine by the hydrolysis of ATP released from axons inhibits 
proliferation of OPCs and stimulates their differentiation into premyelinating 
oligodendrocytes in turn increasing myelination (Stevens et al., 2002). Soluble factors 
produced and released from neurons in culture affect membrane condensation and co-
culturing oligodendrocytes with neurons increases raft clustering in the cells (Fitzner et al., 
2006).  
1.2.4 Astrocytes  
Astrocytes are star shaped glial cells that perform a variety of functions in the CNS.  
Astrocytes provide physical support to neurons and have some ability to remove debris 
within the brain. They also provide neurons with some of the chemical factors needed for 
proper functioning playing a role in providing nourishment to neurons and help control the 
chemical composition of fluid surrounding neurons; they are an important component of 
the blood brain barrier. Oligodendrocytes are supplied factors such as PDGF by astrocytes. 
Volterra and Meldolesi reviewed the changing understanding of the role of astrocytes over 
the years (2005). 
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In order to provide physical support for neurons, astrocytes form a matrix to keep them in 
place. In addition, this matrix serves to isolate synapses from one another. This limits the 
dispersion of transmitter substances released by terminal buttons; thus aiding in the smooth 
transmission of neural messages. Astrocytes provide nourishment to neurons by 1) 
receiving glucose from capillaries 2) breaking the glucose down into lactate (the chemical 
produced during the first step of glucose metabolism) 3) releasing the lactate into the extra 
cellular fluid surrounding the neurons. The neurons receive the lactate from the extra 
cellular fluid and transport it to their mitochondria to use it for energy. In this process 
astrocytes store a small amount of glycogen, which stays in reserve for times when the 
metabolic rate of neurons in the area is especially high. 
Astrocytes outnumber neurons by 10:1. Astrocytes are generated from two sources, early 
in development they are formed from elongated precursors that have their cell bodies in or 
near the ventricular zone and later in development they originate from a distinct set of cells 
in the subventricular zone (Jessen 2004). They have many radiating processes that 
interweave in complex ways between neuronal cell bodies and fibres (Jessen 2004). Some 
processes contact blood vessels and may have a role to play in the controlling the blood-
brain barrier which protects the CNS while other processes form cuffs or veils around 
individual synapses (Jessen 2004). Astrocytes are also involved in the removal of excess 
neurotransmitters and can help control levels of potassium in the extracellular space. 
Astrocytes with no GFAP failed to form processes in the presence of neurons in vitro 
(Liedtke et al., 1996). Glial cells were originally viewed as providers of physical and 
trophic support for neurons in the nervous system. Of the glial cells, astrocytes have been 
shown to be important in migration, positioning and maintenance of environment for 
neurons (Liedtke et al., 1996). However, very little is known about the interaction between 
oligodendrocytes and astrocytes in the CNS and is a matter of ongoing study.  
Astrocytes are a potential source of growth factors/mitogens such as Insulin growth factor -
1 (IGF-1) and Leukemia inhibitory factor (LIF). The IGF-1 gene has been found to be 
active in areas of demyelination due to drug treatment and localised next to immature 
oligodendrocytes expressing the IGF-1 receptor (Komoly et al., 1992). Ishibashi and 
colleagues (2006) reported the release of ATP after action potential firing triggers LIF 
release from astrocytes. LIF then goes on to promote myelination by mature late–stage 
MOG- positive oligodendrocytes. The role of astrocytes in promoting myelination in the 
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CNS has been confirmed by work carried out using 120µm slices of embryonic murine 
spinal cords cultured on a bed of astrocytes (Thomson et al., 2006). 
1.2.5 Microglia 
Microglia are the smallest of the glial cells and act as the immune cells of the CNS. They 
are resident macrophage-like cells that originate from blood monocytes (Jessen 2004). 
Microglia can act as phagocytes, cleaning up CNS debris and protecting the CNS from 
invading micro-organisms. Microglia are close cousins of other phagocytic cells including 
macrophages and dendritic cells. Microglia are derived from myeloid progenitor cells (as 
are macrophages and dendritic cells) which come from the bone marrow. During 
embryonic development they migrate to the CNS and differentiate into microglia. They are 
highly mobile cells that play several roles in protecting the NS (Streit et al., 2004). They 
are a rich source of cytokines and are thought to play in neurodegenerative disorders such 
as Multiple Sclerosis (MS), dementia, Alzheimer’s and amyotrophic lateral sclerosis. 
Microglia are part of early component of the inflammatory response in the CNS (Perry, 
1994) and there is ongoing debate as to whether they merely respond to damage or actually 
form part of the pathogenetic mechanism (Block et al., 2007).  
1.3 Protein and Lipid content of CNS Myelin 
Some of the main proteins and lipids involved in myelination are discussed in this section. 
Many of the main proteins and lipids in myelin are produced by oligodendrocytes. Martini 
and Schachner (1997) reviewed glial cell surface molecules including PLP, MAG and 
MBP and what is known about their functions as elucidated through experiments with null 
mice.   
1.3.1 Myelin proteins  
1.3.1.1 PLP/DM20 
PLP/DM20 makes up 50% of all myelin protein in the CNS. PLP is 30 kDa while DM20 
the smaller isoform is 26 kDa in size. In normal myelin PLP is only incorporated after the 
compaction of the lamellae has started. PLP/DM20 is made up of four hydrophobic 
segments of more than 30 amino acids which are linked by shorter hydrophilic sequences 
with clusters of positively and negatively charged residues. These four hydrophobic 
segments make up four transmembrane domains. The protein can undergo post-
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translational modifications such acetylation and acylation or covalent linking of fatty acid 
chains (see 1.5 The Plp1 Gene: Structure and Function). 
1.3.1.2 Myelin Basic Protein (MBP) 
Myelin basic protein (MBP) is the component of myelin thought to stabilise the 
cytoplasmic apposition of oligodendrocyte surface membranes in compact myelin. MBP 
isoforms are positively charged molecules thought to play a key role in myelin compaction 
by bringing together cytoplasmic surfaces presumably by electrostatic interactions with the 
negatively charged lipid bilayer (Jacobs 2005). The nucleotide and resulting amino acid 
sequence of MBP is highly conserved in mammals. The Mbp gene is encoded by 7 exons 
spanning 32 kb of mouse chromosome 18 situated within a larger transcription unit known 
as Golli-MBP (Campagnoni and Campagnoni 2004). This larger unit spans 105 kb in 
mouse and 179 kb in humans and contains 3 transcriptional start sites (tss) with tss3 the 
most active one producing classic MBP. Golli (Gene of Oligodendrocyte Lineage) MBP 
has 11 exons in mice and 10 in humans of which the last 7 give rise to classic MBP 
isoforms.  
At least 6 closely related extrinsic membrane proteins are encoded by the Mbp gene 
accounting for 30% of all CNS myelin proteins and 18% of PNS myelin proteins (Lemke 
1988). The four isoforms produced through splicing of the transcript, seen in CNS myelin 
range from 14.0 kDa to 21.5 kDa and are extremely basic (Figure 3). MBP is localised to 
the MDL of myelin thus confined to the interior of the cell. In most species that produce 
myelin, the predominant form of MBP is the 18.5 kDa isoform (Zeller et al., 1984). 
However, in mice and rats two isoforms predominate, the 18.4 kDa and 14 kDa isoforms. 
Alternative splicing of the exons within the Mbp gene leads to the production of the four 
isoforms seen in myelin (De Ferra et al., 1985, Takahashi et al., 1985). Kamholz et al., 
(1986) identified three MBP isoforms in humans and found the 18.5 kDa isoform is the 
major one in man. Expression of the isoforms is different and they are located in different 
parts of the cell and myelin suggesting various functions.  
Myelination in mouse brain occurs from postnatal day 8-10 and continues actively for 7-10 
weeks with maximum activity around P18-21. Maximum synthesis of MBP isoforms is 
seen at peak myelination. The developmental profile of Mbp transcripts suggests that the 
Mbp gene is transcriptionally controlled (Cook et al., 1992). The proportion of the MBP 
isoforms in myelin change as development and myelination continues in the mouse. MBP 
 1-31
Saadia Ansari Karim 2007    
mRNA may be transported to its site of incorporation in myelin for translation to avoid 
non-specific binding of the protein to acidic lipids (Trapp et al., 2004). MBP is a 
structurally disordered basic protein until post-translational modifications. Post-
translational modifications can enhance and regulate its multiple functions (Boggs 2006). It 
is involved in adhesion of cytosolic membranes of compact myelin and may have a role in 
interactions with the cytoskeleton and transmission of extracellular signals. It is the one 
protein that is essential of the formation and maintence of myelin. Fitzner et al., (2006) 
propose that MBP is essential for the rearrangement of the plasma membrane of the 
oligodendrocyte in myelin. The possible multiple functions of classic MBP in CNS myelin 
are reviewed by Boggs (2006).  
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Figure 3. Organisation of Mbp gene in mice. 
A) The Mbp gene containg all 7 exons (not to scale). B) The exon composition of the four 
MBP isoforms produced in myelin. 
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1.3.1.3 Myelin associated glycoprotein (MAG) 
Myelin associated glycoprotein (MAG) was first discovered in 1973 by Quarles and 
colleagues (Georgiuo et al., 2004). The MAG gene is located on human chromosome 19 
and mouse chromosome 7 and consists of 13 exons spanning 16 kb. MAG is a heavily 
glycosylated glycoprotein expressed at low levels in both CNS and PNS myelin around 1% 
of all myelin proteins (Lemke 1988). The protein is located at the periaxonal margin of the 
myelin sheath next to the axon (Trapp et al., 1984). This periaxonal space is the 12-14 nm 
interface between the axon and the innermost myelin layer (Georgiuo et al., 2004). MAG 
is also present in paranodal loops and in the PNS is a prominent component of Schmidt-
Lantermann incisures. 
MAG is detected prior to any of the other myelin proteins at the very earliest stages of 
myelination suggesting a role in the initial axon-glial recognition events that occur before 
myelination and indicate the path of myelin deposition. Indirect evidence that MAG is an 
adhesion molecule important for initiation of myelination includes the fact the extracellular 
part of MAG is made up of five homologous immunoglobulin-like domains and contains 
the sequence Arg-Gly-Asp, a peptide involved in binding of extracellular matrix adhesion 
molecules to their receptors (Lemke 1988). The demonstration that in vitro MAG 
facilitates neuron-oligodendrocyte and oligodendrocyte-oligodendrocyte adhesion provides 
direct evidence for this role (Poltorak et al., 1987). MAG undergoes post-translational 
modifications which include phosphorylation and glycosylation and shares a transport 
pathway to myelin with PLP/DM20 (Georgiuo et al., 2004). 
Two MAG transcripts, L-MAG (72 kDa) and S-MAG (67 kDa), are produced by 
alternative splicing of the cytoplasmically disposed C-terminus of MAG. L-MAG 
knockout mice which still produced S-MAG generated by Fujita et al., (1998) showed 
CNS myelin abnormalities but not any changes in PNS myelin. L-MAG is found to 
dominate during early stages of CNS myelination, whereas, in mature myelination L-MAG 
and S-MAG are found in similar concentrations. S-MAG is preferentially expressed in 
PNS myelin and late in neuronal development (Lai et al., 1987). During the early stages of 
myelination L-MAG is enriched in endosomes and therefore could play a role in 
membrane remodelling (Bo et al., 1995, Trapp et al., 1989a). The large extracellular 
domain of MAG dominates the extracellular spacing between the membranes in myelin 
leaving them at 12-14nm. MAG has been implicated in the regulation of neurofilament 
spacing and axonal calibre in mature myelinated axons (Yin et al., 1998).    
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1.3.1.4 
1.3.1.5 
2’,3’-Cyclic Nucleotide 3’-Phosphodiesterase (CNP) 
2’,3’-Cyclic nucleotide 3’-phosphodiesterase (CNP) hydrolyses 2’3’-nucleotides to 
nucleoside 2’-phosphate (Braun et al., 2004). The CNP gene is located on human 
chromosome 17 and mouse chromosomes 3 and 11 with the Cnp1 gene on mouse 
chromosme 11. Two CNP mRNA species of 2.4 kb and 2.8 kb generated by the presence 
of alternative translation start sites in the Cnp1 gene, have been identified in the nervous 
system resulting in two CNP polypeptides (48 and 46 kDa) (Bernier et al., 1988). CNP is 
synthesised like MBP on free polysomes, but unlike MBP, not at its site of incorporation 
into myelin but in the perinuclear regions of the oligodendrocytes (Gillespie et al., 1990). 
CNP shows a 70% homology across species and properties of the protein suggests a 
regulatory role in myelination. Post translational modification of the protein by 
polyisoprenylation, known to confer membrane-binding capabilities on cytoplasmic 
proteins, hints at the regulatory role too.   
 The protein is localised to the uncompacted myelin in the CNS and associated with 
cellular membranes. While the amount of CNP activity correlates with the degree of 
myelination, its function in the process is unknown. Over the years studies have been 
carried out to elucidate the role of CNP within the CNS and the myelination process. In 
one such study using CNP overexpressing mice generated by Gravel et al., (1996) findings 
highlighted CNP’s role in the extension of membranous processes and in influencing the 
temporal myelination program. Lee et al., (2005) also found that in oligodendrocytes CNP 
was essential for process outgrowth. Recent studies by Bifulco and colleagues (2002) 
highlighted a function for CNP in normal microtubule distribution within cells acting as an 
anchor for tubulin. The hypothesis that oligodendrocytes support axons was backed up by 
Cnp1 null mice which developed axonal loss causing a severe neurodegenerative disorder 
and premature death but did not have any changes to myelin assembly (Lappe-Siefke et al., 
2003).  
Myelin-associated oligodendrocytic basic protein (MOBP)  
Myelin-associated oligodendrocytic basic protein (MOBP) is a small highly basic protein 
which has three isoforms (8.2, 9.7, and 11.7 kDa) due to alternative splicing of the Mobp 
gene on mouse chromosome 9 (Baumann and Pham-Dinh 2001, Montague et al., 2006). In 
murine myelin they are more abundant then CNP but less so than PLP. The proteins are 
located in the MDL (Yamamoto et al., 1994, Montague et al., 1997) but their function is 
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still uncertain as Mobp null mice have no obvious phenotype (Yool et al., 2002) although 
subtle changes in the radial component have been proposed (Yamamoto et al., 1999).  
1.3.1.6 
1.3.2.1 
Minor proteins 
Some of the other proteins involved in the myelination of the CNS include 
oligodendrocyte-specific protein (OSP, also known as claudin 11), oligodendrocyte-myelin 
glycoprotein (OMgp), myelin/oligodendrocyte specific protein (MOSP), RIP antigen and 
NI-35/250 proteins (Baumann and Pham-Dinh 2001). 
1.3.2 Other proteins  
Aspartoacylase (ASPA) 
Aspartoacylase (ASPA) is a marker for oligodendrocyte cell bodies as it has been shown 
that ASPA activity is detectable only in oligodendrocytes in the CNS thus is used as a 
control to compensate for any differences in oligodendrocyte cell numbers, so all samples 
for western analysis are normalized for ASPA (Kirmani et al., 2003, Madhavarao et al., 
2004). ASPA is known to catalyse deacetylation of N-acetylaspartate (NAA), which is a 
highly abundant nervous system specific amino acid derivative, into acetate and aspartate 
(Kirmani et al., 2002). Aspartate in the CNS is used for acetyl CoA synthesis and then 
subsequently the synthesis of fatty acid/lipid required for myelination (Kirmani et al., 
2003). 
1.3.3 Lipids 
Lipids were initially thought to play one of two roles in the body, as repositories of energy 
in storage fat and as structural components of cell membranes (Taylor et al., 2004). Later 
more functions were assigned to lipids in cells. In the CNS lipids make up 70% of the dry 
weight of purified myelin (Morell and Norton 1980). In bulk membrane the main lipids are 
cholesterol and glycerophospholipids but myelin is composed mainly of cholesterol and 
galactocerebroside (GalC) and its sulphated derivative sulphatide. The cerebrosides in 
myelin contain long chains which can be as long as 24 carbons and are saturated (Lee 
2001). However the galactolipids, galactocerebroside (GalC) and sulphatide account for 
30% of all lipids and are the most abundant lipids in CNS myelin (Coetzee et al., 1999). 
Lipid turnover in mice is dependant on age, the younger the animal the longer the half-life 
of the lipid (Taylor et al., 2004). As oligodendrocytes, during active myelination, produce 
huge amounts of myelin membrane per cell per day they must also produce and transport 
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masses of lipids. During active myelination the concentration of GalC in the brain is 
directly proportional to myelin accumulation. Mice lacking galactolipids appear to form 
myelin sheaths with normal periodicity and compaction but animals’ deficient in 
cholesterol show severe hypomyelination (Coetzee et al., 1999, Saher et al., 2002).  
Mice lacking both galactolipids and PLP however, have abnormal myelin in that it is 
poorly compacted but they have relatively normal IPL formation. PLP was shown to 
interact with cholesterol and galatctosylceramide-enriched membrane domains, known as 
myelin rafts and this association of PLP with lipids in rafts may be critical to proper sorting 
of the protein (1.3.3.1 Myelin rafts) (Simons et al., 2000). Simons and colleagues (2002) 
went on to show the accumulation of PLP, cholesterol and other raft components in late 
endosomes/lysosomes (LE/Ls) at the perinuclear region in BHK cells (hamster fibroblast 
line) and oligodendrocyte cultures and transgenic mice overexpressing PLP. As import of 
cholesterol is poor in the brain oligodendrocytes produce their own through the same 
pathway as PLP, the ER/Golgi apparatus.  
Cellular mechanisms in oligodendrocytes ensure cholesterol levels are kept low in late 
endosomes (LEs). Any accumulation of cholesterol by co-transport with PLP into these 
organelles is an obvious change. Mutant PLP/DM20 with either the rumpshaker (rsh) or 
msd mutation has a perturbed relationship with lipids and myelin rafts impairing the vital 
cholesterol binding. Both rsh-PLP and msd-PLP have impaired cholesterol binding and 
lipid raft association (Kramer-Albers et al., 2006). They suggest this impairment of PLP 
and lipid association contributes to disease phenotype in humans.  
1.3.3.1 Myelin rafts  
Rafts are liquid-ordered domains that are more tightly packed than the surrounding lipid 
bilayer (Rajendran and Simons 2005). This is due to the saturated hydrocarbon chains in 
raft sphingolipids and phospholipids. As rafts are dynamic, both proteins and lipids can 
move in and out of raft domains; however, this movement and the rafts themselves can be 
too small to visualise. Rafts in biological membranes are thought to be microdomains with 
a lipid structure like the liquid ordered (Lo) phase surrounded by liquid disordered (Ld) 
phase membrane (Hancock 2006). It is thought rafts modulate the biological function of 
proteins and molecules that are associated with them (reviewed by Gielen et al., 2006). 
Proteins associated with lipid rafts can be identified by their resistance to detergent 
extraction and PLP was recovered from detergent resistant membrane fractions.  
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Compact myelin represents the bulk of the sheath and contains myelin rafts composed of 
proteins and lipids specific to the membrane (Kramer et al., 2001). There are several 
mechanisms by which oligodendrocytes could transport components of myelin to produce 
the final myelin sheath, directed transport, transcytosis or endosomal sorting, regulated 
exocytosis or myelin rafts. The sorting of PLP/DM20 with lipids in fluid myelin rafts 
supports the final method of transport although they may not all be mutually exclusive 
(Simons et al., 2000). However, none of the other myelin proteins co-localise with 
PLP/DM20 (Kramer et al., 2001). 
1.4 The Plp1 Gene: Structure and Function  
The structure and function of the human and mouse PLP1 genes are highly homologous 
therefore many details in this section relate to the human PLP1 gene. Where there are 
notable differences these are mentioned. 
1.4.1 The PLP1 Gene  
PLP was first discovered in 1951 by Folch and Lees in bovine white matter (Lerner et al., 
1973). The PLP1 gene in humans consists of 7 exons spanning 17kb at a single locus 
(Macklin et al., 1987) mapping to Xq21.33-22 in humans next to glycine receptor, alpha 4 
subunit (Glra4) gene. Exon 1 of the gene contains 5’ non-coding region, the codon for 
initial methionine and the first base of next codon (glycine) which due to cleavage of the 
methionine will become the amino-terminal of the mature PLP1 gene products. Exon 2 
encodes amino acids 1-63. The 7th and last exon encodes the C terminus and 3 
polyadenylation sites. The coding sequence of the PLP1 gene is highly conserved with 
100% identity between human, mouse and rat sequences (Wight et al., 1997). There is also 
a high degree of conservation in the 5’ and 3’ un-translated regions among species 
(Macklin et al., 1987). However, in the mouse the Plp1 gene contains an extra exon 1.1 
within intron 1 located 122 base pairs downstream from exon 1 (Figure 4A). These 
produce splice variants that are expressed in neuronal subpopulations known as soma-
restricted PLP (sr-PLP) and soma-restricted DM20 (sr-DM20) (Figure 4B) (Bongarzone et 
al., 1999). Splicing of the 3rd exon in humans and mice at the mRNA level leads to two 
protein isoforms, PLP and DM20 (Nave et al., 1987).  
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Figure 4. The murine Plp1 gene. 
A) The murine Plp1 gene with all exons (light grey section of exon 3 is alternatively 
spliced exon 3B); arrows depict the three polyadenylation sites (not to scale). B) The four 
isoforms produced by the Plp1 gene through alternative splicing, PLP and DM20 and 
soma-restricted (sr) PLP and DM20. 
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1.4.2 Evolution and Conservation of the Plp1 gene  
1.4.2.1 
1.4.2.2 
Evolution of the Plp1 gene 
The evolution of early vertebrates led to the requirement of insulation of the axons for the 
speedy conduction of electrical impulses. P0 was the initial structural protein of the CNS 
along with the DM20 protein which was expressed by the ancestral vertebrate Plp1 gene in 
cartilaginous fish as early as 440 million years ago (Yoshida and Colman 1996, Hudson 
2004, Yin et al., 2006). The PLP protein appeared around 400 million years ago after the 
divergence of bony fish (Yoshida and Colman 1996). Mammals, birds and reptiles all 
express both PLP and DM20 and in these species the proteins have developed to perform 
different functions in CNS myelin. The change from P0 to PLP as the main structural 
protein in CNS myelin also provides a neuroprotective function as seen in transgenic mice 
with P0 expression in place of Plp1 expression (Yin et al., 2006). These animals have 
myelin in the CNS with a highly regular and compact PNS-like structure but developed 
degeneration of myelinated axons and their lifespan was reduced by 50% (Yin et al., 
2006). The slow evolution of the Plp1 gene over the past 80 million years implies the 
intense selective pressure that led to the modern mammalian PLP and DM20 proteins.  
Conservation of the Plp1 gene 
A remarkable level of sequence conservation between species at both the amino acid and 
nucleotide levels in the Plp1 gene restricts the further reshaping of PLP and DM20. Amino 
acid sequence homology achieves 100% in rodents, >99% in the dog and >97% in the cow 
when compared to PLP and DM20 sequence in man (Milner et al., 1985, Macklin et al., 
1987). Any nucleotide changes that are tolerated tend to be silent. Any other nucleotide 
changes lead to disease in man and animals as evidenced by PMD/SPG2 in humans and 
rumpshaker, jimpy and shaking pup disorders in animals. 
This conservation also extends to the non-coding and non-transcribed regions of the Plp1 
gene. There is greater than 95% identity at the nucleotide level of the coding regions and at 
least 90% conservation between man and mouse for the 5’ and 3’ UTRs (Wight and 
Dobretsova 2004).  The homology of the entire 3’UTR between mouse and rat is greater 
than 90% and some regions within the 3’UTR have almost 100% homology (Macklin et 
al., 1987). The proximal region of the 5’UTR is one of the most highly conserved areas, at 
100% between rodents and man, of the Plp1 gene (Macklin et al., 1987). Of all the introns, 
intron 3 is the most highly conserved with 80% homology between man and mouse (Wight 
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and Dobretsova 2004). This intron is important in the splicing of exon 3B to form DM20 
(Nave et al., 1987).    
This level of conservation in non-coding regions is almost unique to the Plp1 gene. Other 
genes have a lower homology of sequence between species in non-coding regions. Another 
X chromosome gene, hypoxantine phosphoribosyltransferase (Hprt) shows 74% homology 
between the human and mouse genes which is considered high for the 3’UTR. The high 
level of conservation within the non-coding and non-transcribed regions of the Plp1 gene 
is highly unusual and may be of more interest than the conservation of the amino acid 
sequence (Macklin et al., 1987). This high level of conservation could indicate that the 
Plp1 gene is under tight regulatory control that may be vital for the function of the gene. 
This suggests mutations in the gene whether in the coding or non-coding regions are not 
tolerated. The almost complete conservation of the transcription initiation sites and the 
adjacent 5’ flanking sequence of the Plp1 gene supports this hypothesis (Macklin et al., 
1987). 
1.4.2.3 The DM gene family 
PLP is part of a large proteolipid protein gene family with sequence homology, the 
lipophilin/DM family which may encode pore-forming polypeptides (Gow 1997). There 
are two other members of the DMα/DM20/PLP family, DMβ/M6A/EMA and 
DMγ/M6B/Rhombex 29 and these have been isolated from fish, amphibians and mammals 
(Hudson et al., 2004). These gene products are mainly located in the CNS and include the 
glycoprotein-encoding genes DMα, DMβ and DMγ in bony fish (Kitagawa et al., 1993) 
and M6A and M6B in mammals (Yan et al., 1993).  
The main features of this family are four transmembrane (TM) domains, a large 
extracellular loop between TM domains 3 and 4 and an intracellular part between TM 
domains 2 and 3 (Figure 5). All the members of this protein family share a remarkable 
level of amino acid conservation in the four transmembrane domains and the four cysteine 
residues present in PLP and DM20 that are for fatty acid attachment are also conserved 
(Weimbs and Stoffel 1992). Expression of these family members does however differ with 
DMα/DM20/PLP the main structural component of myelin in the CNS. The neuronal 
components of the family are DMβ/M6A/EMA, whereas DMγ/M6B/Rhombex 29 are 
expressed in both cell types, neurons and myelinating glia (Hudson 2004). 
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1.4.3 Expression of Plp1 gene  
Plp and Dm20 cDNAs have been isolated from human, bovine, canine, rodents as well as 
chickens, zebra finch, trout and zebrafish (Wight and Dobretsova 2004). The Plp1 gene is 
primarily expressed in oligodendrocytes, although it is transcribed in low levels in 
Schwann cells in the PNS, cardiac myocytes and foetal thymus and spleen (Puckett et al., 
1987, Campagnoni et al., 1992, Pribyl et al., 1996). As the gene is so highly conserved 
across species it is likely regulation of the gene is equally well maintained. There are two 
closely spaced (30bp) transcriptional initiation sites in the Plp1 gene beginning 147-160 
bases upstream of ATG initiator methionine.  Homology is strong between human and 
mouse for this region suggesting functional constraints on this region (Hudson 2004). The 
two transcriptional initiation sites are used differentially during development, in different 
tissues and following injury. Both sites are utilised in the CNS but the downstream site is 
mainly utilised in the PNS. At peak myelination, most transcription is initiated from 
upstream site. Promoter useage is known to affect splice site selection. During early 
myelination downstream site is utilised and DM20 is predominantly expressed. This is also 
the case in Schwann cells where DM20 is mainly expressed and the downstream site is 
utilised (Scherer et al., 1992). The inclusion of exon 1.1 in mice produces two different 
proteins, srPLP and srDM20, soma-restricted isoforms which are not targeted to compact 
myelin (Figure 4B) (Bongarzone et al., 1999). Their function is still not known.  
1.4.3.1 Temporal and spatial control of expression of Plp1 gene 
The intronic sequence between exons 1.1 and 2 in mice is the largest of the Plp1 gene and 
possibly has important regulatory functions, similarly the intron between exon 1 and 2 in 
other species (Wight and Dobretsova, 1997). Maintenance of Plp1 gene regulation control 
is preserved across species lines. The high levels of conservation in non-coding regions in 
the Plp1 gene suggest these have a role in gene regulation and/or expression. In 
oligodendrocytes the gene is temporally regulated and there is a dramatic surge in its 
expression during active myelination in the CNS although PLP is present in pre-
myelinating oligodendrocytes. PLP becomes the predominant isoform as development 
progresses. Deletion-transfection studies by Dobretsova and Wight (1999) using Plp-lac Z 
fusion genes suggested that intron 1 contains an enhancer element involved in the increase 
in expression. Experiments characterised this region as autosilencer/enhancer (ASE) (Li et 
al., 2002b). The functional core of the ASE, refined to positions 1093-1117 of intron 1, 
contains target sites that are recognised by a number of proteins from a large superfamily 
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of basic leucine zipper (bZIP) transcription factors. These can function as positive or 
negative regulators of expression and may be critical in the assembly of a nucleoprotein 
complex required for the dramatic upswing in expression mentioned above (Dobretsova et 
al., 2004).   
Along with temporal control, intron 1 plays a role in the spatial control of Plp1 gene 
expression. Deletion-transfection experiments with constructs containing the 5’ UTR, 
promoter and/or intron 1 identified intron 1 as the essential region for spatial control (Li et 
al., 2002b). Intron 1 confers this control through a transcription repression mechanism in 
non-expressing cell types via a negative regulatory element near the 3’ end of the intron. 
This element is active in mouse liver cells but not in glial cells whereas the opposite is true 
for the ASE, which is inactive in +/+ Li liver cells (Li et al., 2002a)  
1.4.4 Regulation of the Plp1 gene 
There are three polyadenylation sites in the Plp1 gene leading to three major classes of 
mRNA, 1.6, 2.4 and 3.2 kb (Gardinier et al., 1986, 1990). Both Plp and Dm20 transcripts 
are present in the three mRNA classes. The most abundant Plp mRNA is 3.2 kb and it 
contains all 5 regulatory elements situated within the 3’UTR. The main area of control of 
the Plp1 and also the Mbp gene is at transcription. mRNA synthesis of the two genes 
mirrors steady state transcript levels and protein levels throughout myelinogenesis. The 
molecular basis for transcriptional control includes trans-acting regulatory elements and 
their cis-acting enhancer/promoter elements (Hudson 1990). Although oligodendrocytes do 
produce myelin transcripts in the absence of neurons, these transcript levels increase 4 fold 
in the presence of neurons (Macklin et al., 1986). 
Findings, such as partial rescue of dysmyelination by the insertion of both Plp and Dm20 
only transgenes suggests both isoforms are required for oligodendrocyte maturation 
(Nadon et al., 1997). The levels of expression of the two transgenes were however; lower 
than levels of wild type PLP and DM20 observed in wild type mice suggesting the 
endogenous Plp1 gene had an effect on expression of the transgenes (Nadon et al., 1997). 
The discovery that overexpression of 3’ UTR of the Plp1 gene caused down regulation of 
the endogenous Plp1 gene mRNA showed transgenes also have an effect on expression 
and regulation of PLP/DM20 in oligodendrocytes in culture and in animals (Mallon and 
Macklin 2002).  
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1.4.5 Splicing of the Plp1 gene 
Alternative splicing of the Plp1 gene precursor mRNA (pre-mRNA) leads to two mRNAs 
producing PLP (30kDa) and the smaller isoform DM20 (26 kDa) (Nave et al., 1987). 
Alternative 5’ splice site selection is utilised in pre-mRNA splicing within exon 3 splicing 
out exon 3B to produce a transcript with a 105bp deletion resulting in a loss of 35 amino 
acids from Val-116 to Lys-150 (Nave et al., 1987). The part of PLP absent in DM20 is 
highly hydrophilic thus making DM20 more hydrophobic than PLP.  
The splicing of exon 3 is the rate-limiting step in Plp/Dm20 transcript synthesis. 
Significant levels of pre-mRNA were found to contain intron 3 (Vouyiouklis et al., 2000). 
Of all the introns, intron 3 is the most highly conserved and disrupting intron 3 selectively 
reduces Plp mRNA levels. In studies by Hobson et al., (2002) deletion of nucleotides +28-
+46 within intron 3 led to disablement of Plp splicing and a late onset, mild neurological 
phenotype similar to PMD characterised by dysmyelination and axonal loss. This region is 
a purine rich sequence located near the intron’s 5’ end which can act as a splicing enhancer 
and is required for efficient PLP-specific splice site selection in oligodendrocytes but not 
useful in non-glial cells (Hobson et al., 2002). 
1.4.6 Translation and post-translational modification of PLP/DM20 
protein 
1.4.6.1 
1.4.6.2 
Translation and post-translational modification 
Both PLP and DM20 are modified with long chain fatty acids. Palmitate, oleicate and 
stearate, all acyl moieties attach to PLP via thioester bonds to cysteine residues 5, 6, 9, 
108, 138 and 140 (Weimbs and Stoffel 1992). PLP has six sites whereas there are only four 
sites in DM20 as Cys138 and Cys140 are not present in this isoform. Bizzozero and 
colleagues (2002) showed that the majority of PLP and DM20 in CNS myelin is fully 
acylated using mass spectrometry. Palmitoylation deficient mutants of PLP highlight the 
necessity of palmitoylation for the targeting of PLP to myelin-like-membranes (Schneider 
et al., 2005).  
PLP and DM20 protein topology 
Of all the models proposed for the topology of PLP, the one put forward by Popot et al., 
(1991) is the most widely accepted (Figure 5). As the DM20 isoform lacks amino acids 
 1-44
Saadia Ansari Karim 2007    
116-150, it is more hydrophobic than PLP and therefore its topology may be different 
which could indicate varying roles for the two Plp1 isoforms. 
1.4.7 Proposed functions of the Plp1 gene 
PLP is an intrinsic protein which is responsible for the stabilising of the apposition of 
extracellular surfaces of the plasma membranes of oligodendrocytes (Boison et al., 1995) 
(Klugmann et al., 1997). There is a structural role for PLP ensuring the regularity of the 
IPL but there may also be a role in oligodendrocyte/axon communication. The axon 
appears to require ongoing interaction with glial cells for its normal development and also 
continued maintenance after myelination. Null mice develop normally and assemble 
compact myelin ensheathing both small and large calibre axons (Klugmann et al., 1997). 
However, from 6-8 weeks onwards, these mice develop increasing numbers of focal axonal 
swellings which contain organelles throughout the CNS (Griffiths et al., 1998). The myelin 
sheath was eventually lost around larger swellings.  These axonal swellings are related to 
the loss of PLP/DM20 in the null mice supporting a function for the proteins in 
oligodendrocyte/axon communication and interactions. Both retrograde and anterograde 
fast axonal transport along the length of the axon shows a progressive impairment in null 
mice (Edgar et al., 2004). This supporting function of the oligodendrocyte and possibly 
PLP/DM20 is reviewed by Edgar and Garbern (2004). 
DM20 is expressed in a wide range of embryonic and adult tissues independent to 
myelination. A Dm20 only transgene constructed to contain the “shaking pup” mutation 
conferred embryonic lethality to the recipient animals suggesting a role in the function of 
many cell types (Nadon et al., 1997). When Plp or Dm20 only transgenes were introduced 
into jp mice, PLP incorporated into PNS compact myelin whereas DM20 was retained in 
the cytoplasmic regions of the Schwann cells but the periodicity of the myelin did not 
change (Anderson et al., 1997). It is possible a signal is contained in the part of the protein 
present in PLP but absent from DM20. Yamada et al., (1999) proposed function for 
PLP/DM20 early in CNS development. A portion of PLP/DM20 was found to be secreted 
into medium in vitro and increased the number of GalC- and GFAP-positive cells in 
culture. This activity could be mimicked by a synthetic peptide corresponding to PLP 
amino acids (aa) 215-232 (Yamada et al., 1999). However, the exact function, cells 
stimulated and pathway involved in the activity of this portion of PLP/DM20 is still 
unclear.  
 1-45
Saadia Ansari Karim 2007    
 
 
 
 
 
 
 
 
 
Figure 5. Proposed topology of the PLP isoforms.  
Shows each exon, the exon 3B in blue missing from DM20, the six acylated
cysteine residues (red zigzag lines) located at the cytoplasmic membrane surface 
and the two disulfide bridges in the hydrophilic loop connecting TMD III and 
TMD IV. 
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1.4.8 Protein dynamics  
Niemann et al., (1999) highlighted the necessity of maintaining a steady balance of myelin 
synthesis and turnover to prevent demyelination in a mature myelin sheath. The synthesis 
and degradation of PLP/DM20, the major protein of myelin can be studied at the culture 
and brain slice level. 
1.4.8.1 Synthesis 
1.4.8.2 Degradation 
The predicted site of PLP/DM20 synthesis was the RER and using intracranial injections 
of 35S-methionine, PLP was initially observed in the rough microsomal membrane fraction 
which contains the RER. More specific investigations found PLP/DM20 is synthesised in 
bound polysomes at the RER (Nussbaum and Roussel 1983).  After synthesis in the RER 
and prior to transport to myelin PLP/DM20 is packaged and modified in the Golgi 
apparatus (Nussbaum and Roussel 1983). Current knowledge is that PLP/DM20 is 
translated on the ER and modified in the Golgi apparatus before transportation to the cell 
surface for incorporation into compact myelin as are lipids 
Using techniques such as protease domain protection assays, immunocytochemical epitope 
mapping and glycosylation scanning, the orientation of PLP/DM20 in the ER and plasma 
membrane was elucidated. Wahle and Stoffel (1998) proposed that only PLP/DM20 with 
the correct topology of both the N and C termini on the cytoplasmic face is transported to 
the cell surface. The synthesis of rumpshaker PLP and DM20 occurs at a rate comparable 
to wild type PLP and DM20 synthesis. McLaughlin and colleagues (2006) showed that the 
misfolded rumpshaker PLP/DM20 can be transported to the cell surface in cultured 
oligodendrocytes but to a lesser extent than wild type PLP/DM20.  
The concept of protein turnover is fairly new being barely 60 years old as originally 
proteins were thought to be stable. Rodulf Scheonheimer challenged this in 1942 and 
showed proteins are continuously synthesised and degraded. Proteins are degraded at 
different rates, giving them varying half-lives. Housekeeping proteins have a long half-life 
while proteins involved in events such as development or cell cycle are likely to have short 
half-lives. There are two major systems for protein turnover in eukaryotic cells, the 
lysosome and proteasome. Originally the lysosome, first discovered in 1953, was thought 
be the main site of protein degradation. The lysosome carries out degradation by 
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microautophagy, a process where a membrane-bound compartment containing cellular 
proteins fuses with a lysosome resulting in digestion of proteins (Ciechanover, 2005). 
However, this is a rather non-selective method of degradation and does not fit with the 
varying protein half-lives observed. Lysosomal inhibitors further elucidated the role of the 
lysosomes in degradation highlighting many proteins not turned over by this method.    
The discovery of the proteasome in 1986 led to the advancement of the investigation into 
degradation. The majority of proteins whether they are misfolded, unfolded and in excess 
are hydrolysed via the ATP-dependant proteasome pathway. ER-associated proteins, short-
lived proteins such as p53, cyclins and activating transcription factor 3 (ATF3) and long-
lived proteins are also degraded via the proteasome (Lee and Goldberg 1998). 
1.4.8.2.1 Proteasome mediated degradation  
The 20S proteasome is a cylinder or barrel shaped protein core which can assemble with 
other proteins complexes to form the 26S proteasome complex and is involved in the 
degradation of proteins in eukaryotes and certain archaebacteria (Peters, 1994). The 
proteasome in mammalian cells accounts for 1% of all cell proteins (Lee and Goldberg 
1998) and is located mainly in the cytosol of cells (Nandi et al., 2006). It is involved in the 
degradation of short-lived proteins such as transcription factors, tumour suppressors and 
rate limiting enzymes and also in the degradation of long-lived proteins too. Proteins 
labelled by a small (76 residues) heat stable, highly conserved protein ubiquitin, and are 
preferentially degraded by the proteasome. (Ciechanover 2005, Von Mitecz 2006). Not all 
proteins are ubiquitined as the proteasome has a role in ubiquitin independent degradation.  
The ubiquitin-proteasome system is involved in many biological processes such as 
regulation of cell cycle, immune response, protein misfolding, and disease progression 
(Nandi et al., 2006). Previously, it was assumed that only lysosomes were involved in 
turnover of long lived proteins. However, by using proteasome inhibitors such as MG132, 
a peptide aldehyde, which is a substrate analogue and potent transition-state inhibitor of 
chymotrypsin-like activity of the proteasome, 80-90% of protein degradation was blocked 
thus confirming the involvement of the proteasome (Lee and Goldberg 1998). Cell 
viability and growth was not generally affected for 10-20 hrs after exposure to these 
inhibitors.  
Accumulation of unfolded or misfolded protein in the ER can trigger the unfolded protein 
response (UPR). BiP (1.4.8.2.1 BiP (GRP78)) has been identified as the master regulator of 
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this process and X-box DNA-binding protein 1 (XBP1) (1.4.8.2.2 X-box DNA-binding 
protein 1 (XBP1)) can participate either directly or indirectly in this process too (Shang 
2005).  The misfolding of PLP/DM20 due to mutations such as rumpshaker can lead to the 
activation of the UPR as evidenced by McLaughlin and co-workers (2007). Southwood 
and colleagues (2002) presented data showing UPR activation in animals with Plp1 coding 
mutations but there was no activation of the UPR in transgenic mice that had extra copies 
of the wild type Plp1 gene. This demonstrates that the UPR has the potential to modulate 
PMD disease severity dependant of the mutation involved. Turnover of the mutant 
PLP/DM20 protein was increased when compared with wild type PLP/DM20 with msd 
PLP/DM20 degraded faster than rumpshaker PLP/DM20 (Kramer-Albers et al., 2006). 
The rate of degradation of PLP/DM20 appears to be dependant on the mutation in the Plp1 
gene with the mutation that causes the most severe disease phenotype (msd) the fastest 
degraded. 
1.4.8.2.2 BiP (GRP78) 
BiP also known as glucose regulated protein 78 (GRP78 (78kDa)) an ER chaperone 
protein, is a peptide-dependant ATPase and member of the heat shock 70 protein family, 
that binds transiently to newly synthesised proteins translocated into the ER and more 
stably to misfolded, unassembled or unglycosylated proteins (Zhang and Kaufman 2004). 
It has also been implicated in calcium sequestration in the ER. When the cells are subjected 
to ER stress, in particular the depletion of stored calcium and/or the accumulation of 
abnormal proteins, the rate of transcription of grp78 is enhanced (Zhang and Kaufman 
2004).   
1.4.8.2.3 X-box DNA-binding protein 1 (XBP1) 
Xbp1 mRNA splicing is initiated by release of BiP from Ire1p upon accumulation of 
unfolded protein in the ER. Spliced Xbp1s mRNA encodes a potent transcription factor 
which binds to consensus sequences of many UPR target proteins (Shang 2005). The 
splicing event converts a 267 amino acid Xbp1u encoded by unspliced Xbp1 (U) mRNA to 
a 371 amino acid Xbp1(S) encoded by the spliced product (Lee et al., 2003). Xbp1s is then 
translocated to the nucleus where it binds its targets, chaperone genes inducing their 
transcription. The unspliced Xbp1u can act as a negative regulator of the spliced form 
XBP-1(S) during the recovery phase of ER stress (Yoshida et al., 2006).  
1.4.8.2.4 Lysosome-Associated Membrane Protein 1 (LAMP-1)  
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Lysosome-Associated Membrane Protein 1 (LAMP-1) is one the major lysosomal 
membrane glycoproteins along with the structurally related LAMP-2. Both LAMP-1 and 
LAMP-2, which are highly glycosylated, contribute 50% of protein in of the lysosomal 
membrane (Eskelinen 2006). The lysosomal membrane itself is responsible for the 
acidification of the interior of the organelle, sequestration of active lysosomal enzymes, 
transport of degradation products from the lumen to the cytoplasm and regulation of fusion 
and fisson events between lysosomes and other organelles (Andrejewski et al., 1999). The 
Lamp-1 gene is expressed ubiquitously encoding a polypeptide of 382 amino acids 
corresponding to 42 kDa. However, the final product after N- and O-glycosylation is 92 
kDa (Andrejewski et al., 1999). Staining with anti-LAMP1 antibody labels up all the 
lysosomes within cells. 
1.5 PLP1 gene mutations and disease 
1.5.1 PLP1 gene-related disorders in man 
PMD is the main disease focus of this thesis. It is an inherited dysmyelinating disorder 
caused by mutations in the PLP1 gene on the X chromosome. MS is the most well known 
demyelinating disorder associated with oligodendrocyte cell loss in man and is thought to 
involve an autoimmune response to a myelin protein such as MBP.  
1.5.1.1 Pelizaeus-Merzbacher disease  
Pelizaeus-Merzbacher disease (PMD) (OMIM 312080) is an X-linked dysmyelinating 
disorder of the CNS caused by mutations in the PLP1 gene in humans. PMD is considered 
a leukodystrophy with a variable clinical and neuropathological phenotype (Koeppen 
2005). In Germany the incidence of the disorder is low accounting for 6.5% of all 
leukodystrophies (Heim et al., 1997) and this is probably similar elsewhere. The disorder is 
characterized clinically by nystagmus, delayed psychomotor development, spasticity, 
cerebellar ataxia, optic atrophy, laryngeal stridor, seizures and mental deterioration (Inoue, 
2005).  
1.5.1.1.1 History of PMD 
Pelizaeus first described PMD in meticulous detail in 1885 as a clinical entity in five of his 
patients from one family. He observed all the patients were males and sons of healthy 
sisters thus identifying it as an X-linked disorder (Koeppen 2005). Merzbacher preformed 
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the first autopsy study on a patient in 1910 confirming it as a disorder of the white matter 
of the CNS. 
A marked variation in severity of symptoms of PMD was noted in patients leading to 
classification of the types of PMD in the later half of the last century (Renier et al., 1981). 
These include the most common, classic PMD with an onset of within the first 5 years and 
death in 3rd to 7th decade of life. Congenital or connatal PMD is the severest form with 
onset from birth and death in childhood to 3rd decade. The mildest form of PMD merges 
with X-linked SPG2 in regards to phenotype (Hudson et al., 2004). The link between PMD 
and the PLP1 gene was made in 1964 by Zeman and colleagues. 
1.5.1.1.2 Symptoms of PMD 
The connatal form begins in infancy as early as the eighth day and usually no later than the 
third month and is progressive so that the victim may survive to middle age. Initial 
symptoms are hypotonia (decreased muscle tone), respiratory distress, stridor (high pitched 
sound from upper airway), nystagmus (involuntary eye movement), and occasional 
seizures. The patients go onto develop severe spasticity with very little voluntary 
movement and never walk (Hudson et al., 2004).  
Patients suffering from classic PMD develop symptoms as early as the first year of life. 
Symptoms include but are not exclusive to nystagmus, hypotonia, weakness of lower limbs 
and head titubation. Muscle tone decreases throughout infancy progressing to spasticity 
later in childhood. The patients develop spastic quadriparesis which is worse in the lower 
limbs than upper (Hudson et al., 2004). Axonal loss was seen in the white matter of the 
centrum semiovale in a patient whose mutation was a duplication of the PLP1 gene 
(Koeppen and Robitaille 2002). Many of the patients survive until they are in their 50s. 
The mildest form of PMD is very similar to SPG2 (1.5.1.2 X-Linked Spastic Paraplegia 
Type 2). 
1.5.1.1.3 Clinically affected Females 
As PMD is a recessive X-linked disorder it mainly affects males with females as carriers of 
the mutation. However the incidence of PMD in females is higher than the incidence of 
Duchenne Muscular dystrophy (DM), which is also a recessive X-linked disorder. Females 
who carry duplication of the PLP1 gene have heavily skewed X-inactivation in favour of 
the normal X chromosome inactivating the duplicated X chromosome. Therefore these 
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females are asymptomatic whereas, females carrying a copy of the PLP1 gene with point 
mutations are unlikely to undergo any skewing thus 50% of cells will be expressing the 
mutant PLP1 gene (Woodward et al., 2000). Oligodendrocytes expressing a mild 
phenotype survive; thus, females go onto develop late onset neurological symptoms.  
1.5.1.2 
1.5.1.3 
X-Linked Spastic Paraplegia Type 2 
X-linked spastic paraplegia 2 (SPG2) is a rare disorder that occurs in two clinically distinct 
forms in humans. The mild or pure spastic form is characterised by spasticity of the lower 
limbs with normal mental function (Hudson et al., 2004). Most cases reported take on a 
more complicated phenotype of spasticity, cerebellar ataxia, mental retardation and, 
occasionally, congenital malformations. SPG1 (OMIM 312920) results from mutations of 
the L1 cell adhesion molecule (L1CAM) gene at Xq28 locus. Other cases of complicated 
SPG and uncomplicated (pure) SPG map to the PLP1 gene locus and are known as SPG2 
(OMIM 312920) (therefore allelic to PMD). SPG2 begins with pure spastic leg weakness 
but gradually developed other symptoms such as sensory loss, optic atrophy, nystagmus, 
dysarthria and dementia (Koeppen and Robitaille 2002). Some of the clinical features of 
SPG2 are similar to those of PMD including the mental retardation, nystagmus and optic 
atrophy. As with PMD males are mainly affected.  
Genetic basis of PLP1 related disorders 
PMD in humans occurs as a consequence of a number of mutations, including point 
mutations in coding regions, mis-splicing at the transcript level, deletion, 
duplication/triplication of the gene or changes in gene expression regulation. Figure 6 
shows the genetic mechanisms for PMD in patients. The main cause of PMD in humans is 
duplication of the PLP1 gene accounting for 50 to 75% of all cases (Sistermans et al., 
1998, Garbern et al., 1999). The breakpoints in the duplications causing PMD vary as does 
the size of the duplication from 300Kb to 4.6Mb (Woodward et al., 1998, Inoue et al., 
1999). Very rare cases of PMD are caused by triplication of the PLP1 gene and the 
severity of the disease is greater than cases caused by duplication (Wolf et al., 2005). Real-
time quantitative PCR can now be utilised to detect PLP1 copy numbers for diagnosis of 
humans (Regis et al., 2005). Mimault and colleagues (1999) describe analysis of 82 
sporadic cases of PMD caused by duplications showing that the duplications arise most 
frequently in the male germline.   
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Point mutations make up a further 15-20%, 2-3% is caused by null mutations and the rest 
have no known cause. Some mild forms of PMD cases with no known mutation in the 
coding region may be caused by mutations in splicing at other exon-intron borders within 
the PLP1 gene. A point mutation at the 3’ border of exon 6 was found in a patient with 
mild PMD (Hobson et al., 2000, Hubner et al., 2005). This mutation did not cause an 
amino acid change but did affect splicing and caused partial skipping of exon 6 in the 
PLP1 mRNA. The reading frame remained intact however it led to the absence of amino 
acids 232-253 which represent the main part of the fourth transmembrane domain. 
However wild type PLP1 mRNA was also produced leading to the milder phenotype 
(Hubner et al., 2005). To date there have been three further mutations affecting the exon 6 
donor splice site leading to disease published. The severity of the disease phenotype 
depends on whether any wild type splicing also occurs. (Jimpy mice mirror this with 
skipping of exon 5/partial rescue with wild type PLP and DM20). A case of PMD caused 
by mis-splicing at the exon 5 donor site due to a point mutation has also been documented 
(Aoyagi et al., 1999).  
Recent cases of PMD (and SPG2) caused by a positional effect have been reported. A 
duplication of a region of the X chromosome downstream from the PLP1 gene in a patient 
is the cause of the disease (Lee et al., 2006a). Lee et al., (2006a) proposed that this 
duplication leads to PLP1 gene silencing, thus, causing the disease. An inverted X 
chromosome with a breakpoint within GLRA4, a putative pseudogene similar to glycine 
receptor alpha-2 chain was found in a patient with a subset of PMD symptoms (Muncke et 
al., 2006). They suggest that a positional effect spanning 70kb is the cause of the 
symptoms and that GLRA4 is not involved. Carango and colleagues (1995) described two 
brothers with PMD with no mutations in the coding regions of the PLP1 gene. The 
brothers had a 6-fold higher level of Dm20 mRNA in their cultured skin fibroblasts 
compared to RNA from an unaffected male which could be mirrored in their CNS tissue. 
This reflects the patients with PMD who have duplications or triplications of the PLP1 
gene. Any change in the expression of this gene has a detrimental effect on myelination. 
PMD in humans involves at least three mechanisms, loss of function, gain of toxic function 
and increased dosage. The loss of function pertains to null mutations and is the least severe 
whereas the gain of toxic function relates to point mutations and causes a range of severity 
depending on the specific mutation. PMD caused by duplication lies in between the two 
but the rare cases of triplications increase severity.  
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1.5.1.4 
1.5.2.1 
Other myelin disorders caused by gene dosage 
The disorders Charcot-Marie-Tooth disease type 1 (CMT1A) and Hereditary neuropathy 
with liability to pressure palsies (HNPP) are examples of other myelin disorders caused by 
dosage effects and mutations of a myelin protein gene. The major cause of CMT1A is 
duplication of the peripheral myelin protein 22 (PMP22) gene, and HNPP by a decrease in 
dosage of the same gene (Woodward and Malcolm 1999). Other human diseases such as 
Familial Hypercholesterolemia, Duchenne Muscular Dystrophy (DMD) and Lesch-Nyhan 
syndrome, another x-linked disorder, have be found to be caused by partial gene 
duplications (Hu and Worton 1992). 
1.5.2 Plp1 gene mutations in animals  
Spontaneous mutants 
The jimpy (Plpjp) (abbreviated to jp) mouse was described in 1954 and since then several 
other animal myelin deficiencies caused by mutations of the Plp1 gene have been 
discovered. These include the myelin synthesis-deficient jp mouse (Plpjp-msd) (abbreviated 
to msd), Plp jp-4j, myelin deficient (md) rat, the shaking (sh) pup, the rabbit with paralytic 
tremor (pt) and the rumpshaker (Plp jp-rsh) (abbreviated to rsh) mouse.  
1.5.2.1.1 Jimpy (jp) mouse and myelin synthesis-deficient jp (msd) mouse  
The jp and msd are the most severely affected mutants and are characterised by an almost 
complete absence of myelin, reduction in mature oligodendrocyte numbers and death by 3-
4 weeks. The msd mutation (A242V) occurs in patients with severe PMD. 
1.5.2.1.2 Rumpshaker (rsh) mice 
The rumpshaker mouse is a spontaneous occurring mutant with a mild disease phenotype 
dependant on genetic background. The rsh mutation leading to an amino acid substitution 
(I186T) in mice is identical to a mutation in humans causing SPG2 (Kobayashi et al., 
1994). This mouse is hypomyelinated, with some naked axons and thinner sheaths on 
axons that are myelinated. While many of the axons have normal periodicity, some have 
condensed IPLs (Griffiths et al., 1990). Genetic background has a role in the severity of 
disease in mice with the rsh mutation causing a lethal phenotype in the C57BL/6 mice with 
death around postnatal day 30 (P30) (Al-Saktawi et al., 2003). Wallerian-type degeneration 
is also seen in these mice (Edgar et al., 2004). 
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1.5.2.1.3  Other known mutants 
Yool et al., (2000) and Nave and Griffiths (2004) reviewed the known animal mutants of 
PMD and SPG2. 
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Figure 6. Pie chart showing the proportion of PMD caused by the different types of 
mutations with ~70% caused by duplications of the PLP1 gene.  
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1.5.2.2 Transgenic animals 
1.5.2.2.1 #66 and #72  transgenic mice 
Readhead et al., (1994) generated two lines of transgenic mice containing a cassette with 
extra copies of the wild type murine Plp1 gene. One line, #72 had a cassette with 3 extra 
copies and could be bred to homozygosity with 6 extra copies with an endogenous copy of 
the Plp1 gene on the X chromosome. The other line, #66, had 7 extra copies of the Plp1 
gene in tandem and when bred to homozygosity had 14 extra copies of wild type gene as 
well as the endogenous copy on the X chromosome. The entire Plp1 gene containing 8 
exons and 3.5kb of the 5’ regulatory region was present in 7 copies in the cassette which 
was inserted into an unknown autosome in the mouse genome. The transgene was checked 
for mutations and was found to be indistinguishable from the endogenous copy of the gene. 
Both dysmyelination and demyelination are seen in the #66 transgenic mice. 
Dysmyelination or the aberration of the normal myelination process is seen the animals 
with the highest Plp1 gene copy numbers (homozygous) with premature death around 2 
months. The homozygous #66 mice develop a tremor that is visually noticeable after 2 
weeks and continues throughout their life. These animals are fertile but tend to die by 
seizures prior to mating. Although the Plp1 transgenic cassette is inserted into an autosome 
the gene’s expression is still area and cell specific. Readhead and colleagues (1994) noted 
that the dysmyelination in the homozygous animals was less severe in the spinal cord and 
brain stem and more prominent in the forebrain and optic nerve. This may suggest that 
areas that myelinate later in CNS development are more severely affected by loss of 
myelin.  
Astrocytosis is increased in the homozygous #66 animals with increased numbers of 
processes noted in early and late CNS development. It was noted that mature 
oligodendrocytes in #66 transgenic mice accumulate PLP/DM20 and other myelin proteins 
and have a high level of oligodendrocyte death (Anderson et al., 1999). Dysmyelination 
occurring in mice with extra copies of wild type Plp1 gene was previously thought to be 
caused by a defect in oligodendrocyte differentiation; however it may be due to the cell’s 
inability to maintain contact and/or remyelinate nearby axons (Woodward and Malcolm 
1999).  
Demyelination is noted in animals with the lower Plp1 gene copy number (hemizygous) 
and is the loss over time of properly laid down myelin. Demyelination, as well as axonal 
degeneration is seen in older #66 hemizygous animals (Anderson et al., 1998). These 
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animals are able to reproduce and are clinically normal for several months. However, they 
go on to develop a progressive neurological disorder characterised by loss of weight, 
ataxia, tremors and seizures. The loss of myelin in the hemizygous mice is different from 
that seen in other mutants with signs of tract and fibre size specificity observed. A 
significant level of axonal degeneration is also observed in these animals. Clinically 
unaffected animals older than 1 year usually show changes in the brain and spinal cord but 
the optic nerve showed abnormalities at 4 months. Ip and colleagues (2006) discovered that 
in these mice the immune response contributes to the degeneration of the myelin. CD8+ 
lymphocytes and CD11b+ macrophage like cells are elevated in the white matter of these 
animals.  
A viral expression construct used to infect primary oligodendrocyte cultures, causing 
overexpression of PLP, led to mistrafficking of the protein to LE/Ls instead of the normal 
route of the Golgi apparatus. It also led to the sequestering of cholesterol to these cellular 
compartments (Simons et al., 2002). Transgenic #66 mice accumulate PLP and cholesterol 
in LE/Ls and this leads to the perturbation of the myelination process affecting the viability 
of the oligodendrocytes (Simons et al., 2002). Accumulation of the protein in the ER of 
oligodendrocytes with extra copies of the Plp1 gene can also trigger apoptosis (Gow et al., 
1998).  
Oligodendrocytes die by apoptosis in homozygous #66 transgenic mice. Apoptosis 
involves the cleavage/activation of caspase family members which occurs in a cascade 
manner and the pathways leading to apoptosis activation in Plp1 mutants vary dependant 
on the mutation involved as seen by evidence from the jimpy and #66 transgenic animals 
(Cerghet et al., 2001). 
1.5.2.2.2  Other transgenic animals  
Yool et al., (2000) also reviewed the known animal models of PMD and SPG2. Several 
transgenic and knockout animals have been generated over the years to investigate 
different aspects of human dysmyelinating and demyelinating diseases. These include the 
aforementioned #66 transgenic and Plp1 null mice. Other transgenic animals include the 
#72 line generated by Readhead et al., (1994), 4e-Plp transgenic mice (Kagawa et al., 
1994), PLP or DM20 only lines (Nadon et al., 1994) and ND3A and ND4 transgenic mice 
generated to express high levels of DM20 only (Barrese et al., 1998, Mastronardi et al., 
1993,  Johnson et al., 1995). 
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The 4e-Plp transgenic line of mice containing extra copies of the wild type Plp1 gene show 
evidence pointing to the dual role PLP plays in myelination (Kagawa et al., 1994). The 
cassette here contains 40kb gDNA encompassing all 8 exons of the mouse Plp1 gene as 
well as 20kb of the 5’ flanking region and 4kb of the 3’ flanking sequence. The copy 
number is estimated to be 2 Plp1 genes per transgene cassette thus hemizygotes have 2 
extra copies of Plp1 while homozygotes have 4. The expression of the transgene has been 
found to similar to the endogenous gene in this case the jimpy Plp1 gene. In hemizygous 
mice the message levels were up to 132% of wild type levels while in homozygous mice 
the levels were down to 60% of wild type levels. Protein levels were reduced even further 
than transcript levels in the 4e-Plp animals. 
Both homozygous males and females exhibit ataxia, tremors and convulsions leading to 
premature death around postnatal day 30. At P20 in homozygous 4e mice the majority of 
axons are found to be naked or ensheathed by a thin myelin sheath in white matter of 
spinal cords. Oligodendrocyte maturity is compromised in these animals with 
oligodendrocytes producing less Mbp mRNA than wild type controls. Kagawa et al., 
(1994) confirmed also the hypomyelination seen in their animals was not caused by 
insertional mutagenesis.    
A line of transgenic rats LewPLP, were generated by Bradl and colleagues (1999). These 
homozygous animals have a dysmyelinating phenotype with the death of mature 
oligodendrocytes as well as the arrest in immature oligodendrocyte development. The 
homozygous rats die before weaning age while the hemizygous animals myelinate 
normally then go on to develop myelin degeneration throughout their life. When studying 
the hemizygous animals further Bauer et al., (2002) uncovered oligodendrocytes with 
swollen and aberrant RER in the CNS gray matter. All these models are useful in studying 
the underlying pathological mechanisms leading to disease in humans.  
1.5.2.2.3 Plp1 null mice  
The complete loss of the PLP1 gene products in humans leading to a mild form of PMD is 
caused by point mutations like a (C-to-A) mutation in the initiation codon of the gene 
(Sistermans et al., 1996). As there were no spontaneous animal models of complete loss of 
the PLP1 gene, Klugmann et al., (1997) generated a transgenic mouse lacking the Plp1 
gene by targeting a vector to delete the translation start site of PLP/DM20. These mice did 
not go on to develop the expected dysmyelinating phenotype seen in Plp1 mutants and 
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developed normally showing no other signs usually associated with dysmyelinating 
disorders (Griffiths et al., 1998). The myelin did not immunostain for PLP or DM20 but 
did for MBP as excepted. Myelin sheaths were of approximately normal thickness but 
exhibited variability in the amount of compaction with some sheaths showing normal 
periodicity and others having widely spaced IPLs (Klugmann et al., 1997). There were no 
signs of astrocytosis when stained with GFAP and the PLP/DM20 deficient 
oligodendrocytes showed no evidence of increased cell death or degenerative changes.  
The main difference in the myelin ultrastructure was the loss of distinction between the 
IPL and MDL (Klugmann et al., 1997). Griffiths et al., (1998) discovered that the 
PLP/DM20 null mice generated by Klugmann et al., (1997) went on to develop axonal 
swellings and degeneration of axons later in life suggesting the progressive impairment of 
fast retrograde and anterograde transport in axons (Edgar et al., 2004).  Patients with 
mutations causing a complete lack of PLP/DM20 in the CNS, exhibit the same length 
dependant axonal degeneration seen in null mice (Garbern et al., 2002). This axonal 
degeneration in mouse and human may be caused by the loss of PLP/DM20 mediated 
axonal-oligodendrocyte interactions. Studies by Rosenbluth and colleagues (2006) 
highlighted ultrastructural changes in PLP null myelin such as irregularly filled and diffuse 
interlamellar spaces and distorted radial components that may be the cause of the axonal 
damage. As this is one of the major phenotypic symptoms in Plp1 null mice and is not seen 
in shiverer mice (deficient in MBP) it suggests the correct expression of PLP and DM20 is 
essential for the oligodendrocyte function of maintaining the interaction between the cell 
and axons.  
1.5.3 Spontaneous mutations of other myelin genes 
1.5.3.1 Shiverer (shi) mice 
The shiverer mutation was mapped to mouse chromosome 18 by Sidman and colleagues 
(1985). Both Roach et al., (1985) and Kimura et al., (1985) showed that shiverer mice had 
a deletion of a large proportion of their Mbp gene. Shiverer animals show behavioural 
changes from postnatal day 14, developing shivers, then tonic seizures and finally 
premature death. 
Information on the function of MBP has mainly come from this recessive neurological 
mutant shiverer. The shiverer mutation causes a defect in CNS myelination which leads to 
tremors, then convulsions and eventually premature death (Lemke 1988). In homozygous 
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shiverer animals there is almost no CNS myelin present and where there is myelin, the 
MDL is uncompacted. Around 20 kb of the Mbp gene which maps to mouse chromosome 
18 is deleted from the shiverer genome (Roach et al., 1985). The reintroduction by 
Readhead et al., (1987) of a cloned MBP gene restored the mutant phenotype to a wild 
type phenotype. One surprising finding with the shiverer mouse was the lack of effect on 
the PNS where MBP is also expressed suggesting another protein compensates for the loss 
of MBP. Alterations in phosphorylation of cytoskeleton proteins and neuronal perikaryon 
functions like cytoskeletal gene expression are seen in these mice suggesting compact 
myelin is important for normal maturation of the neuronal cytoskeleton in the CNS (Brady 
et al., 1999).  
Kimura and colleagues (1998) showed that overexpression of one of the major MBP 
isoforms (14 kDa) in shiverer mice restores CNS myelination in these mice. They also 
demonstrated a similar restoration of CNS myelination in shiverer animals with a minor 
isoform (17.2 kDa). Shine et al., (1992) generated shiverer mice crossed to carry MBP 
transgene producing a range of mice with varying MBP expression levels. Mice with MBP 
expression above 50% of wild type levels showed no difference in numbers of myelinated 
axons and myelin thickness.  
Myelin deficient (shimd) mouse  1.5.3.2 
1.5.3.3 
The myelin deficient mouse is allelic to the shiverer animal and was shown to carry a 
duplication rather than a deletion of the MBP gene with one copy containing an inversion 
at its 3’ end (Popko et al., 1988). Shimld mutation is caused by an inversion of exons 3-7 
and a duplication of exons 2-7 resulting in the formation of antisense MBP heterogeneous 
nuclear RNA eliminating MBP mRNA from the nucleus (Okano et al., 1991).  
Shimld mice produce 2.5-5.0% MBP mRNA compared to normal wild type levels. In 
neonatal md mice MAG and MBP are both present, the MAG in the cell body and early 
myelin sheaths and the MBP only in the myelin sheaths. However, at P17 when 
dysmyelination is evident MAG is less obvious in the oligodendrocytes.  
Quaking mice  
Quaking mice show a generalised hypomyelination in both the CNS and PNS caused by an 
autosomal recessive mutation on chromosome 17 (Bray et al., 1981). This mutation is in 
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the quaking (qkI) gene, of which one protein isoform is involved in the alternative splicing 
of MAG (Trapp 1988, Georgiou et al., 2004). The MDL does not form in these mutants. 
1.6 Aims of thesis 
This study aims to investigate the effects of increased Plp1 gene dosage in #66 transgenic 
mice (Readhead et al., 1994). The contribution of only the transgene cassette with an 
endogenous Plp1 gene to PLP/DM20 message and protein amounts is investigated to get a 
better measure of the control on transgene expression. The effects of increased Plp1 gene 
dosage on message and protein levels of its own products and other myelin gene products 
have been explored. In addition to steady state levels, the effects on protein dynamics have 
been studied. Changes to myelin ultrastructure have also been described and quantified 
using morphometric analysis.  
In the final discussion, the findings from this study and any future work that could help 
answer questions raised are discussed.  
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2 Materials and Methods 
2.1 Miscellaneous  
All procedures were conducted in accordance to health and safety guidelines outlined in 
specific risk assessments. Inorganic chemicals were sourced from Sigma or BDH and were 
of AnalaR® or molecular biology grade. Solutions were sterilised as appropriate, bulk 
solutions were autoclaved whereas smaller volumes that could not autoclaved were filter 
sterilised using a Flowpore 0.22μm filter (Sartorius, Epsom, UK). Toxic powders, fixatives 
and other volatile liquids were prepared in fume cupboards.  
The Appendix (page 207) gives details of the preparation of fixatives, stains, buffers and 
solutions as well as of staining and processing protocols. These are all cross-referenced to 
pages in this section. 
2.2 Mouse Breeding 
2.2.1 Animal breeding facilities 
Mice were bred at the Glasgow Parasitology Unit, University of Glasgow Veterinary 
School. The breeding facility at Glasgow is known to have evidence of murine hepatitis 
virus and picorna virus infections both of which have been associated with neurological 
disease in mice (Lipton et al., 1994, Fujiwara, 1994). During the period of this study, the 
mice were routinely screened and monitored for pathogens that may have a detrimental 
effect and there was no evidence of clinical disease and the phenotypes and pathology 
identified in transgenic mice were not identified in wild type controls also bred in this 
facility. Similarly, mice bred at ZMBH, a specific-pathogen free facility, had phenotypes 
and pathology that were consistent with those seen in the mice bred at Glasgow. This 
suggests that these viruses did not contribute to the phenotypes and pathology described in 
this study.  
2.2.2 Transgenic Lines 
2.2.2.1 #66 mice 
#66 mice were generated by Readhead et al., (1994). The murine Plp1 gene was isolated 
from a cosmid library and used to construct a 26.6kb transgene insert. The transgenic 
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cassette is predicted to include all eight exons of the Plp1 gene, 3.5kb of the 5′ regulatory 
region and a small vector fragment containing the T7 promoter sequence at the 3′ end of 
the transgene (Figure 7A). This was introduced into B6D3F2-fertilised ova by pronuclear 
microinjection and produced two lines of transgenic mice containing the intact Plp1 
transgene (#66 and #72). These were assessed by Southern blot analysis and were 
estimated to respectively contain seven and three copies of the transgene per haploid 
genome. The transgene copies co-segregated in subsequent generations following an 
autosomal inheritance pattern suggesting that, in both lines, the transgenes had inserted in 
tandem at autosomal sites (Readhead et al., 1994). The presence of the transgene can to 
detected by conventional PCR using primers for the end of exon 7 and beginning of the 5’ 
UTR (forward primer) and the T7 sequence (reverse primer) (Figure 7B and C). 
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Figure 7. Transgene construct from the #66 and #72 lines. 
The figure shows PCR primer positions for identifying the transgene (the exons are 
represented by numbered boxes, coding regions are shaded black with exon 3B shaded 
light grey; the transgene-specific T7 promoter sequence is represented by a green box, a 
black arrow indicates the orientation of this sequence) (Readhead et al., 1994). A) The 
transgene construct with relevant restriction sites shown. B) The primer positions on the 
endogenous Plp1 gene. C) The transgene construct (forward primer in red and reverse 
primer in blue).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2-65
Saadia Ansari Karim 2007    
2.2.2.2 Plp1 gene null mice 
Plp1 gene null transgenic mice were generated by Klugmann et al., (1997) at ZMBH, 
Heidelberg. The endogenous Plp1 gene was disrupted by introducing a targeting vector 
designed to disrupt the ATG translation start codon in exon 1 (Figure 8A-E). The targeting 
vector is also predicted to disrupt exon 1.1, preventing the transcription of srPlp and 
srDm20 mRNA (Bongarzone et al., 1999). The targeting vector replaced exons 1 to 3 of 
the wild type allele by homologous recombination and was introduced into R1 embryonic 
stem cells by electroporation. The neo gene, in reverse orientation to the Plp1 gene and 
under the control of the herpes simplex virus (HSV) promoter, was used to disrupt the 
translation start codons. It replaced the 3′end of exon 1 and 2.5kb of intron 1 between the 
BamH1 site in exon 1 and the Kpn1 site in intron 1. A negative selector, the thymidine 
kinase (tk) gene also under the HSV promoter, was used to select against random (non-
homologous) vector insertion as it was located immediately upstream of the 5′ homology 
region of the targeting vector (Figure 8B). Construct-mediated G418 resistance positively 
selected for stem cells containing the targeting construct and cells that had random vector 
insertion were negatively selected against using gancyclovir. Homologous recombination 
and a single integration event were confirmed by Southern blot analysis. Cells containing 
the Plp1 gene-null allele (Plptmkn1) were microinjected into blastocysts from C57BL/6J 
mice to produce chimeras. The chimeras were used to establish founder stock of Plp1 gene 
null mice containing the Plptmkn1 allele by back crossing onto C57BL/6J mice (Klugmann 
et al., 1997). The wild type Plp1 gene and the disrupted Plptmkn1 allele are shown in Figure 
8D and 8E with primer positions marked by arrows. 
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Figure 8. The steps involved in generating Plp1 null mice.  
A) The endogenous murine Plp1 gene with all numbered exons (coding regions in black; 
exon 3B shaded light grey, arrows in exon 7 representing polyadenylation sites). B) The 
targeting vector containing the negative selectable marker (tk gene) which is lost during 
homologous recombination and the positive selectable marker (neo gene) which is retained 
(selectable markers are denoted by green boxes). C) The resulting recombined null gene. 
D) The endogenous Plp1 gene (forward primer in red and reverse primer in dark blue). E) 
The mutated Plptmkn1 gene (forward primer in red and reverse primer in light blue).  
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2.2.3 Maintenance of transgenic lines of mice 
The #66 line of transgenic mice was maintained by creating harems containing transgene 
positive and negative animals of 2 months and older from the same background. Brother-
sister matings were avoided and background strains were not mixed. The Plp1 gene null 
transgenic line was maintained by creating harems of Plptmkn1 hemizygous male and 
homozygous female mice. In addition, harems containing wild type mice from this line and 
mice carrying the Plptmkn1 allele ensured the production of Plptmkn1 heterozygotes and wild 
type littermate controls.  
2.2.4 Crossing of transgenic lines of mice 
For transgenic complementation of the Plp1 gene null mice with the #66 transgene, 
hemizygous transgene positive #66 males were bred with Plptmkn1 heterozygous females. 
This ensured that all F1 males were Plptmkn1 hemizygotes or wildtype and that a number 
were also transgenic hemizygotes. Transgene negative littermates from the same breeding 
programme were used as internal controls.  
2.3 Isolation and manipulation of DNA 
2.3.1 Tail Biopsy and mouse identification 
The mouse was anesthetised in a chamber using Halothane (Rhone-Poulenc Chemicals 
Ltd, Stockport, UK). Once anesthetised, 5mm of the tip of the tail was removed using 
aseptic techniques with a clean scalpel blade on a glass slide. The wound was cauterised 
and treated with Rimadyl analgesic (Pfizer, Tadworth, UK) which contains 50mg/ml 
Carprofen. The dose rate for the mice is 5mg/kg. While the mouse was still unconscious 
the ear was punched to allow for identification later. The mouse was returned to cage and 
allowed to recover under a heat lamp while regularly checked for wound bleeding. 
The tail tip was placed into labelled tube and stored at -20°C until needed. 
2.3.2 Genomic DNA (gDNA) extraction 
gDNA for genotyping was extracted from tail samples collected at biopsy and at post 
mortem. This was conducted using a Promega kit following the manufacturer’s protocol.  
Over night protein digestion with 7μl 50 mg/ml Proteinase K solution with 120μl 0.5M 
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EDTA in Nuclei Lysis solution was carried out. Frozen tail tips were placed in a 1.5ml 
fresh tube on ice.  
The following morning 200μl ammonium sulphate containing Protein Precipitation 
solution (Promega, Southampton, UK) was added to aid precipitation. The DNA was 
extracted by mixing supernatant with 600μl iso-propanol and gently inverting. After a high 
speed spin (13,000rpm for 5 minutes) the pellet was washed with 600μl 70% ethanol. 
Finally, the pellet was resuspended in DNA Rehydration solution (Promega). Volume for 
resuspension was dependent on size for pellet. 
Alternatively, a 3mm piece of tail was placed into a fresh tube containing 100μl 50mM 
Sodium Hydroxide and heated to 95°C for 1 hour 30 minutes. 10μl 1M Tris pH5.0 was 
added and samples vigorously vortexed. The crude DNA extractions could then be stored 
at 4°C or diluted 1 in 10 in ddH2O and stored at -20°C. 
2.3.3 gDNA quanitification and storage 
gDNA was quantified using a GeneQuant RNA/DNA calculator with a spectrophotometer 
cell. gDNA was assessed for degradation by electrophoresis on an agarose gel (Figure 9). 
The gDNA was diluted for genotyping PCRs to working concentrations of 25 ng μl-1 in 
ddH2O and stored at -20°C. 
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Figure 9. gDNA separated on a 0.8% agarose gel.  
Lanes 1-6 show 250ng DNA separated on a 0.8% agarose gel, Lane M shows 1kb plus 
DNA ladder. 
 
 
 
 
 
 
 
denaturing temperature 94° C 3 min 
annealing temperature 58° C 1 min 
Initial cycle 
extension temperature 72° C 2 min 
denaturing temperature 93° C 40 secs 
annealing temperature 58° C 1 min 
Step cycles  
(25 cycles) 
extension temperature 72° C 40 secs 
denaturing temperature 93° C 40 secs 
annealing temperature 58° C 1 min 
Final cycle 
extension temperature 72° C 2 min 
Table 1. Standard PCR program used for genotyping PCRs or RT-PCRs 
(annealing temperature can be altered depending on temperature of primers). 
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2.3.4 PCR Genotyping  
2.3.4.1 
2.3.4.2 Genomic 
2.3.4.3 
PCR Program  
Amplifications for genotyping were performed on a DNA thermal cycler following the 
program in Table 1. 
PCR 
25μl PCR reaction were carried out in 0.5ml thin walled tubes containing Ready-to-go 
PCR beads (Amersham, Chalfont St.Giles, UK). 25ng gDNA, forward and reverse primers 
at 0.2M concentration and ddH2O was added to the beads. The reaction was overlaid with 
50μl of molecular biology grade mineral oil (Sigma, Poole, UK) to prevent evaporation of 
the reaction mix. The reaction was stopped by storing at 4° C before analysis.  
PCR Primers 
Primer sequences and product sizes are listed in Table 2 and the PCR products are 
demonstrated in Figure 10. Primer positions are represented graphically in Figures 7 and 8 
describing the transgenes and are cross-referenced in the text. A positive control (a known 
DNA sample) was included with each set of samples dependant on the PCR. A negative 
control reaction where the sample was replaced by ddH2O was also included to ensure that 
there were no contaminating nucleic acids.  
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Amplify Primer Sequence Size Reference 
PLP 
5′ CAG-GTG-TTG-
AGT-CTG-ATC-TAC-
ACA-AG 3′ #66 and #72 transgenes 
 
αT7 
5′ GCA-TAA-TAC-
GAC-TCA-CTA-TAG-
GGA-TC 3′ 
~400bp 
 
Readhead et 
al., 1994 
 
Ex1f 5′ GGA-GGA-TTA-AGA-ACC-CCT-CC 3′ Plp1 wild type allele 
 αPLP5′anti 5′ CTG-TTT-TGC-GGC-TGA-CTT-TG 3′ 
389bp 
  
Ex1f 5′ GGA-GGA-TTA-AGA-ACC-CCT-CC 3′ 
Plptmkn1 allele 
αMKneo1 
5′ TAC-GGT-ATC-
GCC-GCT-CCC-GAT-
TCG-CA 3′ 
429bp 
Griffiths et 
al., 1995 
CyclC 5′ ACC-CCA-CCG-TGT-TCT-TCG-AC 3′ Cyclophilin 
transcript 
cDNA 
αCyclG 5′ CAT-TTG-CCA-TGG-ACA-AGA-TG 3′ 
300bp Danielson et al., 1988 
XBP1.3S 
5′ AAA-CAG-AGT-
AGCTCA-GAC-TGC 
3′ Xbp1 transcript 
cDNA 
XBP1.12AS
5′ TCC-TTC-TGG-
GTA-GAC-CTC-TGG-
GAG 3′ 
~ 500bp Marciniak et al., 2004 
Forward 
5′ AGA-GGG-AAA-
TCG-TGC-GTG-ACA-
T 3′ 
Reverse 5′ AGG-AAG-GCT-GGA-AAA-GAG-CC 3′ 
Β-actin 
transcript 
(Probe 3′ 
Blackhole 
Quencher, 5′ 6-
FAM) 
(NM_007393) TaqMan Probe 
5′ TGG-CCA-CTG-
CCG-CAT-CCT-CTT-
C 3′ 
~180bp Karim et al., 2007 
 
Mbp transcript  
Forward 
 
5′ AGA-CCC-TCA-
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CAG-CGA-TCC-AA 3′ 
Reverse 
5′ CCC-CTG-TCA-
CCG-CTA-AAG-AAG 
3′ 
all isoforms 
(Probe 3′ 
Blackhole 
Quencher, 5′ 6-
FAM) 
(NM_0010252
59) 
TaqMan 
Probe 
5′ CAA-GTA-CCA-
TGG-ACC-ATG-CCA-
GGC-A 3′ 
 
 
~130bp 
 
 
Karim et al., 
2007 
Forward 
5′ GTA-TAG-GCA-
GTC-TCT-GCG-CTG-
T 3′ 
Reverse 
5′ AAG-TGG-CAG-
CAA-TCA-TGA-AGG 
3′ 
Plp1 transcript 
both isoforms 
(Probe 3′ 
Blackhole 
Quencher, 5′ 6-
FAM) 
(NM_011123) TaqMan 
Probe 
5′ TGG-CAA-GGT-
TTG-TGG-CTC-CAA-
CCT-T 3′ 
200bp Karim et al., 2007 
Table 2. PCR primers for genotyping, semi-quantitative RT-PCR and realtime RT-
PCR 
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Figure 10. Genotyping PCRs.  
A) #66 PCR of wild type, hemizygous and homozygous samples using Plp1 forward 
primer and T7 reverse primer (Lane M 1kb plus ladder, Lanes 1-4 and 6 transgene positive 
(hemizygous or homozygous) and Lane 5 transgene negative (wild type)). B) Plp1 and 
Plptmkn1 allele PCR (Lanes M 1kb plus ladder, Lanes 1-5 samples and Lane 6-9 controls, 
wild type, heterozygous, null and blank).  
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2.3.5 Agarose gel 
Regular analysis of DNA and PCR products was performed in 1-2% agarose gels in 1 x 
TAE (Tris acetate ethylene-di-amine-tetra-acetate) buffer (appendix). 1% agarose gels 
were used to examine DNA and 2% for PCR products (Figures 9 and 10). Gels were made 
from ultra pure electrophoresis grade agarose (Invitrogen, Paisley, UK) melted in TAE 
buffer. Once cooled Ethidium Bromide 1mg/ml was added to the gel to give final 
concentration of 0.5μg/ml. Samples were loaded with 6x Orange G loading dye (appendix) 
and 1 x TAE used as electrophoresis buffer. 
2.3.6 Visualisation of PCR Products 
Agarose gels were viewed with a “Fotoprep I” ultraviolet (UV) transilluminator (Fotodyne 
Inc.)  
2.4 Isolation and manipulation of RNA 
2.4.1 Tissue/Sample Collection 
Mice were culled by CO2 inhalation. Tissues were removed immediately after death, 
placed in freezer tubes (Nunc, Loughborough, UK) and snap frozen in liquid nitrogen. The 
tissues were then stored at -80°C until required. 
2.4.2 Extraction of RNA 
The extraction of RNA from tissue using RNAsol B is a modification of a one step 
procedure described by Chomczynski and Sacchi (1987) and was carried out following 
manufacturer’s recommendations. RNAsol B contains a monophasic solution of guanidium 
and phenol chloroform. Guanidium rapidly inactivates RNase activity and forms 
complexes with RNA and water allowing the RNA to be retained in the aqueous phase 
while DNA and proteins separate in the phenol/chloroform phase. 
1 ml prechilled RNAsol Bee (TelTest Inc) was added to previously prepared tissue 
(powdered in liquid nitrogen then snap frozen and stored in -80°C) on ice. The tissue was 
homogenised by tituration through sterile needles of decreasing sizes (23-14g) until the 
RNAsol Bee was clear. The resulting solution was aliquoted into a fresh 1.5ml tube. 200μl 
Chloroform was added to each tube, the tubes vortexed for 30 seconds and placed on ice 
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for 5 minutes. The samples were then centrifuged for 15minutes at 13,000 rpm at 4°C. The 
upper aqueous layer (~500μl) was transferred to a fresh tube.  
Depending on starting material 4μl glycogen was added (cultures, spinal cord). Equal 
volume 100% isopropanol (Sigma) was added to the samples. After 10 minutes at room 
temperature the samples were centrifuged for 15 minutes at 13,000 rpm at 4°C (RNA 
forms pellet and is visible to eye). The supernatant was discarded and 1ml 70% Ethanol 
was added to the pellet.  After vortexing, the samples were centrifuged for 8 minutes at 
13,000 rpm at 4°C. The supernatant was once again removed and a further spin for 2 
minutes at the same setting was preformed. The excess ethanol was removed using a P200 
gilson pipette and tip. The pellet was left to air dry for no more than 10 minutes and pellet 
resuspended using 100μl DEPC treated H20 (appendix). For long term storage the RNA 
was kept at -80°C. 
2.4.3 Quantification and Quality check 
Prior to storage the RNA was checked for concentration and quality. For quantification, 
RNA samples were initially diluted 1 in 10 with milliQ H20. A blank of only milliQ H20 
was also prepared. On a Genequant (Pharmacia Biotech, Little Chalfont, UK) the blank 
was read for single stranded RNA at absorption of 260/280nm. This gave a reading of zero 
after which all the samples were read. The resulting concentration was multiplied by a 
factor of 10 to give final concentration for each RNA sample. 
500ng RNA was run out on a 1.5% agarose gel in 1xTAE at 75 volts for 45 minutes to 
resolve the major RNA species and access their integrity (Figure 11). The gel was 
photographed using UV image capture system.  
2.4.4 cDNA generation from total RNA 
Ensuring all tubes and tips were RNAse free and H2O DEPC treated, cDNA was produced 
from total RNA.  Prior to reverse transcription 2μg total RNA was treated with 2 units of 
DNAse I for 45 minutes at 37°C. This was to remove genomic DNA contamination. To 
stop the reaction 5μl de-act slurry was added to each sample. The samples were left for 2 
minutes at room temperature then centrifuged for 2 minutes at 10,000 rpm. 
Fresh tubes were prepared for reverse transcription. 25μl supernatant (1μg DNAse I treated 
RNA) was heated at 65°C for 5 minutes to denature any secondary structures then mixed 
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with reverse transcription reaction mix [1x RT buffer (Invitrogen), 5mM DTT, 1mM 
dNTPs, Random primers, 20 units RNAsin (Promega), 200 units RTase (Invitrogen) in 
total volume of 25μl] to give 50μl reaction volume. Three incubation/heating steps 
followed: 37°C for 30 minutes, 40°C for 1 hour and finally 72°C for 15 minutes. 150μl 
DEPC treated was added to each sample to give final working volume of 200μl (Figure 
12). 
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Figure 11. 500ng total RNA from P20 spinal cords. 
Lanes 1-8 show 500ng aliquots of total cellular RNA separated on a 1.5% non-denaturing 
agarose gel, Lane M shows 1kb plus DNA ladder. All three bands of ribosomal RNA are 
visible (28S, 18S and 5S bands).  
 
 
 
 
 
 
 
 M     1       2       3      4      5
 
 
 
 
 
 
 
 
 
 
 
Figure 12. cDNA from P20 mouse spinal cord.  
Lane 1-5 show 10µl cDNA separated on a 0.8% agarose gel, Lane M shows 1kb plus DNA 
ladder.  
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2.4.5 RT-PCR  
The amino acid mutation leading to a misfolded protein or the introduction of extra wild 
type gene copies resulting in protein overproduction, may induce an addition process 
burden for the ER. One consequence is the activation of cellular quality control 
mechanisms which involve the upregulation of many chaperone proteins. One way of 
measuring ER stress is by studying the X box protein 1 (Xbp1). Xbp1 was used as it is one 
effector of the UPR which is expressed on ER stress-mediated splicing of the Xbp1 
mRNA. XBP1 induces certain ER-targeted proteins, eg, glucose-regulated protein 78 
(GRP78), which help resolve the ER stress and foster cell survival. cDNA produced from  
spinal cord RNA was utilised for X box protein 1 (Xbp1) and cyclophilin RT-PCR 
(Marciniak et al., 2004). The cyclophilin message was used as an endogenous control as 
levels of message are not altered during development or between tissues. Also used as a 
control was cDNA from cultured oligodendrocytes, which had been exposed to stress 
inducing conditions such as treatment with tunicamycin and were processed in tandem 
with the spinal cord tissue. The samples were taken out of the freezer and placed on ice to 
thaw slowly. While the samples thawed, primers (Table 2) were also allowed to thaw. As 
the cDNA was not quantified 2µl of each sample was used. The PCR was set up as normal 
gDNA PCRs were (2.3.4.2 Genomic PCR). The PCR conditions were similar to gDNA 
PCR conditions (Table 1).  
4µl from each PCR was run out on a 2% agarose gel to confirm PCR was successful along 
side cyclophilin.  The PCR products for Xbp1 were cleaned up using the Qiagen PCR clean 
up kit (Qiagen, Crawley, UK) following the manufacturer’s instructions. The Xbp1 PCR 
products could be digested with Pst1, which cuts only the unspliced cDNA. The spliced 
product is a result of ER stress. A varying volume for each test PCR was selected 
dependant on cyclophilin levels and put into a fresh tube. Into these a digestion mix (1.5µl 
enzyme, 3µl 10x buffer and ddH2O up to 30µl) was added and all were placed into a 37ºC 
waterbath for 2 hours. The digestion was put on ice to stop the reaction then 15µl digest 
and 5µl orange G loading dye were placed in a fresh tube. The products were resolved on a 
2% agarose gel containing ethidium bromide for visualisation. Finally the captured images 
were quantified using Scion Image for Windows software (Scion Corporation, Maryland, 
USA). The intensity of the signal was corrected for the relative density of cyclophilin.   
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2.4.6 Northern blotting 
Hayes et al., (1989) reviewed the general principles of Southern, northern and western 
blotting. 
2.4.6.1 Sample preparation 
RNAs were removed from -80°C on dry ice and put at 60°C until thawed. RNA requires a 
rapid thaw to avoid degradation and thawing at 60°C ensures there is minimal degradation 
of the samples. 20μg each RNA was aliquoted into RNAse-free tubes on ice. The tubes 
were placed on dry ice and the original samples were returned to the -80°C freezer. The 
20μg samples were put in dry ice to freeze. As sample concentration varied thus leading to 
varying sample volumes, each was reduced to a final volume of approximately 5μl by a 
sequential process of freezing and evaporation under vacuum.  Once frozen their volumes 
were reduced to 5μl using a vacuum pump. Once the pump was stopped if the volumes 
were not down to 5μl then the samples were placed in dry ice again. This process 
continued until all samples were reduced to 5μl. The RNAs were then resuspended in 20μl 
RNA loading buffer (appendix) on ice in a fume hood. 20μl RNA loading buffer was also 
added to two aliquots of 5μl RNA ladders (Gibco, Paisley, UK). Both the samples and 
RNA ladders were heated at 65°C for 15 minutes to denature the RNA secondary structure 
and placed on ice. Prior to loading onto the gel 5μl RNA loading dye (appendix) was 
added to each sample including ladders. 
2.4.6.2 Denaturing agarose gel for northern blotting  
A 1% denaturing agarose was prepared to run out RNA for northern blotting. 2g agarose 
was weighed out, added to 147ml ddH2O and melted in a microwave oven. The agarose 
was put into a water bath at 60°C to cool. 20ml 10x MOPS (appendix) was dispensed and 
also placed into the 60°C water bath. This was to allow easier mixing of MOPS with 
agarose. 33ml 37% formaldehyde was aliquoted into a 50ml tube in a fume hood and 
placed in a 37°C water bath. 
The gel caster apparatus was set up in a fume hood ensuring it was level. Aliquoted 10x 
MOPS and formaldehyde were mixed in with the agarose in a fume hood making a final 
volume of 200ml. This was then poured into the gel caster and left to set. After 30 minutes 
the gel caster apparatus was dismantled and the gel was placed into a tank containing 2 
litres 1x MOPS. 
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2.4.6.3 Running of gel 
The samples were loaded onto the gel and the gel was electrophoresed at 100 volts for 10 
minutes without buffer circulation. This allowed the samples to run into the gel. The power 
was turned off and 1μl normal BPB/XC glycerol loading dye (appendix) was loaded into 
the empty wells. The power was turned on again as was buffer circulation using a 
peristaltic pump. The gel electrophoresed until the dye front was 2/3rd down the gel. 
2.4.6.4 Staining of gel and ladders 
At the end of the run the buffer was discarded down the fume hood sink. The gel was 
trimmed and stained for 10 minutes in ddH2O containing a few drops of 3mg/ml Ethidium 
bromide. The gel was washed twice in ddH2O the once in 10x SSC (appendix). It was 
photographed with an UV ruler (Figure 13). The ladders were cut off and left in ddH2O 
overnight to destain some more. The ladders were also photographed using an UV ruler.  
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Figure 13. 12.5µg total mRNA separated on a denaturing agarose gel. 
A) P20 Plp1 null x #66 northern gel, WT wild type, Null Plp1 null and Null/#66 Plp1 null 
x #66, M RNA molecular ladder. B) Destained photograph of RNA ladder with sizes of 
bands in Kb. 
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2.4.6.5 Northern transfer and Cross-linking blot 
The RNA was transferred from the agarose gel to nitrocellulose membrane by upwards 
capillary action. This was based on the transfer technique for DNA used in Southern 
blotting devised by Dr E. Southern (Southern, 1975) (Figure 14). 
Three large pieces of 3MM Whatman paper were cut. Three smaller pieces of 3MM 
whatman paper measured to the size of the gel as well as one piece of Hybond N 
membrane (Amersham) were cut. Paper towels and a heavy weight were also obtained. 
The three large pieces of paper were wetted in 10x SSC and placed over a glass sheet 
placed in the centre of a tray. All air bubbles were rolled out using a clean pipette. The gel 
was placed in the centre of the paper, well side up and dry membrane placed very carefully 
on to it ensuring there were no air bubbles. The three smaller pieces of whatman paper 
were wetted in 10x SSC and placed on top of the membrane. Paper towels were placed 
over these ensuring that they were not touching around the side of the gel. A heavy weight 
was placed on the very top. 500ml 10x SSC was added to the tray and the transfer was left 
over night.  
After 16-18 hours the blotting apparatus was dismantled, the gel was discarded safely and 
the blot UV cross-linked at optimum energy, dried and stored until required. 
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Lablled RNA of known sizes 
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Separated RNA species blotted onto 
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Figure 14. Northern blotting (very similar to Southern blotting method described by 
Southern). 
A) The total RNA is separated according to length by electrophoresis. B) A sheet of either 
nitrocellulose paper or nylon paper is laid over the gel, and the separated RNA is 
transferred to the sheet by blotting. The gel is supported on a layer of sponge in a bath of 
alkali solution, and the buffer is sucked through the gel and the nitrocellulose paper by 
paper towels stacked on top of the nitrocellulose. As the buffer is sucked through, it 
denatures the RNA and transfers the single-stranded fragments from the gel to the surface 
of the nitrocellulose sheet, where they adhere firmly. This transfer is necessary to keep the 
RNA firmly in place while the hybridization procedure is carried out. C) The nitrocellulose 
sheet is carefully peeled off the gel and RNA UV-crossed link to membrane. 
Figure modified from Essential Cell Biology, Second Edition.  
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2.4.6.6 Preparation of cDNA probe 
A specific probe complementary to the target mRNA species was generated by PCR. A 
PCR was set up using 2μl cDNA of wild type origin with primers from exons of gene of 
interest (Table 2), ddH2O and beads (2.3.4.2 Genomic PCR). In all respects including 
programme this PCR was identical to gDNA PCR only the product contained no introns. 
Specific probes for β-actin as a control and Mbp and Plp1 as test probes were produced.  
The generation of a PCR product of the appropriate size was confirmed by running a small 
aliquot on an agarose gel (Figure 15). The rest of the PCR product was cleaned up 
following manufacturer’s protocol using a PCR clean-up kit (Qiagen). The final volume of 
EB solution added was 30μl to give a more concentrated cDNA probe product. 
2.4.6.7 Incorporation of isotope  
Before hybridisation of the probe to the northern blot, a radiolabelled probe is required. All 
appropriate precautions were taken when handling and working with radio-iostopes.  
32P αCTP was removed from -20°C and thawed on bench behind a screen. A 50μl labelling 
reaction contained the following: [20ng cDNA previously boiled for 5 minutes, 20μl 
RadPrime buffer (Invitrogen), 1μl NTPs except CTP, 2.5μl 32P αCTP (Amersham), 1μl 
Kleonow enzyme and ddH2O to volume]. The mixture was incubated for 15 minutes at 
37°C.  
A NICK column (Amersham) was prepared by washing it through with TE (appendix). 
The reaction was stopped by placing on ice and all 50μl was added to the centre of the 
column. 350μl TE was added and allowed to run through column allowing any 
unincorporated isotope to be removed and discarded. A further 400μl TE was added and 
collected in a screw top tube as the final probe. The cleaned probe was put into a lead 
container and stored at -20°C until use. All waste was disposed off either in a waste bin or 
down the sink. Blots were hybridised with probes 0.5x106 to 1x106 cpm/ml specific 
activity with amounts determined by liquid scintillation counting. 
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Figure 15. cDNA probes for northern hybridisation. 
A) Plp/Dm20 cDNA probes, the strongest probe in Lane 4 was used for northern 
hybridisation. B) β-actin cDNA probes, where again the probe with the strongest signal in 
Lane 2 was used for northern hybridisation.  
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2.4.6.8 Pre-hybridisation, hybridisation and washes 
10ml RapidHyb solution (Amersham) was aliquoted into a 20ml universal and placed into 
a hybridisation oven (Hybaid) set at 65°C. Meanwhile the blot was wetted in 2x SSC 
(appendix), rolled up and put in a hybaid bottle ensuring RNA side faced in and there were 
no air bubbles. 
100μl Salmon sperm was boiled for 5 minutes, put in ice and then added to RapidHyb 
solution. This was poured into the hybaid bottle containing the blot and bottle put into the 
oven. The bottle was rotated for 30minutes and this was the pre-hybridisation step. The 
probe was also boiled for 5 minutes and left on ice. The probe was added to the solution at 
bottom of bottle behind a screen ensuring the probe did not touch the blot at any point. 
After at least 2 hours the hybridisation solution was poured down the sink. The blot was 
rinsed quickly in the bottle with 2x SSC then high stringency wash buffer (0.1x SSC, 0.5% 
SDS) which had been heated in a 60°C waterbath was added. The temperature on the oven 
was turned down to 60°C and blot washed by rotation three times for 20 minutes each. 
After the third wash the blot was removed from the bottle and sealed in a plastic bag. The 
blot was then taped into a cassette and exposed to x-ray film overnight at -70°C. The film 
was developed and exposures of various durations obtained. The blot could be reprobed 
with a second cDNA probe for a control mRNA species such as β-actin after the initial 
signal had decayed usually after 3-4 weeks.   
2.4.7 qRT-PCR 
PCR is a popular method to amplify specific nucleic acid sequences. Reverse transcription 
polymerase chain reaction (RT-PCR) is an in vitro method of emzymatically amplifying 
defined regions of RNA allowing quantification of transcript produced by a certain gene. 
Conventional RT-PCR is an end-point quantification of transcript amounts and therefore 
not accurate with low resolution, low sensitivity and the results are not expressed as a 
number. A more accurate measurement would be of transcript amounts in each cycle of the 
PCR and fluorescence based qRT-PCR utilising TaqMan technology is one way to achieve 
this (Figure 16). Bustin (2000) and Lie et al., (1998) both reviewed the principles of the 
method, instrumentation available and possible applications of real-time RT-PCR.  
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Figure 16. TaqMan technology.  
Two fluorescent dyes, a reporter (green circle) and a quencher (black circle), are attached 
to the 5' and 3' ends of a TaqMan probe which anneals to a central region in the target 
sequence, when both dyes are attached to the probe, reporter dye emission is quenched, 
and during each extension cycle, the Taq DNA polymerase cleaves the reporter dye from 
the probe, once separated from the quencher, the reporter dye emits its characteristic 
fluorescence. 
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Both one- and two-step real-time RT-PCRs are possible. In two-step RT-PCR the total 
RNA is first used to produce cDNA by reverse transcription then the qRT-PCR step using 
fluorescence is carried out. This process is time consuming and also limited by sample 
handling numbers by the operator. Also required are two kits, one to complete the RT step 
and one for the PCR step. The one-step qRT-PCR requires one kit to carry out both the RT 
and PCR steps in the one tube. This kit can be expensive but the time saved counteracts 
this. The one-step RT-PCR was utilised in this study due to the number of samples. 
However, choice of real-time RT-PCR method is only one of the decisions required and 
Bustin (2002) reviewed practical issues and problems with this technique.  
2.4.7.1 Sample/tissue collection (see section 2.4.1) 
2.4.7.2 RNA Preparation (see section 2.4.2) 
2.4.7.3 RNA Quantification and Quality Check (see section 2.4.3) 
2.4.7.4 
2.4.7.5 
qRT-PCR primers and probes 
The Primer Express program (Applied Biosciences) was used to design possible primer 
and probe sets from the relevant mRNA sequences following guidelines laid out by Dorak. 
The primer/probes sets were selected using the program’s recommendations and taking any 
limits into consideration.  The accession numbers for the mRNA sequences and selected 
primer/probe sets are shown in Table 2. Primer and Taqman probes for Plp1 and Mbp were 
to amplify transcripts for all the isoforms produced by the genes and were labelled Plpall 
and Mbpall respectively. Primers and TaqMan probes were purchased from MGI with a 
blackhole quencher on the 3’ end and a 6-Fam reporter on the 5’ end of the TaqMan probe. 
These were stored in the dark at -20°C until required. 
qRT-PCR on ABI 7500 
The ABI 7500, a Personal Computer (PC) based real-time PCR machine was utilised for 
this study. The threshold, baseline setting and internal ROX dye (from kit) as a reference 
remained the same for all reactions with all primer and probe sets. These were set from the 
standard curves produced for each primer and probe set. 
2.4.7.5.1 Primer and probe reconstitution 
Both the primers and probes were reconstituted to a stock concentration of 100µM with 
DEPC treated water. Once reconstituted, the primers and probes were diluted to 10µM 
working stocks with DEPC treated water. 100µl and 50µl aliquots of the probes were 
made, the tubes wrapped in foil, placed in a light resistant bag and stored at -20°C. MGI 
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recommend no more than two freeze thaws for the probes as it reduces the fluorescence 
emitted during real-time PCR.  
2.4.7.5.2 Primer and Taqman Probe Optimisation 
A 96 well plate was set up with various combinations of forward and reverse primers and a 
set concentration of probe (100nM) to optimise the PCR reaction (Table 3). 50ng wild type 
RNA per reaction was utilised as the template for all optimisation reactions. As this was a 
one-step RT-PCR the SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen) was 
used to perform the experiment on the ABI 7500. The basic PCR program was 50°C for 2 
mins; 95°C for 10 mins; 40 cycles of 95°C for 15 secs, 60°C for 60 secs. The total run was 
2 hour however, the initial 50°C was extended to 30 mins to reverse transcribe the cDNA 
from the RNA template. In order to ensure the entire product was amplified the 60°C for 
60 sec step was altered to best match/fit the melting temperatures for all three primer and 
probe sets and also extended to 2 mins.  
The primer pair that gave the highest deltaRn and the lowest Ct (cycle at which threshold is 
crossed) was chosen for each primer set (800nM/800nM) (Figure 17). The same process of 
optimisation was carried out for the probe with varying concentration of the probe used 
with the most efficient primer concentrations. 
 
2.4.7.5.3 Test plate set-up 
96 well plates (ABgene) were used to set the real-time RT-PCR experiments. A standard 
curve was generated using serial dilutions of an abundant wild type RNA sample (Figure 
18). Dilutions of 1000ng, 100ng, 10ng, 1ng, 0.1ng and 0.01ng were used with β-actin 
primers and probe initially, then the other primer/probe sets. Each sample was loaded in 
the duplicate for the standard curve    
The ideal assay will have a slope of -3.3 with a R2 of 0.99999 (as close to 1 as possible). 
The standard curves were optimised using the PCR conditions, threshold and baseline 
settings until as close to the ideal as possible. Once the conditions to achieve a good 
standard curve were obtained they were applied to the plates with test samples. 
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 Forward primer 
Reverse primer 800 nM 400 nM 200 nM 50 nM 
800 nM 800/800 400/800 200/800 50/800 
400 nM 800/400 400/400 200/400 50/400 
200 nM 800/200 400/200 200/200 50/200 
50 nM 800/50 400/50 200/50 50/50 
Table 3. Optimisation of the forward and reverse primers for real-time RT-PCR 
 
  
Figure 17. An example of the typical output from the ABI 7500 showing the increase 
in signal at each cycle.  
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Figure 18. Standard curve produced from serial dilutions of wild type RNA and β-
actin primers and probe set.    
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2.4.7.5.4 Set up of reaction plate 
Each plate was set up to include all the wild type, hemizygous and homozygous samples 
available for that experiment with all three primer/probe sets if possible to reduce 
variability between the reactions. This also ensured the threshold and baseline settings 
were the same for the reactions.  
2.4.7.5.5 Analysis of results 
The standard curve produced is then used as a reference standard for extrapolating 
quantitative information for mRNA targets of unknown concentrations. The use of 
absolutely quantitated RNA standards helps generate absolute copy number data. The 
variation introduced due to variable RNA inputs, can be corrected by normalisation to a 
housekeeping gene. The other method of analysis, the comparative Ct method was not 
utilised in this study.  
The Ct values from each sample were then used for the analysis. The calculation is as 
follows (Ct-intercept)/y or slope value then In LOG. This is the un-normalised amount in 
ng of message in initial 50ng total RNA sample. The average of the duplicated or 
triplicated values are then normalised to β-actin values (ng Test/ng β-actin) to give the 
final normalised message amount in initial 50ng total RNA used. 
2.5 Protein Analysis 
2.5.1 Tissue/Sample Collection 
Mice were killed by CO2 asphyxiation; tissues rapidly removed and snap frozen in liquid 
nitrogen in labelled freezer tubes. The tissue was stored at -80°C until required. 
2.5.2 Isolation of Myelin proteins  
This technique was used to extract myelin from CNS tissue and is based on the method of   
Norton and Poduslo (1973). The principle is based on centrifugal enhanced flotation of the 
myelin fraction due to the highly buoyant nature of lipids. By-products of the technique 
include the pellet fraction containing the membranous and nuclear components of the 
spinal cord and brain homogenate and supernatant fraction is enriched in cytoplasmic 
components. 
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2.5.2.1 
2.5.2.2 
Myelin preparation 
Firstly the cord was thawed in 7.5ml high sucrose buffer (0.85M sucrose, 10mM Hepes, 
2mM Dithiothreitol (DTT) and 1mM Nα-p-tosyl-l-lysine chloro-methyl ketone (TLCK)) 
and homogenised using an ultra turrax polytron homogeniser at high speed for 12-15 
strokes. 500μl of this total homogenate were removed and frozen. For tissue dissected from 
P3 mice only the total homogenate was produced. For older (P20 and P60) mice the 
reminder of the total homogenate was transferred to a Beckman centrifuge tube and 
overlain slowly with 3ml of buffer (0.25M sucrose, 10mM Hepes (pH7.4), 3mM DTT) and 
centrifuged at 70,000g for 90 minutes at 4ºC using SW41 rotor on a Beckman 
ultracentrifuge. This produced a biphasic solution with cellular debris left in the lower 
phase (0.85M sucrose) and myelin protein trapped at the interface between the 
0.25M/0.85M phases. The myelin haze between the two phases, the supernatant from 
lower phase and the pellet were removed and also kept. When CNS tissue is homogenised 
myelin spontaneously forms micelles. Trapped within the micelles are also cytoplasmic 
components. Hypotonic shock bursts open micelles and helps wash away contaminants. 
6ml of ddH2O was added to the myelin sample and this was centrifuged at 23,000g for 30 
minutes to sediment the protein. The supernatant was discarded and the process was 
repeated another two times with the final centrifugation at 17,000g to ensure that only 
proteins were sedimented. The protein pellet was resuspended in 100μl of ddH2O.  
Lipid Raft Preparation 
PLP and DM20 are known to associate in CHAPS insoluble lipid rafts. Lipid rafts can be 
isolated from the myelin fraction by density gradient centrifugation as different lipids float 
differently (Simons et al., 2000). Myelin can further be fractionated into lipid rafts using a 
method modified from Simons and colleagues (2000).   
250µg myelin from wild type and homozygous brain were utilised to prepare the lipid 
rafts. 250µg myelin was added to 60µl 5xTE (appendix) (final concentration 1xTE), 30µl 
CHAPS (20mM) and added ddH2O to make a final volume of 300µl. Each sample 
incubated with rotation at 4°C for 30 mins. For the density gradient centrifugation, a 
discontinuous gradient was prepared. After rotation, 300µl sample was added to 600µl 
Optiprep (60%) to make a 40% solution. This was overlaid with 1.2ml 30% Optiprep 
(600µl 5xTE, 900µl ddH2O and 1.5ml Optiprep, 3ml total volume) and finally 500µl 
extraction buffer. The samples were centrifuged for 2hrs at 40,000rpm in a SW50.1 rotor 
(Beckman). Six fractions of 430µl were collected and labelled 1-6. Fraction 1 was the 
 2-93
Saadia Ansari Karim 2007    
lightest (at top) and fraction 6 the heaviest (at bottom). After quantification the samples 
were treated as normal to prepare a western blot or phosphorimage if radiolabelled samples 
used.   
2.5.2.3 Protein 
2.5.3.1 
2.5.3.2 
Assay 
Total protein concentrations were quantified in order to ensure equal loading of samples on 
subsequent SDS-Page gels. 
The assay was performed using the Pierce protein BCA assay system (Perbio) based on the 
Lowry Method using bicinchoninic acid (BCA) as the reagent. The reaction was initiated 
by the addition of the reagent and incubated at 37ºC for 30 minutes. 2mg/ml BSA 
standards (Perbio) were diluted (0.025, 0.05, 0.1, 0.2, 0.4, 0.6mg/ml) and prepared at 10X 
the concentration of the samples which were routinely 5µl of sample/1ml of reaction 
reagent. Measurement of the absorbance of the final product was performed on a 
spectrophotometer (Cecil 1100) set to a wavelength of 562nM.  A standard curve was 
generated and the sample concentrations calculated from this. 
2.5.3 Western Blotting 
The transfer of size separated proteins onto a membrane was described by Burnette (1981). 
Sample preparation 
Aliquots of the protein samples (1-2.5μg of myelin extracts and 10-15μg of total 
homogenate extracts dependant on protein investigated) were made up to a volume of 24μl 
in 3x Sample buffer (62.5mM Tris (pH6.8), 40mM DTT, 5% 2-mercaptoethanol, 0.002% 
bromophenol blue, 2% SDS, 10% glycerol) and denatured by placing in water heated to 
90°C for 5 minutes. The process linearises the protein with the addition of SDS to give an 
unique negative charge and permit migration towards the anode. Separation is based in 
size. The samples were loaded onto the gel with size markers as controls for transfer 
efficiency. 
SDS PAGE (sodium dodecyl (lauryl) sulphate polyacrylamide 
gel electrophoresis)  
At the onset of the project hand-poured gels from stock solutions were utilised (Table 4). 
However precast gels were employed later for safety, convenience and economy of time. 
Precast gels employed were NuPage 4-12% 10 or 12 well (Invitrogen) with MES Page 
buffer (Invitrogen). Both types of gels were run with identical samples to investigate the 
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efficiency, speed and resolution of each with both types to buffer and showed no 
difference.  
2.5.3.3 Protein electrophoresis 
Hand-poured gels were electrophoresed in SDS-PAGE running buffer (appendix). Pre-cast 
gels were electrophoresed in a discontinuous buffer system using 1x MES buffer 
(Invitrogen). The samples were electrophoresed for 1 hour at 100volts to resolve the 
proteins. Towards the end of this project the hand-poured gels were replaced with precast 
gels. The resolution and sensitivity of the western blots were not significantly different. 
2.5.3.4 Electrophoretic protein transfer 
The gel was removed from the plates, wells were cut off and the gel was placed in cathode 
buffer. The proteins were transferred to PVDF membrane (Millipore) using a semi dry 
blotter and a buffering system based on the Towbin method which enabled the transfer 
(appendix). The transfer was carried out at 225mA for 1 hour. To confirm the transfer was 
successful the blot was stained briefly with Ponceau S (0.1% Ponceus S w/v, 5% Acetic 
acid v/v), a water soluble stain which highlighted the separated proteins and allowed a 
visible inspection of loading. 
2.5.3.5 Immunostaining 
The membrane was blocked for 2 hours at room temperature or overnight at 4° C by 
soaking in blocking buffer containing 5% dried milk in 0.1% TritonX-100 in TBS (pH 7.4) 
to ensure no non-specific proteins were picked up by the antibodies. Blocking buffer was 
removed and antibody in freshly 5% dried milk in 0.1% TritonX-100 in TBS (1x T-TBS) 
(pH 7.4) was added for at least 2 hours or overnight at 4° C (Table 5). The membrane was 
washed repeatedly in T-TBS (pH 7.4) for 3 x 10 minutes and the appropriate secondary 
antibody conjugated to horse radish peroxidase (HRP) was applied at 1:10,000 in 5% dried 
milk in T-TBS (pH 7.4) for 60 minutes. The membrane was washed again in T-TBS (pH 
7.4). The membrane was incubated in equal volumes of luminol enhancer solution and 
stable peroxide solution (both from Amersham) for five minutes at room temperature, 
dried slightly and wrapped in Saran wrap. X-omat imaging film (Agfa) was exposed to the 
membrane for a range of exposures to give optimal signals. The film was developed in an 
automatic processor (Dupont Cronex CX-130). 
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 12.5% 14% Stacker (4%) 
Acrylamide 8.3ml 9.7ml 880μl 
1.5M Tris pH8.8 (Resolver) 
0.5M Tris pH6.8 (Stacker) 
5.0ml 
 
 
5.0ml   
1.64ml 
10% SDS 200μl 200μl 30μl 
10% Ammonium Persulphate 150μl 
 
150μl 75μl 
 
MilliQ H20 6.4ml 5.0ml 4.0ml 
 
Temed 10μl 10μl 9μl 
 
Table 4. Volumes for hand-poured SDS-PAGE gels. 
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Primary 
antibody 
Host Dilution Target Source 
226 Rabbit 
Polyclonal 
1:20,000 Myelin, mature 
oligodendrocytes 
NP Groome 
 
AA3 Rat Monoclonal 1:5,000 Myelin, mature 
oligodendrocytes 
S Pfeiffer  
 
ASPA Rabbit 
Polyclonal  
1:1,000 Oligodendrocyte 
marker 
J Garbern  
 
β-actin Mouse 
Monoclonal 
1:1000 Actin Sigma  
 
CNP 
 
Mouse 
Monoclonal 
1:500 Myelin, mature 
oligodendrocytes 
Chemicon 
GFAP Monoclonal, 
Polyclonal  
1:250,000 
 
 
Astrocyte marker Dako 
MAG Monoclonal, 
Polyclonal 
1:10,000 Myelin, mature 
oligodendrocytes 
Chemicon,  
 
 
 
NP Groome 
RH Quarles 
MBP Mouse 
monoclonal 
Rabbit 
polyclonal 
 
 
 1:5,000 Myelin, mature 
oligodendrocytes 
NP Groome 
  
Chemicon 
BiP Rabbit 
polyclonal 
1:5,000 
 
 
 ER Stress 
response  
Stressgen 
Anti-Rabbit 
2° 
 1:10,000 
 
  
 
 
 
 
 
New 
England 
Biolabs 
Anti-Mouse 
2° 
 1:10,000  
 
New 
England 
Biolabs 
Anti-Rat 2°  1:10,000  New 
England 
Biolabs 
 
Table 5. Primary and Secondary Antibodies used for western blotting. 
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2.5.4 Oligodendrocytes Cultures 
2.5.4.1 Primary cell culture 
Oligodendrocytes were prepared from the spinal cord of postnatal 5 day animals. The 
animals were euthanased in a halothane chamber and decapitated to ensure exsanguination. 
The tail was removed and frozen and part of the brain stem and spinal cord was placed in 
bottle containing Karnovsky’s modified fixative for aid genotyping (Montague et al., 
1998). 
Using sterile technique and with the aid of a dissecting microscope the spinal columns 
were removed and the cord dissected out into Hanks balanced salt solution (HBSS) 
(Invitrogen). The meninges were stripped from the cord and the cord masticated with a 
sterile scalpel. The connective tissue of the cord was digested by the addition of 2ml 0.25% 
trypsin and 200µl 1% collagenase and incubation at 37ºC for 1hour. The digestion was 
quenched by the addition of 1ml stop solution (appendix, Fanarraga et al., 1995). The cord 
was then triturated through 23g needle (three times) and 26g needle (three times) before 
the addition of 10ml Dulbeccos modified eagle medium (DMEM) (Invitrogen) containing 
10% Foetal bovine serum (FBS) (Invitrogen) and centrifugation at 800rpm for 5minutes. 
The supernatant was removed and the pellet resuspended in 1ml DMEM containing 
10%FBS. The cell density was determined and plated out in 2x35mm poly-L-Lysine 
coated dishes at an approximate density of ~250,000 cells/dish. The cells allowed to settle 
down onto the plate for 2 hours at 37ºC 5%CO2 before the addition of 1.5ml Sato 
conditioned medium (appendix, Fanarraga et al., 1995). The cells were grown in culture 
for at least six days with medium change every second/third day. At harvest the cultures 
comprised 70-80% O4 positive cells along with astrocytes, occasional neurons and other 
cells (McLaughlin et al., 2006). 
2.5.4.2 Charaterisation by Immunostaining 
Paraffin and resin (Trapp et al., 1981) sections were stained for PLP/DM20 and MBP 
using either the PAP or the ABC techniques. Immunostaining for caspase-3 and the CC-1 
antigen was carried out on cryosections from animals perfusion fixed with 4% 
paraformaldehyde. Sections were washed in PBS for 20 min followed by 0.5% Triton X-
100/PBS 30 min at room temperature, and blocked in 0.1% Triton X-100, 0.2% pigskin 
gelatin in PBS for 30 min at room temperature. Primary antibodies were applied overnight 
at 4°C and the secondary fluorescent conjugates for 30 min at room temperature, in the 
blocking buffer. 
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Cryosections were fixed in 4% paraformaldehyde for 20 min at room temperature and 
treated with 50% HCl/1% Triton X-100 for 10 min at room temperature. Sections were 
permeabilised with methanol for 10 min at -20°C, before primary antibodies were applied 
overnight at 4°C. Sections stained for CC-1 antigen were labelled with 4, 6-diamidino-2-
phenylindole (DAPI) 2.2 µg/ml in ddH2O for 1 min at room temperature. To determine the 
nature of the apoptotic cells, sections stained for caspase-3 were double labeled with 
various cellular markers. All cryosections were mounted in Citifluor antifade medium. 
2.5.4.2.1 Immunostaining of coverslips 
For immunochemistry cells were plated out onto coverslips at ~20,000 cells in a volume of 
140μl /coverslip. The cultures were incubated for 7days at 37ºC 5%CO2 with the media 
being changed every two days before harvesting. Although the cultures were a mixed 
population of cells including neurons and astrocytes the conditioned growth medium 
employed favoured oligodendrocyte proliferation. All immunostaining was carried out 
under aseptic conditions. O10 antibody is used to label PLP on live cells when it reaches 
the surface of the cell in a certain conformation (Sommer et al., 1982). The existing media 
was drained from each coverslip and 100µl O10 antibody (diluted 1:6 in SATO media) 
was added. The coverslips were left to incubate for 1 hour at RT then washed 5-6 times in 
media. Secondary antibody mouse IgM texas red was added at 1:50 dilution in media and 
incubated for 30 mins at RT. The secondary antibody was washed off with 1x PBS and 
150-200µl 4% paraformaldehyde was added for 15 mins thus fixing the cells. Once again 
the coverslips were washed with 1xPBS and ice cold 20% methanol was added for 10 mins 
to permeablise the cells. The coverslips were then washed well with 1xPBS 5-6 times one 
coverslip at a time to avoid drying out.  
Double staining was carried out to label surface and internal PLP/DM20 within the 
cultured cells. 100µl AA3 antibody diluted 1:10 in 1% Normal Goat Serum was added and 
coverslips kept at 4° over night. 18-20 hours later the coverslips were washed 5-6 times in 
1xPBS. Secondary antibody rat FITC diluted 1:50 in PBS was added for 30 mins. The 
coverslips were again with 1xPBS and DAPI was added at 1:1200 in PBS for 1 min before 
mounting face down onto slides with a drop of citifluor. The coverslips were sealed with 
clear nail varnish ready to view with fluorescence microscope. 
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2.5.4.3 Harvesting for Biochemistry 
The 35mm dishes were removed from the incubator and placed on the bench. All media 
was removed using either a tip or pipette and put into a beaker for waste. The dishes were 
then rinsed with 1ml chilled PBS twice. At this stage the second and final rinse with PBS 
was removed and either the dishes were snap frozen in liquid nitrogen or 75µl lysis buffer 
(appendix) was added on ice. 
 If the dishes were frozen then they were stored in -80ºC until needed. If lysis buffer was 
added, cells were scraped using a cell scraper and buffer transferred to 1.5ml tube. The 
samples were then rotated for 30 minutes at 4ºC to achieve complete cell lysis. Following a 
5000g spin for 5 minutes at 4ºC the supernatant was transferred to a fresh tube and stored 
at -20ºC. 
2.5.4.4 Radiolabelling for dynamic investigation 
For investigating protein turnover dynamics [35S]-Pro-Mix (cysteine/methionine) 
(Amersham) was added to the serum free HBSS. The hot amino acids were incorporated 
into all newly synthesised proteins over time and the rate of nascent protein formation 
could then be measured using a phosphorimage cassette which generates an 
autoradiographic image. 
The initial few steps were the same regardless of type of dynamic study. The media was 
removed and 1.5ml of fresh warmed Sato media was added to the cultures which were 
incubated for 2 hours at 37ºC 5%CO2. 50ml HBSS was prepared and put into the 37°C 
waterbath. After 2 hours the SATO media was removed and each dish was washed with 
1ml HBSS. 1ml HBSS was then added and cultures incubated for 30 minutes at 37ºC 
5%CO2. This starved the cells allowing for a more efficient uptake of isotope when it was 
added. For each spinal cord used for culture 2 dishes were plated and for each cord 100µCi 
(3.7MBq) of [35S]-Pro-Mix was added to 1ml of HBSS. At this stage the steps differ 
depending on type of study (see below). Due to mixed litters from 
hemizygous/hemizygous crosses and the necessity for genotyping only two time points 
were achievable from individual animals in any of the primary cultures studies.  
2.5.4.4.1 Synthesis 
To investigate synthesis two time points for incubation with isotope were selected, 45 
minutes for one dish and 90 minutes for the second dish. This would enable the study of 
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levels of newly synthesised protein over a doubling in time. After 30 minutes the HBSS 
was removed and 500µl HBSS containing [35S]-Pro-Mix was added to each dish. The 
cultures were incubated for 45 minutes or 90 minutes at 37ºC 5%CO2. After the first time 
point one dish was washed quickly with HBSS then three times with ice cold PBS and snap 
frozen. The second dish was washed with HBSS and as with the first dish washed with ice 
cold PBS three times and snap frozen.  
2.5.4.4.2  Degradation of proteins using Pulse/Chase experiments 
Degradation was determined by the pulse chase technique. This involves radiolabelling 
proteins during a short pulse period and monitoring their fate “chase” by saturating the 
cells with cold amino acids. To investigate decay of proteins, cells were labelled for 60 
minutes, the pulse phase and chased by replacing the HBSS with Sato medium 
supplemented with 2.5mM cysteine/2.5mM methionine for 24 hours.  
After 30 minutes the HBS was removed and 500µl HBSS containing [35S]-Pro-Mix was 
added to each dish. After 1 hour the HBS was removed then each dish was washed once 
with HBSS. One dish labelled 0 hours (T0) was washed with chilled PBS and snap frozen. 
The second dish labelled 24 hours was chased by adding Sato medium supplemented with 
2.5mM cysteine/2.5mM methionine. After 24 hours incubation at 37ºC 5%CO2 the second 
dish was washed with PBS as before and snap frozen. 
2.5.4.4.3  Blocking of Degradation  
The nature of the biochemical pathway involved in protein decay can be determined by 
including specific inhibitors during the chase phase of the experiment. The cultures were 
treated as before and put through the pulse phase of the experiment. To show that the 
chosen compound had an effect initially both dishes were put through the chase, one with 
media containing the compound and the other either ddH2O or solvent the compound was 
made up in. 
As before on day 6 the cells had fresh SATO added then HBS. After 30 minutes the HBS 
was removed and 500µl HBSS containing [35S]-Pro-Mix was added to each dish. After 1 
hour the HBSS was removed and each dish washed once with HBSS. The two dishes were 
chased by adding Sato medium supplemented with 2.5mM cysteine/2.5mM methionine. 
The Sato for one dish labelled 24 hours + also contained 50μM MG132 and the other 
labelled 24 hours - contained an equal volume DMSO as MG132 was dissolved in this. 
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Both dishes were incubated for 24 hours at 37ºC 5%CO2 after which they were washed 
with chilled PBS and snap frozen. 
Once it was confirmed the compound in this case MG132 was having an effect on rate of 
degradation then pulse/chase experiments were set up. One dish was snap frozen directly 
after the pulse phase and labelled 0 hour. The second dish labelled 24 hours + was put 
through the chase phase with Sato medium supplemented with 2.5mM cysteine/2.5mM 
methionine and 50µm MG132.  
All these cultures were lysed in the same way as previously described (2.5.4.3 Harvesting 
for Biochemistry) 
2.5.5 Synthesis at P20 
In order to investigate PLP dynamics in a system containing an oligodendrocyte, myelin 
and axon unit, a brain slice system was employed. This investigation involved generating 
the 300µm thick slices of brain and maintaining them in a metabolically active state   
oxygenated artificial CSF media supplemented with [35S]-Pro-Mix. A proportion of the 
slices were removed over set periods of time and levels of newly synthesised radiolabelled 
protein studied. Prior to the dynamics study a series of experiments were carried 
investigating the stability of the system (Figure 19).  
2.5.5.1 Brain slice 
250ml Kreb’s buffer (pH 7.4) (appendix) was prepared and oxygen (95% O2 5% CO2) was 
bubbled through it for at least 30 minutes. The pH was re-checked and flow of the oxygen 
bubbling was continued. Following rapid removal, the brain was halved through the 
midline and each half immersed in a 2% agarose DMEM solution and allowed to solidify 
on ice. This allowed vibratome sections to be to be prepared and minimised movement and 
distortion of the brain during slicing. 
A P20 male mouse was sacrificed with CO2, the brain was dissected out and placed in 
chilled O2 saturated Kreb’s buffer in a Petri dish. The meninges were striped using fine 
forceps and the brain was cut in half down the midline. Each half was transferred to fresh 
chilled buffer. The agarose was transferred to a beaker in the 37ºC waterbath to cool and 
the foil cups were put on ice then the cooled agarose was poured into the foil cups. Each 
brain hemisphere, held by the cerebellum as straight as possible, was submerged in the 
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agarose. The hemispheres in their individual moulds were carefully orientated so the 
frontal lobes were pointing down. The agarose was left to cool and set. 
The foil cup was removed from around one hemisphere. The agarose cylinder was placed 
on its side and cut through by the cerebellum, this surface acted as a base. The cylinder 
was stood on its base and the excess agarose was trimmed from the top to the base to form 
a pyramid like structure. One half razor blade was wiped and placed onto the vibratome. 
Some superglue was added to the vibratome platform and the tissue block was gently 
pressed onto it. The platform with block was put in place and wound down to start. 
Chilled Kreb’s buffer was gently dropped into blade and block using a glass pasteur 
pipette. The block was trimmed at 600µm until the blade reached the tissue. 300 micron 
thick slices were continuously cut from the tissue; ensuring chilled buffer was added as the 
blade was slicing. The slices were transferred to a petri dish containing chilled Kreb’s 
buffer. Slicing was stopped when the cerebellum was reached. The agarose around each 
slice was removed and the same was done for the 2nd hemisphere of the brain. 
Once both hemispheres were cut and agarose removed, the slices were transferred to a 
flask containing 10ml room temperature O2 saturated buffer. 5ml was removed and a fresh 
5ml added. The slices were incubated for 10 minutes at RT with oxygenation. 5ml was 
again removed and replaced with fresh buffer, the slices were gently agitated and 5ml 
buffer removed, leaving the slices in 5ml buffer. This process diluted any cellular 
components such as proteolytic enzymes that could have been released by ruptured cells.  
Before the actual experiments were carried out a test of the actual slice protocol was 
undertaken. The brains of two wild type animals were used for the test. One half of one 
brain was homogenised without slicing and the other half of the brain was sliced then 
immediately homogenised. One half of the 2nd brain was sliced and treated as a normal 
slice experiment without any isotope in the Kreb’s buffer. The other half was treated the 
same except the addition of MG132 into the buffer. The resulting fractions from the myelin 
preparation were separated on a gradient NuPage gel and the blots stained for MBP 
(Chemicon, Chandlers Ford, UK) (Figure 19)   
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Figure 19. Test brain slice experiment. 
A) MBP signal in 15µg total homogenate. B) MBP signal in 15µg pellet fraction. C) MBP 
signal in 15µg supernatant. D) MBP signal in 1µg myelin fraction (also showing the 
enrichment of MBP from total homogenate to myelin) (UN unsliced brain half, SL sliced 
brain half, SB sliced buffered half and MG sliced half buffered in presence of MG132). 
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2.5.5.2 
2.5.5.3 
Isotope incorporation 
Once the slices were washed and had equilibrated in the buffer the [35S]-Pro-Mix could be 
added to start the experiment. The flask containing slices in 5ml Kreb’s buffer was 
transferred to the 37ºC waterbath with gentle agitation and continual oxygenation. After 10 
minutes [35S]-Pro-Mix (100µCi/ml) was added to start the experiment. Dependant on the 
experiment, the slices were removed at certain time points of incubation.  
For synthesis and incorporation studies the slices were removed at 2, 4 and 6 hours after 
the addition of isotope. The slice experiments were not left for longer than 6 hours as the 
integrity of the slices was comprised as demonstrated by a lactate dehydrogenase (LDH) 
assay which is measured to evaluate the presence of tissue or cell damage (McLaughlin, M. 
personal communication). The slices were washed three times in a 15ml tube with 10ml 
RT Kreb’s buffer. After the final wash as much of the buffer was removed as possible 
using a 1000µl tip and pipette, and snap frozen in tube with liquid nitrogen. The slices 
were stored at -20ºC short term or -80ºC long term. 
Myelin prep (2.5.2.1 Isolation of Myelin proteins) 
2.5.5.4 Protein Assay (2.5.2.1 Protein Assay) 
2.5.5.5 Covalent linking of Antibodies to sepharose beads 
The covalent linking of antibodies to sepharose beads allows the precipitation of the 
relevant protein from a tissue or cellular lysates. pH is important in this experiment as the 
change in pH for one solution to the other allows the proteins to bind to the antibody and 
beads, be washed while bound and then be eluted off. AA3, an anti-PLP antibody was used 
for PLP/DM20 immunoprecipitations (Yamamura et al., 1991).  
Prior to carrying out immunoprecipitation covalently coupled beads with required 
antibodies were needed.  This method allows covalent linking of antibody molecules to 
sepharose beads. The coupled bead then can be utilised to extract a specific protein from a 
sample to which the antibody is targeted. Dependent on the antibody two types of 
sepharose bead are available. Protein A Sepharose beads are better for cross-linking to 
polyclonal and Protein G Sepharose beads for monoclonal antibodies.  
Initially 200μl beads were washed three times in 1ml PBS to remove any alcohol from the 
beads and resuspended in a final volume of 1ml PBS. 10-50μl of antisera was added to 
beads dependent of efficiency of antibody. The sample was then rotated for 1-2 hours at 
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4°C. After rotation the beads were washed three times in 100mM sodium borate pH 9.2 
and resuspended in 900μl sodium borate pH 9.2. 100μl 200mM DMP (dissolved in sodium 
borate pH 9.2) was added and the sample rotated for a further 30 minutes at room 
temperature (RT). This step was repeated (900μl +100μl RT). Once the beads had been 
rotated twice with DMP they were washed three times with 50mM glycine pH 2.5. Then 
the beads were washed further with 50mM Tris pH 8.0 three times and finally resuspended 
in 1ml 50mM Tris pH 8.0 and stored at 4°C until required.  
2.5.5.6 Imunoprecipitation and western blotting 
Using antibody coupled beads immunoprecipitation (IP) was preformed on the 
radiolabelled protein samples. This allowed the extraction and study of specific proteins 
from the mixture of proteins obtained from a myelin preparation. Using sepharose beads 
coupled with AA3 antibody (Yamamura et al., 1991) (2.5.5.5 Covalent linking of 
Antibodies to sepharose beads) immunoprecipitations were preformed on either 
radiolabelled protein extracts from brain slices or oligodenrodcyte cultures. 
Four fractions of proteins were obtained from brain slices; total homogenates, pellet 
(containing membranous organelles), supernatant (containing mainly the cytosolic 
components) and the myelin fraction. Set amounts of protein were used for each IP. For the 
total homogenate, pellet and supernatant fractions 200-400µg protein was utilised. 20 times 
less protein was used from the myelin fraction (10-20µg). This ratio gave a roughly equal 
signal of PLP/DM20 from the total and myelin fractions, highlighting the enrichment of 
PLP/DM20 in myelin. The amounts selected were determined by the yield recovered from 
the homozygous mice which produce the least amount of myelin. 
The appropriate volume of protein for each sample was added to a 1.5ml tube to which 1ml 
lysis buffer (appendix) was also added. The samples were rotated at 4ºC for 30 minutes. 
The tubes were then centrifuged at 5,000 rpm for 5 minutes also at 4ºC. The supernatant 
was transferred to a fresh tube containing 40-50µl AA3 coupled beads. The samples were 
then rotated for at least 4 hours or overnight at 4ºC. During this rotation PLP/DM20 bound 
to the antibody linked to the beads.  
After the rotation the beads were washed three times with chilled wash buffer (1x TBS, 1% 
Triton X 100). On the final wash all the supernatant was removed ensuring no beads were 
lost. 8µl 3x SB with DTT giving a final 1x concentration was added to each tube and the 
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beads were then either stored at -20ºC until use or heated in waterbath at 90ºC for 6 
minutes.  
2.5.5.7 Phosphorimage 
Once heated the samples were separated out on a hand poured SDS-Page gel or a pre-cast 
Nu-Page gel (2.5.3.3 Protein electrophoresis). The proteins were transferred onto PVDF 
membrane as described previously (2.5.3.4 Electrophoretic protein transfer). Once 
transferred the blot was air dried rather than blocked with 5% milk and wrapped in saran 
wrap. The blot was then put down on a Phosphorimage screen (Fugi) for a short exposure 
of a few days and a long exposure of two weeks. The screen was scanned using a STORM 
scanner (Molecular Dynamics). Each image was then analysed using the Image Quant 
programme.
2.5.5.8 Reprobe blot 
Once all exposures were obtained from the blot, it was reprobed with the appropriate 
antibody to ensure loading was equal across the gel. The blot was activated by placing it in 
a dish containing methanol for 1 min. After a quick wash with 1x TBS-T the blot was then 
blocked with 5% milk for 1 hr. The blocking milk was poured off and milk containing 
antibody was added. In most cases the antibody used was 226 in a 1:20,000 dilution. The 
immunostaining process continued as previously described (2.5.3.5 Immunostaining) and 
the exposed films developed to provide images of the blot.  
2.6 Myelin Morphology/Analysis 
2.6.1 Tissue Fixatives and Fixation 
2.6.1.1 Karnovsky’s modified fixative 
(paraformaldehyde/glutaraldehyde 4%/5%) 
Karnovsky’s modified fixative (appendix) was used for the preservation of tissues for resin 
embedding before light and electron microscopy. 
2.6.1.2 4% Paraformaldehyde in PBS 
4% paraformaldehyde in PBS (appendix) was used for the preservation of tissues used for 
immunohistochemsitry and for post fixation of cyropreserved sections.  
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2.6.1.3 Immersion 
2.6.1.4 
2.6.2.1 
 
Brain and spinal cord from mice under 10 days were immersion fixed in Karnovsky’s 
modified fixative prior to indenfication of genotype. 
Cardiac prefusion  
All prefusions were carried out in a fume cupboard. Mice under 10 days were killed in a 
halothane chamber. Mice over 10 days of age were humanely euthanased using an 
overdose of carbon dioxide in a closed chamber. Following death the carcass was weighed 
and the tip of the tail was removed to aid genotyping. Once the carcass was pinned out on a 
cork board, the thoracic cavity was opened and the right atrium of heart nicked. This 
allowed blood and prefusion fluids to escape. Prefusion was carried out by instilling 
solutions into the left ventricle through a 21 or 25 gauge hypodermic needle dependant on 
body size. 
The blood was flushed from circulation with 0.85% saline and this was followed by the 
fixative. 20ml to 60ml fixative was used dependent on carcass size. After fixation the 
carcass was immersed in fixative for up to 2 hours. Tissue was dissected using a low power 
dissection microscope and microsurgical instruments. The brain, optic nerves and spinal 
cord were removed, cut into appropriate blocks, placed in fixative and stored until further 
processing. 
2.6.2 Tissue Processing and Sectioning 
Resin processing and sectioning 
Tissue blocks prepared for resin embedding were processed using a Lynx el microscopy 
tissue processor (Leica). The tissues were passed through increasingly graded alcohols and 
infiltrated with araldite resin (appendix). The tissue blocks were oriented in resin-filled 
silicone moulds and placed at 60°C for 24 hours to allow polymerisation. Utilising an 
Ultracut-E ultratome (Reichert-Jung), 1μm light microscopy sections were cut with a glass 
knife from the  resin blocks and the sections mounted on cleaned glass microscope slides, 
while for electron microscopy 70nm sections were cut with a diamond knife and mounted 
on 200-mesh 3.05mm-diameter copper grids. 
2.6.2.2 Cryopreservation and sectioning  
Tissue blocks from fresh and 4% paraformaldehyde or P-L-P fixed animals were 
suspended in a foil mould filled with Tissue-Tec O.C.T compound (Miles Inc) and frozen 
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in isopentane cooled in liquid nitrogen. The frozen blocks were wrapped with NescoFilm 
(Bando Chemical Ind. Ltd.) and stored at -20°C. 15μm sections were cut using an OTF 
cryostat (Bright Instrument Company) and mounted onto APES-coated microscope slides 
(appendix) which were then stored at -20°C. 
2.6.3 Staining Techniques 
2.6.3.1 Methylene blue/azure ΙΙ 
1μm resin sections were dried onto microscope slides on a 60°C hot plate. The sections 
were flooded with methylene blue/azure ΙΙ stain (appendix) for 30-60 seconds and rinsed in 
running water. After drying, slides were mounted in DPX. 
2.6.3.2 Electron microscopy (EM) 
For electron microscopy, the 70nm resin sections on copper grids were “stained” with 
uranyl acetate and lead citrate (appendix). 
2.6.4 Immunohistochemistry (2.5.6.2 Charaterisation by 
immunostaining) 
2.6.4.1 ABC Technique (Avidin biotin complex) 
This technique was utilised for immunolabelling resin sections with anti-MBP in order to 
facilitate the measurement of myelin density. 
To enable staining the araldite resin was etched from the sections by agitation of the slides 
in sodium ethoxide (50% ripened sodium ethoxide 50% absolute alcohol) for 30 minutes. 
Slides were washed in absolute alcohol (6 changes) over 30 minutes. Endogenous 
peroxidase activity was quenched using 3% hydrogen peroxide in water for 30 minutes. 
Sections were again washed in running water for 30 minutes. 
Non specific immunoglobulins were blocked with 10% normal goat serum (NGS) in PBS 
for 2 hours at room temperature. Excess NGS was removed and primary antibody, diluted 
in 1% NGS/PBS, was immediately applied and the sections incubated overnight in a 
humidity chamber at 4°C. The following day sections were allowed to warm to room 
temperature and washed in several changes of PBS. The appropriate biotinylated link 
antibody diluted in 1% NGS was applied for 1 hour at room temperature and then washed 
in PBS six times over 30 minutes. Sections were then incubated with ABC complex for 30 
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minutes at room temperature and washed again six times in PBS. The chromogen was 
developed in filtered PBS containing 0.5 mg/ml 3, 4, 3, 4-tetraminobipheyl hydrochloride 
(DAB) and 0.003% hydrogen peroxide for up to 5 minutes. Excess DAB was removed by 
washing in PBS for 2 minutes and running water for 5 minutes. The chromogen was 
intensified with 1% osmium tetroxide. The slides were then dehydrated in alcohols, cleared 
in xylene and mounted in DPX. 
2.6.4.2 Immunofluorescence 
2.6.4.3 
Indirect immunofluorescence was the preferred method of labelling frozen cryostat 
sections. The sections were allowed to come to room temperature before washing in PBS 
to remove the tissue-tec. If the animal had not been perfused with fixative then the sections 
would be immersed in 4% paraformaldehyde for 20 minutes and then washed once more in 
PBS. Some antibody labelling required permeabilisation in -20ºC methanol or 0.5% triton 
X-100 (Sigma), others require the non specific immunoglobulins to be blocked with 10% 
Normal goat serum (NGS) or 0.1% tritonX-100 with 0.2% Pig skin Gelatin (Sigma). 
Primary antibodies were diluted in 1% NGS or triton/gelatin blocking buffer as above; the 
sections were incubated in primary antibody overnight at 4ºC. On day two sections were 
allowed to come to room temperature before being washed in several changes of PBS.  
Secondary antibodies labelled with fluorescein isothiocyanate (FITC) or Texas red (TxR) 
were diluted in PBS or the blocking buffer as before and applied to the sections for 30 
minutes at room temperature. Slides were briefly washed in PBS before mounting in 
citiflour antifade mounting medium (citifluor). Sections were examined by 
epifluorescence. FITC absorbs light with a wavelength 495 nm and emits it at 525 nm, 
which can be visualised as green light using a blue filter. TxR absorbs light at 596 nm and 
emits it at 620 nm, which can be visualised as red light using a green filter. 4, 6-diamidino-
2-phenylindole (DAPI), a nuclear marker employed, produces a blue fluorescent light with 
excitation of 345 nm and emission of 455 nm. 
Antibodies and Markers 
Commercially available and gifted antibodies were used and their sources and dilutions are 
illustrated in Table 6. 
Anti-Caspase-3 antibody (R&D systems) was used to recognise apoptotic cells. The CC-1 
antibody (Oncogene) was employed to distinguish mature oligodendrocytes (Fernandez et 
al., 2000). Anti-MBP antibody (N.P. Groome, Oxford, UK) was used to stain central 
compact myelin. 
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Primary 
antibody 
Host Isotype Dilution Target Source 
Anti-Lamp1 Rabbit 
polyclonal 
Clone 
ID4B 
 Late endosomes 
/lysosomes 
(LE/Ls) 
Developmental 
Studies 
Hybridoma 
Bank 
Anti-MBP Rat 
monoclonal 
IgG 1:500 Myelin, mature 
oligodendrocytes 
N.P. Groome 
CC-1 Mouse 
monoclonal 
IgG2b 1:100 Mature 
oligodendrocytes 
Oncogene 
Anti-caspase-
3 
Rabbit 
polyclonal 
IgG 1:4000 Apoptotic cells R&D  
226   1:600 Myelin, mature 
oligodendrocytes 
Applied 
Neurobioloy 
Grp 
AA3 Rat 
Monoclonal 
 1:15 Myelin, mature 
oligodendrocytes 
S. Pfeiffer 
O10 Monoclonal IgM 1:6 Conformationally 
sensitive cell-
surface epitope of 
PLP 
M. Jung 
Table 6. Primary antibodies, dilutions used and target. 
 
 
 
 
 
Link antibody Dilution ABC Dilution Source
Rabbit-anti-rat IgG 
Biotinylated 
1:100 Vector 
labs 
10 μl of A and B in 625 μl PBS 
Table 7. Link antibody and Avidin biotin Complex (ABC) 
 
 
 
 
 
 
Secondary antibody Dilution 
Goat anti-rabbit IgG FITC 1:80 
 
 
Goat anti-rat IgG FITC 1:50  
Goat anti-mouse IgG2b FITC 1:100  
Table 8. Secondary antibodies 
(Sourced from Southern Biotech) 
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2.6.4.4 
2.6.4.5 
2.6.4.6 
CC-1 staining of oligodendrocytes 
Sections were permeabilised in 0.5% triton X-100 for 30 minutes and non-specific binding 
blocked with 0.1% triton x-100, 0.2% pig skin gelatin in PBS for 30 minutes. Excess 
blocking solution was removed and CC-1 antibody at 1:100 diluted in blocking solution 
applied and the sections and incubated at 4°C overnight. The slides were washed and 
incubated with goat anti-mouse IgG2b FITC secondary antibody diluted in blocking 
solution for 30 minutes, the nuclei stained with DAPI and the slides washed and mounted. 
APC has been used to label mature oligodendrocytes (Fernandez, 2000). 
Caspase-3 staining of apoptotic cells 
Following permeabilisation in 0.5% triton X-100 sections were blocked with 0.1% triton 
X-100, 0.2% pig skin gelatin in PBS for 30 minutes. Excess blocking solution was 
removed and anti-caspase-3 antibody diluted in blocking solution applied and the sections 
incubated at 4°C overnight. The sections were washed and incubated with goat anti-rabbit 
IgG FITC secondary antibody diluted in blocking solution for 30 minutes the nuclei 
stained with DAPI and the slides washed and mounted. 
DAPI Staining 
Following immunolabelling cell nuclei were stained with 1μg/lml 4, 6-diamidino-2-
phenylindole (DAPI), the fluorescent dye, for 30-60 seconds. 
2.6.4.6.1 Quantification of Labeled Cells in Cryosections. 
 Cells were quantified in the ventral columns adjacent to the ventromedian fissure in 15-
μm cryosections. Multiple sections were cut with at least 15 μm between sections. 
Fluorescent images were recorded using a 20x objective and a digital camera (Colour 
CoolView, Photonic Science, Robertsbridge, England, UK) and stored on computer. In all 
instances, cells were counted within a defined area of interest using Image-Pro Plus-4 
software set to count objects wholly within the frame or touching two of the sides. 
Caspase-3-labeled cell bodies were counted together with DAPI-labelled nuclei. 
Approximately 20 fields were counted from each animal. CC-1 antigen labelled cells were 
counterstained with DAPI and separate images of the two fluorophores were merged 
(Adobe Photoshop 6, Adobe Systems, San Jose, CA, USA) and the number of labelled cell 
bodies containing a nucleus were counted, as above. Cell densities were derived and, 
where appropriate, the labelling index or percentage of labelled cells calculated in relation 
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to the total number of DAPI stained nuclei. APC CC-1 antibody labels mature 
oligodendrocytes and lightly labels progenitors and astrocytes. 
2.6.5 Morphological Quantitative studies 
2.6.5.1 
2.6.5.2 Axon 
2.6.5.3 
Myelin volume  
Cervical segment 2 (C2) of spinal cords were dissected out following perfusion-fixation in 
Karnovsky’s Modified Fixative and processed for resin embedding. Following 
polymerisation the resin blocks were trimmed and thin sections (70nm) cut and placed onto 
copper grids which were subsequently stained with uranyl acetate and lead citrate 
(appendix). All measurements were performed on the ventral columns of the white matter 
tract.  
Myelin volumes were derived using a point counting technique {Williams, 1977). Ten 
electron micrographs (Jeol CX-100) at 4,000x magnification were obtained by random 
photography of the ventral columns and printed at ~3.5 enlargement to occupy an A4 sheet 
of printing paper. A transparent grid square (2cm) was placed over each print and the 
number of intercepts overlying compact myelin was expressed as a ratio of the total 
intercepts. This was superseded by the digital method very early on where this analysis 
was carried out on the computer using a grid generated by the software (Image Pro-Plus 
4.1 software (Media Cybernetics, Silver Spring, MD, USA))  (Karim et al., 2007).
Vv = Points overlying compact myelin/Total points available on grid. 
status 
Utilising the same photomicrographs as above a simple line grid (2 lines running 
diagonally from corner to corner) was overlaid and the number of non-myelinated and 
myelinated axons touching the line were counted. The number of each was expressed as a 
percentage of total fibres. Once again this was superseded by the digital method very early 
on where this analysis was carried out on the computer using a grid generated by the 
software (Image Pro-Plus 4.1 software). 
Myelin Density 
Myelin area was measured on semi thin (1µm) resin sections immuno-labelled with anti 
Myelin Basic Protein using the ABC technique. Four areas, two either side of the 
ventromedian fissure were captured with x40 dry lens using a CCD camera (Colour 
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Coolview, Photonic Science). The digital images were converted to black and using Image 
Pro Plus software (Media Cybernetics). An area of interest (AOI) of 2500µm2 was placed 
over two separate areas of each of the four captured images and the total area of black 
objects (MBP labelled myelin) measured. The density of myelin (µm 2/mm2) of white 
matter was calculated.  
2.6.5.4 
2.6.5.5 
2.6.5.6 
Quantification of APC+ cells 
Cell counts were performed on cryosections (15μm) of the ventral columns, adjacent to the 
ventromedian fissure, from rostral cervical spinal cord. Images of APC-labelled cells 
(green channel) and DAPI-labelled nuclei (blue channel) from the same sampling area 
were collected at x20 objective using a CCD camera system (Photonic Science Colour 
Coolview) and stored in the computer. The green and blue channels were merged using 
Adobe Photoshop (Adobe systems Inc., San Jose) and the image quality adjusted. For each 
combined image, a frame (35804μm2) outlining the AOI was placed on the screen. The 
number of APC+ cell bodies containing a DAPI-stained nucleus was counted within the 
AOI or those touching the top or left side but excluding those touching the bottom or right 
sides. The density of DAPI-labelled nuclei was counted automatically with an AOI of 
10,000μm2. The density of APC-labelled cells and DAPI-stained nuclei (nuclei/mm2) and 
the percentage of APC+ cells (APC cells/DAPI nuclei x 100) were calculated. 
Quantification of caspase-3+ cells 
Cell counts were performed on cryosections (15μm) of the ventral columns, adjacent to the 
ventromedian fissure, from rostral cervical spinal cord. Images of caspase-3-labelled cells 
were collected at x20 objective using a CCD camera system (Photonic Science Colour 
Coolview) and stored in the computer. For each image, a frame (35804 μm2) outlining the 
AOI was placed on the screen. The number of caspase-3+ cell bodies was counted within 
the AOI or touching the top or left side but excluding those touching the bottom or right 
sides. The density of DAPI-stained nuclei was taken from the sections stained for 
APC/DAPI. The density of caspase-3-labelled cells and the percentage of caspase-3+ cells 
(Caspase-3+ cells/DAPI nuclei x 100) were calculated. 
Calculation of cell numbers 
Quantification of cells or nuclei was determined by their density in the ventral funiculi. As 
the area of the white matter varied between different genotypes, the total number of 
cells/nuclei in the white matter of a transverse section was calculated. This calculation 
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assumed that the density was equally distributed throughout the white matter when there 
was variation between tracts and at different ages. In fact the nuclear density altered across 
the width of the ventral column, being greater in the central region adjacent to the grey 
matter. The alternative strategy was to define a precise sub-region of the ventral column in 
which to calculate total numbers, a task that would be problematic to ensure consistent 
identification of the same region. The calculation based on the total white matter area 
therefore offers an acceptable way of comparing cell numbers between different genotypes 
and ages. 
2.6.6 Statistical analysis 
2.6.6.1 Group 
2.6.6.2 
2.6.6.3 Statistical 
sizes 
The number of animals included in a group varied between ages, genotype and technique. 
In general, 4 or more animals were included in a group and where possible littermates were 
used. At P3 and P5 no phenotype was displayed by any of the animals therefore 
identification of genotype by carried out by PCR and morphology therefore no pooling of 
samples was possible for cultures. Homozygous animals could be identified by P20 as the 
phenotype was displayed. Wild type and hemizygous animal selection was random and 
genotype was confirmed subsequently. In the case of the brain slice experiments 
identification occurred after the completion of the experiment.  In general this factor put a 
practical appreciation of the experimental design.  
Data presentation 
Graphs are presented as mean ± SEM. 
tests 
As group sizes were always relatively small no assumptions were made that the data was 
distributed normally. Groups were first compared using one-way An O Vaalysis f riation 
(ANOVA). If a significant difference (p<0.05) was detected, individual groups were 
compared using the Bonferroni multiple comparison test. P value was taken at <0.05 (one 
star <*0.05, two stars <**0.01 and three stars <***0.001). Analyses and curve fittings 
were performed using Graphpad Prism4 software (GraphPad Software, San Diego, CA, 
USA).  
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3 Effects of #66 transgene cassette 
3.1  Background 
The #66 transgene cassette contains no sequence tags or mutations to distinguish its 
expression from the endogenous copy of Plp1 gene on the X chromosome. However, it is 
necessary to investigate the contribution of the transgene to total PLP message and protein 
levels in the CNS.  Readhead et al., (1994) did this by quantifying Plp1 expression in the 
F2 generation after breeding transgenic male mice with heterozygous jimpy (jp/+) females. 
The two Plp1 messages were distinguishable from one another via PCR as the endogenous 
jimpy Plp and Dm20 mRNA contained a 74 nucleotide deletion of exon 5 allowing for the 
quantification of the transgene message.  
3.2 Aims 
The aims of this chapter were to investigate the levels of plp/dm20 message and 
PLP/DM20 protein attributable solely to the transgene cassette utilising the Plp1 gene null 
mice generated by Klugman et al., (1997). 
3.3 Methods 
The study of activity of the transgene cassette was performed at P20 (peak of myelination). 
Spinal cord was collected for RNA and myelin preparation and tail for DNA preparation. 
The steady state mRNA levels of Plp1 were assessed by northern hybridisation and qRT-
PCR using β-actin as an internal endogenous control. The protein levels were assessed by 
western blot analysis of the myelin fraction from spinal cord. 
3.3.1 Animal breeding  
The breeding of the #66 hemizygous males with Plp1 gene null females was carried out as 
described in 2.2 Mouse Breeding. The offspring were genotyped as described (2.2.4 
Crossing of transgenic lines of mice) for the transgene and the null locus (Figure 10) and 
only male animals were used for this study.  
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3.3.2 Genotype and Sample Selection 
Brain and spinal cord tissue from three genotypes was utilised: from male mice that were 
wild type for the transgene and wild type for the Plp1 gene null locus; from male mice that 
were wild type for the transgene and null positive; and from male mice that were transgene 
and null positive (Figure 10). 
3.3.3 Tissue Preparation  
Total cellular RNA was extracted from powdered spinal cord as described in 2.4 Isolation 
and Manipulation of RNA. Preparation of myelin from spinal cord is described in 2.5 
Protein Analysis. gDNA from tails was prepared for genotyping as described in 2.3 
Isolation and Manipulation of DNA.  
3.3.4 Transcript Analysis  
3.3.4.1 Northern analysis  
This experiment was performed on total cellular RNA extracted from spinal cord. The 
procedure of northern transfer and hybridisation is described in 2.4.6 Northern Blotting. 
The preparation of radiolabelled probes is described also in 2.4.6 Northern Blotting.  
Staining of the gel with ethidium bromide was used to check for equal loadings of sample 
and presence of bands in ladder (Figure 14A and B) and hybridisation with β-actin (a 
measure of invariant expression) was used to monitor equivalence of transfer. 
Hybridisation analysis was under taken using labeled cDNA products from PCRs using 
primers for Plp1 (Table 2) (Figure 15). The blot was left for a 3-4 weeks to allow the 
signal to decay then probed for β-actin and finally Mbp 3-4 weeks later. 
3.3.4.2 qRT-PCR analysis 
Standard curves were produced using serial dilutions of an appropriate wild type RNA 
sample as described in 2.4.7 qRT-PCR. Once all the parameters for the reactions were set 
and equivalent for both genes, the test plate, containing both Plp1 and β-actin reactions for 
the relevant samples selected, was run (2.4.7 qRT-PCR).   
Each sample was loaded in duplicate or triplicate and blanks containing ddH2O were also 
loaded as controls. Once the PCR was complete then the results were stored on a CD for 
analysis. Following the analysis protocol in 2.4.7 qRT-PCR the uncorrected concentrations 
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of Plp1 and β-actin mRNA in 50ng total RNA loaded was calculated. The Plp1 
concentration was then normalised to β-actin and expressed as a percentage of WT/WT 
levels giving the actual concentration of Plp1 message in total RNA.  
3.3.5 CNS Myelin Analysis  
3.3.5.1 Myelin Preparation 
Myelin was prepared from spinal cord, protein was quantified and analysed by western blot 
as described in 2.5 Protein Analysis. Blots were immunostained for PLP/DM20 using C-
terminal antibody 226 and for MAG (Table 6).  
3.4 Results 
3.4.1 #66 transgene expression  
3.4.1.1 Northern Hybridisation 
Transcript analysis by northern hybridisation of the Plp1 transgene on the Plp1 null 
background is demonstrated in the Figure 20 where the results were compared to wild type 
(WT/WT) and null (Ko/WT) littermates. There was no detectable signal for Plp1 in the 
null sample (Figure 20A Null) whereas the β-actin signal (Figure 20B Null) confirmed 
presence of RNA and amount transferred to the membrane. The signals for both Plp1 and 
β-actin message in the null/#66 (Ko/#66) sample (Figure 20A and B Null/#66) were higher 
than those for wild type (Figure 20A and B WT). Two classes of Plp/Dm20 mRNAs were 
detected 2.4kb and 1.6 kb (Figure 20A). Both Plp and Dm20 transcripts are present in the 
two bands seen on the northern blot (Figure 20A). The β-actin signal is also around 1.6kb 
in size which masks the lower Plp/Dm20 mRNA signals as seen in Figure 20B. Once the 
Plp1 signal was corrected for the β-actin signal and normalised to wild type levels the 
message levels in both wild type and null/#66 were comparable. The wild type levels are 
100% and null/#66 levels 115%. However, this analysis has been carried out only two sets 
of samples. The same blot was reprobed for Mbp (Figure 20C) showing an increase in Mbp 
levels in both the null and null/#66 samples compared to the wild type sample. However 
when corrected for β-actin this increase was nort so marked as demonstrated by the 
northern. 
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3.4.1.2 
3.4.2.1 
qRT-PCR analysis  
Transcript analysis by qRT-PCR of the Plp1 transgene on the Plp1 gene null background is 
demonstrated in Figure 21. As with northern hybridisation analysis there is no Plp1 signal 
for the null (Ko/WT) genotype whereas the β-actin signal in all three genotypes is similar.  
Once the signals were analysed and normalised to β-actin they were expressed as a 
percentage of wild type levels (standard, 100%). No difference is seen between the 
message levels for wild type and null/#66 (Figure 21).  
3.4.2 CNS Myelin analysis 
Western analysis 
Protein analysis by western blotting of wild type, null and null/transgene (null/#66) 
animals is demonstrated in Figure 22. All three samples show positive staining for MAG 
confirming the presence and equal amount of myelin proteins on the blot as MAG was 
used as control for loading (Figure 22A). Neither PLP nor DM20 protein isoforms are 
detected in null mice (Figure 22B Null). There is no difference between PLP and DM20 
protein levels between wild type and null/#66 samples (Figure 22B and Figure 23). 
3.5 Discussion 
Data presented in this chapter demonstrates that mice positive for the Plp1 wild type 
transgene cassette and null for the endogenous Plp1 gene produced similar levels of 
Plp/Dm20 message and PLP/DM20 protein isoforms as wild type littermates. The 7 extra 
copies of the Plp1 gene did not produce a 7 fold increase at either the transcript or protein 
level as might have been expected.   
Readhead et al., (1994) measured transcription efficiency of the transgene on a jimpy 
background. In mice that were #66 transgene and jimpy positive the message level 
measured 115% by RT-PCR with an error margin of 10%. In this study the transcript levels 
of only transgene cassette on a null background were comparable. These experiments also 
confirmed previous studies showing the Plp1 gene null mouse produces no Plp/Dm20 
message or PLP/DM20 protein (Griffiths et al., 1998).  
The slight difference in message levels between the northern hybridisation and qRT-PCR 
can be explained by the fact only one set of animals was used in the former and the 
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different quantity of RNA at the start of each experiment. 12.5µg total RNA was used for 
the northern hybridisation experiment and 50ng for the qRT-PCR experiments. Leske et 
al., (2004) also found discrepancies between their northern and qRT-PCR results. 
Although they observed differences in absolute values, the overall trends in mRNA levels 
were very similar between the methods.  
Originally the Plp1 gene promoter was thought to control the gene transcription in 
oligodendrocytes. However Plp1 promoter activity was discovered to be distinct from the 
rate of accumulation of Plp/Dm20 mRNA (Mallon and Macklin 2002), therefore there 
must be another mechanism controlling the transcription rate of the wild type Plp1 gene. 
Previously it had been discovered the nucleotide sequence of exon 7, the largest exon 
(>2kb) of the mouse Plp1 gene, which contains the 3’ untranslated region (UTR) and the 
three polyadenylation sites, has a high degree of conservation between species. The 
homology of the entire 3’UTR between mouse and rat is greater than 90% and some 
regions have almost 100% homology (Macklin et al., 1987). Other genes have a lower 
homology between species in this region. Another X chromosome gene Hypoxantine 
phosphoribosyltransferase (Hprt) shows 74% homology between the human and mouse 
genes which is considered high for this region.  
Studies to investigate whether the 3’ UTR region regulates the transcription rate and 
expression of Plp/Dm20 mRNA in cells were undertaken by Mallon and Macklin (2002). 
The 3’UTR of Plp1 gene was fused to luciferase under CMV promoter control and 
transfected into C6 cells in excess amounts. Results showed a dramatic decrease of the 
endogenous Plp1 mRNA in these cells. They then confirmed this data using a different 
vector and promoter. Thus overexpressing of the Plp1 3’UTR downregulated the 
transcription of the endogenous Plp1 mRNA and also changed the adhesion properties and 
morphology of the C6 cells. The cells took longer to attach to the tissue culture dish than 
cells without the 3’UTR and formed aggregates at high density.   
In transgenic mice generated to express the EGFP protein fused to the Plp1 3’UTR and 
under control of the Plp1 regulatory regions the endogenous Plp1 mRNA in total brain 
RNA decreased by 30-54% (Mallon and Macklin 2002). As there is no endogenous Plp1 
gene present in the null/#66 mice in this study and the transgene contains all 17kb of the 
wild type gene, it is a possibility that the 3’UTR is having an effect on the expression of 
the transgene itself. There is no difference between the endogenous Plp1 gene and the 
 3-120
Saadia Ansari Karim 2007    
copies in the transgene therefore cells may be unable to distinguish between the two and 
thus regulate both in the same way.  
Readhead et al., (1994) were unable to demonstrate that PLP is overexpressed at the 
protein level in the #66 transgene and jimpy positive mice in their studies. In this study 
PLP/DM20 protein isoforms produced in the null/#66 animals was equivalent to the levels 
in wild type littermates. The 7 copies of the wild type Plp1 gene in the transgene produced 
around 100% protein. The oligodendrocyte can control the expression of the 7 copies of 
the Plp1 gene ensuring adequate transcript and protein is produced. In conclusion, data 
presented in this chapter suggests that there is a mechanism by which the oligodendrocyte 
controls transcription and translation of the Plp1 gene to ensure tight regulation of levels of 
PLP/DM20 present in myelin. As PLP/DM20 is the most abundant protein in the CNS it is 
essential that the oligodendrocytes have the ability to maintain the levels required to 
produces myelin. The possible breakdown of controls in place to carry out this process 
may contribute to disease in humans and animals. 
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Figure 20. Transcript analysis of P20 Null x #66 total RNA. 
A) Northern hybridisation analysis of Plp1 gene transcription showing the two major 
murine mRNA species with no mRNA signal present in the null sample (Null). B) 
Northern hybridisation analysis of Plp1 and β-actin gene transcription confirming the 
presence of RNA in the middle lane with a β-actin signal. C) Same blot left for 3-4 weeks 
for signal to decay and then reprobed for Mbp showing an increase in Mbp message in the 
null and null/#66 samples. 12.5µg spinal cord total RNA loaded per lane and 5µl RNA 
ladder loaded. 
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Figure 21. Representative graph showing mRNA (message) levels in the three #66 x 
null genotypes using qRT-PCR.  
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Figure 22. Western blot analysis of the Plp1 wild type transgene on a Plp1 null 
background.  
A) Western blot immunostained with MAG antibody (WT wild type, Null Plp1 null and 
Null/#66 Plp1 null x #66) highlighting the presence of MAG in the null sample. B) Same 
blot washed then re-immunostained for PLP/DM20 highlighting the lack of PLP/DM20 
signal in the null sample (WT wild type, Null Plp1 null and Null/#66 Plp1 null x #66).  
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Figure 23. Quantitative data for Plp/Dm20 mRNA, measured by qRT-PCR and PLP 
protein, measured by western blotting for Plp1 gene null mice carrying the Plp1 
transgene.  
Results (M, N = 2) are expressed as a percentage of a wild type mouse from the same litter. 
There is no difference between groups for either parameter. 
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4 Effects of Increased Plp1 gene dosage on Pre- 
and Early Myelinating Oligodendrocytes 
 
4.1 Background 
The principle function of oligodendrocytes is to provide support to axons and to produce 
the myelin sheath, which insulates axons. Oligodendrocytes begin to produce myelin when 
they enter terminal differentiation and contact neurons. This occurs at a remarkable scale 
>104 µm2 myelin membrane surface area/cell/day (Pfeiffer et al., 1993). Oligodendrocytes, 
unlike Schwann cells of the PNS, form myelin internodes of numerous axons. The 
processes of a given oligodendrocyte wrap themselves around portions of the surrounding 
axons. As each process wraps itself around, it forms layers of myelin. Each process thus 
becomes a segment of the axon's myelin sheath. This process of myelination by 
oligodendrocytes is highly organized and coordinated. However it has been shown that 
oligodendrocytes cultured without neurons, as in my study, produce considerable amounts 
of myelin proteins and possibly attempt a few myelin whorls (Dubois-Dalcq et al., 1986). 
The expression of myelin proteins is not dependant on the presence or absence of neurons 
(Lemke et al., 1986). However recent evidence has shown that there is communication 
between oligodendrocytes and neurons which may involve a cAMP modulating factor 
(Trajkovic et al., 2006). 
In the early stages of myelination the oligodendrocytes come into contact with axons and 
produce membranous sheets extending as cell processes to the axon. These membranous 
sheets are not yet myelin. Changes in protein to lipid ratio or levels of proteins produced 
may have adverse effects on myelination. Originally studies on spontaneous Plp1 gene 
mutants provided evidence for the roles of the Plp1 gene in oligodendrocyte development. 
Mutants such as jimpy and rumpshaker have dysmyelinating phenotypes and display 
reduced numbers of mature oligodendrocytes and small numbers of thin myelin sheaths. 
However unlike these mutants the #66 line have extra copies of the wild type Plp1 gene. In 
humans extra copies of the PLP1 gene cause PMD (reviewed in introduction of this thesis) 
although the mechanisms of the disease process are not yet known. Any light shed on the 
effects of extra wild type copies of the gene on oligodendrocytes and the early myelination 
process would be useful.   
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4.2 Aims 
At the beginning of this project there was very little information on the effects of increased 
Plp1 gene dosage on the early stages of myelination or on the oligodendrocytes 
themselves. Therefore one of the first aims of this study was to investigate the effects of 
increased Plp1 gene dosage on oligodendrocytes and on the early stages of myelination 
when the oligodendrocytes are just coming into contact with axons.  
This chapter describes the in vitro studies into protein composition in oligodendrocytes via 
immunostaining and western blot analysis in homozygous mice in comparison to age-
matched wild type and hemizygous animals. Also described is analysis of P3 spinal cord at 
morphologic, message and protein levels.  
4.3 Methods 
These studies were carried on spinal cord from P3 and P5 male #66 mice. Spinal cord was 
collected for RNA and myelin preparation and tail for DNA preparation. The steady state 
mRNA levels of Plp1and Mbp were assessed by northern hybridization and qRT-PCR 
using β-actin as an internal control. The protein levels were assessed by western blot 
analysis of the myelin fraction from spinal cord. 
4.3.1 Animal breeding  
The breeding of the #66 hemizygous males with #66 hemizygous females was carried out 
as described in 2.2 Mouse Breeding. The offspring were genotyped as described (2.3 
Isolation and Manipulation of DNA) for the transgene and only male animals at P3 or P5 
were used for this study. As there is no visible phenotype in young #66 mice another 
method was used to further identify the hemizygous and homozygous animals. Readhead 
et al., (1994) correlated gene copy number with pathology and this was verified in 
subsequent publications (Anderson, 1997, Anderson et al., 1999). Homozygous mice can 
be distinguished from hemizygotes by the dysmyelination that is evident at all ages in the 
present study. A small block of cervical spinal cord from mice used for RNA, protein or 
tissue culture studies was immersion-fixed in paraformaldehyde/glutaraldehyde fixative 
and processed for resin sections, and where necessary EM (2.6.3 Staining Techniques).  
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4.3.2 Sample Selection 
Tissues from mice wild type and hemizygous or homozygous for the #66 transgene were 
used. Tails were taken for genotyping, spinal cord for tissue culture studies, or RNA and 
protein extractions. 
4.3.3 Primary Cell Culture Analysis 
Primary cell cultures for oligodendrocyte analysis were set up from P5 mice as described 
in 2.5.4.1 Primary Cell Culture. Cells on coverslips were immunostained to highlight 
presence or absence of proteins (2.5.4.2 Characterisation by Immunostaining) and cells in 
culture dishes were lysed to study proteins (2.5.4.3 Harvesting for Biochemistry).  
4.3.4 Transcript Analysis   
4.3.4.1 Northern analysis  
This experiment was performed on total cellular RNA extracted from spinal cord. The 
procedure of northern transfer and hybridisation is described in 2.4.6 Northern Blotting. 
The preparation of radiolabelled probes is described also in 2.4.6 Northern Blotting.  
Staining of the gel with ethidium bromide was used to check for equal loadings of sample 
and presence of bands in ladder and hybridisation with β-actin (a measure of invariant 
expression) was used to monitor equivalence of transfer. Hybridisation analysis was under 
taken using labeled cDNA products from PCRs using primers for Plp1 and Mbp (Table 2) 
(Figure 15). The blot was left for 3-4 weeks to allow the signal to decay then probed for β-
actin. 
4.3.5 CNS Myelin Analysis  
4.3.5.1 Myelin Preparation 
Myelin was prepared from powdered spinal cord, protein was quantified and analysed by 
western blot as described in 2.5 Protein Analysis. Blots were immunostained for 
PLP/DM20 using C-terminal antibody PLP226, MAG, MBP, ASPA and β-actin (Table 6). 
To compensate for any differences in oligodendrocyte cell numbers in culture lysates, 
samples for western analysis were normalised for aspartoacylase (ASPA), a marker of 
oligodendrocyte cell bodies (Kirmani et al., 2003, Madhavarao et al., 2004). 
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4.4 Results 
4.4.1 Identification of Genotype 
Homozygous animals have to be distinguished from hemizygous animals after PCR as both 
are transgene positive and there is no phenotype at P5. Many axons in hemizygous spinal 
cord are surrounded by myelin sheaths (Figure 24A) and at this age hemizygous spinal 
cord is indistinguishable from wild type spinal cord. However there are naked axons and 
axons with thin myelin sheaths visible in homozygous spinal cord (Figure 24B). The cord 
at P3 is very similar to spinal cord at P5 therefore all animals used for either tissue culture 
or P3 analysis were identified using this method.  
4.4.2 Immunostaining  
Oligodendrocytes in cultures were immunostained using fluorescent techniques.  
PLP/DM20 is present in the cell bodies and rudimentary processes of oligodendrocytes 
form wild type animals (Figure 25A) cultured for 6 days from P5 spinal cord. No obvious 
difference is noted in the cellular distributions of PLP/DM20 between oligodendrocytes 
cultured from wild type and homozygous animals (Figure 25B).  
Oligodendrocytes in culture from each genotype were also immunostained for MBP 
(Figure 26). There appears to be no visual difference in MBP staining in the wild type and 
hemizygous cells (Figure 26A and C) whereas, there is a reduction in MBP staining in the 
homozygous cells (Figure 26D). MBP-stained membranes in the wild type cultures that are 
not obvious in the homozygous culture are shown in Figure 26B.  
4.4.3 Protein Analysis of Culture Lysates 
Protein analysis by western blotting of lysates from cultured oligodendrocytes of wild type, 
hemizygous and homozygous mice are illustrated in Figure 27A. ASPA, a marker for 
oligodendrocyte cell bodies is used a control to compensate for any differences in 
oligodendrocyte cell numbers between samples. Whereas the level of PLP/DM20 is 
elevated in the homozygotes, the amount of the MBP isoforms is decreased in the same 
cells. PLP/DM20 levels in homozygotes are significantly elevated (p <*0.05) compared 
with wild type and hemizygote levels, once normalised to ASPA and expressed relative to 
wild type (Figure 27B). Steady state levels of PLP/DM20 in hemizygotes and wild types 
are similar. 
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4.4.4 Analysis of Early Myelination in P3 spinal cord 
4.4.4.1 
4.4.4.2 
4.4.4.3 
Transcript Analysis  
Transcript analysis by northern analysis is demonstrated in Figure 28A. Both Plp1 and 
Mbp messages in total RNA from spinal cord of P3 hemizygotes are not different from 
wild type message levels. However in homozygotes both Mbp and Plp1 messages are 
significantly reduced compared with wild type (p <*0.05). 
Protein Analysis 
Protein analysis by western blotting of wild type, hemizygous and homozygous P3 spinal 
cord lysates (total homogenates) is demonstrated in Figure 28B. As found in the cultured 
oligodendrocytes there is a progressive increase of PLP/DM20 levels with gene dosage 
with the homozygotes (Figure 28B Homo) having the highest protein levels. Conversely, 
(Figure 28B Homo) there is a marked decrease in MBP levels in the homozygote spinal 
cord total homogenate (Figure 28B Homo).  
Morphological Analysis of P3 spinal cord 
A 1µm resin section of a P3 spinal cord immunostained for PLP/DM20 is shown in Figure 
29. Strongly stained oligodendrocyte cell bodies and myelin sheaths are evident showing 
the oligodendrocyte contains significant amounts of PLP/DM20. Some oligodendrocyte 
cell bodies contain dark immunopositive structures (arrow in Figure 29A). In immediately 
adjacent EM sections (Figure 29B, C) the immunopositive cells have distended RER and 
autophagic vacuoles/lysosomes, which probably correspond to the dark structures seen in 
the resin section.  
4.5 Discussion 
Data presented in this chapter demonstrate that there is increased PLP/DM20 protein 
present in oligodendrocytes from homozygous mice in vitro and in P3 spinal cord. 
Conversely there is a marked reduction in message levels for PLP/DM20 in the 
homozygous lysates. MBP at both message and protein levels is reduced in the 
homozygous oligodendrocytes and P3 spinal cord RNA and lysates.  
To understand how oligodendrocytes cope with increased Plp1 gene dosage and how 
axonal factors might interact with or influence this, PLP/DM20 levels were studied in 
naïve oligodendrocytes with no axonal contact and in the absence of a myelin sheath. It is 
 4-129
Saadia Ansari Karim 2007    
generally accepted that the presence of PLP in oligodendrocytes defines a mature myelin-
forming oligodendrocyte (Griffiths et al., 1998) therefore the oligodendrocytes present in 
the primary cell cultures from spinal cord in this study can be classed as such. O10 
immunostaining confirmed cultured oligodendrocytes produced PLP/DM20 and the protein 
reached the cell surface. O10 antibody stains the surface of live cells and recognizes a 
conformation-sensitive epitope within the large extracellular loop (C-D loop) of 
PLP/DM20 (Figure 5) (Jung et al., 1996). Oligodendrocytes in vitro produce PLP/DM20 
protein and it can reach the cell surface in the absence of neurons. 
During normal in vivo development the level of Plp1 gene expression closely parallels 
myelination. However, expression commences prior to myelin formation and is influenced 
by axonal contact and the amount of myelin produced by the cell (McPhilemy et al., 1990, 
Thomson et al., 2005). In the homozygous P3 spinal cord there is reduction in mRNA for 
Plp/Dm20 compared with wild type and hemizygous levels but an increase in protein 
levels. There is evidence to show that there is not a one-to-one relationship between 
message and protein levels. One message does not necessarily translate into only one 
polypeptide molecule. The oligodendrocyte has the ability to increase production of protein 
from the respective transcript. This may be the case the homozygous oligodendrocytes 
prior to full scale myelination.    
Intuitively, one would anticipate increased Plp1 gene dosage to result in higher levels of 
PLP/DM20 in oligodendrocytes. However, other factors, such as the myelination status, 
can have a major influence. To separate these influences in cultured oligodendrocytes 
which, lack myelin sheaths, PLP/DM20 levels were investigated and showed that levels in 
cells from homozygous mice were elevated. PLP/DM20 was also elevated in homozygous 
mice during very early myelination in P3 spinal cords, and to a lesser extent in hemizygous 
mice. However in these same cells in vitro and in P3 spinal cord MBP was reduced. 
Oligodendrocytes from homozygous animals do not produce membranous sheets as the 
oligodendrocytes from wild type animals do.  
Premyelinating oligodendrocytes express many but not all the myelin proteins they need 
during myelination and they extend processes radially in many directions. All the myelin 
proteins detected in premyelinating oligodendrocytes appears to been evenly distributed 
throughout the entire cell body. However in the homozygous oligodendrocytes (Figure 
29A) there are highly PLP/DM20 immunostained structures seen in the cell bodies. The 
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accumulation of PLP/DM20 protein overexpressed in the homozygous oligodendrocytes in 
the cell body whether it is in the RER or in autophagic vacuoles/lysosomes may tax or 
saturate the availability of molecules that help fold or move PLP/DM20 through the cell. 
P0 protein is also concentrated due to the lack of available myelin in the cell bodies of 
Schwann cells overexpressing P0 (Yin et al., 2000). Similarities also exist with increased 
dosage of the PMP22 gene, the commonest cause of Charcot-Marie-Tooth disease type 1A. 
Transgenic rodent models of the disorder exhibit dysmyelination proportionate with 
Pmp22 dosage (Huxley et al., 1998, Niemann et al., 2000) and Schwann cells contain 
autophagic vacuoles reminiscent of those seen in oligodendrocytes described in this 
chapter (Chies et al., 2003, Niemann et al., 2000). 
Immunostaining and EM show that the strongly immunopositive oligodendrocyte cell 
bodies contain numerous autophagic vacuoles and lysosomes. PLP, when overexpressed, is 
known to associate with the endosomes/lysosome system (Simons et al., 2002). In normal 
myelination PLP may also associate temporarily with endosomes before axon-derived 
signals promote its insertion into myelin (Trajkovic et al., 2006). An increase in 
PLP/DM20 levels and a reduction in available myelin and decreased axonal contact, as 
occurs in the homozygous state, would exacerbate the accumulation of PLP in lysosomes. 
Prior to myelination, MBP production at message and protein levels is impaired, this is 
seen in the reduction of steady state MBP by western blotting in cultured oligodendrocytes 
and premyelinating spinal cord. Mbp message is translocated in granules containing 
hnRNP A2, ribosomal RNA, the elongation factor EF1-α and arginyl-transfer RNA 
synthetase (Trapp et al., 2004). These granules are transported at speeds consistent with 
microtubule-mediated transport to the myelin internode. The excessive load/burden on the 
homozygous cell may impair the production or this transport of Mbp mRNA to the myelin. 
A very similar paradoxical effect has been observed in the nerves of mice 
“overexpressing” P0 the major myelin gene of the PNS. A reduction in the levels of MBP 
was noted in mice hemizygous and homozygous for the P0 transgene (Wrabetz et al., 
2000).  
The levels of Plp1 gene expression are strictly regulated in oligodendrocytes (Wight et al., 
2004). This is highlighted by the fact that any change in Plp1 gene expression at message 
or protein levels can lead to disease in man or animal. These changes can be point mutation 
or gene dosage changes as seen in the #66 mice in this study. How these alterations in 
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expression lead to disease is still unknown and the major question to be answered. Whether 
the increase of PLP/DM20 in homozygous oligodendrocytes is an important clue to the 
disease mechanism is a matter for further investigation. 
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A B  
Figure 24. Resin sections (1µm) of white matter in the ventral funiculus of P5 mice.  
A) Hemizygous mouse with many axons surrounded by a myelin sheath indistinguishable 
from wildtype at this age. B) The homozygous mouse is dysmyelinated with thin myelin 
sheaths around a few axons but the majority of axons lack a sheath. Bar = 50μm. 
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Figure 25. Representative PLP/DM20 immunostained oligodendrocytes after 6 days 
in culture. 
A) PLP/DM20 staining of wild type oligodendrocytes in culture and B) PLP/DM20 
staining of homozygous oligodendrocytes in culture. (Green = PLP/DM20, Blue = DAPI 
staining of nucleus) Bar = 50µm 
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Figure 26. Representative MBP immunostained oligodendrocytes after 6 days in 
culture.  
A B
C D
WT WT
Hemi Homo
A) MBP staining of wild type oligodendrocytes in culture. B) MBP staining of wild type 
oligodendrocytes to show the membranous sheets not seen in homozygous 
oligodendrocytes. C) MBP staining of hemizygous oligodendrocytes in culture. D) MBP 
staining of homozygous oligodendrocytes in culture showing much lower MBP 
immunofluorescence compared to in both wild type and hemizygous cells. (Green = MBP, 
Blue = DAPI staining of nucleus) Bar = 50µm 
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Figure 27. Protein analysis of lysates from #66 oligodendrocyte cultures.  
A) Western blot immunostained for ASPA, an oligodendrocyte-specific cell body protein, 
PLP/DM20 and MBP showing an increase in PLP/DM20 with a reduction in MBP in the 
homozygous cultures compared to the other two genotypes (WT wild type, Hemi 
hemizygous and Homo homozygous). B) Levels of PLP/DM20 in oligodendrocytes 
normalised to ASPA and expressed relative to wild type (WT) showing a significant 
increase in PLP/DM20 in homozygous oligodendrocytes p <*0.05 but no difference in 
hemizygous amounts of the protein. 
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Figure 28. Plp1 and Mbp gene expression in spinal cord of P3 mice hemizygous and 
homozygous for the Plp1 transgene.  
A) Transcript analysis graph of northern blotting showing lower mRNA levels in 
homozygous CNS tissue compared to wild type levels (100%) for both Plp and Mbp and 
no difference between hemizygous and wild type levels (p <*0.05). B) Representative 
western blots of total homogenates from P3 spinal cords probed for ASPA (to check 
loading), PLP/DM20 and MBP showing similar results to the culture profile with an 
increase in PLP/DM20 with decrease in MBP (WT wild type, Hemi hemizygous and 
Homo homozygous). 
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Figure 29. PLP/DM20 in sections of spinal cord of P3 mice homozygous for the Plp1 
transgene.  
A) Accumulation of PLP/DM20 in cell bodies of oligodendrocytes from a P3 mouse 
homozygous for the transgene. Resin section immunostained for PLP/DM20 showing two 
oligodendrocytes with strongly immunopositive cell bodies. The thin myelin sheaths are 
also stained. The ventral pial surface is to the bottom. The arrows (B, C) indicate the sites 
of the EM images shown in Figures B and C, which were obtained from an immediately 
serial thin section. B) Part of oligodendrocyte soma showing loss of the normal cisternal 
arrangement of the RER (*). C) Oligodendrocyte soma showing autophagic vacuoles 
(arrows). Bars = 1μm. 
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5 Effects of Increased Plp1 gene dosage on Peak 
Myelination (P20) 
 
5.1 Background 
The main cause of PMD in humans is duplication of the chromosome region containing the 
PLP1 gene. This gene is highly conserved therefore mice can be used as an animal model 
for the disease. Unfortunately there are currently no spontaneous models of disease caused 
by gene dosage differences. Readhead et al., (1994) amongst others generated a transgenic 
mouse (#66) carrying extra copies of the entire mouse Plp1 gene including regulatory sites 
in 5’ and 3’ regions (to act as a model for PMD).  
Both dys and demyelination are seen in the #66 animals dependant on the genotype of the 
transgenic mice. Mice with two copies of the Plp1 gene cassette classed as homozygous 
showed severe dysmyelination, causing tremors, seizures and premature death. The 
hemizygous animals with only one copy of the cassette developed normally early on, 
however, in later life went on to suffer from tremors and seizures caused by demyelination. 
Anderson et al., (1998) carried out an in-depth study of late onset demyelination observed 
in the hemizygous #66 animals. 
Peak myelination in mouse occurs around postnatal day 20-21 in mouse. This is when the 
oligodendrocytes are producing the most proteins and lipids to incorporate into myelin 
sheaths. The burden on the oligodendrocytes is greatest at this point in CNS development. 
There is a huge quantity problem to be overcome by the oligodendrocytes in the CNS at 
peak myelination. They have to produce up to 3 times their weight in proteins and lipids 
per day of myelinogenesis. Transcription of the genes, trafficking of the mRNAs, 
translation and then trafficking of the protein is all very carefully coordinated and 
regulated. Gain or loss of one copy of the Plp1 gene produces CNS myelinopathies as can 
be seen in humans with PMD and in transgenic rodents. The effects of increased Plp1 gene 
dosage on the myelination process are the focus of this study; therefore, P20 is ideal age to 
investigate the effects on peak myelination. 
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5.2 Aims 
The aim of this chapter was to investigate the effects of increased Plp1 gene dosage at peak 
myelination. This was on several fronts; 1) at the message/transcript levels of Plp/Dm20 
and other myelin genes, 2) at the PLP/DM20 protein level in CNS tissue, 3) how increased 
dosage affects other myelin proteins in the CNS, 4) what happens to the PLP/DM20 
produced, 5) whether stress responses such as the UPR are activated and 6) finally how 
myelin morphology overall is affected by any changes/differences caused by increased 
Plp1 gene dosage. 
5.3 Methods 
5.3.1 Animal breeding  
The breeding of the #66 hemizygous males with #66 hemizygous females was carried out 
as described in 2.2 Mouse Breeding. The offspring were genotyped as described (2.3 
Isolation and Manipulation of DNA) for the transgene and only male animals at P20 were 
used for this study (Figure 10). All three genotypes were used for this study. Hemizygous 
mice in this study were used prior to any demyelination changes in their myelin state. In 
contrast, mice homozygous for the transgene exhibit tremors from the second week 
followed later by seizures and thus were easily identified by eye. 
5.3.2 Sample Selection 
Tissues were collected from wild type, hemizygous and homozygous male mice at P20. 
Tails were taken for genotyping, brain and spinal cord for RNA and protein extractions. 
Brain cryosections were used for single or double immunofluorescence. Spinal cord 
sections were used to confirm genotypes and also for myelin morphology studies.   
5.3.3 Transcript Analysis   
5.3.3.1 Northern analysis  
This experiment was performed on total cellular RNA extracted from spinal cord. The 
procedure of northern transfer and hybridisation is described in 2.4.6 Northern Blotting. 
The preparation of radiolabelled probes is described also in 2.4.6 Northern Blotting.  
 5-140
Saadia Ansari Karim 2007    
Staining of the gel with ethidium bromide was used to check for equal loadings of sample 
and presence of bands in ladder and hybridisation with β-actin (a measure of invariant 
expression) was used to monitor equivalence of transfer. Hybridisation analysis was under 
taken using labelled cDNA products from PCRs using primers for Plp1 and Mbp (Table 2) 
(Figure 15). The blot was left for 3-4 weeks to allow the signal to decay then probed for β-
actin. 
5.3.3.2 qRT-PCR analysis 
Standard curves were produced using serial dilutions of an appropriate wild type RNA 
sample as described in 2.4.7 qRT-PCR. Once all the parameters for the reactions were set 
and equivalent for the genes, the test plate, containing Plp1, Mbp and β-actin reactions for 
the relevant samples selected, was run (2.4.7 qRT-PCR). The Plp1 and Mbp are labelled 
Plpall and Mbpall as the primer/probe sets were designed to amplify all isoforms. 
Set up of the experiment was as before and following the analysis protocol laid out in 2.4.7 
qRT-PCR the uncorrected concentrations of Plp1, Mbp and β-actin mRNA in 50ng total 
RNA loaded were calculated. The Plp1 and Mbp concentrations were then normalised to β-
actin and expressed as a percentage of wild type levels giving the actual concentration of 
Plp1 or Mbp message in total RNA.  
5.3.3.3 RT-PCR analysis of stress responses 
Standard RT-PCR experiments using cyclophilin and Xbp1 primers were carried out on 
cDNA from P20 spinal cord as described in 2.4.5 RT-PCR. 
5.3.4 CNS Myelin Analysis  
5.3.4.1 Myelin Preparation 
Myelin was prepared from powdered spinal cord or brain, protein was quantified and 
analysed by western blot as described in 2.5 Protein Analysis. Blots were immunostained 
for myelin proteins using AA3 (for PLP/DM20), MAG, MBP and CNP antibodies (Table 
5). Blots were also immunostained for BiP, an ER resident protein. 
5.3.5 Morphometric analysis 
To study neural development and maturation, glial cell quantification and myelin 
morphometry were performed on the ventral columns of spinal cord (C2-3) (2.6 Myelin 
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Morphological Analysis). Analysis at 20 days was chosen as a stage when the myelination 
process was at its peak in the CNS.  
To count the number of mature oligodendrocytes in sections of spinal cord CC-1 
immunostaining was carried out as described in 2.6.4.5 CC-1 staining of oligodendrocytes. 
5.3.6 Immunostaining 
Cyrosections from P20 brain were immunostained as described in 2.6.4.2 
Immunofluorescence.   
5.4 Results 
5.4.1 Identification of Genotype  
PCR using the Plp and T7 primers identified the presence or absence of the #66 transgene 
cassette. All animals negative for the PCR product were wild type and all animals positive 
for the PCR product were considering transgene positive. Dependant on age the transgene 
positive animals could either be homozygous or hemizygous. At P20 however the two 
genotypes are distinguishable by sight as the homozygous animals have tremors whereas 
the hemizygous animals look normal. To confirm the genotypes immersion fixed sections 
of spinal cord were also examined. 
5.4.2 Transcript Analysis of P20 wild type, hemizygous and 
homozygous animals 
Prior to electrophoresis on a denaturing northern gel 500ng total RNA from each animal 
was electrophoresed on a 1.5% agarose gel to check quality (Figure 11). 20µg total RNA 
from wild type, hemizygous and homozygous P20 spinal cord was then electrophoresed on 
a denaturing northern gel (Figure 13). In Figures 11 and 13 the three ribosomal species of 
RNA can be seen verifying the RNA has not degraded. The resulting blot was probed with 
Plp/Dm20 and β-actin (Figure 30A). The signals of the hemizgyous for β-actin and 
Plp/Dm20 (Hemi) are very similar to the signals of the wild type RNA (WT) suggesting no 
difference in Plp/Dm20 levels in the hemizygous animals in comparison to the wild type 
control. The signal for β-actin for the homozygous sample (Homo) is comparable but the 
Plp/Dm20 signal is lower than the signals for both wild type and hemizygous samples 
(Figure 30A WT and Hemi).  
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When analysed and normalised to β-actin, the message levels of Plp/Dm20 for the 
hemizygous RNA are not statistically different from wild type as demonstrated in Figure 
30B at 122% compared to 100%. This is true for the northern analysis and the qRT-PCR. 
However, there is a difference in Plp/Dm20 mRNA levels in homozygous samples. There 
is a decrease in message to 60% of wild type levels which is statistically significant (p 
<**0.01) in the northern analysis.  
The same blot was then hybridised with Mbp and shows there is no difference in Mbp 
levels between wild type and hemizygous samples but there is a decrease in Mbp message 
levels in homozygous RNA (Figure 30C). Mbp mRNA levels, representative of other 
myelin genes, are not different from wild type in the spinal cords of P20 hemizygous mice 
but reduced (p <**0.01) in homozygotes. The data (M ± SEM, N = 5) are expressed 
relative to wild type (Figure 30D).  
Wild type RNA from different time points was used to investigate development profiles of 
the two messages by qRT-PCR. Figure 30E shows the profile for Plp/Dm20 and Mbp from 
embryonic day 12 to postnatal day 80. The message levels for both peaks between 
postnatal day 10 and 20 then drop off towards P80. This concurs with the myelination state 
in the CNS where peak myelination is around P20 and then the oligodendrocytes are 
involved in maintenance of myelin in the CNS.   
5.4.3 PLP/DM20 levels in CNS 
Protein extracts from CNS tissue were studied in this section. Total homogenates, 
produced from spinal cord or brain from each genotype, were fractionated into myelin and 
pellet fractions. Western blots of each of the three sample types were immunostained for 
PLP/DM20 using the AA3 antibody (Figure 31A). There is a gradual decrease across the 
genotypes in PLP/DM20 levels in the total homogenate fraction with wild type having the 
most protein and the homozygous spinal cord the least. PLP/DM20 levels in the wild type 
and hemizygous myelin fractions are very similar but there is less PLP/DM20 protein the 
homozygous myelin.  
Surprisingly the pellet fraction shows a different PLP/DM20 profile. There is more 
PLP/DM20 protein in the pellet fractions of the hemizygous and homozygous spinal cord 
relative to the wild type spinal cord. The levels of PLP/DM20 in the total homogenate and 
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myelin fraction from homozygous mice are reduced compared with wild type whereas in 
the pellet fraction the converse applies (Figure 31A). 
In the spinal cord of hemizygotes at P20, the levels of PLP and DM20 in myelin-enriched 
fractions are not different from wild type littermates but are significantly lower in 
homozygous animals (Figure 31B). Similar results were obtained for myelin fractions from 
the brain (data not shown). In comparison with wild type (100%), the levels of PLP and 
DM20 are greater in pellet fractions from hemizygotes (158% ± 9 and 227% ± 28, 
respectively, N = 5, p<*0.05) while for homozygotes PLP was similar (124% ± 10, NS) 
and DM20 is elevated (207% ± 38, p<*0.05). 
5.4.4 Effects of increased dosage on other myelin proteins 
CNP, MAG and MBP were chosen to represent other myelin proteins in the CNS. As 
mentioned previously, MBP makes up 30% of myelin proteins in the CNS whereas MAG 
shares a similar translation and transport pathway with PLP/DM20. These proteins are 
present in the myelin fraction from spinal cord; therefore, myelin was immunostained on 
western blots for each protein (Figure 32A).  
All three proteins are reduced in homozygous mice (Figure 32A Homo) and MBP and 
CNP are also lower in hemizygotes (Hemi), compared with wild type (WT). In the 
hemizygotes, MBP (p <***0.001) and CNP (p <**0.05) are reduced relative to wild type 
while MAG levels are similar. All proteins are markedly lower (p <***0.001) in 
homozygous mice (Figure 32B). Only MBP is reduced in myelin prepared from 
hemizygous brain compared to in homozygous brain myelin where all three proteins are 
reduced (Figure 32C).  
To ensure equal loading 10 µg myelin fraction from each genotype was separated on a 
SDS-Page gel and stained with coomassie blue (Figure 32D). Many proteins are present on 
the gel and PLP and MBP stain very well and can be seen near the bottom of gel. A visual 
reduction of these proteins in homozygous myelin (Figure 32D Homo) can be observed 
compared to the wild type and hemizygous myelin fractions (Figure 32D WT and Hemi). 
Not all proteins stain well using coomassie blue, for example DM20 and one of the MBP 
isoforms are not visible on this gel.  
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However not all proteins are reduced in the homozygous animals relative to their wild type 
and hemizygous littermates (Figure 32D). A western blot of myelin proteins 
immunostained with anti-MOBP antibody shows a higher nonspecific protein in the myelin 
that is increased in the homozygous CNS.  
5.4.5 Stress responses in #66 animals 
No difference is seen in the induction of Xbp1 transcription between the three genotypes 
(Figure 33A). There are two forms of the Xbp1 mRNA, the inactive form Xbp1 (Unspliced) 
(Xbp1 (U)) and the active form Xbp1 (Spliced) (Xbp1 (S)). The message levels are similar 
for all the mice in spinal cord. Activation of Xbp1 converts some if not all the unspliced 
message to a spliced mRNA that is resistant to digestion by the restriction enzyme Pst1. 
When digested with PstI, only the unspliced form is digested (Figure 33B).  
BiP, a molecular chaperone implicated in protein folding, is upregulated when a cell is 
subjected to ER stress. However, no difference in BiP levels is seen between the three #66 
genotypes (Figure 33C). The levels of BiP are the same throughout the changes of Plp1 
gene dosage. 
5.4.6 Morphometric analysis of P20 #66 myelin in spinal cord and 
brain 
As shown above, Plp1 gene dosage has an influence on its transcript and protein levels as 
well as on other myelin gene products especially MBP. This in turn could have an impact 
on the formation of myelin in the CNS. Electron micrographs of cervical ventral columns 
of all three genotypes are shown in Figures 34A-C.  
A higher magnification electron micrograph of an oligodendrocyte cell body in a P20 #66 
homozygous spinal cord section is shown in Figure 35. There is a well developed RER, 
which is not obviously disrupted in this cell, vacuolation of the Golgi apparatus (arrow 1) 
and numerous autophagic vacuoles (arrow 2). 
The volume of myelin from P20 spinal cord of all the genotypes was quantified from 
electron micrographs of cervical ventral columns using a point counting method (Figure 
36A). Hemizygous animals contain slightly less myelin (81%) than wild type and are not 
significantly different whereas homozygous mice have considerably less myelin than the 
other two genotypes.  
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Morphometric analysis indicates that while axon diameters are similar in the three 
genotypes, the mean g ratio is elevated in hemizygous and more especially homozygous 
transgenic mice compared with wild type, due to a reduction in myelin thickness (Figure 
36B, C). The morphometric changes are reflected by differences in cervical cord area; both 
hemizygous (2.54 ± 0.03 mm2, n =6) and homozygous (2.14 ± 0.02) mice have reduced 
areas compared with wild type (2.89 ± 0.06, p <***0.001) and the two mutants differ from 
each other as well (p <**0.01).  
The myelin recovery from whole brain (expressed as myelin protein per unit weight of 
brain tissue) obtained during the biochemical fractionation is also assessed. There is no 
difference in recovery between wild type and hemizygous mice but markedly less myelin 
is obtained from the dysmyelinated homozygous mice (Figure 36D).  
The calculated number of CC-1+ oligodendrocytes in white matter per transverse section 
for P20 wild type, hemizygous and homozygous mice are 337 ± 13, 358 ± 12 and 349 ± 52 
cells/mm2, respectively; these values are not significantly different (data not shown).  
5.4.7 Storage of PLP/DM20 in the oligodendrocyte cell body 
As observed there is more PLP/DM20 present on the pellet fraction of CNS tissue from 
homozygous mice compared to wild type and hemizygous counterparts. To investigate 
where in the oligodendrocyte cell body the protein is situated cyrosections of brain were 
immunostained with a PLP antibody, anti-Lamp1 (an antibody for lysosomes) and DAPI 
for cell nuclei (Figure 37A, B). An oligodendrocyte cell body is strongly stained for 
PLP/DM20 throughout the majority of cytoplasm including regions containing Lamp1+ 
structures (Figure 37A). Further magnification shows intense co-labelling of structures 
within the cell body for PLP/DM20 and Lamp-1 (Figure 37B). Analysis of the circled area 
(Image-Pro Plus 6 co-localisation software) shows co-localisation (r = 0.68, overlap 
correlation = 0.925) between the two markers.  
MAG, which shares the same biosynthetic pathway as PLP/DM20, is also concentrated in 
oligodendrocyte cell bodies in homozygous mice whereas MBP, which has a different 
pathway, is not enriched in the soma and is present in the myelin ensheathing axons 
(Figure 38A, B). 
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5.5 Discussion 
In this chapter the effects of increased Plp1 gene dosage on peak myelination in mouse 
were investigated. In previous chapters the effects of the increased gene dosage on pre and 
early myelination were investigated as well as the contribution of the transgene only on the 
null background on message and protein levels. Very similar results are seen for Plp1 
transcript levels in #66 hemizygous animals pre myelination (Chapter 4) and during peak 
myelination at P20. Levels of Plp1 gene message are consistent with the levels seen with 
the transgene on a null background in Chapter 3. The hemizygous oligodendrocytes 
regardless of stage of CNS myelin development can produce normal levels of message.  
Readhead et al., (1994) found there were higher Plp1 transcripts levels in the hemizygous 
animals compared to the homozygous mice. In 4e-Plp mice generated by Kagawa et al., 
(1994) which contain 2 or 4 extra copies of the entire Plp1 gene including 5’ and 3’ 
noncoding regions, the Plp1 messages levels were at 132% in hemizygous animals. The 
message levels in homozygous mice were reduced to 60% of wild type levels. This reflects 
the findings in the #66 transgenic animals in this chapter. Mallon and Macklin (2002) put 
forward the proposal from evidence in their transfected cells and transgenic mice showing 
a decrease in endogenous Plp1 mRNA ranging from 30%-54% that extra copies of the 
3’UTR of the Plp1 gene can cause a downshift in endogenous Plp1 gene expression 
compared to wild type counterparts. As the Plp1 genes in the transgenic cassette are wild 
type and there is no distinguishable factor between them and the endogenous copy this 
down regulation may go some way to explaining the levels of Plp and Dm20 message in 
the hemizygous mice where levels are close to wild type levels. In homozygous mice the 
message levels are much lower and other issues such as threshold could be an influencing 
factor.  
There is a discrepancy between the message levels from qRT-PCR analysis and northern 
analysis. The trends are the same; Plp/Dm20 message is lower in the homozygous animals 
than in the hemizygous mice. Leske et al., (2004) also found discrepancies between their 
northern and qRT-PCR results. Although they observed differences in absolute values, the 
overall trends in mRNA levels were very similar between the methods. One of the major 
differences in the methods is quantity of initial sample, in the qRT-PCR it is only 50ng 
whereas the sample loaded onto a northern gel is 20µg.  
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With Mbp the message levels are reduced in homozygous mice (50%) but not in 
hemizygous CNS tissue. This is the case at all stages of myelinogenesis in the CNS.  This 
reflects the changes seen prior to peak myelination. The Mbp message is reduced in P3 
spinal cord at the stage where oligodendrocytes are just coming into contact with axons 
and only rudimentary sheaths are formed. The Mbp message levels in 4e-Plp mice were 
also similar to those in the #66 transgenic mice. The transcript levels were reduced from 
wild type > hemizygous > homozygous (Kagawa et al., 1994). Mbp message and protein 
levels were also reduced in Cnp overexpressing transgenic mice (Gravel et al., 1996) 
There is an increase in PLP/DM20 levels in oligodendrocytes prior to peak myelination in 
the homozygous animals compared to wild type animals. This, however, is reversed at 
peak myelination where there is less PLP/DM20 protein in the total homogenates. Less 
PLP/DM20 is also seen in the myelin enriched fraction from CNS tissue in the 
homozygous transgenic mice. Conversely, the pellet fraction of homozygous mice which is 
enriched in membranous organelles, nuclei and non-soluble components has more 
PLP/DM20 protein compared to wild type littermates.  
Wrabetz et al., (2000) generated transgenic mice with extra copies of the P0 PNS myelin 
protein. Animals with more than 20 copies of the Mpz gene developed a severe phenotype 
similar to homozygous #66 animals.  In one line, Tg80.3, containing 2 extra copies of the 
gene, P0 protein was overexpressed at P28 in sciatic nerves. Like the #66 mice at higher 
copy numbers the level of P0 protein fell and was associated with severe dysmyelination. 
Tg80.2 with 31 copies of Mpz gene had significantly reduced levels of P0 protein 
compared to controls. These findings are very similar to data from the #66 transgenic 
animals in this study. The PLP/DM20 protein levels in the 4e-Plp mice were lower than the 
message levels indicating, as in #66 animals, translational or post-translational 
irregularities affect levels. McLaughlin et al., (2006) also reported discrepancies between 
message and protein levels in the rumpshaker mice. They noted that although levels for 
PLP and DM20 per unit of myelin were 9% and 15% respectively, Plp mRNA was 66% of 
wild type levels. 
The increase in Plp1 gene dosage in these transgenic animals also causes a disruption to 
the other myelin protein studied in this project. CNP, MAG and MBP are all significantly 
reduced in the homozygous mice compared to wild type in both brain and spinal cord. In 
the hemizygous mice CNP and MBP are down in the spinal cord but CNP is not reduced 
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relative to wild type in the brain. In P0 overexpressor mice MBP levels were reduced in 
sciatic nerves to 50% normal wild type levels, as was PMP22, another PNS myelin protein 
(by 33%) (Wrabetz et al., 2000). As in #66 transgenic mice myelin protein levels are 
disturbed in Mpz transgenic mice regardless of dysmyelination. 
Over the course of this study more variability was found in the brain tissue for message, 
protein and also myelin status compared to spinal cord in all genotypes. This may possibly 
be due to the fact that the spinal cord is more uniformly myelinated compared to the brain. 
It was also noted that in general, hemizygous animals as a group showed more variability 
than the wild type or homozygous mice. This variation could be reflected in the differing 
ages of onset of demyelination and neurodegeneration seen in these animals. One possible 
theory is that the hemizygous animals with the lowest MBP at message and protein levels 
are the ones that will show signs of demyelination the earliest. MBP was suggested as the 
possible vital factor in causing disease pathology in myelination by McLaughlin et al., 
(2006) as MBP is critical for myelin formation and influences the amount of myelin 
formed (Shine et al., 1992). 
There is a marked reduction in PLP/DM20 and other myelin proteins in the homozygous 
CNS. As PLP/DM20 and MBP makes up to 80% of the myelin proteins in the CNS, this 
reduction has a marked effect on overall protein concentration in the sample. Wrabetz et 
al., (2000) suggested that in their P0 transgenic mice, overexpression of P0 may cause a 
reduction in the amount of other proteins detected by western blotting. However, there is 
an increase in Plp1 gene products at either the message or protein level in the #66 
transgenic mice that could explain the lowering of other myelin protein levels to such a 
degree.   
Equal loading of protein from the biological fractionation process is essential for proper 
quantification of protein levels so after meticulous quantification equal concentrations of 
proteins were loaded into the wells of SDS-Page gels. Coomassie blue staining of the 
myelin fraction allowed a visual check of loading. Unfortunately many proteins do not 
stain well therefore were not visible. Bands of unknown proteins appeared stained to the 
same intensity across the three genotypes. PLP and three isoforms of MBP were visible 
reduced in the homozygous sample when compared to the wild type and hemizygous 
myelin. It is possible that as proteins are reduced in the #66 transgenic animals, protein 
levels can also be increased. One example of this increase in protein levels was noted on 
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the MOBP stained western blot. Although like the other myelin proteins investigated in 
this study MOBP levels were decreased in homozygous mice a second nonspecific band 
higher up on the same blot was increased in the same sample. It is entirely possible there is 
a subpopulation of proteins in the homozygous mice that are increased due to the Plp1 
gene increase. 
The UPR (unfolded protein response) is triggered by the accumulation of unfolded or 
misfolded proteins in the ER (Shang 2005). It has a role to play or can be activated in the 
disease process in other myelin mutants such as rumpshaker (McLaughlin et al., 2007). 
Xbp1 and BiP both take part in this process and are upregulated in the CNS of these 
animals. The expression of the Xbp1 gene changes from the unspliced RNA product to the 
spliced RNA product upon the activation of the UPR. The spliced product is resistant to 
digestion by PstI therefore the difference in UPR between samples can be measured. 
Unlike in rumpshaker where there is a slight activation of Xbp1 producing the spliced 
products, all the Xbp1 gene product is digested in all three genotypes in #66 transgenic 
mice. No difference is observed in the induction of BiP between the wild type, hemizygous 
and homozygous #66 mice. These findings suggest that the UPR does not come into play 
in the #66 mice and this may be due to the fact that the protein produced by the transgenic 
cassette is wild type and not unfolded or misfolded in any way. 
Increase in Plp1 gene dosage causes a clear change in myelination state in the #66 mice. 
The axons myelinate in proportion to their diameter; the bigger the diameter of axon then 
the thicker myelin sheath insulating it. The hemizygous animals have slighter thinner 
sheaths than those of the wild type mice. However in the homozygous animals there is very 
little myelin ensheathing axons leaving many axons naked. An increase in Plp1 gene 
dosage, therefore, leads to a commensurate reduction in myelin formation in spinal cord. In 
the case of hemizygous mice this is subtle and due only to slightly thinner myelin sheaths. 
In the more severely affected homozygous mice this reduction is a combination of 
markedly thinner sheaths and amyelinated axons. Homozygous LewPLP rats also have a 
dysmyelinated CNS and this is due to the death of mature oligodendrocytes and the 
arrested development of immature oligodendrocytes (Bauer et al., 2002). The hemizygous 
rats are normal then demyelinate later in life, as do #66 hemizygotes (Chapter 6). 
Closer examination of the #66 homozygous oligodendrocytes showed abnormalities of the 
Golgi apparatus and vacuolar structures within the cell body. Similar abnormalities are 
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seen in LewPLP rats (Bauer et al., 2002) and 4e-Plp mice therefore are very unlikely to be 
an insertional effect or due to disruption of an important gene. In 4e-Plp mice at P14 and 
P20 the white matter in spinal cord of the homozygous animals contained either naked or 
very thinly sheathed axons. Swelling of the Golgi apparatus and abnormal vacuolar 
structures were observed in the oligodendrocytes of these animals (Kagawa et al., 1994).  
Overall myelin volumes in the spinal cord of #66 transgenic mice differ significantly 
between all three genotypes. There is a step reduction from wild type to homozygous 
myelin. This reduction in myelin volume is reflected in the increase in g ratios in the 
transgenic animals. The g ratio is the ratio between axon diameter and total fibre diameter 
including the sheath. As the myelin around the axon decreases the g ratio increases. Myelin 
sheath thickness (MT) should increase with axon diameter as shown by the scatter graph 
for wild type mice and the corresponding linear regression. However the slopes of 
regression lines for the transgenic mice are reduced compared with wild type and also 
differ from each other.  
As myelin recovery in the spinal cord was reduced, the myelin recovery from whole brain 
(expressed as myelin protein per unit weight of brain tissue) obtained during biochemical 
fractionation was also assessed. There was no difference in recovery between wild type 
and hemizygous mice but markedly less myelin was obtained from the dysmyelinated 
homozygous mice. The failure to detect subtle differences between wild type and 
hemizygous mice may indicate differences between myelination in brain and spinal cord or 
reflect the lower sensitivity of this technique compared with the morphometric analyses. 
Total levels of PLP/DM20 (as contained in total homogenates) are slightly lower than wild 
type, the reduction probably reflecting downregulation of myelin genes associated with 
dysmyelination. What is striking though is the alteration in distribution of PLP/DM20 with 
the somal pellet fractions containing more protein, relative to the low levels in the myelin 
sheath. There is more PLP/DM20 present in homozygous mice in oligodendrocytes in 
vitro, in P3 oligodendrocytes in spinal cord and in the pellet fraction of P20 spinal cord and 
brain.  
Where this extra protein is situated in the cell is a major question to be answered. 
Forebrain sections of P20 brain were immunostained for PLP/DM20 and Lysosomal-
associated membrane protein 1 (Lamp-1). Lamp-1 is a highly glycosylated protein in 
lysosomal membranes. Lysosomes represent the final destination for many endocytic, 
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autophagic and secretory molecules targeted for destruction or recycling but have more 
complex functions than simply being the end-point on a degradative pathway (Eskelinen et 
al., 2003). Co-localisation of PLP/DM20 and Lamp-1 was noted in the sections suggesting 
PLP/DM20 is stored in lysosomes in the oligodendrocyte cell body. Trajkovic et al., 
(2006) report degradation of PLP/DM20 does not occur in the late endosomes/lysosomes 
the protein is stored in as these organelles appear to be utilised for storage by the 
oligodendrocytes. Intense immunostaining of oligodendrocyte cell bodies in P3 spinal cord 
sections points to the likelihood the increased levels of PLP/DM20 are stored in the cell 
body from early on in the myelinogenesis. 
The quantitative change in PLP/DM20 protein amounts in myelin and pellet is matched by 
immunocytochemical demonstration of strong PLP/DM20 reactivity in the cell bodies in 
#66 transgenic mice and in the transgenic LewPLP rat model (Bauer et al., 2002, Bradl et 
al., 1999). Immunostaining and EM show that the strongly immunopositive 
oligodendrocyte cell bodies contain numerous autophagic vacuoles and lysosomes. PLP, 
when overexpressed, is known to associate with the endosomes/lysosome system (Simons 
et al., 2002).  
In normal myelination PLP may also associate temporarily with endosomes before axon-
derived signals promote its insertion into myelin (Trajkovic et al., 2006). A reduction in 
the available myelin and decreased axonal contact, as occurs in the #66 homozygous mice, 
would exacerbate the accumulation of PLP in lysosomes. Trajkovic et al., (2006) report 
PLP and Lamp-1 co-localisation only occurs in immature oligodendrocytes suggesting the 
oligodendrocytes in the #66 homozygous animals at peak myelination have arrested in 
development prior to full maturity. A range of membrane proteins of both myelin and non-
myelin origin were also concentrated in oligodendrocyte cell bodies in the Plp1 transgenic 
rats (Bauer et al., 2002). Schwann cells overexpressing P0 also concentrate the protein in 
their cell bodies due to the paucity of available myelin (Yin et al., 2000). PLP positive 
vacuoles were also observed in brain sections of Cnp overexpressing transgenic animals 
(Gravel et al., 1996).  
Similarities also exist with increased dosage of the PMP22 gene, the commonest cause of 
Charcot-Marie-Tooth disease type 1A. Transgenic rodent models of the disorder exhibit 
dysmyelination proportionate with Pmp22 dosage (Huxley et al., 1998, Niemann et al., 
2000) and Schwann cells contain autophagic vacuoles reminiscent of those seen in 
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oligodendrocytes in this study (Chies et al., 2003, Niemann et al., 2000). Additionally with 
increased Pmp22 dosage, dysmyelination of the peripheral nerves is associated with 
reduced levels of myelin proteins (Sereda et al., 1996), as occurred with the #66 Plp1 
transgenic mice. 
As suggested by Yin et al., (2000) and Wrabetz et al., (2000) there is dose dependant 
mechanisms involved in the myelination process in the three genotypes of the #66 animals. 
This is similar to the disease process in humans as PMD severity does correlate with levels 
of PLP1 copy number (Wolf et al., 2005). Patients with 3 copies of the PLP1 gene were 
more severely affected than patients with a duplication of the gene. However the patient 
with 5 copies of the gene was not any more severely affected than the patients with 3 
copies again suggesting a threshold effect of the disease process. How the threshold effect 
and the different fates of PLP/DM20 in the homozygous #66 animals induce 
dysmyelination in the CNS is still a matter for ongoing study.   
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Figure 30. Transcript analysis of P20 #66 spinal cord RNA.  
A) Representative northern blot for Plp/Dm20 and β-actin mRNA from spinal cord of P20 
mice demonstrating reduction in Plp1 transcript levels in homozygous P20 spinal cord. B) 
Quantification of Plp/Dm20 mRNA in P20 spinal cord, (M ± SEM, N = 5), expressed 
relative to wild type. The increase in hemizygotes is not significant whereas the level in 
homozygotes is reduced (p <**0.01). 
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Figure 30 (continued). 
C) Representative northern blot for Mbp and β-actin mRNA from spinal cord of P20 mice 
showing a reduction in Mbp mRNA in homozygous spinal cord (Lane 3) compared to both 
wild tyoe (Lane 1) and hemizygous spinal cord (Lane 2). D) Mbp mRNA levels, 
representative of other myelin genes, are not different from wild type in the spinal cords of 
P20 hemizygous mice but reduced (p <**0.01) in homozygotes. The data (M ± SEM, N = 
5) are expressed relative to wild type. E) Graph of steady state levels of all the transcripts 
produced by Plp1 and Mbp at different ages showing a very similar developmental profile 
for the two genes with an increase in levels in the lead up to peak myelination at P20 then a 
slight reduction at P80. 
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Figure 31. PLP/DM20 protein analysis in #66 animals at P20.  
A) Representative western blot for PLP/DM20 of myelin enriched and pellet fractions and 
the total homogenate (TH) from spinal cord of P20 mice highlighting a reduction in total 
PLP/DM20 amounts (as seen in TH) and amount in myelin in the homozygous spinal cord 
(Homo) with a corresponding increase in the amounts of PLP/DM20 in the pellet fraction. 
B) Steady state levels of PLP and DM20 proteins in myelin fractions from P20 mice show 
no change from wild type in hemizygous animals but significant reductions down to 50% 
of wild type levels in homozygous mice (M ± SEM, N = 5, p <*0.05). 
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Figure 32. Increased Plp1 gene dosage affects expression of other myelin protein 
genes.  
A) Representative western blots of myelin enriched fractions from P20 spinal cord probed 
for MBP, CNP and MAG showing a marked reduction in amounts of all three proteins in 
homozygous spinal cord (Homo). B) Levels of MBP, CNP and MAG in myelin enriched 
fractions from spinal cord of P20 hemizygous and homozygous mice highlighting the 
significant decrease in all three proteins in homozygous tissue (p <***0.001) and a less 
marked reduction in CNP and MBP levels in hemizygous tissue (p <*0.05, **0.01) (M ± 
SEM).  
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Figure 32 (continued). 
C) In myelin enriched fractions from whole brain of P20 mice only MBP (p <***0.001) is 
reduced in hemizygous animals while all three proteins are lower in homozygous mice (p 
<*0.05, ***0.001) (M ± SEM). D) Coomassie blue staining of 10µg myelin separated on a 
SDS-Page gel showing the positions of PLP and some isoforms of MBP. E) Representative 
western blot of myelin enriched fraction from P20 spinal cord probed for MOBP showing 
reduction in levels corresponding to genotype, however higher band showing increasing 
amounts coresponding to genotype (WT wild type, Hemi hemizygous and Homo 
homozygous). 
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Figure 33. Stress responses in #66 transgenic mice.  
A) Agarose gel of Xbp1 PCR with cDNA from P20 spinal cord of all three genotypes, (WT 
wild type, Hemi hemizygous, Homo homozygous and M 1kb plus ladder). B) Agarose gel 
image of PstI digested Xbp1 PCR, all PCR product is digested thus was Xbp1 (U) showing 
no difference in stress responses in the three genotypes. C) Western blot of BiP 
immunostaining showing no difference between the three genotypes (WT wild type, Hemi 
hemizygous and Homo homozygous). 
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Figure 34. Electron micrographs of white matter in the ventral columns of P20 mice. 
A) Wild type mouse with all axons surrounded by an appropriately thick myelin sheath. B) 
All axons are myelinated in the hemizygous mouse in which the general structure appears 
normal; morphometric analysis showed that the average sheath was slightly thinner than its 
wild type counterpart. C) The homozygous mouse is dysmyelinated with thin myelin 
sheaths around the majority of axons. An oligodendrocyte cell body is abnormal and 
contains numerous autophagic vacuoles (arrow). Bar = 2 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Oligodendrocyte cell body from spinal cord white matter of P20 
homozygous transgenic mouse. 
There is a well developed RER, which is not obviously disrupted in this cell, vacuolation 
of the Golgi apparatus (arrow 1) and numerous autophagic vacuoles (arrow 2). Bar = 1μm. 
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Figure 36. Myelin status of wild type and transgenic mice at P20.  
A) Myelin volume in ventral columns of cervical spinal cord was determined from electron 
micrographs using a point counting method. Values are reduced in both transgenics 
compared with wild type and also differ with each other. B) The g ratio is increased in 
transgenic mice compared with wild type. The ratio provides an indication of whether the 
thickness of myelin sheath is appropriate for axon diameter; a higher value indicates a 
disproportionately thin sheath. C) Myelin sheath thickness (MT) should increase with axon 
diameter as shown by the scatter graph for wild type mice and the corresponding linear 
regression. The slopes of regression lines for the transgenic mice are reduced compared 
with wild type and also differ from each other. The individual points for the transgenics are 
not shown. D) Myelin recovery from whole brain is similar in mice hemizygous for the 
transgene and wild type; both groups differ from homozygous mice. The level of proteins 
in myelin is expressed as a proportion of the dry weight of whole brain. (The bar charts 
show M ± SEM, N = 6 for A, B, C & 10 for D, p<** 0.01, ***0.001). 
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Figure 37. PLP/DM20 immunostaining of P20 homozygous forebrain. 
A) Forebrain from P20 homozygous mouse immunostained for PLP/DM20 and Lamp1 and 
stained for DAPI.  B) A confocal slice (0.5μm) through the cell body shows several 
structures co-labelled for PLP/DM20 and Lamp1. Bars = 50μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Forebrain from P20 homozygous mice immunostained.  
A) Immunostained for MAG and PLP. B) MBP, PLP and SMI-31 to show axons.  
Oligodendrocytes in the cortex and corpus callosum (CC) are intensely stained for PLP and 
MAG (arrows) but not for MBP. The myelin sheaths are stained for all three myelin 
proteins. Bars = 100μm. 
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6 Effects of Increased Plp1 gene dosage on 
Maintenance of Myelination (P60) 
6.1 Background  
Once myelination has occurred, oligodendrocytes in the CNS are involved in maintenance 
of the myelin. This, as it suggests, does not require as much energy as myelination itself 
and there is less physiological pressure on the cell. Homozygous #66 mice die prematurely 
after suffering tremors and developing seizures, as mentioned in the previous chapter. Most 
are culled as soon as seizures occur or at P20 to avoid any suffering by the animal. 
Therefore oligodendrocytes in homozygous mice are not involved in the prolonged 
maintenance of any myelin they may have in their CNS.  Hemizygous mice however live 
for a potentially normal murine life span thus can be used for the study of effects of 
increased Plp1 gene dosage on maintenance of myelin.  
Myelination in the mouse starts in the spinal cord at birth; therefore the myelination status 
is more uniform compared to the brain at P20 or P60. Myelination is achieved in most 
regions in the brain around P45-60 (Baumann and Phin-Dinh, 2001). Anderson et al., 
(1998) noted that hemizygous #66 mice show signs of late-onset neurodegeneration 
associated with demyelination. Other phenotypic symptoms include axonal degeneration, 
astrocytosis and microgliosis. Some animals go on to develop tremors. The age of onset 
varies greatly between animals with some exhibiting signs of 
demyelination/neurodegeneration as early as P120 and some remain healthy until they die 
of old age. However, hemizygous animals at P60 are unlikely to be suffering from any 
phenotypical abnormalities as this age is prior to any changes previously observed and 
there is no difference in gross appearance in the mice as the hemizygous animals at P60 are 
similar in weight to P60 wild type animals (Anderson 1997). These mice may have 
abnormal pathology but this has not had an effect on the phenotype of these animals. 
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6.2 Aims 
The aims of this study were to describe the effects of increased Plp1 gene dosage on 
maintenance of myelin in mature transgenic animals, through comparison to their wild type 
littermates. The message and protein levels of PLP/DM20 and representative myelin 
proteins, along with morphometric analysis of CNS myelin composition were chosen as 
descriptors of the activity. 
6.3 Methods 
These studies were carried on spinal cord and brain where appropriate from P60 male 
hemizygous mice and their wild type littermates. P60 mice were chosen in the light of the 
temporal characteristics of CNS myelination and the late-onset demyelination known to 
occur in these mice (see 6.1 Background). 
6.3.1 Animal breeding  
The breeding of the mice was carried out as described in 2.2 Mouse Breeding. The 
offspring were genotyped as described (2.3 Isolation and Manipulation of DNA) for the 
transgene.     
6.3.2 Sample Selection 
Tissues from wild type mice (n.3) and those hemizygous (n.6) for the #66 transgene were 
used. Tails were taken for genotyping, spinal cord for tissue culture studies, or RNA and 
protein extractions.  
6.3.3 Transcript Analysis   
6.3.3.1 Northern analysis  
This experiment was performed on total cellular RNA extracted from spinal cord. The 
procedure of northern transfer and hybridisation is described in 2.4.6 Northern Blotting. 
The preparation of radiolabelled probes is described also in 2.4.6 Northern Blotting.  
Staining of the gel with ethidium bromide was used to check for equal loadings of sample 
and presence of bands in ladder and hybridisation with β-actin (a measure of invariant 
expression) was used to monitor equivalence of transfer. Hybridisation analysis was 
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undertaken using labelled cDNA products from PCRs using primers for Plp1 and Mbp 
(Table 2) (Figure 15). The blot was left for 3-4 weeks to allow the signal to decay then 
probed for β-actin. 
6.3.3.2 qRT-PCR analysis 
Standard curves were produced using serial dilutions of an appropriate wild type RNA 
sample as described in 2.4.7 qRT-PCR. Once all the parameters for the reactions were set 
and equivalent for the genes, the test plate, containing Plp1, Mbp and β-actin reactions for 
the relevant samples selected, was run (2.4.7 qRT-PCR).   
Set up of the experiment was as before and following the analysis protocol laid out in 2.4.7 
qRT-PCR the uncorrected concentrations of Plp1, Mbp and β-actin mRNA in 50ng total 
RNA loaded were calculated. The Plp1 and Mbp concentrations were then normalised to β-
actin and expressed as a percentage of wild type levels giving the actual concentration of 
Plp1 or Mbp message in total RNA.  
6.3.4 CNS Myelin Analysis  
6.3.4.1 Myelin Preparation 
Myelin was prepared from spinal cord and brain and protein concentrations were 
quantified and analysed by western blot as described in 2.5 Protein Analysis. Blots were 
immunostained for PLP/DM20 using C-terminal antibody PLP 226, MAG, MBP and CNP 
(Table 5). The results of the hemizygous protein analysis were quantified compared with 
wild type protein amounts. Total homogenates were immunostained for ASPA, a marker 
for oligodendrocytes and GFAP (Glial fibrillary acidic protein), a protein produced by 
astrocytes. 
6.3.5 Morphometric analysis 
To study neural development and maturation, glial cell quantification and myelin 
morphometry were performed on the ventral columns of spinal cord (C2-3) (2.6 Myelin 
Morphological Analysis). Analysis at 60 days was chosen as a stage when neural 
development was complete and there was no phenotypic abnormalities seen in the animals. 
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6.4 Results 
6.4.1 Identification of Genotype  
PCR using the Plp and T7 primers identified the presence or absence of the #66 transgene 
cassette. All animals negative for the PCR product were wild type and all animals positive 
for the PCR product were considered transgene positive. Dependant on age the transgene 
positive animals could either be homozygous or hemizygous, as in this chapter the male 
#66 mice were P60 and all homozygous animals were culled before this age they were all 
hemizygous. This was confirmed by resin sections as mentioned in previous chapters for 
genotyping. 
6.4.2 Transcript Analysis of P60 wild type and hemizygous #66 
male mice 
As described previously 20µg total RNA from wild type and hemizygous P60 spinal cord 
was separated by size through electrophoresis on a denaturing northern gel (Figure 39A). 
The resulting blot was probed with Plp/Dm20 and β-actin (Figure 39B). The signals of the 
hemizgyous for β-actin and Plp/Dm20 are stronger (Hemi) compared to the signals of the 
wild type RNA (WT) suggesting a very slight increase in Plp/Dm20 levels in the 
hemizygous animals in comparison to the wildtype control. The same blot was then 
hybridised with Mbp identifying a slight reduction in Mbp levels in the hemizygous RNA 
(Hemi) compared to the wild type RNA (Figure 39C).  
When analysed and normalised to β-actin, the message levels of Plp/Dm20 and Mbp are 
not statistically different to wild type as demonstrated in Figure 39D. The trend therefore is 
similar to in P20 hemizygous mice, in fact there is no difference in amounts of Plp/Dm20 
and Mbp in the hemizygous animals compared with wild type (previous Chapter).  
6.4.3 Protein Analysis of P60 wild type and hemizygous #66 male 
mice  
Proteins from brain and spinal cord were studied in this section. The western blots from the 
brain tissue are not shown but the data are represented in a graph (Figure 40A). Both PLP 
and DM20 are increased compared to P60 wild type littermates; however, this increase is 
not significant. MBP, CNP and MAG are decreased to a varying degree in hemizygous 
brain myelin compared to levels in wild type brain myelin. Once again this decrease in 
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levels of myelin proteins is not statistically significant. Two non-myelin proteins, ASPA 
and GFAP, were also examined. There is also no statistical difference in the amounts of 
these proteins in comparison to wild type levels.  
Figure 41B demonstrates the immunostained blots for the four myelin proteins investigated 
in this thesis. Visually there is no difference in amounts between the two genotypes (WT 
wild type and Hemi hemizygous) for any of the proteins (shown in order of size). When 
plotted as a graph, the average levels for each of these proteins do not differ from to the 
wild type levels. There is less inter-animal variation in protein levels between animals for 
the spinal cord in comparison to the levels in the brains of the same hemizygous animals 
(Figure 40A and C). 
6.4.4 Morphometric Analysis of P60 Myelin 
Electron micrographs of cervical sections of P60 spinal cord are demonstrated in Figure 
41A and B. The wild type P60 spinal cord in Figure 41A shows appropriately thick myelin 
sheaths wrapping all the axons in the spinal cord. The slight distortion of the central large 
axon’s sheath was probably caused by sub-optimal prefusion of the animal. However, the 
axons are all ensheathed by myelin of the appropriate thickness for the diameter of the 
axon. A normal looking oligodendrocyte is also in the EM (arrow Figure 41A).  
The electron micrograph of the hemizygous spinal cord section is shown in Figure 41B. 
There is no apparent visual difference in the myelin between the wild type and the #66 
hemizygous P60 cords. All axons are ensheathed by tightly packed, highly structured 
myelin sheaths of appropriate thickness for the axons. There is no difference in myelin 
volume between P60 wild type and hemizygous spinal cords (Figure 41C). The g ratios in 
both genotypes are the same (Figure 41D). The variation in the volume of myelin and g 
ratios as seen by the error bars is very small for the spinal cord.   
There is also no difference observed in axon diameter versa myelin thickness (Figure 41E). 
All these measurements were preformed on the spinal cord of P60 wild type and #66 
hemizygous animals. Overall, in all aspects of myelin morphology studied, no difference 
could be observed between the #66 hemizygous animals and their wild type littermates. 
There is no difference in myelin volume in the brain between the two genotypes (Figure 
41F). 
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6.5 Discussion 
In this chapter the effects of Plp1 gene dosage on the maintenance of myelin at P60 were 
investigated. Prior to and during peak myelination the hemizygous #66 mice produced 
similar to wild type levels of Plp/Dm20 message. This is still the case at P60 when 
myelination is complete in the spinal cord. There is no increase in Plp/Dm20 message to 
the levels implied by Plp1 copy number at any stage of the myelination process in 
hemizygous animals. Even with the 7 extra copies of the wild type Plp1 gene present, in 
these animals the oligodendrocyte appear to be able to control the expression levels 
ensuring similar levels to normal are produced. This was also observed when the transgene 
was on the Plp1 null background (Chapter 3).  
mRNA levels for Mbp were also unchanged in the hemizygotes compared with wild type 
in P60 animals. This was not the case at earlier ages where Mbp message levels were 
reduced even when the Plp/Dm20 transcript levels were normal. The increased Plp1 gene 
dosage even at the low dosage level of hemizygous animals affects Mbp message in an 
adverse manner but the oligodendrocyte is able to correct this imbalance or deficit in 
transcript by maturation of the myelin at P60. 
At the protein level there was again no difference in PLP and DM20 compared to the wild 
type in either brain or spinal cord. This reflects the observations for message levels for PLP 
and DM20. When the other myelin proteins were investigated in both brain and spinal 
cord, levels in hemizygous animals were comparable to wild type levels. There was no 
difference between the two genotypes in the protein levels of PLP, DM20, MBP, CNP and 
MAG in myelin from brain or spinal cord. There is however more variation in the protein 
levels for the hemizygous brain compared to the hemizygous spinal cord. This may be 
attributed to the status of myelination in the brain in comparison to the spinal cord. The 
process of myelination is completed in most brain regions by P45-60, therefore it is 
possibly that the entire brain was not fully myelinated or myelinated to the same extent in 
the all the animals used in this study.  
At peak myelination, MBP and CNP were significantly reduced in hemizygous myelin, 
MBP protein levels were also reduced in oligodendrocytes in vitro and in premyelinating 
oligodendrocytes at P3. However this difference has resolved during completion of 
myelination. Neither CNP or MBP are reduced at P60, moreover both proteins are 
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comparable to wild type levels. As with the message levels for Mbp, the hemizygous 
oligodendrocytes have controls for the decrease of protein and over time compensate for 
the loss.    
Apparently the oligodendrocytes not only have the ability to compensate for the reduction 
in message or protein but also for the reduction in overall myelin volume. At P20, myelin 
volume in hemizygous spinal cord was significantly reduced compared to wild type 
(Chapter 5) yet by P60 the myelin volume in the two genotypes is the same. Concurrently, 
there is a subtle myelin defect due to a slight reduction in sheath thickness at P20, which 
also recovers by age P60. There is no variation in the myelin volume, g ratio or axon 
diameter/myelin thickness relationship in spinal cord at this age either.  
Unlike with the variation between genotypes in protein levels in brain compared to spinal 
cord there are no differences in the overall myelin volume of the brain between the two 
genotypes. Myelin protein expressed as a proportion of the dry weight of whole brain is 
shown in Figure 41F. Myelin is prepared from powdered whole brain thus eliminating the 
variation between regions of the brain. These results concur with the findings by Anderson 
(1997), who observed no difference in glial cell density or myelin volume between the two 
genotypes. The cervical cord white matter was also similar between wild type and 
hemizygous animals.  
The recovery of protein levels and myelin volume by P60 in hemizygous animals indicates 
that there is possibly a recovery mechanism that comes in play during maturation of 
myelin. The actual mechanism of this possible recovery is not yet known. However this 
recovery process is likely to be temporary as dependant on age the hemizygous animals 
suffer from signs of demyelination and neurodegeneration. It is likely as MBP message and 
protein are the most affected through development and myelination of the CNS that the 
loss of the oligodendrocytes’ ability to sustain normal levels of MBP is a contributing 
factor to the breakdown of maintenance leading to loss of myelin.   
MBP is considered very important in the formation of myelin. Studies on shiverer mice 
which carry a large deletion of the MBP gene have demonstrated that MBP is essential to 
the formation of intact myelin (Fitzner et al., 2006). It has been suggested by both 
Campagnoni and Skoff (2001) and Harauz and colleagues (2004) that it acts as a lipid 
coupler due to the interaction of the highly positively charged MBP to the negatively 
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charged cytoplasmic membrane surface. Therefore without MBP there would be no 
apposition of adjacent membrane surfaces in myelin.  
McLaughlin et al., (2006) have also put forward the hypothesis that MBP is the important 
protein in regards to levels in myelin and loss of myelin. In their study levels of MBP were 
markedly reduced in rumpshaker oligodendrocytes and particularly when the mutation was 
expressed on the C57BL/6 background (McLaughlin et al., 2006, Al-Saktawi et al., 2003). 
In ongoing studies (Barrie et al., unpublished) the C57 rumpshaker mice were 
complemented with wild type Plp1 (#66) transgene, increasing their PLP/DM20 levels to 
normal. Surprisingly, MBP levels remained low and severe dysmyelination was still 
present. It is, therefore, possible that the low levels of MBP in rumpshaker contribute to the 
hypomyelination. Unlike protein levels, Mbp mRNA levels were only minimally reduced, 
suggesting the rumpshaker mutation operates at a translational or post-translational level to 
perturb MBP, presumably through the action of misfolded PLP/DM20 through an, as yet, 
unknown mechanism.  This may be true for the #66 mutation where, through excess copies 
of the wild type gene, the burden on the cell and resulting changes may lead to perturbation 
of MBP production. 
In other transgenic hemizygous animals carrying extra wild type copies of the Plp1 gene 
abnormalities show up fairly early on in life. In transgenic heterozygous 4e-Plp mice 
generated by Kagawa et al., (1994) containing 2 extra copies of the Plp1 gene the first sign 
of myelin degeneration was noted at P71. Heterozygous 4e-Plp oligodendrocytes contained 
abnormal vacuoles similar to those observed in #66 homozygous oligodendrocytes. As 
with the #66 hemizygous mice that show late-onset neurodegeneration, the 4e-Plp 
heterozygotes also developed signs consistent with neurodegeneration, such as hind limb 
tremors and ataxia after several months. The onset of myelin degeneration was 2-3 months 
after birth in these animals. 
In hemizygous Plp1 transgenic rats profound regional differences in oligodendrocyte 
physiology were noted (Bauer et al., 2002). Oligodendrocytes and myelin sheaths 
displayed pathological changes in the CNS gray matter when compared to 
oligodendrocytes in the white matter. They studied spinal cord sections from 7-week wild 
type and hemizygous adults and revealed 26% less myelin in the gray matter of 
hemizygotes. There was no difference seen in the white matter. Vacuolation of myelin in 
the gray matter was also seen at 7 weeks, as was the presence of abnormal vacuoles in the 
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cell bodies. Hemizygous transgenic mice eventually progress to clinically overt 
demyelination, which usually starts 6–7 months or 12–18 months after birth dependant on 
the line. Interestingly, despite having identical transgene sequences as the transgenic mice, 
the 18-month-old hemizygous transgenic rats remain healthy and do not develop this 
profound demyelination. 
Later in life the #66 hemizygous animals do go on to develop signs of demyelination with 
varying age of onset of these signs. What causes this variation is not yet known but one 
possibility is that the #66 hemizygous animals with the lower end of the MBP levels at a 
young age develop degeneration sooner than the animals with the higher MBP levels. How 
this could be investigated is still to be worked out. The possibility that the recovery process 
between P20 and P60 in the hemizygous animals fails in the run up to the first 
abnormalities and leads to loss of myelin proteins, volume and overall morphology has to 
be thoroughly investigated in the future.  
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Figure 39. Transcript analysis of P60 wild type and hemizygous message.  
A) 20µg P60 wild type and hemizygous spinal cord RNA separated on a denaturing gel. B) 
The resulting blot probed for Plp/Dm20 and β-actin showing similar levels of Plp1 
transcript when utilising β-actin levels for the comparsion. C) The same blot then 
hybridised with a Mbp probe showing lower Mbp transcript levels in the Hemi sample. D) 
Transcript analysis graph (northern hybridisation and qRT-PCR) showing mRNA levels of 
all Plp/Dm20 and Mbp transcripts in P60 hemizygous spinal cord compared to wild type 
levels (line at 100%).   
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Figure 40. Protein analysis of P60 brain and spinal cord myelin.  
A) Graph showing average protein % in P60 hemizygous brain relative to wild type (line at 
100%) showing no difference between the two (ASPA and GFAP in total homogenates and 
others in myelin). B) Western blots from P60 spinal cord myelin immunostained for MAG, 
CNP, PLP/DM20 and MBP highlight the similar levels for the proteins in both wild type 
and hemizygous CNS (WT wild type and Hemi hemizygous). 
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Figure 40 (continued). 
C) Graph showing average protein % in P60 hemizygous spinal cord myelin relative to 
wild type demonstrate the lack of difference for all proteins studied in hemizygous spinal 
cord compared with wild type (line at 100%). 
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Figure 41. Electron micrographs and graphs of P60 wild type and hemizygous 
animals’ myelin morphology. 
A) Electron micrograph of P60 wild type spinal cord section. B) Electron micrograph of 
P60 hemizygous spinal cord section. No difference in amount of myelin or thickness of 
sheath can be observed between the two animals. Bar = 5µm. 
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Figure 41 (continued). 
C) Quantitative data of myelin volume in P60 spinal cord. D) Quantitative data of G Ratio 
between both genotypes. No difference is detected between wild types and hemizygotes 
using either myelin volume measurements in spinal cord or g ratios. 
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Figure 41 (continued). 
E) Quantitative data of Axonal Diameter versa Myelin Thickness in P60 spinal cord. 
F) Quantitative data of myelin volume in P60 brain of both genotypes. No difference is 
detected between wild types and hemizygotes using either axon diameter via myelin 
thickness or myelin volume in brain. (Results M ± SEM, WT N = 3 Hemi N = 6) 
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7 Effects of Increased Plp1 gene dosage on 
PLP/DM20 Dynamics 
7.1 Background 
Proteins are constantly synthesised and degraded in cells and the rate is dependant on the 
protein but can vary under different conditions (Ciechanover 2005) In general proteins can 
be divided into short-lived rapid turnover proteins and long-lived slow turnover proteins. 
Their rate of turnover is influenced by their function. Myelination of the CNS requires a 
mass and concerted production of proteins and lipids and transport of these in the correct 
proporation to the myelin membrane by the oligodendrocytes. How the oligodendrocyte 
handles the synthesis, incorporation and degradation of any given protein within the 
process is an important area of study. In rumpshaker animals, synthesis of PLP and DM20 
in oligodendrocytes is similar in profile and intensity to that of wild type oligodendrocytes 
(McLaughlin et al., 2006). The difference between the two genotypes is seen at the 
degradation level where rumpshaker PLP/DM20 is degraded faster than wild type 
PLP/DM20 (McLaughlin et al., 2006).  
The proteasome, which degraded many proteins including wild type proteins, is involved 
in the degradation of misfolded proteins exiting the ER as part of Endoplasmic Reticulum 
(ER)-Associated Degradation (ERAD) (Meusser et al., 2005).  To elucidate the role of the 
proteasome in degradation of rumphaker PLP and DM20 in the CNS MG132 an inhibitor 
of the ubiquitin–proteasome pathway in mammalian cells was utilised. McLaughlin et al., 
(2006) discovered MG132 blocked the degradation of wild type and rumpshaker 
PLP/DM20 indicating the proteasome is indeed involved the degradation of these proteins 
in the CNS. Whether this is the case for the PLP and DM20 produced by the #66 
transgenic animals is matter for investigation. 
Another aspect of the dynamic nature of PLP/DM20 and myelination is the association of 
proteins in specialised lipid domains that are detergent resistant known as lipid rafts. 
Simons et al., (2000) discovered that PLP/DM20 was recovered from cultured 
oligodendrocytes in a low-density CHAPS-insoluble membrane fraction (CIMF) enriched 
in myelin lipids. PLP was associating with the CIMF after leaving the endoplasmic 
reticulum but prior to exiting the Golgi apparatus, suggesting that myelin lipid and protein 
 7-178
Saadia Ansari Karim 2007    
components assemble in the Golgi complex. Correct association of PLP/DM20 with certain 
lipids to form myelin rafts may be critical to for the sorting of PLP/DM20 and assembly of 
myelin (Simons et al., 2000). 
7.2 Aims 
The main objective of this section was to investigate the effects of increased Plp1 gene 
dosage on the dynamics of protein synthesis and degradation. Previously the effects on 
static transcript and protein levels at various ages were examined. How oligodendrocytes 
manage the balance of synthesis and degradation normally in the whole myelination 
process is of vital importance for understanding myelin formation and stability. What 
happens in the disease state as in PMD with extra copies of the normal gene is therefore an 
essential part of the understanding of this disease. The possible pathway involved in the 
degradation of PLP and DM20 was also an area to investigate. Another important aspect of 
the study was whether oligodendrocytes from #66 transgenic animals could form myelin 
rafts consisting of PLP and DM20 and essential lipids such as cholesterol. 
7.3 Methods 
Synthesis rate studies were carried on brain from P20 (early adulthood) male wild type, 
hemizygous and homozygous littermates for the brain slice experiments. The synthesis, 
degradation and blocking of proteasome degradation experiments were carried out on 
primary oligodendrocyte cultures from P5 spinal cord from all three genotypes.  
7.3.1 Animal breeding  
The breeding of the #66 hemizygous males with #66 hemizygous females was carried out 
as described in 2.2 Mouse Breeding. The offspring were genotyped as described (2.3 
Isolation and Manipulation of DNA) for the transgene and only male animals at P5 or P20 
were used for this study.    
7.3.2 Sample Selection 
Tissues from mice wild type, hemizygous and homozygous for the #66 transgene were 
used. Tails were taken for genotyping, spinal cord for tissue culture studies and brain for 
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brain slice experiments. Spinal cords from P5 animals were also used for genotype 
identification (Chapter 4). 
7.3.3 Primary cell cultures 
Spinal cord from P5 males pups were used to set up primary cell cultures as described in 
2.5.4.1 Primary cell culture. 
7.3.3.1 Synthesis 
Protein synthesis in culture was investigated as described in 2.5.4.4.1 Synthesis. All values 
are expressed relative to the T0 sample. 
7.3.3.2 Degradation 
Degradation of newly synthesised proteins was studied in primary oligodendrocyte cultures 
using the pulse/chase method described in 2.5.4.4.2 Degradation of proteins using 
Pulse/Chase experiments. All values are expressed realtive to the T0 sample. 
7.3.3.3 Blocking of Proteasome mediated Degradation 
The effects of blocking a degradation pathway using a chemical compound (MG132, an 
inhibitor of proteasomes and calpains) were investigated (2.5.4.4.3 Blocking of 
Degradation). All values are expressed realtive to the T0 sample. 
7.3.4 Brain Slice system 
Whole brains from P20 male animals were used to study the synthesis rates of PLP and 
DM20 at peak myelination (2.5.5 Synthesis at P20). Incorporation of newly synthesised 
PLP and DM20 in myelin fraction was also investigated. All values are expressed relative 
to total homogenate/synthesis T . 2
7.3.5 Lipid Rafts 
Lipid rafts were isolated from myelin produced from wild type and #66 homozygous CNS 
tissue as described in 2.5.2.1 Lipid Raft Preparation.  
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7.4 Results 
7.4.1 Identification of Genotype 
PCR using the Plp and T7 primers identified the presence or absence of the #66 transgene 
cassette. All animals negative for the PCR product were wild type and all animals positive 
for the PCR product were considered transgene positive. Dependant on age and whether 
the mice exhibit a phenotype, the transgene positive animals could either be homozygous 
or hemizygous. Both hemizygous and homozygous animals were available at P5 and P20. 
The genotype at P20 was confirmed visually prior to tissue collection as the animals have 
developed tremors by this age. At P5 genotypes were all confirmed by resin sections as 
shown in Chapter 4. 
7.4.2 Newly Synthesised PLP and DM20 in Oligodendrocytes 
Due to the nature of genotyping it was only possible to produce only two dishes of cells 
from each spinal cord. Therefore to study synthesis of protein over time one plate was 
treated for 45 minutes with [35S]-ProMix (cysteine/methionine) labelled HBSS medium 
while the other was treated for 90 minutes. Figure 42A shows phosphorimages of newly 
synthesised (radiolabelled) PLP and DM20 from all three genotypes at the two time points. 
An increase in the amount of newly synthesised PLP and DM20 can be seen at 90 minutes 
compared to 45 minutes in all three genotypes. When the blots were then probed with anti-
PLP 226 antibody, the total PLP and DM20 present in the lysates was immunostained. The 
amounts of total PLP and DM20 in the lysates were the same over both time points in each 
genotype.  
The change in newly synthesised PLP and DM20 over time was quantified and illustrated 
graphically (Figure 42B). There was no significant difference in synthesis of PLP or DM20 
over time between wild type and hemizygous mice. However the rate of translation 
expressed as percentage change per minute of PLP in cultures from homozygous mice was 
significantly lower, relative to wild type and hemizygous mice, more so compared to wild 
type. For DM20 the rate was only significantly different between cultures from wild type 
and homozygous mice. As with all detection techniques there is an optimal range of 
detection and sensitivity in the system and it is essential to ensure the best exposure for 
each experiment is found.        
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7.4.3 Degradation of Newly Synthesised PLP and DM20 over time 
Degradation rates were also studied in oligodendrocyte cultures. As before, only two 
dishes were available from each spinal cord therefore one dish was taken as the start point 
of 0 hours (T0) after pulse period and the other taken after the chase period after 24 hours. 
Figure 43A shows the decrease in levels of newly synthesised PLP and DM20 signals from 
T0 to 24 hrs. A visual examination of all genotypes displayed a decrease in following the 
24 hr chase. There appears to be a small drop in signal for both labelled PLP and DM20 in 
the wild type and hemizygous lysates. However, there is a clear decrease in amounts of 
PLP and DM20 present after 24 hours in the homozygous sample. The magnitude of this 
decrease is more marked in the homozygotes. Indeed statistical analysis demonstrates that 
the homozygous decrease (to 40%) is statistically different from the wild type and 
hemizygous decrease (to 70%) (Figure 42D). 
Again, as with the synthesis experiment, when the blot was probed with anti-PLP 226 
antibody the levels of PLP and DM20 were the same at both time points. This showed that 
equal amounts of total PLP and DM20 had been immunoprecipitated from the lysates from 
both dishes.  
7.4.4 Blocking of Proteasome Mediated Degradation 
As most proteins in mammalian cells are degraded by the ubiquitin–proteasome pathway 
and MG132 blocks this pathway (Lee and Goldberg 1998), dishes were treated with 50µM 
MG132 or DMSO (the solvent MG132 was dissolved in) for 24 hours (Figure 43B). This 
experiment was to establish whether the proteasome pathway contributes to wild type 
PLP/DM20 degradation in oligodendrocytes. Degradation of PLP and DM20 after 24 hours 
is reduced in lysates from MG132 treated cells when visually compared to phosphorimages 
of lysates treated only with DMSO. Once again western blotting highlights the equal 
loading of total PLP and DM20 when comparing the two dishes of each genotype.  
The change in degradation from T0 to 24 hours under MG132 treatment was then 
investigated. As before, one dish was taken at T0 and the other after 24 hours in medium 
supplemented with MG132 (Figure 43C). The wild type and hemizygous PLP and DM20 
signals at 24 hours are similar to the signals at T0 suggesting MG132 completely blocked 
the degradation of these proteins in culture. The blocking of degradation in homozygous 
lysates is not as complete in these cultures as PLP/DM20 levels at 24 hours do not reach T0 
amounts. Western blotting of the membrane with anti-PLP 226 antibody immunostained 
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the all PLP and DM20 present in the lysates and showed there was no difference in total 
amounts of protein immunoprecipitated at the two points in each genotypes.  
Quantification of the results showed that degradation rates of the wild type and 
hemizygous PLP/DM20 were very similar (Figure 43D). Newly synthesised or nascent 
protein levels of PLP/DM20 are down to 80% of T0 levels for both genotypes whereas, the 
homozygous levels at 24 hours are reduced to less than 50% of those at T0. This is a 
significant reduction in nascent protein and therefore a significant increase in the 
proteasome mediated degradation process in the homozygous oligodendrocytes.  
The influence of MG132 a proteasome inhibitor, revealed degradation is completely 
blocked in the wild type and hemizygous oligodendrocytes, stopping almost all PLP/DM20 
degradation thus allowing amounts to remain at 100% of T0 amounts and showing a 
significant change from the original degradation levels. The homozygous PLP and DM20 
levels in MG132 cells also showed a significant increase at 24 hours compared to levels in 
untreated samples at the same time point and equated to 80% of initial T  amounts.     0
7.4.5 Synthesis in Brain Slices 
The synthesis rates of PLP and DM20 were then investigated in P20 brain slices in which 
the oligodendrocyte/axon unit is intact. Phosphorimages of PLP/DM20 
immunoprecipitations from total homogenates and myelin fractions from brain slices are 
demonstrated in Figure 44A. Between 2 hours to 6 hours an increase in newly synthesised 
PLP and DM20 is seen in all three genotypes. The total homogenates from wild type and 
hemizygous mice show a steady increase whereas in the total homogenate from 
homozygotes 4 hours and 6 hours signals are very similar. The reprobes of each blot with 
anti-PLP 226 antibody confirmed that the total amounts of PLP and DM20 were equal 
across the time points.  
The percentage increases for PLP synthesis over time (synthesis rate/slope) in wild type 
and hemizygous total homogenates are very similar over the 6 hours (Figure 44B). The 
slopes reflect change in signal over time and represent the rate of translation in each 
genotype. All values are expressed relative to T2 total homogenate levels. The rates for 
DM20 are very similar to the PLP synthesis rates. Although the 6 hour signals for PLP and 
DM20 are stronger in the hemizygous total homogenate phosphorimages there is no 
difference in the overall synthesis rates (from 100% to approximately 400-500%). On the 
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other hand the synthesis of PLP and DM20 in the homozygous total homogenates is 
decreased compared to wild type and hemizygous PLP and DM20 synthesis (100% to 
approximately 300%) (Figure 44B).  
7.4.6 Incorporation of Newly Synthesised PLP and DM20 into 
Myelin 
The PLP and DM20 signals from the myelin fractions are also on the same 
phosphorimages (Figure 44A). These signals represent the amount of newly synthesised 
PLP and DM20 incoporating into the myelin over the three time points. At 2 hours, in any 
of the genotypes, 10-20% of the pool of newly synthesised PLP and DM20 is incorporating 
into the myelin fraction. At 4 and 6 hours, PLP and DM20 are incorporated into the myelin 
in all the genotypes to differing extents. Similar amounts of PLP and DM20 are 
incorporated into  myelin in the wild type and hemizygous animals over time. Although 
PLP and DM20 is synthesised by oligodendrocytes in the homozygous CNS, at 6 hrs only 
around 80% of the total pool of newly synthesised protein (300%) is incorporated into 
myelin as can be seen in Figure 44A. More than half of the total pool of wild type and 
hemizygous newly synthesised PLP and DM20 at 6 hrs is incorporated into myelin.  
The resulting western blots show equal amounts of total PLP and DM20 in the myelin 
fractions between 2, 4 and 6 hours (Figure 44A). Figure 44C shows the rate of 
incorporation of PLP into myelin over the same 6 hour period as for the synthesis rates. 
The incorporation of PLP and DM20 in the homozygous #66 myelin is impaired compared 
wild type and hemizygotes. 
7.4.7 PLP and DM20 in Lipid Rafts  
Further fractionation of the myelin allows the study of the formation of lipid rafts. As the 
synthesis rates and incorporation efficiency are compounded in homozygotes, the 
PLP/DM20 that does associate with myelin may not insert into the correct environment. To 
test this, a fractionation of myelin using the detergent method by Simons et al., (2000) was 
carried out. The distribution of PLP and DM20 in different fractions of a sucrose gradient 
in wild type and homozygous myelin is shown in Figure 45.  PLP/DM20 from 
homozygous myelin is less buoyant than wild type. The majority of PLP and DM20 from 
wild type myelin are in the 2nd and 3rd fraction with most in the 2nd, while the PLP and 
DM20 from the homozygote are in present in fractions 2-5 with the majority in fraction 3. 
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Some PLP and DM20 protein is seen in fraction 5 in the homozygous myelin whereas 
there is only a very faint signal in the 5th fraction in the wild type myelin.  
7.4.8 All Newly Synthesised Proteins in Oligodendrocytes 
A proportion of the lysates from oligodendrocyte cultured were examined by 
phosphorimage (Figure 46). No difference in band amount and strength of signal for the 
bands present is noted between the two lanes demonstrating no variance in radiolabelled 
amino acid incorporation between the samples.  
7.5 Discussion 
The effects of increased Plp1 gene dosage on dynamics of PLP/DM20 during myelination 
of the #66 animals were the main focus of this chapter. This included synthesis of the 
proteins over time in oligodendrocytes prior to contact with axons, rate and pathway of 
degradation of the proteins in oligodendrocytes, synthesis of PLP/DM20 within a brain 
slice system and how PLP/DM20 interacts with lipids in myelin. All the controls necessary 
for each type of experiment were not carried out due to the limits of tissue used. Only two 
culture dishes were obtainable from each spinal cord at P5 and genotyping necessitated 
single cultures.  
The rate of synthesis of PLP and DM20 in the #66 homozygous CNS was impaired 
compared to synthesis in wild type and hemizygous oligodendrocytes. The rate of 
synthesis dropped from a 4% increase of newly synthesised PLP per minute in wild type to 
a rate of a 2% increase in homozygous oligodendrocytes. No difference was observed 
between the wild type and hemizygous oligodendrocytes in the synthesis of PLP and 
DM20. This is not observed in other Plp1 mutation; in rumpshaker for example, 
oligodendrocytes synthesise PLP at a rate comparable to wild type (McLaughlin et al., 
2006). Total steady state levels of PLP and DM20 are reduced in the rumpshaker 
oligodendrocytes unlike in the #66 homozygous oligodendrocytes where there is more 
PLP/DM20 present (Chapter 4).  
Degradation of PLP and DM20 is increased in homozygous oligodendrocytes when 
compared to their wild type or hemizygous counterparts. Wild type and hemizygous 
degradation rates for PLP/DM20 are very similar as were total steady state protein amounts 
at P3 and P20 (Chapters 4 and 5). The differences observed between wild types and 
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hemizygotes were mainly in other myelin protein such as MBP. Degradation of PLP and 
DM20 in #66 homozygous is enhanced as is rumpshaker and jimpy-msd PLP/DM20 
(Kramer-Albers et al., 2006, McLaughlin et al., 2006). Only 10% of jimpy-msd PLP and 
DM20 were present after 24 hours, 30% of rumpshaker PLP/DM20 and 45% of #66 
homozygous PLP and DM20. This difference in degradation is most likely due to the 
mutation present; jimpy-msd (A242V) and rumpshaker (I186T) have been identified in 
humans and are models of severe conatal PMD and mild SPG-2, respectively, whereas in 
#66 animals, which models classic PMD, PLP and DM20 are wild type.  
89-90% of all protein degardation occurs through the ubiquitin-proteasome pathway 
whereas lysosomal proteolysis accounts for only 10-20% (Lee and Goldberg 1996). 
MG132 has been reported to be an inhibitor of the ubiquitin-proteasome pathway in 
mammalian and yeast cells (Lee and Goldberg 1996). Therefore inhibition of proteasome 
degradation with MG132 should block PLP/DM20 degradation and allow the protein 
levels/amounts remain near or at initial amounts. When MG132 was used to block 
degradation in oligodendrocyte cultures, PLP and DM20 amounts in wild type and 
hemizygotes returned to normal (back to 100% of T0). In the homozygotes PLP and 
similarly DM20 amounts went from around 45% to 90% of T .   0
Therefore, in the #66 homozygotes about 50% of nascent PLP/DM20 but not all 
PLP/DM20 is degraded by a MG132-sensitive mechanism, compared with 30% in wild 
type and hemizygotes and 70% in the rumpshaker mutation (McLaughlin et al., 2006). 
This suggests that MG132 only partially blocks degradation of these proteins in 
oligodendrocytes. These findings are supported by Kramer-Albers et al., (2006) who also 
demonstrated the proteasome was the major site of degradation for both wild type and 
mutant PLP/DM20 using a different proteasome inhibitor ALLN.  
MG132 treatment at the concentrations regularly used for proteasome inhibition has been 
reported to cause ubiquitination of proteins with cells (Goldbaum and Richter-Landsberg 
2004, McLaughlin, M. personal communication). MG132 treatment also induces an 
increase in heat shock protein levels in cells and in some cases an apoptotic response 
(Cervello et al., 2004, Goldbaum and Richter-Landsberg 2004). In this study the 
concentration of MG132 (50µM) used will undoubtedly affect other systems and pathways 
in the cells. However to ensure oligodendrocyte number were the same between samples, 
amounts of ASPA, an oligodendrocyte marker, were probed for in the untreated and treated 
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cell lysates. No difference was observed suggesting no induction of apoptosis in the treated 
cells and no reduction in oligodendrocyte numbers between the two (data not shown).   
When synthesis of PLP and DM20 in P20 #66 animals was investigated using the brain 
slice experiment, newly synthesised PLP and DM20 accumulated progressively over the 6 
hr period. The rate of accumulation of these proteins over the 6 hrs was different for the 
homozygotes when compared to the wild type and hemizygotes. There was a marked 
reduction in synthesis of PLP and DM20 in the homozygous CNS. However, rumpshaker 
PLP and DM20 is synthesised at a similar rate to wild type PLP and DM20 in P20 CNS 
(McLaughlin et al., 2006). This would suggest that the oligodendrocyte “copes” with 
misfolded PLP and increased dosage of wild type PLP by different mechanisms. Indeed it 
has been shown that stress molecules such as BiP are elevated in rumpshaker but not #66 
transgenic animals (Chapter 5).  
The incorporation of PLP and DM20 into myelin in the brain slice system was also 
investigated. PLP and DM20 for the wild type and hemizygous brain slices are 
incorporated into myelin at a similar rate. The incorporation of PLP and DM20 from 
homozygous brain slices was greatly reduced. There was newly synthesised PLP and 
DM20 present in myelin of all genotypes at 2 hours but the initial amount of these proteins 
in myelin from homozygotes was lower compared to wild type and hemizygous. Similar 
data were seen in rumpshaker animals where rumpshaker PLP was incorporated at a much 
lower rate than wild type PLP and the initial amount at 2 hours was also lower 
(McLaughlin et al., 2006). How extra copies of the Plp1 gene could effect incorporation of 
PLP and DM20 into myelin and thus influence the overall stoichometry of myelin is 
critical to understand.  
One of the initial pieces of evidence to suggest PLP and DM20 is translocated into myelin 
with lipids comes from the observation that inhibition of glycosphingolipid synthesis in 
brain slices reduced PLP/DM20 translocation by 50% (Kramer et al., 2001). Saher et al., 
(2005) discovered that conditional mutations of the squalene synthase (SQS) gene, which 
is involved in cholesterol production, led to severely perturbed myelin synthesis in 
oligodendrocytes. This is an indication that oligodendrocytes normally produce cholesterol 
in brain white matter. However the oligodendrocyte can adapt to the loss of cholesterol by 
acquiring it from external sources. PLP associates with galactocerebroside and cholesterol 
in the Golgi apparatus to form lipid rafts which appear to be essential for sorting of PLP 
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into myelin (Simons et al., 2000). Disruption of the myelin raft pathway may represent a 
possible pathogenetic mechanism for how Plp1 mutations can lead to Pelizaeus-
Merzbacher disease (Hudson 2004). Myelin assembly could be perturbed by the 
sequestering of myelin lipids by PLP/DM20 produced due to gene duplication in humans.  
An impairment of the PLP/DM20 and lipid relationship is seen in the #66 homozgyous 
animals. When compared to PLP and DM20 from wild type myelin more of the PLP and 
DM20 in homozygous myelin is in the lower fractions. As the CIMF float in the sucrose 
gradient the PLP and DM20 associated with the lipids would be in the higher more 
buoyant fractions. This is not the case in the homozygous where the PLP and DM20 
produced in the CNS is not in the higher fractions, thus, not associated with lipids such as 
cholesterol and galactosylceramide, a sphingolipid. Overexpressed PLP in 
oligodendrocytes was found to co-localise with cholesterol in LE/Ls which was unique to 
overexpressed PLP as it was not observed when MOG was overexpressed in the cells 
(Simons et al., 2002). This was also observed in sagittal sections of 3 week old brain where 
labelling with filipin was seen on LAMP-1, PLP-positive structures (Simons et al., 2002).     
It appears oligodendrocytes, due to the high rate of myelin synthesis during 
myelinogenesis, are sensitive to any imbalance in synthesis and turnover of their proteins 
and lipids. A important aspect of these results is how loss of normal PLP/DM20 interaction 
with lipids could affect the assembly of the different myelin subdomains and myelin 
stiochiometry in the #66 mice. How the dysmyelination seen in homozygous animals or 
human patients is induced by any of the above processes is still an open question. This will 
be discussed in the following chapter. 
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Figure 42. Synthesis of PLP and DM20 in wild type, hemizygous and homozygous 
oligodendrocytes.  
A) Cells were radiolabelled for the time shown above each image prior to lysis and 
immunoprecipitation. The upper panels are phosphorimages (Ph) and the lower, western 
blots (W) using an antibody for PLP and DM20 (45, 45 mins 90, 90 mins). B) 
Quantification of radiolabelled PLP and DM20 over time. The data are expressed relative 
to the 45 min sample   (M ± SEM, NS non significant, N= 4 for wild type and 5 for 
hemizygous and homozygous, p <*0.05, **0.01). 
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Figure 43. Degradation of PLP and DM20 in wild type, hemizygous and homozygous 
oligodendrocytes. 
Hemi
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T0 24
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T0 24
Ph
W
PLP
DM20
PLP
DM20
C 
A) Representative experiments from the three genotypes showing the phosphorimages (Ph) 
and western blots (W). Cells were pulse radiolabelled for 90 mins then chased for the times 
shown (T0, 0 hours 24, 24 hours). B) Representative experiments from the three genotypes 
showing the phosphorimages (Ph) and western blots (W). Cells were pulse radiolabelled 
for 90 mins then chased for 24 hours in absence or presence of 50 μM MG132). C) 
Representative experiments from the three genotypes showing the phosphorimages (Ph) 
and western blots (W). Cells were pulse radiolabelled for 90 mins then chased for the times 
shown (T0, 0 hours 24, 24 hours with 50 μM MG132). 
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Figure 43 (continued). 
D) Quantification of degradation of radiolabelled PLP and DM20 over time (Control, 
normal degradation over 24 hours; MG132, degradation in presence of MG132 over 24 
hours). The data is expressed relative to the T0 sample in each set (M ± SEM, NS non 
significant, N= 5 wild type control, 6 wild type MG132, 6 hemizygous control, 5 
hemizygous MG132 and 6 homozygous control, 3 homozygous MG132, p <*0.05, **0.01, 
***0.001). 
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Figure 44. Synthesis and incorporation of newly synthesised PLP and DM20 into 
myelin in brain slices from P20 wild type, hemizygous and homozygous animals.  
A) Phosphorimage of newly synthesised PLP/DM20 in total homogenate and myelin from 
brain slices of wild type, hemizygous and homozygous mice. B) Quantitative data from the 
above study of translation of PLP over 6 hours in wild type, hemizygous and homozygous 
mice. 
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Figure 44 (continued). 
C) Incorporation of PLP into myelin in wild type, hemizygous and homozygous mice.  
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Figure 45. Different association of PLP/DM20 from wild type and homozygous myelin 
with lipid rafts.  
Fractions 1 (light fraction) to 6 (heavy fraction) analysed by western blotting. Whereas, 
wild type PLP/DM20 is contained more in the lighter fractions, the proteins in 
homozygous myelin show a more diverse pattern with significant amounts in the dense 
fractions. 
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Figure 46. Phosphorimage of lysates from oligodendrocytes after 1 hr of labelling 
with radiolabelled amino acids.  
Shows all newly synthesised labelled protein within the lysates. No difference is shown 
between the two lanes.  
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8 Final conclusions and future work 
Data presented in this study have provided insights in the effects of increased Plp1 gene 
dosage on myelination from message and protein levels all the way to the structure of 
myelin formed in the transgenic #66 mice. The study aimed to investigate the effects extra 
copies of a wild type gene would have on the mechanisms associated with myelination that 
could lead to disease in humans and animals. The two genotypes described in this thesis 
display very different phenotypes at different ages compared to wild type. The cause of 
this variation is associated with the number of wild type Plp1 genes present in their 
genome. The wild type animals have only the endogenous copy of Plp1 on the X 
chromosome whereas the hemizygous animals have one cassette containing 7 extra copies 
of the gene and homozygous have two cassettes containing in total 14 extra copies of the 
gene. These animals have been and are currently being used as models of PMD in humans 
which, in many cases, is caused by PLP1 gene duplication/triplication. Data presented in 
this thesis have shown that the underlying effects of this increase in gene dosage differs 
between the two genotypes compared to wild type and each also between each other and 
are summarised in Table 9. 
For clarity, the hemizygote and homozygote data are discussed separately followed by a 
comparison between the two genotypes with regards to a mechanistic basis of the findings. 
In the low gene dosage (hemizygous) mice, at P3, premyelinating oligodendrocytes are 
able to maintain PLP/DM20 message and protein concentrations at levels similar to wild 
type expression of the Plp1 gene. The same observations are made of oligodendrocytes 
cultured from P5 spinal cord. A single transgene cassette as in hemizygous animals without 
any endogenous Plp1 gene, established by expressing the transgene on a Plp1 null 
background, has the levels similar to wild type supporting the data for the hemizygous 
animals.  
In cultured oligodendrocytes, the rates of synthesis and degradation of PLP/DM20 over 
time in hemizygous oligodendrocytes are comparable to wild type rates. These results 
imply that at early stages of myelination although the cells have to cope with the additional 
burden imposed by the extra gene dosage, they are able to adapt and maintain a level 
associated with the normal wild type oligodendrocyte. The potential mechanisms by which 
the oligodendrocyte could maintain normal Plp1 message levels either by 1) only 
transcribing normal levels due to repression of expression of the Plp1 gene or 2) by 
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degrading the excess message prior to translation. Whether the downregulation or 
repression of expression of the Plp1 gene occurs through the mechanism reported by 
Mallon and Macklin (2002) utilising the 3’ UTR and the possibility this mechanism may 
play a role in disease in humans requires further investigation. The second hypothesis of 
degradation of the transcript could be tested using a similar method to that utilised in 
bacteria. Rifampicin is a chemical used to treat bacterial infections and in E. coli it inhibts 
DNA dependant RNA polymerase and blocks transcription of mRNA (Ludi and Pace 
1979). Oligodendrocytes could be treated in vitro for different time points, after 
radiolabelling for a fixed time, with a compound that inhibits the same process in 
mammalian cells. The levels of Plp/Dm20 meassage at each time point would be measured 
by realtime qRT-PCR.   
By P20, when the majority of myelination is occurring in murine CNS, the amount of 
protein and lipids that oligodendrocytes have to produce to ensheath axons has increased 
dramatically compared to P3 or P5. In hemizygous mice at P20 although the 
oligodendrocytes are still maintaining Plp1 expression at wild type levels, the adaptive 
response required by the cell to achieve this has a detrimental effect of production of other 
myelin proteins with a significant reduction in CNP and MBP levels. MAG is not reduced 
in these animals. There is no difference in the synthesis or degradation rates of PLP/DM20 
in these animals when compared to their wild type counterparts. No difference was seen in 
the raft profile (data not shown) between the two suggesting once again that 
oligodendrocytes in the hemizygous animals are able to deal with or manage the increase 
in gene dosage sufficiently to survive and myelinate. By P60 when most of the 
myelinogenesis has taken place the status of myelin proteins in myelin has changed with 
all studied myelin proteins including MBP, which showed the greatest reduction at P20, 
have recovered to wild type levels by P60.  
However, these hemizygous animals do go on to develop abnormalities in the CNS leading 
to phenotypic changes as reported by Anderson et al., (1998). Surprisingly, the point or 
stage at which this occurs varies from mouse to mouse with some displaying changes by 
P120 and some only developing abnormalities as late as 18 months. The mechanism 
behind this variation is not yet understood but MBP may have a role to play. While 
studying the hemizygous animals, one observation was noted, these mice showed a 
variation in amount of MBP present in their CNS tissue leading to a higher SEM than any 
other protein studied. One hypothesis to explain the variation in phenotype is that 
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phenotypic variation and MBP amount variation are linked. MBP, as mentioned 
throughout this thesis, is essential to myelin. As mentioned in the introduction of this thesis 
there are many putative roles for MBP, however, it is known to be important in compaction 
of myelin. A lower MBP level at P20 may be indicative of an earlier onset of abnormalities 
while the higher levels of MBP observed may suggest a later onset of myelin changes and 
abnormalities. This may possibly be related to the turnover of myelin after it has been 
formed and therefore represent the maintenance phase of myelination and would require 
further investigation to elucidate. 
Homozygous #66 animals behave very differently in terms of protein levels, dynamics 
axon diameter, g ratios and level of myelination compared to their wild type and 
hemizygous littermates. From P3 onwards there is marked difference in the fate of 
PLP/DM20 in these animals. Prior to myelination there is an increase in PLP/DM20 at the 
protein level, which is inversely related to MBP amounts at both the message and protein 
level. During peak myelination the homozygous animals still express less MBP either 
through decreased production or increased degardatiom or a combination of the two as 
with PLP/DM20 in this study. This could be tested with the same methods utilised in the 
PLP/DM20 investigation. At this stage of myelinogenesis the PLP/DM20 levels in total 
homogenates are also reduced compared to wild type levels but this may be reflective of 
the low myein content per unit of tissue. This decrease in PLP/DM20 present in the 
oligodendrocyte in the effort to control the amount of protein produced affects other 
myelin proteins such as CNP, MAG and MBP as previously mentioned in this study.  This 
variation in PLP/DM20 present in homozygotes through development of the mature CNS 
could affect the level of palmitoylation of the protein. Palmitoylation occurs in the Golgi 
apparatus, is one of the few reversible post-translational modifications and anchors a 
protein more securely to the plasma membrane than a protein with no post-translational 
modifications (Basu et al., 2004). The overproduction of PLP/DM20 prior to and at the 
early stages of myelination could lead to the sequestering of much of the available fatty 
acid chains thus altering PLP/DM20’s hydrophobicity and insertion into myelin 
membrane. As the increased gene dosage is a universal transformation affecting all 
oligodendrocytes and in these cells this sequestering of the fatty acid chains could be a 
global effect in the CNS. A reduction in the incorporation of PLP/DM20 into myelin and 
steady state levels in myelin at P20 is observed in the homozygous animals.  
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Another effect of increased gene dosage was reported by Giambonini-Brugnoli et al., 
(2005). They investigated the effects of increased PMP22 gene dosage in transgenic mice. 
PMP22 is required for the formation of PNS myelin. Increased copy number of the gene 
was found to cause reduced expression of 58 different genes involved in the cholesterol 
biosynthesis pathway at P4 compared to wild type animals. This is also observed in the 
older PMP22 transgenic mice at P60. It could be hypothesised that the same is occurring in 
the homozygous #66 mice with proteins involved in lipid biosynthesis affected just as the 
myelin proteins are. Cholesterol can be obtained by oligodendrocytes from neighbouring 
cells (Saher et al., 2005). However in homozygous animals all the oligodendrocytes are 
under the same burden and there can only be a limited supply of cholesterol available for 
uptake. Therefore the horizontal transfer reported from wild type cells to SQS deficient 
oligodendrocytes by Saher et al., (2005) is not an option for these homozygous #66 
oligodendrocytes. The oligodendrocytes could, however, acquire cholesterol from other 
cells in the CNS such as astrocytes or neurons but these cells may not be able to provide 
sufficient amounts of cholesterol for the production of myelin.  This could be an avenue for 
future study in these animals.  
The partitioning of PLP/DM20 changes in the homozygotes with more protein present in 
membranous organelles in the cell body as demonstrated by the increase signal of the 
protein in the pellet fraction at P20. The membranous organelles were found to be LE/Ls 
by immunostaining with an anti-Lamp1 antibody. Supporting evidence comes from P0 
transgenic mice (Wrabetz et al., 2000) where overexpressed P0 may be targeted to the 
LE/Ls pathway like PLP/DM20. The accumulation of transgenic wild type PLP/DM20 
with lipids such as cholesterol in LE/Ls may be a factor in disease pathology in PLP1 gene 
duplications in humans. Simons and Trajkovic (2006) reported PLP/DM20 and cholesterol 
cycle from the membrane to LE/Ls in the absence of axons. In #66 homozygous 
oligodendrocytes even in the presence of axons PLP/DM20 and lipids are cycled to the 
LE/Ls and retained there. The way the oligodendrocyte deals with the increased Plp1 gene 
dosage is dependant on whether the cell is generating myelin especially in the presence of 
axons. These changes in dosage do alter the distribution of PLP/DM20 within the 
oligodendrocyte and myelin unit. Incorrect partitioning of PLP/DM20 when in lipid rafts 
must perturb the transport and insertion of PLP/DM20 into myelin and also of other myelin 
proteins (Simons et al., 2002, Kramer-Albers et al., 2006). This has been demonstrated by 
colocalisation of PLP/DM20 with MAG in oligodendrocytes in corpus callosum and 
cortex. PLP/DM20 and MAG share a transport pathway for insertion in myelin (Georgiuo 
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et al., 2004), whereas MBP is transported as a transcript to myelin and translated at its site 
of incorporation (Trapp et al., 2004). No colocalisation of MBP with PLP/DM20 was seen 
in the same oligodendrocytes reiterating the possibility of a selective transport defect in the 
homozygous #66 oligodendrocytes. Abnormal long lasting immunoreactivity of MBP, 
MAG and CNP in the cell body of oligodendrocyte-like cells in a patient with PMD have 
previously noted (Koeppen and Robitaille 2002), suggesting accumulation or abnormal 
transport of these proteins in the cell body due to the mutation in the PLP1 gene.  
Aberrant insertion of PLP/DM20 into myelin would change the overall protein to lipid 
ratio and ratios between proteins also. The decrease in available myelin and decreased 
contact with axons in the homozygous animals could lead to an exacerbation of the 
accumulation of PLP/DM20 in LE/Ls. Although oligodendrocytes have been hypothesised 
to be able to sense the imbalance in the protein and lipid ratio and alter expression of genes 
to suit the change in situation (Saher et al., 2005) this mechanism is likely to be lost in the 
homozygous animals with high gene dosage. 
Steady state levels of this protein are higher in the pellet (membranous fraction) and can 
been seen to persist through the life of the oligodendrocyte in the cell body from non-
myelinating to pre-myelinating and through to the mature peak-myelinating cells. This 
pool could be classed as long-lived storage pool (Trajkovic et al., 2006) of protein possibly 
residing in the LE/Ls along with lipids and could have different dynamic properties to the 
PLP/DM20 transported to myelin or directed for degradation to the proteasome. These 
pools have been noted in astrocytes for GFAP as there is evidence that there are short and 
long term pools of GFAP in astrocytes with different decay rates for each (Rolland et al., 
1990). The hypothesis required validation and study which could be achieved by 
radiolabelling oligodendrocytes in culture at an earlier stage such as day 3 and 
investigating synthesis and degradation at the same end point of day 6 as mentioned in this 
thesis.            
The synthesis rates of PLP and also DM20 at P20 in homozygous animals are similar to the 
rates of synthesis in oligodendrocytes in vitro; however, there is a decrease in the rates of 
synthesis of PLP and DM20 in both oligodendrocytes in vitro and at P20 compared to wild 
type and hemizygous animals. Overall less PLP/DM20 is produced and less is incorporated 
into myelin at peak myelination and the degradation rate for PLP/DM20 is also higher. The 
investigation of the dynamics of PLP/DM20 in conjunction with an assessment of the 
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distribution of PLP/DM20 would imply that the net reduction of PLP/DM20 observed in 
myelin is a consequence of the combined alteration in synthesis with accelerated 
degradation.  
The increased degradation rate in homozygous #66 animals along with decreased synthesis 
and incorporation rates, steady state levels and co-localisation of PLP/DM20 with Lamp-1 
in LE/Ls suggests multiple fates for the protein. A proportion of PLP/DM20 is 
incorporated into myelin correctly as seen by the steady state levels, while some 
PLP/DM20 along with cholesterol and other lipids is sequestered to the LE/Ls and some of 
the protein is likely to be synthesised and degraded quickly without even reaching its site 
of incorporation in compact myelin.  
Unlike the rsh or msd mutations the UPR leading to an apoptotic response does not appear 
to play a role in the disease/phenotype severity in #66 transgenic mice (Southwood et al., 
2002). There is no misfolded protein produced to activate ER stress responses leading to 
UPR, however, accumulation of PLP/DM20 in the oligodendrocyte cell body could affect 
other essential cellular processes leading to apoptosis of the cell through different pathway 
and contribute to the disease phenotype.  
In humans increase of PLP1 gene copy number from 1 to 2 copies causes PMD and an 
increase from 2 to 3 copies is associated with a more severe disease phenotype. However, 
an increase from 3 to 5 copies seen in one patient as reported by Wolf et al. (2005) showed 
no significant difference in clinical symptoms from that patient to the other with only 3 
copies. This suggests that the threshold for change in gene copy number is; 1) much lower 
in humans than mice and 2) oligodendrocytes are pushed to their furthest limits at 3 wild 
type PLP1 copies in humans. The level of oligodendrocyte cell death may be a 
contributing factor to the severity of disease and may vary from 2 to 3 copy numbers but 
not beyond this point. The area of the X-chromsome containing the PLP1 gene that is 
duplicated varys in PMD (Inoue et al., 1998, Lee et al., 2006b, Woodward et al., 1998, 
2000). The #72 mice and also the 4e-Plp mice display different degrees of severity 
(Readhead et al., 1994, Kagawa et al., 1994). This variation in phenotype severity may be 
caused by the variation in area of duplication or a positional effect due to area of insertion 
of the duplication. The proposal that PLP overexpression results in arrest of 
oligodendrocyte and myelin development was put forward by Simons et al., (2002), 
Kagawa et al., (1994) and Readhead et al., (1994). A similar arrest in Schwann cell 
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development prior to sorting to axons is seen P0 transgenic mice with the highest gene 
copy number (Wrabetz et al., 2000). The increased Plp1 gene dosage has an impact on 
oligodendrocyte and myelin development in the #66 transgenic animals as homozygous 
oligodendrocytes in vitro do not produce as much PLP or MBP or membranous sheets as 
observed in wild type oligodendrocytes. Also PLP and Lamp-1 co-localisation is observed 
at P20 in the homozygous CNS suggesting the oligodendrocytes are immature even at peak 
myelination. Whether it causes a complete arrest in development is yet to be determined 
but a possible experiment could be to culture #66 oligodendrocytes in the presence of 
axons and astrocytes to produce myelinating cultures (Thomson et al., 2007). 
PLP makes up 50% of all CNS myelin proteins while MBP accounts for 30% and this ratio 
between the two appears also to be essential to myelin formation as alterations in 
PLP/DM20 levels has a detrimental effect on MBP levels although this is not the case with 
a complete loss of PLP/DM20. In the case of the Plp1 null animals, the complete loss of 
PLP/DM20 may cause the possible activation of another member of the lipophilin/DM 
family present in the genome to replace the protein’s function. Also in the absence of MBP 
a higher proportion of PLP/DM20 is found in heavy fractions in lipid rafts. MBP is critical 
for myelin formation and influences the amount of myelin formed by an oligodendrocyte 
(Shine et al., 1992). A series of experiments by Fitzner et al., (2006) demonstrated that 
MBP is also essential for the reorganisation of the oligodendrocyte plasma membrane and 
the mediation of raft clustering. There is a likelihood that increasing the levels of MBP to 
correspond in the correct ratio/proportion to the increase of the PLP1 gene dosage in these 
cells may improve myelin formation. This could be achieved by crossing the #66 
transgenic animals with MBP transgenic animals generated by Readhead et al., (1987) and 
studying the fate of both PLP/DM20 and MBP and myelin as a whole.  
Another avenue of investigation could be similar to the one taken in Rett syndrome (RTT) 
(Giacometti et al., 2007, Guy et al., 2007). The data from their experiments highlights the 
potential to rescue an aberrant CNS phenotype. Transgenic mice with a knockout of the X-
linked Mecp2 gene displayed a phenotype caused by a deficiency in neurons. The mice 
develop RTT-like symptoms from 4-5 weeks which include reduced brain weight, 
decreased neuron size, hindlimb clasping and impaired locomotor function. However due 
to the knockout process the investigators retained the ability to turn the gene back on and 
demonstrated phenotypic reversal in both young and old mice. Although in a different cell 
type than in #66 mice this displays plasticity to the state of the cells in the CNS and 
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highlights the possibility a rescue of an aberrant phenotype can occur in the CNS. This is 
also seen by the recovery of myelin proteins in hemizygous #66 animals by P60 in this 
study. The causes of the dysmyelination observed in homozygous animals and the later 
demyelination that occurs in the hemizygous animals are not yet understood but with this 
study we may be part way in understanding the effects of increased gene dosage on the 
CNS. Ip et al., (2007) generated #66 heterozygous mice on the C57/Bl6 background then 
crossbred them with Sialoadhesion (Sn)-deficient mice. Sialoadhesion is a sialic acid 
binding protein involved in macrophage-lymphocyte interactions and is expressed on 90% 
of CNS macrophage-like cells in #66 heterozygous PLP mutants. When knocked out in 
PLP mutants a significant reduction in pathological alterations such as demyelination is 
observed at 12 months (Ip et al., 2007). In the #66 transgenic mice crossed with Sn 
deficient mice the improvement in phenotype is indicative of a recovery process by 
repressing the immune response to the myelin defect. With further investigation into the 
questions raised from this study we may be able to aid the oligodendrocyte in the as yet 
unknown recovery process seen and this would be beneficial to PMD patients in the future.   
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Table 9. Summary of results in this study on #66 transgenic mice. 
Stage  Hemizygous (Low gene 
dosage) 
Homozygous (High gene 
dosage) 
 
Non-myelinating  normal PLP/DM20 increase of PLP/DM20 
(in culture)   
Synthesis normal as WT decrease in rates 
Degradation normal as WT increase in rates 
   
MBP normal MBP decrease of MBP 
   
OL/Myelin normal no membranous sheets 
 lower PLP/DM20 
lower MBP 
 
normal Plp1 transcript levels lower Plp1 transcript levels Pre-myelinating 
 small increase in PLP/DM20  increase of PLP/DM20 
   
normal Mbp transcript levels lower Mbp transcript levels MBP 
 normal MBP decrease of MBP 
   
OL/Myelin normal autophagic vacuoles 
 distended RER 
 
normal Plp1 transcript levels lower Plp1 transcript levels Peak myelinating 
TH normal PLP/DM20 small decrease in PLP/DM20 
Myelin normal PLP/DM20 marked decrease in PLP/DM20 
Pellet increase of PLP/DM20 increase in PLP/DM20 
   
Synthesis  normal decreased 
Incorporation normal decreased 
Rafts  normal (not shown) abnormal raft distribution 
   
normal Mbp transcript levels lower Mbp transcript levels Other proteins 
 decrease of MBP and CNP decrease of MBP, CNP and 
MAG  
 co-localisation of PLP/DM20 
with Lamp1 in LE/Ls  
 
normal Plp1 transcript Maintaining 
myelin 
N/A  
normal PLP/DM20  Dead 
  
normal Mbp transcript MBP 
normal MBP 
 (OL = oligodendrocytes, N/A = not applicable). 
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Figure 47. Schematic representation of the fate of PLP/DM20 at P20 in wild type, 
hemizygous and homozygous #66 oligodendrocytes. 
A) Schematic representation of the fate of PLP/DM20 in P20 wild type oligodendrocytes 
showing the normal processing of the protein via the ER and Golgi apparatus to compact 
myelin. B) Schematic representation of the fate of PLP/DM20 in P20 hemizygous 
oligodendrocytes showing the processing of the protein via the ER and Golgi apparatus to 
compact myelin which very similar to wild type. C) Schematic representation of the fate of 
PLP/DM20 in P20 homozygous oligodendrocytes showing the abnormal processing of the 
protein via the ER and Golgi apparatus to compact myelin and/or vacuoles likely to be 
LE/Ls in the cell body. (N = nucleus, ER = endoplasmic reticulum, P= proteasome, V = 
vacuole, thick black line = PLP/DM20,      lipid, solid arrows = established pathways, 
dashed arrows = possible pathways). 
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9.1.3.1 
9 Appendix  
9.1.1 APES-coated slides 
APES-coated slides were generally used for immunohistochemistry because they keep the 
sections adhered. To clean greaseon the slides, they were soaked overnight in 5% Decon 
90 (Decon Lab Ltd) then washed in distilled water and oven dried. The dried slides were 
then soaked in 0.25% APES (Sigma) in methylated spirit in a fume hood for 2 minutes. 
Finally, the slides were rinsed in DEPC-treated water for 2 minutes and oven dried 
wrapped in foil. APES-coated slides were stored at room temperature. 
9.1.2 DEPC-treated water 
0.1% solution of DEPC was made in distilled water and left for at least 12 hours to 
inactivate contaminating RNases. The water was autoclaved at 151b.in-2 for 20 minutes to 
destroy the DEPC before use and stored sealed at room temperature until require. 
9.1.3 Fixatives 
Karnovsky’s modified fixative 
(paraformaldehyde/glutaraldehyde 4%/5%) 
Preparation of 500 ml of the fixative: 
8% Paraformaldehyde: 20 g of paraformaldehyde was added to 250 ml of ddH2O and heat 
to 65°C. Few drops of 1M NaOH was added to clear and solution was allowed to cool. 
0.08M Cacodylate buffer: 17.1224 sodium cacodylate was dissolved in a 1 litre of dH2O 
and adjusted to pH 7.2. 
250 ml 8% Paraformaldehyde 
100 ml 25% Glutaraldehyde 
150 ml 0.08M Cacodylate buffer
250 mg Calcium chloride 
Add appropriate volumes, dissolve calcium choride, adjust to pH 7.2, filter, and store at 
4°C. 
 
9.1.3.2 4% paraformaldehyde 
Preparation of 500 ml of the fixative: 
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9.1.3.3 
9.1.3.4 
20g paraformaldehyde was added to 500ml PBS and heat to 65°C. Few drops of 1M NaOH 
were added to clear the solution, filtered, cooled, and adjusted to pH 7.2. 
Periodate-lysine-paraformaldehyde (P-L-P) fixative 
Preparation of 1litre of the fixative: 
Buffered lysine solution: 13.7g lysine monohydrate dissolved in 375ml ddH2O. 1.8g 
sodium hydrogen phosphate dissolved in 100ml ddH2O. The two solutions were mixed to 
give 475ml and pH 7.4 
10% Paraformaldehyde: 20g paraformaldehyde dissolved in 200 ml ddH2O and heated to 
65°C. Few drops of 1M NaOH were added to clear and allowed to cool. 
The two solutions were separately stored at 4°C overnight. Immediately before use the two 
solutions were mixed and the final volume is made up to 1litre using 0.1M phosphate 
buffer. 2.14g sodium periodate was also dissolved. 
Buffered neutral formaldehyde 
Preperation of 1 litre of the fixative: 
100 ml 40% formaldeyde (Merck) 
900 ml Tap water 
4 g Sodium dihydrogen phosphate 
8 g Di-potassium hydrogen phosphate
 
 
9.1.4 Tissue processing protocols 
9.1.4.1 Resin processing 
CNS tissues were passed through below various solutions and finally blocked in resin: 
1- Isotonic cacodylate buffer 50 min 4°C 
2- 1% OsO4 in cacodylate buffer 2hr room temperature 
3- Isotonic cacodylate buffer 30 min room temperature 
4- 50% ethanol 5 min 4°C 
5- 50% ethanol 10 min 4°C 
6- 70% ethanol 5 min 4°C 
7- 70% ethanol 10 min 4°C 
8- 80% ethanol 5 min 4°C 
9- 80% ethanol 10 min 4°C 
10- 90% ethanol 5 min 4°C 
11- 90% ethanol 10 min 4°C 
12 Ethanol 20 min 4°C 
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13 Ethanol 20 min 4°C 
14- Propylene oxide 15 min room temperature 
15- Propylene oxide 15 min room temperature 
16- 1:2 resin: propylene oxide 13 hr room temperature 
17- 1:1 resin: propylene oxide 6 hr room temperature 
18- 2:1 resin: propylene oxide 18 hr room temperature 
19- Resin 4 hr 30°C 
 
Isotonic cacodylate buffer: 
16.05 g Sodium cacodylate 
3.8 g Sodium chloride 
0.055 g Calcium chloride 
0.102 g Magnesium chloride
Dissolve in 1litre ddH O and adjust to pH 7.2 2
 
Araldite resin: 
1- 30 g Araldite CY212 (resin) 
2- 25.2 g Dodecanyl succinic anhydride 
3- 1.2 ml 2,4,6-tri-dimethylaminomethyl-phenol
4- 0.75 ml Di-butylphthalate 
Add 1 and 2, place in an oven at 65°C for 10-15 min and mix. Add 3 and 4, and stir until 
mixure well homogenised and store at -20°C. 
 
 
9.1.5 Staining protocols 
9.1.5.1 Dehydration and cleaning of sections 
1- Methylated spirits 2 mins
2- absolute alcohol 2 mins
3- absolute alcohol 2 mins
4- Histoclear 2 mins
5- Xylene 2 mins
 
9.1.5.2 Haematoxylin and eosin 
1- Xylene 2 mins 
2- Absolute alcohol 2 mins 
3- Methylated spirits 2 mins 
4- ddH O 2 mins 2
5- Lugols iodine 1 min 
6- ddH O 1 min 2
7- 5% sodium thiosulphate 1 min 
8- ddH O 2 mins 2
9- Mayers haematoxylin 10 mins
10 1% acid alcohol 3 dips 
11- ddH O 2 mins 2
12- Scots tap water substitute 1 min 
13- ddH O 2 mins 2
14- Methylated spirits 10 secs 
15- Saturated alcoholic eosin 2 mins 
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16- Methylated spirits 10 secs 
17- Absolute alcohol 2 mins 
18- Histoclear 2 mins  
19- Xylene 5 mins 
 
9.1.5.3 Haematoxylin 
1- Running water 2 mins 
2- Mayers haematoxylin 50 secs 
3- Water wash off excess haematoxylin 
4- Scots tap water substitute 30 secs 
 
9.1.5.4 Staining for electron microscopy 
1- Saturated uranyl acetate in 50% ethanol 15 min 
2- 50% ethanol Rinse 
3- 50% ethanol Rinse 
4- ddH O Rinse 2
5- ddH O Rinse 2
6- air dry  
7- Reynold’s lead citrate (Sodium 10 mins 
Hydroxide moistened chamber) 
8- 1M sodium hydroxide rinse 
9- 1M sodium hydroxide rinse 
10- 1M sodium hydroxide rinse 
11 ddH O Several rinses2
 
Reynold’s lead citrate (1.2mM lead citrate, 1.8mM sodium citrate, pH 12.0) 
1- 1.33 g Lead nitrate dissolved in 15 ml ddH O 1 min vigorous shaking 2
2- 1.76 g Sodium citrate dissolved in 15 ml ddH O 1 min vigorous shaking 2
Add 1 to 2 and equilibrate over 30 minutes with occasional shaking. Clear with 1M NaOH 
and make up to the final volume of 50 ml with ddH O. 2
 
 
9.1.6 Staining solutions 
Methylene blue/ azure ΙΙ 9.1.6.1 
1% Methylene blue 
1% Azure ΙΙ 
1% Borax 
Dilute with ddH O and filter before use. 2
 
9.1.6.2 Mayers haematoxylin 
1 g Haematoxylin 
10 g Potassium alum 
0.2 g Sodium iodate 
Dissolve in 1 litre of ddH O, bring to boiling point, allow to cool overnight, and then add: 2
 
1 g Citric acid  
50 g Chloral hydrate 
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9.1.6.3 Scots tap water substitute 
3.5 g Sodium bicarbonate 
20 g Magnesium sulphate
Dissolve in 1 litre of ddH O. 2
 
 
9.1.7 General Buffers 
9.1.7.1 Phosphate buffer saline (PBS) 
8 g Sodium chloride 
1.44 g Disodium hydrogen phosphate 
0.24 g Potassium dihydrogen phosphate
0.2 g Potassium chloride 
Dissolve in 800 ml of ddH2O. Adjust to pH 7.4 with 1M HCl and make the volume up to 1 
litre with ddH O. 2
 
9.1.7.2 0.1 M phosphate buffer 
77.4 ml 1M Disodium hydrogen phosphate  
22.6 ml 1M Potassium dihydrogen phosphate
Combine two volumes and adjust to pH 7.4 with 1M HCl. 
 
9.1.7.3 10x Tris buffer saline (10x TBS) 
12 g Tris base pH 7.5 
87 g Sodium chloride 
Dissolve in 800 ml ddH2O. Adjust to pH 7.4 with 1M HCl and make the volume up to 1 
litre with ddH O. 2
 
9.1.7.4 Tris-EDTA buffer (TE buffer) 
1M Tris pH 8.0 500 μl 
0.5M EDTA 100 μl 
Make up volume to 50 ml with ddH2O. 
 
9.1.7.5 Tris acetate EDTA buffer (TAE buffer) 
48.4 g Tris base 
11.4 ml Glacial acetic acid
20 ml 0.5M EDTA 
Volume made up to 1 litre with ddH O. 2
 
9.1.7.6 20x Sodium chloride/Sodium citrate buffer (SSC buffer)  
175 g Sodium chloride 
88 g Sodium Citrate.2H O3 2
Make up to 900mls with ddH2O. Adjust pH to 7.0 with HCl, then make up to final volume 
of 1 litre with ddH O. 2
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9.1.8.1 
9.1.8 Specific solutions and buffers 
10x MOPS buffer 
200 ml 1M MOPS 
20 ml 250mM Sodium acetate
20 ml 0.5M EDTA pH 7.5 
Make up 900ml with ddH2O. Adjust pH to 7.0 with NaOH then make up to final volume of 
1 litre with ddH O. Filter, wrap bottle in foil and store in dark at RT. 2
 
9.1.8.2 6x Orange G loading dye 
0.4% Orange G powder  
15% Ficoll 400 (Glycerol can be used)
500 µl 1M Tris-HCl  
5 ml 0.5M EDTA 
Make up to 50ml with ddH O. Store at RT. 2
 
9.1.8.3 6x BPB/XC loading dye 
0.04% Bromophenol Blue powder 
0.04% Xylene Cyanol powder 
15% Ficoll 400 (Glycerol can be used)
500 µl 1M Tris-HCl  
5 ml 0.5M EDTA 
Make up to 50ml with ddH O. Store at RT. 2
 
9.1.8.4 RNA loading buffer 
250 µl Formamide (Deionised, COSHH) 
83 µl Fomaldehyde (COSHH) 
500 µl 10x MOPS  
117 µl RNase-free H O 2
Make up in fume hood. 
 
9.1.8.5 
9.1.8.6 
RNA loading dye 
50% glycerol in 1x MOPS buffer. Add a few grains of Bromophenol Blue. 
 
Cell Lysis Buffer  
1 ml 10% Tritin X-100 
1 ml 10x TBS 
20µl 0.5M EDTA 
5 µl 1M DTT 
5 µl 10mg/ml Aprotinin 
5 µl 10mg/ml Leupeptin 
5 µl 10mg/ml Trypsin inhibitor 
100 µl 100mM Benzamidine 
100 µl 250mM Sodium orthovanadate 
100 µl 100mM Sodium pyrophosphate
40 µl 250mM PMSF 
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9.1.8.7 Kreb’s 
Make up to 10ml with ddH O. Add PMSF last. Store at 4°C. 2
 
Buffer 
15.7 ml 2M NaCl 
2M KCl 312 μl 
1M Na HPO300 μl 2 4
1.3 ml 250mM MgSO4
1M CaCl500 μl 2
2.7 ml 1M Glucose 
12.5 ml 0.5M NaHCO3
Make up 230 mls with ddH2O. Adjust pH to 7.4 with NaOH, then make up to final volume 
of 250 mls with ddH O. Bubble oxygen through buffer at RT until use. 2
 
9.1.8.8 10x SDS-Page running buffer 
144 g Glycine 
30.3 g Tris 
10 g SDS 
Add the Glycine first, once dissolved add Tris and finally SDS ensuring final volume of 1 
litre ddH O. 2
 
9.1.8.9 Towbin transfer buffer 
9.1.8.9.1 Anode 1  
36 g Tris  
74 ml Methanol 
Make up to 1 litre with ddH O. Store at 4°C. 2
 
9.1.8.9.2 Anode 2 
3 g Tris  
75 ml Methanol 
Make up to 1 litre with ddH O. Store at 4°C. 2
 
9.1.8.9.3 Cathode 
3 g Glycine 
3 g Tris 
74 ml Methanol 
Make up to 1 litre with ddH O. Store at 4°C. 2
 
 
9.1.9 Tissue culture media 
9.1.9.1 Sato defined medium 
Glucose (1g/l), Glutamine (2mM), Bovine insulin (10µm/ml), Human transferrin 
(100µm/ml), BSA-pathocyte (0.0286%), Progesterone (0.2µM), Putrescine (0.1µM), 
Thyroxin (0.45µM), Selenite (0.224µM), Tri-iodo-thyro-nine (0.5µM) in DMEM. 
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9.1.9.2 Stop solution 
Soya bean trypsin inhibitor (0.52mg/ml), Factor V bovine serum albumin (3mg/ml), DNase 
(0.04mg/ml) made up in HBSS. 
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ABSTRACT
Duplication of PLP1, an X-linked gene encoding the major
myelin membrane protein of the human CNS, is the most
frequent cause of Pelizaeus-Merzbacher disease (PMD).
Transgenic mice with extra copies of the wild type Plp1
gene, a valid model of PMD, also develop a dysmyelinating
phenotype dependant on gene dosage. In this study we
have examined the effect of increasing Plp1 gene dosage on
levels of PLP/DM20 and on other representative myelin
proteins. In cultured oligodendrocytes and early myelinat-
ing oligodendrocytes in vivo, increased gene dosage leads to
elevated levels of PLP/DM20 in the cell body. During myeli-
nation, small increases in Plp1 gene dosage (mice hemizy-
gous for the transgene) elevate the level of PLP/DM20 in
oligodendrocyte soma but cause only minimal and transient
effects on the protein composition and structure of myelin
suggesting that cells can regulate the incorporation of pro-
teins into myelin. However, larger increases in dosage
(mice homozygous for the transgene) are not well tolerated,
leading to hypomyelination and alteration in the cellular
distribution of PLP/DM20. A disproportionate amount of
PLP/DM20 is retained in the cell soma, probably in autop-
hagic vacuoles and lysosomes whereas the level in myelin
is reduced. Increased Plp1 gene dosage affects other myelin
proteins, particularly MBP, which is transitorily reduced
in hemizygous mice but consistently and markedly lower in
homozygotes in both myelin and na€ıve or early myelinating
oligodendrocytes. Whether the reduced MBP is implicated
in the pathogenesis of dysmyelination is yet to be estab-
lished. VC 2006 Wiley-Liss, Inc.
INTRODUCTION
The majority of axons in the CNS have associated
myelin sheaths, which optimize conduction and provide
support for their structure and function. Myelin is a
highly organized, multilamellar structure, rich in lipid
and containing numerous speciﬁc proteins. Differences
in myelin composition occur depending on CNS region
(Amaducci et al., 1962; Mehl and Wolfgram, 1969) and
caliber of ﬁber (Butt et al., 1998), however, the ratios
of myelin proteins are regulated within fairly deﬁned
limits. How these ratios are maintained is not known.
The integral membrane proteolipid protein (PLP) and its
minor DM20 isoform account for 50% of total myelin
protein with the extrinsic myelin basic proteins (MBP)
being 30%; both are located in compact myelin. Other
myelin proteins, such as 20,30-cyclic nucleotide 30phos-
phodiesterase (CNP) and myelin-associated glycoprotein
(MAG) are targeted to uncompacted regions of the myelin
sheath.
Mutations or dosage alterations of the X-linked PLP1
gene cause Pelizaeus-Merzbacher Disease (PMD) and
Spastic Paraplegia Type 2 (SPG2) in man (Inoue, 2005)
and dysmyelinating disorders in a range of animal spe-
cies, including mice (Nave and Grifﬁths, 2004). The
PLP1 gene is highly conserved and the mouse acts as a
valid model of these human disorders. The commonest
cause of PMD is a duplication of the PLP1 gene locus
causing increased gene dosage; rarely triplications occur
(Wolf et al., 2005; Woodward et al., 1998). The size of
the duplicated region, its break points, and site of rein-
sertion are variable, which may account for some of the
phenotypic heterogeneity in patients with PLP1 gene
duplication (Woodward et al., 1998). Pathologically, this
can vary from virtual absence of myelin formation,
through different degrees of dysmyelination to those in
whom axonal changes may be a pronounced feature
(Harding et al., 1995; Hudson et al., 2004; Koeppen,
2005). The cellular mechanisms that lead to such pheno-
types are poorly understood. Although there are no
spontaneous models of gene duplication, transgenic mice
or rats carrying varying extra copies of wild type Plp1
genomic transgenes exhibit a similar range of pheno-
types (Anderson et al., 1999; Bauer et al., 2002; Bradl
et al., 1999; Inoue et al., 1996; Kagawa et al., 1994;
Readhead et al., 1994). Typically, mice with high trans-
gene dosage (usually homozygous for the transgene) are
dysmyelinated and die prematurely whereas mice with
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low dosage (hemizygous) develop normally but then de-
velop late-onset (15–18 months age) demyelination and
axonal degeneration (Anderson et al., 1998).
Although human patients and transgenic animals are
often described as ‘‘overexpressors’’ of the PLP1 gene,
elevations of PLP/DM20 protein levels commensurate
with alterations in gene dosage have not been reported
nor how any such changes might affect other myelin
genes.
We are using transgenic mice to address the mechan-
isms underlying the dysmyelination associated with
increased Plp1 gene dosage. The aims of the present
study were to (i) correlate Plp1 gene dosage with Plp1
gene expression particularly at the protein level and
determine how this affects the distribution of PLP/
DM20 within the oligodendrocyte/myelin sheath unit
and the amount of myelin formed and (ii) determine if
changes in dosage of one myelin gene result in altera-
tion of the proportion of other myelin constituents.
MATERIALS AND METHODS
Mice
Transgenic mice (Line no. 66) were used (Readhead
et al., 1994) in all studies. The transgene was derived
from a C57BL/6J cosmid library and injected into BDF2
eggs; subsequent generations (>20) were maintained on
the C57BL/6NCrlBr (Charles River) background. The
transgene comprises seven copies of the wild type mu-
rine Plp1 gene inserted autosomally. Full details of deri-
vation, genotyping and pathology have been published
(Anderson et al., 1998, 1999; Readhead et al., 1994).
Plp1 null mice were generated as described (Klugmann
et al., 1997). The targeting was performed in Sv129
DNA electroporated into R1 ESCs and injected into
C57BL/6J blastocysts. The phenotype of these mice has
been described (Grifﬁths et al., 1998; Klugmann et al.,
1997; Yool et al., 2001).
To determine the expression level of transgene encoded
PLP/DM20, hemizygous transgenic males were crossed
with heterozygous Plp1 null females to generate Plp1
wild type and null offspring with or without the trans-
gene. Thus, transgene expression on a null background
was compared with wild type PLP/DM20 levels.
For all other studies hemizygous transgenic mice were
mated to generate offspring that were wild type and
hemizygous or homozygous for the transgene.
Only male mice were used in the current study. Stu-
dies were performed at postnatal Day 3 (P3), an age of
very early myelination, P20, an age of active myelin for-
mation and at P60 when myelin formation is complete
and myelin maintenance is established. Mice for immu-
nostaining were perfused with 4% paraformaldehyde
and those for morphometric analysis with a glutaralde-
hyde/paraformaldehyde mixture; details of processing
schedules have been published previously (Al-Saktawi
et al., 2003; Grifﬁths et al., 1981).
Mice were identiﬁed as transgenic or wild type using
PCR genotyping of genomic DNA, as described (Readhead
et al., 1994). Further differentiation between mice hemi-
zygous or homozygous for the transgene was determined
by histological examination of the spinal cord and/or
evidence of clinical signs and by the low myelin yield
following extraction. Our original publication (Readhead
et al., 1994) correlated copy number with pathology and
this was veriﬁed in subsequent publications (Anderson,
1997; Anderson et al., 1999). Homozygous mice may be
distinguished from hemizygotes by the dysmyelination
that is evident at all ages in the present study. A small
block of cervical spinal cord from mice used for RNA,
protein or tissue culture studies was immersion-ﬁxed in
paraformaldehyde/glutaraldehyde ﬁxative and processed
for resin sections, and where necessary EM. Addition-
ally, by P20 homozygous mice show an obvious clinical
tremor.
Cell Culture
Oligodendrocytes were cultured from P5 spinal cords
as described (Montague et al., 1998) and used after
seven days in vitro. Cells from each spinal cord were
divided between two 35 mm poly-D-lysine coated Nunc
tissue culture dishes (250,000 cells/dish); at harvest
the cultures comprised 70–80% O4 1 cells together
with astrocytes, occasional neurons, and other cells
(McLaughlin et al., 2006a). To compensate for any dif-
ferences in oligodendrocyte cell numbers, samples for
western analysis were normalized for aspartoacy-
lase (ASPA), a marker of oligodendrocyte cell bodies
(Kirmani et al., 2003; Madhavarao et al., 2004). For
analysis of protein steady state levels, dishes were
rinsed twice in chilled PBS and lysed with Buffer A
(10 mM Tris pH 7.4, 150 mM NaCl, 1% triton X-100,
and inhibitors of protease and phosphatase activity).
The lysates were rotated at 4C for 30 min and cell de-
bris pelleted by centrifugation at 5,000 rpm for 5 min.
Proteins were quantiﬁed using the BCA assay system
(Perbio Science UK, Tattenhall, UK).
Real Time Quantitative PCR
The ABI prism 7,500 sequence detection system
(Applied Biosystems, Foster City, CA) using Taqman
technologies (PE Biosystems, Foster City, CA, USA) was
employed following the manufacturer’s instructions.
Real time PCR was preformed using the Platinum
Quantitative RT-PCR Thermoscript One-Step System
(Invitrogen, Carlsbad. CA). The PCR primer and probe
sets were designed using the program Primer-Express
(Applied Biosystems). Primer and probe sets used were
the following: b-actin (Accession no. NM_007393) for-
ward 50-AGAGGGAAATCGTGCGTGACAT-30: reverse 50-
AGGAAGGCTGGAAAACAGCC-30: TaqMan probe 50-
TGGCCACTGCCGCATCCTCTTC-30. A combined primer
probe set that ampliﬁed both Plp and Dm20 (Plp/Dm20)
was also utilized, forward 50-GTATAGGCAGTCTCTGC-
GCTGT-30: reverse 50-AAGTGGCAGCAATCATGAAGG-30:
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TaqMan probe 50-TGGCAAGGTTTGTGGCTCCAACCTT-
30. Each probe had FAM at the 50 end and Blackhole
Quencher at the 30 end (MWG Biotech, Germany).
A standard curve generated for each set using serial
dilutions of the RNA prepared from the cultures con-
ﬁrmed the linearity of the method. qRT-PCR was carried
out using the following protocol: 30 min at 50C, 10 min
at 95C followed by 40 cycles of 15 s at 94C, and 2 min
at 64C for ﬁve samples of both genotypes.
Analysis of qRT-PCR was carried out by relative quan-
tiﬁcation using Ct values of the Plp/Dm20 probe versus
b-actin. Normalized expression of target message probe
with respect to b-actin message was determined for all
samples using Microsoft excel data spreadsheets to gen-
erate [mRNA] per 50 lg total RNA initially loaded. The
relative amounts of transgenic mRNA were expressed as
a percentage of wild type.
Northern Blotting
Total RNA was extracted from spinal cord using RNA-
sol Bee reagent (Tel-Test Friendswood, TX) following the
manufacturer’s instructions. RNA was extracted from
wild type, hemizygous and homozygous mice and recon-
stituted in DEPC water. RNA quality and integrity were
determined using spectrophotometer and gel electro-
phoresis. Mouse total (20 lg) RNA was separated on 1%
agarose gel containing 2.2 M formaldehyde along with
RNA ladders (Invitrogen, Paisley, UK), then stained
with ethidium bromide to visualize quality and quantity
of RNA. Transfer to Hybond N membrane (Amersham
Pharmacia Biotech, Little Chalfont, UK) in 103 SSC
took place overnight.
Wild type cDNA probes were generated for Plp/Dm20
and b-actin using the following primers (Plp/Dm20, for-
ward 50-GTATAGGCAGTCTCTGCGCTGT-30: reverse 50-
AAGTGGCAGCAATCATGAAGG-30; b-actin, 50-AGAGG-
GAAATCGTGCGTGACAT-30: reverse 50-AGGAAGGCTG-
GAAAACAGCC-30). For generating an Mbp probe, a
primer set that ampliﬁed all Mbp isoforms was utilised
(forward 50-AGACCCTCACAGCGATCCAA-30: reverse 50-
CCCCTGTCACCGCTAAAGAAG-30).
The probes were radiolabelled by random priming
using a-32P-dCTP (3,000 Ci/mole) (Amersham Pharma-
cia Biotech) to speciﬁc activity >5 3 108 cpm/lg. Filters
were hybridized for 2 h at 65C in Rapidhyb buffer
(Amersham Pharmacia Biotech). The blots were then
washed at high stringency (3 3 20 min, 0.13 SSC, 0.5%
SDS) at 60C and then exposed to ﬁlm at 270C.
Antibodies and Immunostaining
PLP/DM20 was detected with either a rabbit polyclo-
nal or rat monoclonal to the common C-terminal (gifts
from NP Groome and S Pfeiffer, respectively). MBP was
detected with a mouse monoclonal (Clone 12, gift from
Prof. NP Groome) or a rabbit polyclonal (Chemicon
Europe, Chandlers Ford, UK). CNP was detected with a
mouse monoclonal (Chemicon). Monoclonal and polyclo-
nal antibodies to MAG were obtained from Chemicon
(Clone 513) and as gifts from Prof NP Groome and
Dr RH Quarles. ASPA was detected with a rabbit poly-
clonal (gift from Dr J Garbern). The CC-1 antibody
(Oncogene Research Products, CN Biosciences, Notting-
ham, UK) was used to identify oligodendrocytes. b-actin
was detected with a mouse monoclonal antibody (Sigma).
Anti-Lamp1 (Clone ID4B) was obtained from the Deve-
lopmental Studies Hybridoma Bank.
Single or double immunoﬂuorescence was performed
on cryosections, as described (Al-Saktawi et al., 2003).
Morphometric Analysis
Analyses were performed on resin-embedded tissue
from the ventral columns of the second cervical segment
(C2) of spinal cord. Myelin volume was calculated from
electron micrographs using a point counting method, as
described (Al-Saktawi et al., 2003). Axonal area and
total ﬁbre area were measured on semi thin sections
photographed with a 1003 oil immersion lens using a
digital camera. A computer-generated grid was superim-
posed on the image and all ﬁbers contacting intercepts
were analyzed using Image Pro-Plus 4.1 software (Media
Cybernetics, Silver Spring, MD). Axon and total ﬁber
diameters were obtained from the area measurements
and used to derive the myelin thickness and g ratio
(axon diameter/total ﬁber diameter).
Cell Counts in Spinal White Matter
Oligodendrocytes were immunostained with the CC-1
antibody with DAPI co-staining of nuclei. Cell counts
were performed on cryosections of the ventral columns
of white matter at approximately C2 segment, as de-
scribed (Al-Saktawi et al., 2003).
Myelin Extraction and Western Blotting
Myelin enriched fractions were prepared from whole
brain and spinal cord and probed for PLP/DM20, MBP,
CNP, and MAG; total homogenates were also probed for
ASPA as described (Al-Saktawi et al., 2003). The pellets
produced by the high-speed centrifugation of the homog-
enate contained membranous and nuclear fractions and
were analyzed for PLP/DM20 content. Lysed oligoden-
drocyte cultures were blotted for PLP/DM20, MBP, and
ASPA. Proteins were visualized by ECL (SuperSignal
West Pico, Pierce Biotechnology, Perbio Science UK) and
the signal intensity quantiﬁed using Scion Image analy-
sis software.
Statistical Analyses
Statistical signiﬁcance of differences between values was
assessed by ANOVA followed by Bonferonni’s post hoc
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comparison test or by Student’s t test, as appropriate,
with signiﬁcance P < 0.05. Analyses and curve ﬁtting
were performed using Graphpad Prism4 software
(GraphPad Software, San Diego, CA). In the bar charts,
signiﬁcance of the mutants from wild type is indicated
as <0.05 (*), <0.01 (**), and <0.001 (***).
RESULTS
Distinct Phenotypes of Plp1 Transgenic Mice
Full details of #66 mice have been published (An-
derson et al., 1998, 1999; Readhead et al., 1994). Brieﬂy,
mice hemizygous for the Plp1 transgene have no ab-
normal phenotype until over 1 year, typically 15–
18 months, when they lose weight, develop kyphosis,
weakness, and ataxia. No obvious pathology is evident
in young adults but clinically affected older mice show
demyelination and axonal degeneration preferentially
affecting smaller diameter ﬁbers. Oligodendrocytes
appear normal morphologically. Hemizygous mice in the
current study were used prior to the above changes. In
contrast, mice homozygous for the transgene exhibit
tremor from the second week followed later by seizures,
associated with marked dysmyelination, and an in-
creased number of apoptotic oligodendrocytes. Oligoden-
drocytes show swelling of the Golgi apparatus and
numerous autophagic vacuoles. A minority of oligoden-
drocytes show loss of the normal cisternal pattern of the
rough endoplasmic reticulum (RER). Representative
images of the morphology at P20 in the three genotypes
are shown in Fig. 1 and of the homozygote in supple-
mentary Fig. 1.
Expression of Plp Transgene: mRNA and Protein
Levels Are Similar to Wild Type
We expressed the autosomal transgene on a Plp1 null
background to assess transgene-derived levels of mRNA
and product using qRT-PCR and western blotting, respec-
tively. P20 mice harboring one copy of the transgene cas-
sette on the null background expressed Plp/Dm20 mRNA
and PLP and DM20 proteins in the spinal cord at simi-
lar levels to wild type mice generated in the same litter
(Figs. 2A,B). Levels of Mbp mRNA and myelin MBP in
Plp1 null mice with and without the transgene were
also unchanged from wild type (data not shown).
Dosage-Related Expression of the Plp1
Gene in Oligodendrocytes and Spinal
Cord During Myelination
During normal in vivo development the level of Plp1
gene expression closely parallels myelination. However,
expression commences prior to myelin formation and is
Fig. 1. Electron micrographs of white matter in the ventral columns
of P20 mice. A: Wild type mouse with all axons surrounded by an
appropriately thick myelin sheath. B: All axons are myelinated in the
hemizygous mouse in which the general structure appears normal;
morphometric analysis showed that the average sheath was slightly
thinner than its wild type counterpart. C: The homozygous mouse is
dysmyelinated with thin myelin sheaths around the majority of axons.
An oligodendrocyte cell body is abnormal and contains numerous autop-
hagic vacuoles (arrow). Bar 5 2 lm.
Fig. 2. Expression of the Plp1 transgene on a Plp1 null background
in spinal cord of P20 mice. A: Representative western blot for PLP/
DM20 in myelin from wild type (WT), Plp1 null (Null), and Plp1 null
mice carrying the Plp1 transgene (Null/tr). The signal is similar in the
wild type and null/tr mice. MAG is also shown as a control for loading.
B: Quantitative data for Plp/Dm20 mRNA, measured by qRT-PCR and
PLP protein, measured by western blotting for Plp1 null mice carrying
the Plp1 transgene. Results (M 6 SEM, N 5 2) are expressed as a
percentage of a wild type mouse from the same litter. There is no
difference between groups for either parameter.
344 KARIM ET AL.
GLIA DOI 10.1002/glia
inﬂuenced by axonal contact and the amount of myelin
produced by the cell (McPhilemy et al., 1990; Thomson
et al., 2005). To understand how these factors might
interact with increased Plp1 gene dosage we ﬁrst stud-
ied PLP/DM20 levels in na€ıve oligodendrocytes with no
axonal contact and in the absence of a myelin sheath.
Fig. 3. Plp1 gene expression in oligodendro-
cytes and in spinal cord of mice hemizygous
and homozygous for the Plp transgene. A: Re-
presentative western blots of cultured oligo-
dendrocytes from wild type (WT), hemizygous
(Hemi) and homozygous (Homo) mice probed
for PLP/DM20 and for ASPA, an oligodendro-
cyte-speciﬁc cell body protein and for MBP.
Whereas the level of PLP/DM20 is elevated in
the homozygotes, the amount of the MBP iso-
forms is decreased in the same cells. B: Levels
of PLP/DM20 in oligodendrocytes normalized to
ASPA and expressed relative to the wild type
(M 6 SEM, N 5 4). Values for hemizygotes are
similar to wild type whereas the values for
homozygotes are elevated (P < 0.05). C: Repre-
sentative western blots of total homogenates
from P3 spinal cords probed for PLP/DM20 and
MBP and normalized with b-actin. The PLP/
DM20 levels show a progressive increase with
gene dosage whereas the MBP level in the
homozygote is considerably lower than the
other genotypes. D: Accumulation of PLP/
DM20 in cell bodies of oligodendrocytes from a
P3 mouse homozygous for the transgene. Resin
section immunostained for PLP/DM20 showing
two oligodendrocytes with strongly immunopo-
sitive cell bodies. The thin myelin sheaths are
also stained. The ventral pial surface is to the
bottom. The arrows (E, F) indicate the sites of
the EM images shown in Figs. E and F, which
were obtained from an immediately adjacent
serial thin section. E: Part of oligodendrocyte
soma showing loss of the normal cisternal
arrangement of the RER (*). F: Oligodendro-
cyte soma showing numerous autophagic va-
cuoles (arrows). Bars 5 1 lm.
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Primary cultures, established from wild type mice and
those carrying the transgene in the hemizygous or homo-
zygous state, were probed for PLP/DM20 and aspartoa-
cylase (ASPA), a marker speciﬁc for oligodendrocyte cell
bodies (Kirmani et al., 2003; Madhavarao et al., 2004) to
control for loading and cell numbers between cultures.
The normalized levels of total PLP/DM20 protein, rela-
tive to wild type, were similar in hemizygous oligoden-
drocytes but elevated in those from homozygous animals
(P < 0.05) (Figs. 3A,B).
We next investigated Plp1 gene expression in spinal
cord of P3 and P20 wild type, hemizygous and homozy-
gous transgenic littermates. P3 represents an early
stage of myelin formation when oligodendrocytes have
established axonal contact but only a small proportion of
spinal axons have rudimentary sheaths and the majority
of PLP/DM20 is in the cell body whereas P20 is an age
of advanced myelination. Levels of PLP/DM20 in total
homogenates of P3 spinal cord (Fig. 3C) were elevated
relative to wild type in both hemizygotes and homozy-
gotes, more so in the latter. We performed immunostain-
ing and electron microscopy to localize PLP/DM20 in
spinal cords of P3 homozygous mice. In 1 lm immuno-
stained resin sections strongly stained oligodendrocyte
cell bodies and myelin sheaths were evident with some
cell bodies containing dark immunopositive struc-
tures (arrow in Fig. 3D). In immediately adjacent EM
sections (Figs. 3E,F) the immunopositive cells had dis-
tended RER and autophagic vacuoles/lysosomes, which
probably correspond to the dark structures seen in the
resin section.
We evaluated Plp/Dm20 mRNA in the spinal cord of
P20 mice by northern blot, using b-actin as an internal
standard. At P20 levels in hemizygotes were 122% of
wild type (P > 0.05) while homozygotes were reduced
(60% of wild type) (P < 0.01) compared with the two
other genotypes (Figs. 4A,B). Very similar changes in
mRNA levels were reported in the 4e line of Plp1 trans-
genic mice (Kagawa et al., 1994). In the spinal cord of
hemizygotes at P20, the levels of PLP and DM20 in
myelin-enriched fractions were not different from wild
type littermates but were signiﬁcantly lower in homozy-
gous animals (Figs. 4C,D). Similar results were obtained
for myelin fractions from the brain (data not shown).
In normal myelinated white matter the vast majority of
PLP, the major isoform, is present in the compact sheath
while DM20 is located in both myelin and cytoplasm
(Trapp et al., 1997). As oligodendrocytes and pre-myeli-
nating spinal cord of homozygous mice contained more
PLP/DM20 than wild type (Figs. 3A,C) whereas myelin
fractions from P20 mice contained less per unit of ex-
tracted myelin protein, we examined the pellet fraction
(containing nuclei and membranous organelles) remain-
ing after myelin separation (Fig. 4C). In comparison
with wild type (100%), the levels of PLP and DM20 were
greater in pellet fractions from hemizygotes (158% 6 9
and 227% 6 28, respectively, N 5 5, P < 0.05) while for
homozygotes PLP was similar (124% 6 10, NS) and
DM20 was elevated (207% 6 38, P < 0.05). A summary
of the results is presented in Table 1.
The data suggest that in oligodendrocytes from homo-
zygous mice a ‘‘relative excess’’ of PLP/DM20 is stored or
retained in the cell body with a reduced amount translo-
cated to myelin, in comparison with wild type. Based on
the EM, the most probable site for this ‘‘stored’’ PLP/
DM20 is the autophagic vacuoles/lysosomes. In immuno-
stained brain sections, signiﬁcant co-localization of PLP/
DM20 and the lysosomal marker, Lamp1, provided
further evidence that PLP/DM20 accumulates in these
organelles (Supplementary Fig. 2).
Effect of Plp1 Dosage on Expression
of Other Myelin Genes During Myelination
We determined if changes in Plp1 gene dosage affect
the expression of other representative myelin proteins
and their incorporation into the myelin sheath. Unex-
pectedly in homozygous mice, the level of MBP, the sec-
ond most abundant myelin protein, was decreased even
in cultured oligodendrocytes, and prior to myelination in
P3 spinal cords (in contrast to the elevated amounts of
PLP/DM20 in the same samples) (Figs. 3A,C). This
Fig. 4. A: Representative northern blot for Plp/Dm20 and b-actin
mRNA from spinal cord of P20 mice. B: Quantiﬁcation of Plp/Dm20
mRNA in P20 spinal cord, (M 6 SEM, N 5 5), expressed relative to
wild type. The increase in hemizygotes is not signiﬁcant whereas the
level in homozygotes is reduced (P < 0.01). C: Representative western
blot for PLP/DM20 of myelin enriched and pellet fractions and the total
homogenate (TH) from spinal cord of P20 mice. The levels of PLP/
DM20 in the total homogenate and myelin fraction from homozygous
mice are reduced compared with wild type whereas in the pellet frac-
tion the converse applies. D: Steady state levels of PLP and DM20 pro-
teins in myelin fractions from P20 mice show no change from wild type
in hemizygous animals, but signiﬁcant reductions in homozygous mice
(M 6 SEM, N 5 5, P < 0.05).
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down regulation extended to later time points where
levels of Mbp mRNA and MBP protein were reduced in
spinal cords of P20 homozygotes. (Figs. 5A–D). In hemi-
zygotes, message levels were normal, but MBP protein
was reduced compared with wild type (Figs. 5A–D).
Two proteins, CNP and MAG, found in uncompacted
myelin membranes were reduced in the homozygous
mice while CNP, but not MAG was lower in hemizygous
mice (Figs. 5C,D). In myelin fractions derived from
whole brain the level of MBP, but not CNP and MAG,
was reduced in hemizygous mice while all three pro-
teins were markedly lower in homozygous animals rela-
tive to wild type (Fig. 5E). A summary of the MBP data
is presented in Table 1.
Thus, overexpression of the Plp1 gene impacts on
other myelin genes, particularly Mbp, with downregula-
tion at both mRNA and protein levels.
Myelin Proteins During Myelin Maintenance
P20 represents an age in mice at which myelination
in the spinal cord is advanced but incomplete; in the
brain the status is more varied with a caudal to rostral
gradient of myelin development. To determine the inﬂu-
ence of increased Plp1 gene dosage during myelin main-
tenance we examined brain and spinal cord of P60 hemi-
zygotes; mice homozygous for the transgene usually died
prior to this age. mRNA levels for Plp/Dm20 and Mbp
were unchanged in the hemizygotes compared with wild
type. There was no difference between the two genotypes
in the protein levels of PLP, DM20, MBP, CNP, and
MAG in myelin from brain or spinal cord (data not
shown) nor in the myelin morphometry (see below), sug-
gesting the differences in CNP and MBP present at P20
had resolved during maturation.
TABLE 1. Steady State Levels of PLP and MBP Proteins in Cells and Tissues from Mice with Low (Hemizygous) and High (Homozygous)
Transgene Dosage, Relative to the Corresponding Wild Type Samples
Stage of myelination
Low dosage High dosage
PLP/DM20 MBP PLP/DM20 MBP
Nonmyelinating (cultured OLs) Normal Normal Increase Decrease
Early myelination (P3 spinal cord) Small increase Normal Increase Decrease
Myelinated (P20 spinal cord) Normal (T) Moderate decrease (M) Small decrease (T) Marked decrease (M)
Increase (P) Increase (P)
Normal (M) Marked decrease (M)
OLs, oligodendrocytes. In the P20 spinal cords, samples have been fractionated to examine the distribution of PLP/DM20: T, total homogenate; P, pellet; M, myelin-
enriched. For MBP, only myelin-enriched samples were evaluated.
Fig. 5. Increased Plp gene dosage
affects expression of other myelin pro-
tein genes. A: Representative northern
blot for Mbp and b-actin mRNA from
spinal cord of P20 mice. B: Mbp mRNA
levels, representative of other myelin
genes, are not different from wild type
in the spinal cords of P20 hemizygous
mice but reduced (P < 0.01) in homozy-
gotes. The data (M 6 SEM, N 5 5) are
expressed relative to wild type. C: Re-
presentative western blots of myelin
enriched fractions from P20 spinal cord
probed for MBP, CNP and MAG. All
three proteins are reduced in homozy-
gous mice and MBP and CNP are also
lower in hemizygotes, compared with
wild type. D: Levels of MBP, CNP and
MAG in myelin enriched fractions from
spinal cord of P20 hemizygous and
homozygous mice. In the hemizygotes,
MBP (P < 0.001) and CNP (P < 0.05)
are reduced relative to wild type while
MAG levels are similar. All proteins are
markedly lower (P < 0.001) in homozy-
gous mice. E: In myelin enriched frac-
tions from whole brain of P20 mice only
MBP (P < 0.001) is reduced in hemizy-
gotes while all three proteins are lower
in homozygous mice.
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Effects of Plp1 Gene Dosage
on the Oligodendrocyte/Myelin Unit
As Plp1 gene dosage inﬂuences the formation of mye-
lin we quantiﬁed the volume of myelin from electron
micrographs of cervical ventral columns at P20 using a
point counting method. Hemizygotes contained slightly
less myelin (81%) than wild type whereas homozygous
mice had considerably less than the other genotypes
(Fig. 6A). Morphometric analysis indicated that while
axon diameters were similar in the three genotypes, the
mean g ratio was elevated in hemizygous and more
especially homozygous transgenic mice compared with
wild type, due to a reduction in myelin thickness
(Figs. 6B,C). An increase in Plp1 gene dosage, therefore,
leads to a commensurate reduction in myelin formation
in spinal cord, which in the case of hemizygous mice is
subtle and due only to slightly thinner myelin sheaths.
In the more severely affected homozygous mice the
reduction is a combination of markedly thinner sheaths
and amyelinated axons. The morphometric changes are
reﬂected by differences in cervical cord area; both hemi-
zygous (2.54 6 0.03 mm2, n 5 6) and homozygous (2.14
6 0.02) mice had reduced areas compared with wild
type (2.89 6 0.06, P < 0.001) and the two mutants dif-
fered from each other (P < 0.01).
We also assessed the myelin recovery from whole brain
(expressed as myelin protein per unit weight of brain
tissue) obtained during biochemical fractionation. There
was no difference in recovery between wild type and
hemizygous mice, but markedly less myelin was obtained
from the dysmyelinated homozygous mice (Fig. 6D). The
failure to detect subtle differences between wild type
and hemizygous mice may indicate differences between
myelination in brain and spinal cord or reﬂect the lower
sensitivity of this technique compared with the morpho-
metric analyses.
As myelination is incomplete at P20, we evaluated the
amount of myelin at P60 in hemizygous and wild type
mice. There was no difference in myelin recovery from
brain and the myelin volume, g ratio or axon diameter/
myelin thickness relationship in spinal cord at this age
(data not shown).
The calculated number of CC-1 1 oligodendrocytes in
white matter area per transverse section for P20 wild
type, hemizygous and homozygous mice were 337 6 13,
358 6 12, and 349 6 52 cells, respectively; these values
are not signiﬁcantly different.
DISCUSSION
Duplication or even triplication of the PLP1 locus is
the most frequent cause of PMD and patients with
increased gene dosage and the corresponding transgenic
animal models are often referred to as ‘‘overexpressors’’.
Using a transgenic mouse with a ‘‘low’’ or ‘‘high’’ increase
in Plp1 gene dosage we show that the relationship
between dosage and steady state PLP/DM20 levels is
complex and inﬂuenced by whether or not the cell is
generating myelin and that changes in dosage alter the
proportional distribution of PLP/DM20 within the oligo-
dendrocyte/myelin unit. We further show that changes
in Plp1 gene dosage have profound effects on other mye-
lin proteins, particularly MBP.
The Level and Distribution of PLP/DM20
Are Inﬂuenced by Gene Dosage
and State of Myelination
Intuitively, one would anticipate increased Plp1 gene
dosage to result in higher levels of PLP/DM20. However,
other factors, such as the myelination status, have a
major inﬂuence. To separate these inﬂuences we deter-
mined PLP/DM20 levels in cultured oligodendrocytes,
which lack myelin sheaths, and showed that levels in
cells from homozygous mice were elevated. During very
early myelination in P3 spinal cords, PLP/DM20 was
also elevated in homozygous mice and to a lesser extent
in hemizygous mice. As myelination proceeds the level
of gene dosage determines the ability of the oligodendro-
cyte to deal with the potential protein overload. In
Fig. 6. Myelin status of wild type and transgenic mice at P20. A:
Myelin volume in ventral columns of cervical spinal cord was deter-
mined from electron micrographs using a point counting method.
Values are reduced in both transgenics compared with wild type and
also differ with each other. B: The g ratio is increased in transgenic
mice compared with wild type. The ratio provides an indication of
whether the thickness of myelin sheath is appropriate for axon diame-
ter; a higher value indicates a disproportionately thin sheath. C: Mye-
lin sheath thickness (MT) should increase with axon diameter as shown
by the scatter graph for wild type mice and the corresponding linear
regression. The slopes of regression lines for the transgenic mice are
reduced compared with wild type and also differ from each other. The
individual points for the transgenics are not shown. D: Myelin recovery
from whole brain is similar in mice hemizygous for the transgene and
wild type; both groups differ from homozygous mice. The level of pro-
teins in myelin is expressed as a proportion of the wet weight of whole
brain. (The bar charts show mean 6 SEM, N 5 6 for A, B, C, and 10
for D).
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normal myelination the vast majority of PLP/DM20 is
concentrated in myelin and myelin gene expression is
upregulated to deal with the rapid membrane expan-
sion. With P20 hemizygous mice PLP/DM20 is incorpo-
rated into myelin in normal amounts although levels in
the cell soma (as indicated by pellet fractions) remain
elevated compared with wild type. This suggests the
myelinating cell regulates the incorporation of PLP/
DM20 into myelin despite changes in levels in the cell
body.
With P20 homozygotes the situation is more complex.
Total levels of PLP/DM20 (as contained in total homoge-
nates) are slightly lower than wild type, the reduction
probably reﬂecting downregulation of myelin genes asso-
ciated with dysmyelination and the concomitant reduc-
tion in myelin content. What is more striking is the
alteration in distribution of PLP/DM20 with the somal
pellet fractions containing a disproportionate amount,
relative to the low levels in the myelin sheath. This
quantitative change is matched by immunocytochemical
demonstration of strong PLP/DM20 reactivity in the cell
bodies in our mice and in the transgenic rat model
(Bauer et al., 2002; Bradl et al., 1999). Immunostaining
and EM show that the strongly immunopositive oligo-
dendrocyte cell bodies contain numerous autophagic
vacuoles and lysosomes. PLP, when overexpressed, is
known to associate with the endosome/lysosome system
(Simons et al., 2002). In normal myelination PLP
may also associate temporarily with endosomes before
axon-derived signals promote its insertion into myelin
(Trajkovic et al., 2006). A reduction in the available
myelin and decreased axonal contact, as occurs in the
homozygotes, would be predicted to exacerbate the accu-
mulation of PLP in lysosomes.
A very similar paradoxical effect has been observed in
the nerves of mice ‘‘overexpressing’’ P0, the major mye-
lin gene of the PNS. Myelin was maintained with lower
levels of P0 transgene dosage although MBP was re-
duced, while higher expression led to dysmyelination
and decreases in all myelin proteins (Wrabetz et al.,
2000). Schwann cells overexpressing P0 also concentrate
the protein in their cell bodies due to the paucity of
available myelin (Yin et al., 2000). Similarities also exist
with increased dosage of the PMP22 gene, the common-
est cause of Charcot-Marie-Tooth disease Type 1A. Trans-
genic rodent models of the disorder exhibit dysmyelination
proportionate with Pmp22 dosage (Huxley et al., 1998;
Niemann et al., 2000) and Schwann cells contain autopha-
gic vacuoles reminiscent of those seen in oligodendrocytes
of the present study (Chies et al., 2003; Niemann et al.,
2000). Additionally, increased Pmp22 dosage causing dys-
myelination of the peripheral nerves is associated with
reduced levels of myelin proteins (Sereda et al., 1996), as
occurred with our other Plp1 transgenicmice.
We suggest that when using the term ‘‘overexpressor’’
in relation to PLP/DM20 protein a distinction must be
drawn between cell soma and myelin. The term may be
justiﬁed when considering PLP/DM20 levels in the
oligodendrocyte cell bodies but does not appear appropri-
ate in relation to myelin where levels are not increased
at either gene dosage. Total tissue levels also show no
increase proportionate to gene dosage.
Effect of Plp1 Gene Dosage on Other Myelin
Proteins and Possible Consequences
Although the level of PLP/DM20 in spinal cord myelin
from P20 hemizygous mice is normal, MBP is transito-
rily reduced, recovering by the age of P60. Concurrently,
there is also a subtle myelin defect due to a slight reduc-
tion in sheath thickness, which also recovers by age
P60. In P20 homozygous mice, the levels of MBP and
other representative proteins are markedly reduced in
myelin fractions. While a reduction of MBP, associated
with hypomyelination, might be anticipated there must
be a more fundamental dysregulation, which is not
attributable solely to a lack of myelin, as MBP is sub-
stantially reduced in na€ıve oligodendrocytes and P3
spinal cord, even though PLP/DM20 levels are elevated
in the corresponding samples.
Other integral myelin membrane proteins, such as
MAG, which share the same biosynthetic pathway as
PLP, are also concentrated in oligodendrocyte cell bodies
in homozygous mice whereas MBP, which has a different
pathway, is not enriched in the soma (Anderson et al.,
1999) (Supplementary Fig. 3). A range of membrane
proteins of both myelin and non-myelin origin were also
concentrated in oligodendrocyte cell bodies in the Plp1
transgenic rats (Bauer et al., 2002).
The precise cause of the hypomyelination in the homo-
zygotes is still uncertain. Reduced levels of PLP/DM20
do not cause a similar myelin deﬁcit (Klugmann et al.,
1997). The reduction in MBP, either singly or in combi-
nation with other myelin components, may be signiﬁcant
as MBP is critical for myelin formation and inﬂuences
the amount of myelin formed (Shine et al., 1992). We
are testing whether genetically increasing the level of
MBP in Plp1 transgenic mice improves myelin formation
to determine whether the changes in MBP are a causa-
tive factor. The autophagic vacuoles also enclose myelin-
like membranes in addition to PLP/DM20. A further
possible mechanism for dysmyelination may involve
accelerated breakdown of any myelin that does form
during development so that the sheath never acquires
full thickness. An investigation into the turnover dy-
namics of myelin components is also being undertaken.
Comparison with Other Plp1 Mutations
Causing Dysmyelination
Mutations causing changes in the structure of PLP/
DM20, predicted to cause protein misfolding, are a com-
mon cause of PMD and also occur spontaneously in ani-
mals. The dysmyelination associated with missense
mutations and increased gene dosage share similarities
with marked hypomyelination and increased cell death.
Misfolded PLP/DM20 tends to accumulate in the RER,
inducing an unfolded protein response (UPR) and pro-
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teasomal degradation (McLaughlin et al., 2006a,b;
Southwood and Gow, 2001; Southwood et al., 2002). As
PLP/DM20 generated by increased dosage has a normal
structure, a UPR is not anticipated and indeed, markers
of the UPR, such as caspase 12, Chop, and Atf3 are not
induced (Cerghet et al., 2001; Southwood et al., 2002).
Additionally, we have not detected elevation in BiP
levels nor activation of X box-1, which are both induced
by misfolded protein (Karim, unpublished data). There
is also evidence that apoptosis in the two models occurs
via different mechanisms (Cerghet et al., 2001). We are
currently investigating the dynamics of PLP/DM20 in
Plp1 transgenic mice. Interestingly, in homozygotes
about 55% of nascent PLP/DM20 is degraded by an
MG132-sensitive mechanism, probably implicating the
proteasome, compared with 30% in wild type and hemi-
zygotes (Karim, unpublished data) and 70% in the
rumpshaker mutation (McLaughlin et al., 2006a). Our
ongoing work suggests there may be at least three fates
of newly synthesized PLP/DM20 in the Plp1 transgenic
mice, the labile component, a small amount incorporated
into myelin, and a longer-lived pool that persists in
the cell soma. How the dysmyelination is induced by
any of the above processes is still an open question.
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Abstract Mutations of the proteolipid protein gene
(PLP1) cause Pelizaeus-Merzbacher disease (PMD)
and Spastic paraplegia type 2 (SPG2). The rumpshaker
mutation is associated with mild forms of PMD or
SPG2 in man and the identical mutation occurs in
mice, the phenotype depending on genetic background.
The mild phenotype in C3H mice becomes a lethal
disease when expressed on the C57BL/6 background.
rumpshaker PLP is synthesised at a similar rate to wild
type but is rapidly degraded by the proteasome. We
show that the rates of synthesis, degradation and
myelin incorporation of PLP/DM20 are similar in
mutants on both backgrounds and therefore differ-
ences in PLP processing are unlikely to be the basis of
the phenotypic variation. An unfolded protein re-
sponse (UPR) is activated in rumpshaker. Whereas
activation of CHOP correlates with phenotypic sever-
ity, we find no difference in the response of BiP and X-
box protein1 (Xbp1) between the two strains.
Keywords Oligodendrocyte Æ Myelin Æ CHOP Æ
Proteolipid protein Æ Rumpshaker Æ Misfolded protein Æ
Pelizaeus-Merzbacher disease
Introduction
The X-linked proteolipid protein (PLP1/Plp1) gene
encodes PLP and minor isoforms, such as DM20, which
constitute the major proteins of CNS myelin. Muta-
tions of the PLP1/Plp1 gene cause Pelizaeus-Merzb-
acher disease (PMD) and Spastic Paraplegia type 2
(SPG2) in man and dysmyelinating disorders in a range
of animal species [1, 2]. Missense mutations with single
amino acid substitutions are a common cause of PMD/
SPG2 and also account for the majority of the spon-
taneous mutations in animals. Across the whole range
of missense mutations there is a wide spectrum of
disease severity, which is usually ascribed to the
alteration in specific residues and their location within
the molecule. We have also shown that in the murine
rumpshaker mutation (Plpjp-rsh) (Ile186Thr) the phe-
notype is markedly affected by the background strain,
suggesting the influence of modifying gene(s). On the
C3H background the phenotype is relatively benign
with no seizures and normal longevity whereas
expressing the mutation in the C57BL/6 genome re-
sults in a severe and lethal disorder [3]. As the genetic
mutation and primary sequence of PLP are identical,
the rumpshaker mutation provides a system in which to
compare the pathogenetic mechanisms underlying
‘‘mild’’ and ‘‘severe’’ PMD/SPG2.
Many of the missense mutations in the PLP1/Plp1
gene are thought to generate misfolded PLP/DM20,
which is retained in the rough endoplasmic reticulum
(RER) [4] leading to activation of the unfolded protein
response (UPR) and oligodendrocyte apoptosis [5–7].
Despite the considerable amount of data on PLP-
related disorders the dynamics of PLP processing was
relatively under investigated. As a starting point we
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determined how the oligodendrocyte handled wild type
and rumpshaker PLP/DM20 on the C3H background
[8]. Surprisingly, the rate of synthesis was similar in wild
type and mutant but whereas the half life of normal
PLP was ~24 h, the mutant product was degraded twice
as fast, largely by a proteasome dependent mechanism.
Despite the enhanced degradation a small proportion
of rumpshaker PLP was incorporated into myelin at a
slower rate than normal and was also inserted in the
correct topology as shown by immunostaining with the
conformation-sensitive O10 antibody [9]. The acceler-
ated degradation of PLP on the C3H background is
consistent with a survival response of the oligoden-
drocyte to accommodate the production of the mis-
folded mutant protein without activating apoptosis.
We undertook the present study to determine whe-
ther differences in the processing of PLP/DM20 or in
the magnitude of the UPR might underlie the diver-
gent phenotypes of rumpshaker on C3H and C57
backgrounds. Despite the very marked differences in
phenotype, we find very little difference in the
dynamics of PLP processing. The UPR was more var-
iable with some representative markers, such as BiP
and the X box protein 1 (Xbp1) showing a similar
response in the two mutants while CHOP was acti-
vated to a greater extent in the more severe phenotype.
Materials and methods
Animals
The rumpshaker (Plpjp-rsh) mutation arose originally in
C3H mice and was maintained on a hybrid C3H/101
background (referred to hereafter as C3H rumpshak-
er). Female heterozygotes were crossed with wild type
C57BL/6NCrlBR males (Charles River) over 10 gen-
erations and then intercrossed to generate a stable line
(referred to hereafter as C57 rumpshaker). Mutant
mice were genotyped by PCR amplification of genomic
DNA and restriction digest of the novel AccI site.
Animals for immunostaining were perfused with 4%
paraformaldehyde and blocks from cervical cord pre-
pared for cryosections as described [3]. All animal
studies were approved by the Ethical Committee of the
University of Glasgow and licensed by the UK Home
Office.
Antibodies and immunostaining
PLP/DM20 was detected with a rabbit polyclonal
antibody recognising the common C-terminal (gift
from Prof. NP Groome) or a rat monoclonal (AA3,
gift from Dr. S Pfeiffer). MBP was detected with a
mouse monoclonal (clone 12, gift from Prof. NP
Groome) or a rabbit polyclonal antibody (Chemicon
International Ltd., Harrow, England). CNP was de-
tected with a mouse monoclonal (Chemicon).
Monoclonal and polyclonal antibodies to MAG were
obtained from Chemicon (clone 513) and as gifts
from Prof NP Groome and Dr RH Quarles. A rabbit
polyclonal (Santa Cruz Biotechnology Inc. Santa
Cruz, CA) and a mouse monoclonal (Affiniti BioR-
eagents, Cambridge Bioscience, Cambridge, UK)
against CHOP (GAD153) were used. Rabbit poly-
clonal anti-BiP (GRP78) was obtained from Stress-
gen (Bioquote Ltd., York, UK). Anti-caspase-3 was
obtained from R&D Systems Europe (Abingdon,
UK). Oligodendrocytes were stained with the CC-1
antibody (Oncogene Research Products, CN Bio-
sciences, Nottingham, UK).
Immunostaining of cryosections was performed as
described previously [3].
Cell counts in spinal cord
Cryosections of cervical cord ventral funiculi were used
to count CHOP+ nuclei, counterstained with DAPI.
The methods for cell counting have been described [3].
RT-PCR
RNA was extracted from the spinal cord of mice aged
P20 and the reversed transcription reaction performed
as described previously [3, 10]. X box protein 1 (Xbp1)
PCR protocol was performed essentially as described
[11] using the primer sequences, forward 5¢-AAACA-
GAGTAGCTCAGACTGC-3¢ and reverse 5¢-TCCTT
CTGGGTAGACCTCTGGGAG-3¢. The Xbp1 PCR
products were digested with Pst1, which cuts only the
unspliced cDNA and the spliced and unspliced prod-
ucts resolved on a 2.5% agarose gel containing ethidi-
um bromide. RNA extracted from cultured
oligodendrocytes, which had been exposed to stress
inducing conditions were processed in tandem with the
cord tissue to serve as controls.
We also assessed levels of Chop and ATF3 using
cyclophilin as a control for invariant gene expression.
Primers used were; Chop, forward 5¢-CATACACCA
CCACACCTGAAAG-3¢, reverse 5¢ CCGTTTCCTA
GTTCTTCCTTGC-3¢ (accession # X67083.1) product
size 356 bp; ATF3, forward 5¢-CAACATCCAGGCC
AGGTCT-3¢, reverse 5¢-CTCTGCAATGTTCCTTCT
TTT-3¢ (accession # BC064799.1) product size 532 bp.
The primers for cyclophilin and PCR conditions were
as described [10]. The products were resolved on a 2%
168 Neurochem Res (2007) 32:167–176
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agarose gel visualised with ethidium bromide staining
and the captured images quantified using Scion Image
for Windows software (Scion Corporation). The
intensity of the signal was corrected for the relative
density of cyclophilin.
Primary oligodendrocyte cultures
Oligodendrocytes were isolated and cultured from the
spinal cord of male P5 mice as previously described [8,
12]. C3H females homozygous for rumpshaker muta-
tion were mated with hemizygous males to generate
litters in which all pups were affected. Wild type C3H
litters were also produced. As affected C57 mice do not
survive to breeding age, C57 rumpshaker heterozyg-
otes were mated with wild type males thus generating
litters containing wild type and mutant males. Oligo-
dendrocytes from spinal cords of C3H mice were
pooled and plated onto two 35 mm poly-L-lysine
coated plates per mouse. Oligodendrocytes were pre-
pared from individual C57 mice and divided between
two 35 mm plates. The genotype of each pup was
confirmed by PCR of genomic DNA extracted from
tail tips as previously described [3].
At 7 days in culture, the medium was removed, cells
washed twice with Hank’s buffered salt (HBS) then
incubated for 30 min in HBS. The medium was re-
placed with 0.5 ml HBS containing [35S]-Pro-Mix
(Amersham Pharmacia Biotech, Little Chalfont, UK)
at 100 lCi/ml. For analysis of protein synthesis, dishes
were removed at 45 and 90 min, rinsed twice in chilled
PBS and lysed with Buffer A (10 mM Tris pH 7.4,
150 mM NaCl, 1% triton X-100 and inhibitors of pro-
tease and phosphatase activity). For pulse chase
experiments, cells were labelled for 90 min and chased
by replacing the HBS with SATO medium supple-
mented with 2.5 mM cysteine/2.5 mM methionine. At
the appropriate time point, cells were washed twice
with chilled PBS then lysed with 75 ll buffer A. The
lysates were rotated at 4C for 30 min and cell debris
pelleted by centrifugation at 5,000 rpm for 5 min [8].
Brain slices and myelin extraction
A brain slice preparation from P20 mice was used to
measure incorporation of newly synthesised radiola-
belled PLP/DM20 into myelin. Following myelin
enrichment on a sucrose gradient and two rounds of
osmotic shock, PLP/DM20 was immunoprecipitated
and the products resolved by SDS PAGE and trans-
ferred to PDVF membranes for exposure to a high
sensitivity phosphorimage screen (Amersham) for a
period of 1–2 weeks and the image captured on a
Storm phosphorimage system. Western blotting was
then performed. Full details have been published [8].
Preparation of tissue for evaluation of UPR
Due to the marked reduction in the myelin content of
the rumpshaker spinal cord compared with the wild
type, a protocol was established which removed the
bulk of the myelin and generated an organelle enriched
membranous fraction and a cytosolic fraction. Spinal
cords were snap frozen in liquid nitrogen and stored at
–80C until required. Tissues were homogenised using
a Teflon homogenizer in 2 ml of 0.85 M sucrose,
10 mM Hepes (pH 7.4), 10 mM KCl and 1.5 mM
Mg2SO4 containing the following protease and phos-
phatase inhibitors: 1 mM sodium vanadate, 1 mM
sodium pyrophosphate, 1 mM benzamidine, 10 lg/ml
leupeptine, 10 lg/ml aprotinin, 10 lg/ml trypsin
inhibitor, 1 mM EDTA, 1 mM DTT and 1 mM PMSF.
0.5 ml of 0.25 M sucrose with 10 mM Hepes was lay-
ered on top and samples centrifuged for 1 h at
100,000 g in a SW50.1 rotor. The myelin containing
0.85/0.25 M sucrose interface was discarded and a
sample of the supernatant collected to represent the
cytosolic fraction. The membrane rich pellet fraction
was sonicated in 0.25 M sucrose, 10 mM Hepes buffer
supplemented with the protease and phosphatase
inhibitors. About 25 lg of the appropriate fraction was
analyzed by western blotting.
Statistical analysis
Statistical significance of differences between values
was assessed by ANOVA followed by Bonferonni’s
post hoc comparison test with significance P < 0.05
using Graphpad Prism software (GraphPad Software
Inc.).
Results
Genetic background influences steady state level of
myelin proteins in rumpshaker
In a previous study we quantified levels of represen-
tative proteins in myelin fractions from spinal cords of
P20 mice, a time of active myelination [3]. Levels of
PLP and DM20 per unit of myelin in C3H mutants
were 9 and 15%, respectively, of wild type while in C57
rumpshaker values were 6 and 4%, respectively. In the
C3H mutant levels of MBP, CNP and MAG were
approximately 60, 81 and 71%, respectively relative to
wild type whereas in the C57 rumpshaker these
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proteins were only 30, 26 and 32%, respectively. Levels
of Plp mRNA in both mutants were 66–68% of
respective wild type while message for the other myelin
proteins was very similar to control. Analysis of brain
myelin extracts and mRNA levels found changes very
similar to those in the spinal cord (data not shown).
Thus, the genetic background on which the rump-
shaker mutation is expressed appears to have a greater
influence on the level of myelin proteins other than
PLP/DM20, such as MBP.
The rates of PLP synthesis and degradation are not
affected by expressing the rumpshaker mutation on
different genetic backgrounds
Our previous work showed that C3H rumpshaker mice
synthesised PLP and DM20 at similar rates to wild type
although the rate of degradation was markedly
enhanced (T1/2 rumpshaker PLP 11 h, wild type PLP
23 h) [8]. We therefore, compared these parameters in
mutants on the C57 background with their corre-
sponding wild type. As cultures have to be prepared
from individual C57 mice (see Materials and methods)
only 2 time points could be evaluated; a similar protocol
was adopted for the C3H genotype. To determine rates
of translation, primary oligodendrocyte cultures were
radiolabelled with [35S] Pro-Mix for 45 and 90 min. The
rate of accumulation of immunoprecipitated radiola-
belled PLP and DM20 was not significantly different
between wild type and mutant on either background.
However, the total amount of PLP/DM20 (labelled and
unlabelled) recovered was considerably lower in the
mutants (Fig. 1A, B) compared with wild type.
To study degradation, we pulse labelled the cultures
with [35S] Pro-Mix for 90 min and sampled at 0 h
(control) and after 24 h of chase. The decreases in PLP
and DM20 over this period were significantly greater in
the mutants than their respective wild types (Fig. 2A,
B), confirming that rumpshaker PLP and DM20 are
more labile than the wild type isoforms. The relative
decrease of rumpshaker product compared with cor-
responding wild type protein was similar between the
two strains at 70 and 78% for PLP and 70 and 73% for
DM20 in C3H and C57, respectively.
Genetic background does not influence
incorporation of rumpshaker PLP into myelin
rumpshaker mice are hypomyelinated compared with
wild type and the deficit is accentuated on the C57
background. However, immunostaining and western
blotting show both PLP and DM20 to be present in
myelin [3] in both genotypes. Additionally, the intra-
cellular distribution of PLP/DM20 did not appear dif-
ferent between the two mutants with a robust signal
co-localised with the RER and a less intense diffuse
staining throughout the cytoplasm to the cell mem-
brane (see Fig. 4C of McLaughlin at al., 2006). To
compare the correct topographical insertion of PLP/
DM20 into membrane, we stained live oligodendro-
cytes from wild type and mutant mice of both strains
with the O10 antibody [9] prior to permeabilisation
and immunostaining for PLP/DM20. Virtually 100% of
C3H and C57 wild type oligodendrocytes with PLP/
DM20+ cell bodies were also surface stained with
O10. In contrast, 64 ± 10% of C3H (M ± SEM, n = 5)
and 69 ± 6% of C57 rumpshaker oligodendrocytes,
respectively, that expressed cytoplasmic PLP/DM20
had surface staining for O10; the values between the
mutants are not significantly different. As the intensity
of O10 staining in the mutants, particularly for the C57
strain, appeared more variable than for wild type we
quantified the rate of PLP/DM20 incorporation into
myelin.
Fig. 1 Synthesis of PLP/DM20 in wild type and mutant
oligodendrocytes from C3H and C57 mice. (A) Cells were
radiolabelled for 45 or 90 min prior to lysis and immunoprecip-
itation. The upper panel is a phosphorimage (P) of the
radiolabelled precipitates and the lower panel (W) a western
blot using an antibody recognising PLP and DM20. The
radiolabelled protein increases with time in all mice. The amount
of total protein (includes radiolabelled and non-labelled)
precipitated from the mutants, particularly C57, is markedly
lower than from wild type. (B) Comparison of the synthesis rates
for PLP and DM20, expressed as percentage increase in signal
per minute, between C3H and C57 mutants relative to their
respective wild types (M ± SEM, N for C3H = 5, for C57 = 6).
There is no significant difference between mutant and corre-
sponding wild type values
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We labelled brain slices with [35S] Pro-Mix for up to
6 h, prepared myelin enriched fractions at 2, 4 and 6 h
and compared the labelled, immunoprecipitated prod-
ucts between mutants and their respective wild types.
Newly synthesised protein accumulated progressively
over the 6-h labelling period in total homogenates from
the brain slices. Newly synthesised PLP and DM20 were
present in myelin after a 2-h label in wild types and
mutants and increased over the subsequent 4 h. Fig-
ure 3A, B show the results for C57 mice; the data for
C3H mice have been published previously [8]. The rate
and amount of newly synthesised PLP accumulating in
myelin were significantly lower in mutants of both
strains compared with their corresponding wild types.
The rate of DM20 incorporation was not significantly
different in rumpshaker of either strain, relative to wild
type although the weak signal of DM20 did influence the
accuracy of the quantitation procedure and contribute to
the large standard error. The rates of incorporation of
PLP and DM20 were not different in C57 rumpshaker
compared with the corresponding isoforms in C3H mu-
tants (Fig. 3C).
Some parameters of the UPR are affected by
genetic background
Many misfolded proteins induce a cascade of protein
activation resulting in the expression of chaperones,
such as BiP (GRP78), to assist protein folding and
transcription factors such as CHOP and XBP1 [13–15].
By western blotting, BiP protein was elevated in mutants
on both genetic backgrounds at 185 ± 11%, (M ± SEM,
n = 4) for C3H rumpshaker and 187 ± 12% for C57
rumpshaker, compared with their respective wild type
(100%) (Fig. 4A). The values of the mutants are not
significantly different but both are greater than their
respective wild type (P = 0.0002).
We evaluated levels of Chop and ATF3 mRNA in
spinal cords of P20 mice using RT-PCR. Levels of both
transcription factors were significantly higher in
mutants than corresponding wild type. Additionally,
the elevation of Chop was greater in the C57 than the
C3H rumpshaker relative to the respective wild type,
whereas the increases in ATF3 were similar in the two
mutants (Fig. 4B, C). The levels of Chop and ATF3
were similar in wild type mice of both genotypes (not
shown).
Immunostaining of spinal cord from rumpshaker of
both backgrounds revealed numerous CHOP+ nuclei,
more so in the C57 mutants (Fig. 4D). Double immu-
nostaining showed that the CHOP stained nuclei were
associated only with oligodendrocytes (Fig. 4E and
supplementary Fig. 1A, B). The proportion of oligo-
dendrocytes with CHOP+ nuclei in C57 rumpshaker
was approximately double that in C3H mutants when
expressed as a percentage of the total DAPI-stained
glial nuclei or the CC-1 stained cells (Fig. 4F). The
numbers of DAPI nuclei and CC-1+ cells did not differ
between the two mutant genotypes. No nuclear CHOP
staining was detected in wild type spinal cords. Double
immunostaining for CHOP and caspase-3 showed no
obvious co-localisation. Additionally, the caspase-3+
oligodendrocytes had pyknotic nuclei whereas the
CHOP+ nuclei appeared normal when viewed with the
DAPI stain (supplementary Fig. 1C).
We assessed cleavage of the Xbp1 mRNA from
spinal cord of P20 C3H and C57 mice using RT-PCR.
No spliced (active) Xbp1 was detected in wild type
tissue with the entire unspliced message being cleaved
by Pst1 digestion. An equal amount of spliced tran-
script was detected in rumpshaker mice on both genetic
backgrounds but this was small compared with the vig-
orous response to chemically induced ER stress (Fig. 4F).
Fig. 2 Degradation of PLP/DM20 in oligodendrocytes from
C3H and C57 wild type and rumpshaker mice. (A) Represen-
tative experiment from wild type and mutant mice showing the
phosphorimage (P) and corresponding western blot (W) of the
immunoprecipitates. Cells were pulse labelled with [35S] Pro-Mix
for 90 min and then chased out for 24 h, prior to immunopre-
cipitation. The accelerated decay of newly synthesised protein in
the mutant is evident. (B) Decrease in levels of newly
synthesised PLP and DM20 in C3H and C57 wild type and
rumpshaker mice, 24 h after the end of the pulse labelling. The
data (M ± SEM. N for C3H = 4, for C57 = 9 or 10) are
presented as the percentage of the level after the 90-min pulse
(T0). In both strains of mice the levels of mutant PLP and DM20
are significantly lower than the corresponding wild type value.
The ratio (rumpshaker:wild type decay) for C3H and C57 PLP is
0.7 and 0.78, respectively and for DM20 is 0.7 and 0.73,
respectively
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The majority of Xbp1 message in both mutants
remained unspliced and therefore susceptible to Pst1
digestion.
We also examined levels of heat shock proteins 70
and 90, which were not elevated in mutants relative to
wild type (data not shown).
Discussion
Missense mutations of the PLP1/Plp1 gene resulting in
an amino acid substitution are a common cause of
PMD and SPG2 in man. PMD/SPG2 is markedly het-
erogeneous, varying from early lethality in severe
forms of PMD through to milder clinical signs with
longevity associated with SPG2. Similar heterogeneity
exists in the animal models where, for example, early
death occurs in the myelin-deficient rat and the jimpy
mouse while the shaking pup and paralytic tremor
rabbit have a more protracted disease [17]. The basis
for this heterogeneity is unclear but may include dif-
ferences in the mutated codon and its position in the
molecule and the influence of modifying genes. How
such factors might affect pathogenetic pathways is also
Fig. 3 Incorporation of wild type and mutant PLP/DM20 into
myelin. (A) Phosphorimage of newly synthesised PLP/DM20 in
total homogenate and myelin fractions from brain slices of C57
wild type and rumpshaker mice. Slices were radiolabelled for 2, 4
and 6 h and the proteins immunoprecipitated from 400 lg total
homogenate and 20 lg myelin fractions; this ratio was retained
for all studies. The signal intensity increases with time in both
fractions from the two genotypes but the myelin signal relative to
the homogenate signal is lower in the mutant. (B) Quantitative
data from the above study. At each time point the amount of
newly synthesised PLP or DM20 incorporated into myelin
(M ± SEM, n = 3) is expressed as a proportion of the total
homogenate signal at 2 h, which was not different between wild
type and mutant (not shown). The curves for wild type and
mutant are significantly different for PLP but not DM20. (C)
Comparison of the incorporation rates of radiolabelled PLP and
DM20 into myelin between C3H and C57 rumpshaker. The slopes
are not different between the two mutants for either isoform
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Fig. 4 The UPR is activated in rumpshaker but only certain
components show differences between the two genetic back-
grounds. (A) Representative western blots for BiP in spinal cord of
wild type (WT) and rumpshaker (rsh) mice on the C3H and C57
background. As a positive control, wild type oligodendrocytes
(WT oligos) have been ‘‘stressed’’ by treating with 2 lg/ml
tunicamycin for 18 h (Tun) or left untreated (Ctl). Spinal cords
from P20 mice were fractionated to separate membranous, pellet
and cytosolic fractions. BiP analysis was performed on 25 lg of
pellet or on 10 lg of oligodendrocyte lysis. The induction of BiP in
the mutant spinal cord is similar between the two genotypes. The
upregulation of BiP after tunicamycin treatment of rumpshaker
oligodendrocytes was similar to wild type (not shown). (B) RT-
PCR analysis of P20 spinal cords from C3H and C57 wild type
(WT) and rumpshaker (rsh) mice for Chop and ATF3 mRNA
using cyclophilin (Cyclo) as an internal control. Both mutants
show upregulationof the transcription factors relative to their wild
type. (C) Quantification of the RT-PCR data for the two mutants
(n = 5) normalised for cyclophilin and expressed as a percentage
of the respective wild type. The upregulation of Chop is greater
(P < 0.05) in the C57 rumpshaker whereas ATF3 shows a similar
increase in both mutants. (D) Hemisection of spinal cord of C57
rumpshaker immunostained for CHOP. Numerous CHOP+ nuclei
are evident in the white matter (outlined). Bar = 100 lm. (E)
Confocal section of spinal cord from C57 rumpshaker immuno-
stained for CHOP, CC-1 antibody to label oligodendrocytes and
DAPI. The CHOP+ nucleus appears morphologically normal in
the DAPI stain (arrow) (see also Supplementary Fig. 1B, inset).
(F) The proportion of oligodendrocytes with CHOP+ nuclei in the
two mutants is expressed as a percentage of the total DAPI nuclei
or the CC-1 stained cells in the ventral column of spinal cord. The
proportion in the C57 rumpshaker is significantly higher than the
C3H mutant. (G) Activation of Xbp1 converts an unspliced to a
spliced mRNA that is resistant to digestion by Pst1. Wild type
oligodendrocytes untreated controls (Ctl) or treated with DTT,
Brefeldin A (BFA) or tunicamycin (Tun) and then undigested or
digested with Pst1. In the chemically treated, undigested samples
the smaller spliced product (s) is evident particularly after DTT
treatment whereas very little is evident after BFA treatment.
Digestion with Pst1 shows that all the DTT treated product is in the
spliced form and resistant to the enzyme whereas the vast majority
of the control has yielded the two cleavage products (arrows). In
the BFA sample the majority of product has been cleaved, only a
small spliced band is present. The tunicamycin treated sample
shows a predominant spliced band with small amounts of cleavage
products. (M = size markers; s = spliced; u = unspliced; h = a
hybrid species, [see 16]. In the spinal cord from C3H wild type and
rumpshaker the undigested samples show little obvious difference
but after Pst1 digestion a small undigested spliced band is evident
in rumpshaker, however, the majority of the product has been
cleaved (arrows). Digestion of samples from C57 wild type and
rumpshaker mice (middle lanes) produces a pattern very similar to
that from the C3H mice. When compared directly (right lanes) the
pattern from the two mutants is indistinguishable
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uncertain. The rumpshaker mutation encodes an iso-
leucine to threonine substitution (Ile186Thr) in the
putative extracellular ‘‘CD’’ loop of the PLP/DM20
molecule that results in benign or lethal phenotypes
dependent on genetic background. As the primary
structure of the protein is identical in both situations,
the rumpshaker mutation provides a system in which to
test whether changes in processing of PLP/DM20 or
differences in the UPR are associated with the two
extreme phenotypes. Surprisingly, we find that there is
little difference in PLP processing between the two
phenotypes.
Processing of rumpshaker PLP is similar in the two
phenotypes
The majority of misfolded rumpshaker PLP/DM20 is
retained in the RER prior to proteasomal degradation,
only a minority reaching the cell membrane [8]. No
obvious differences were noted between oligodendro-
cytes from C3H and C57 rumpshaker in terms of
ultrastructure or cytoplasmic distribution of PLP/
DM20 after immunostaining [3 and unpublished
observations]. We now find that the rates of PLP/DM20
translation, degradation and myelin incorporation are
also very similar in rumpshaker on the two genetic
backgrounds and different from their respective wild
type. Also, the proportion of oligodendrocytes incor-
porating PLP/DM20 into the plasma membrane is not
influenced by background. Although we did not inves-
tigate the mechanism of degradation in the C57 mutant
it seems safe to assume the proteasome is involved
predominantly, as with the C3H rumpshaker [8].
The apparently similar processing of PLP/DM20 in
two extreme phenotypes caused by the rumpshaker
mutation does not mean that this pathway is unim-
portant in other Plp1 mutants. In the severe pheno-
types associated with the jimpy and jimpymsd mutations
PLP/DM20 does not reach the plasma membrane in
vitro or in vivo [6, 18], a clear difference from the
severe form of rumpshaker. Also, jimpymsd PLP is
complexed with calnexin in the RER [19], whereas we
failed to demonstrate a similar interaction with rump-
shaker PLP [8]. Absence or reduction of wild type
PLP/DM20 in myelin does not cause a severe dys-
myelinating phenotype in mouse or man [20, 21] and
introduction of wild type PLP/DM20 to murine Plp1
mutants does not reverse the phenotype [22] suggesting
that missense mutations may operate by a ‘‘gain of
function’’ mechanism. The present study suggests that
this putative novel function may not directly involve
the PLP/DM20 processing pathway. It is possible that
the burden of processing the abundant rumpshaker
PLP/DM20 disrupts the dynamics of other myelin
components.
Unfolded protein response
Cells have developed mechanisms such as UPR and
ERAD to protect themselves against protein mis-
folding. The presence of unfolded protein within the
ER may activate a cascade of protein interactions and
dissociations initiated primarily by the chaperone BiP
whose association with three stress sensors PERK,
IRE1 and ATF6 maintains these proteins in an inac-
tive state. Upon stress induction, BiP dissociates,
translocates to the ER lumen to assist in protein
folding, and the sensor proteins adopt an active status.
The activated proteins induce a series of interacting
pathways constituting the UPR [23]. PERK activation
inhibits eif2a leading to reduced translation of the
misfolded protein [24] although, conversely, other
pathways involving GADD34 promote protein syn-
thesis [11]. We find no evidence for reduced PLP/
DM20 synthesis, even in the phenotypically severe
C57 rumpshaker. Other aspects of the UPR, such as
the induction of BiP, ATF3 and to a lesser extent the
generation of spliced Xbp1 mRNA, are clearly acti-
vated in rumpshaker. However, there is no difference
in the magnitude of the responses between the two
phenotypes and overall, the response is modest com-
pared with the chemically induced changes in oligo-
dendrocytes. The only clear distinction in the
parameters examined between the two phenotypes is
the CHOP response, where there is at least twice the
number of CHOP+ nuclei in a section of C57 rump-
shaker spinal cord and a corresponding upregulation
of Chop mRNA. In many cell types CHOP acts as a
pro-apoptotic factor, which is activated upstream of
effecter caspases, such as caspase-3. A pro-apoptotic
action of CHOP would correlate with the increased
number of apoptotic cells in the C57 mutant [3].
However, a previous report suggested that in rump-
shaker, CHOP may act as a protective factor, as mu-
tant mice carrying a null Chop allele fared worse than
the unmodified rumpshaker [7]. This apparent dis-
crepancy will need further study.
Pathogenesis of the dysmyelinating phenotype
The present study does not fully resolve the basis of
phenotypic severity in rumpshaker or other PLP1/Plp1
missense mutations. It seems unlikely that differences in
PLP/DM20 processing, such as the rate of degradation
or rate of incorporation into myelin, fully account for
such a diversity of phenotypes. As demonstrated in this
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and other studies, the UPR is clearly activated and some
pathways, most notably CHOP, do correlate with phe-
notypic severity. We propose that the level of glial cell
apoptosis may be related to the magnitude of the CHOP
induction although, as the overall rates of translation
and degradation appear similar in C3H and C57 mu-
tants, it is not obvious why CHOP induction is greater in
the latter. We found no cells simultaneously expressing
CHOP and caspase-3 and whereas the nuclei in cas-
pase+ cells were pyknotic, the majority of CHOP+ nu-
clei appeared normal.
The temporal nature of CHOP induction and the
appearance of apoptotic markers vary depending on
the cell type and nature of the stress inducer. In gen-
eral, caspase-3 cleavage is considered to be an end
stage event in apoptosis, downstream of CHOP
expression [25, 26] and the above findings may reflect
this temporal difference. Alternatively, the lack of co-
localisation of these markers may reflect two distinct
cellular populations where the response to ER stress is
either terminal (caspase-3) or survivable (CHOP) in
cells [7, 27]. This requires clarification and perhaps
examination of markers implicated in events upstream
of caspase-3 would identify a divergence in the stress/
apoptotic response of both populations.
Acknowledgments We are grateful to Prof. NP Groome and
Drs S Pfeiffer and RH Quarles for the gift of antibodies and to
Dr H. Harding for advice on the UPR.Grant Information. This
work was supported by The Wellcome Trust and Birth Defects
Foundation.
References
1. Hudson LD (2003) Pelizaeus-Merzbacher disease and spastic
paraplegia type 2: two faces of myelin loss from mutations in
the same gene. J Child Neurol 18:616–624
2. Nave K-A, Griffiths IR (2004) Models of Pelizaeus-Merzb-
acher disease. In: Lazzarini RA, Griffin JW, Lassmann H,
Nave K-A, Miller RH, Trapp BD (eds) Myelin biology and
disorders. Elsevier, Amsterdam, pp 1125–1142
3. Al-Saktawi K, McLaughlin M, Klugmann M, Schneider A,
Barrie JA, McCulloch MC, Montague P, Kirkham D, Nave
K-A, Griffiths IR (2003) Genetic background determines
phenotypic severity of the Plp rumpshaker mutation.
J Neurosci Res 72:12–24
4. Gow A, Lazzarini RA (1996) A cellular mechanism gov-
erning the severity of Pelizaeus-Merzbacher disease. Nat
Genet 13:422–428
5. Gow A, Southwood CM, Lazzarini RA (1998) Disrupted
proteolipid protein trafficking results in oligodendrocyte
apoptosis in an animal model of Pelizaeus-Merzbacher dis-
ease. J Cell Biol 140:925–934
6. Southwood C, Gow A (2001) Molecular pathways of oligo-
dendrocyte apoptosis revealed by mutations in the proteoli-
pid protein gene. Microsc Res Tech 52:700–708
7. Southwood CM, Garbern J, Jiang W, Gow A (2002) The
unfolded protein response modulates disease severity in
Pelizaeus-Merzbacher disease. Neuron 36:585–596
8. McLaughlin M, Barrie JA, Karim SA, Montague P, Edgar
JM, Kirkham D, Thomson CE, Griffiths IR (2006) Process-
ing of PLP in a model of Pelizaeus-Merzbacher disease/
SPG2 due to the rumpshaker mutation. Glia 53:715–722
9. Jung M, Sommer I, Schachner M, Nave K-A (1996) Mono-
clonal antibody O10 defines a conformationally sensitive
cell-surface epitope of proteolipid protein (PLP): evidence
that PLP misfolding underlies dysmyelination in mutant
mice. J Neurosci 16:7920–7929
10. Montague P, Dickinson PJ, McCallion AS, Stewart GJ, Sa-
vioz A, Davies RW, Kennedy PGE, Griffiths IR (1997)
Developmental expression of the murine Mobp gene.
J Neurosci Res 49:133–143
11. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang YH,
Jungreis R, Nagata K, Harding HP, Ron D (2004) CHOP
induces death by promoting protein synthesis and oxidation
in the stressed endoplasmic reticulum. Genes Dev 18:3066–
3077
12. Montague P, Barrie JA, Thomson CE, Kirkham D, McCal-
lion AS, Davies RW, Kennedy PGE, Griffiths IR (1998)
Cytoskeletal and nuclear localization of MOBP polypep-
tides. Europ J Neurosci 10:1321–1328
13. Rutkowski DT, Kaufman RJ (2004) A trip to the ER: coping
with stress. Trends Cell Biol 14:20–28
14. Zhang KZ, Kaufman RJ (2004) Signaling the unfolded pro-
tein response from the endoplasmic reticulum. J Biol Chem
279:25935–25938
15. Harding HP, Calfon M, Urano F, Novoa I, Ron D (2002)
Transcriptional and translational control in the mammalian
unfolded protein response. Annu Rev Cell Dev Biol 18:575–
599
16. Shang J (2005) Quantitative measurement of events in the
mammalian unfolded protein response. Methods 35:390–394
17. Duncan ID (1995) Inherited disorders of myelination of the
central nervous system. In: Kettenmann H, Ransom BR
(eds) Neuroglia, Oxford University Press, Oxford, pp 843–
858
18. Gow A, Friedrich VL Jr, Lazzarini RA (1994) Many natu-
rally occurring mutations of myelin proteolipid protein
impair its intracellular transport. J Neurosci Res 37:574–583
19. Swanton E, High S, Woodman P (2003) Role of calnexin in
the glycan-independent quality control of proteolipid pro-
tein. EMBO J 22:2948–2958
20. Garbern J, Yool DA, Moore GJ, Wilds I, Faulk M, Klug-
mann M, Nave K-A, Sistermans EA, van der Knaap MS,
Bird TD, Shy ME, Kamholz J, Griffiths IR (2002) Patients
lacking the major CNS myelin protein, proteolipid protein 1,
develop length-dependent axonal degeneration in the ab-
sence of demyelination and inflammation. Brain 125:551–561
21. Klugmann M, Schwab MH, Pu¨hlhofer A, Schneider A,
Zimmermann F, Griffiths IR, Nave K-A (1997) Assembly of
CNS myelin in the absence of proteolipid protein. Neuron
18:59–70
22. Schneider A, Griffiths IR, Readhead C, Nave K-A (1995)
Dominant-negative action of the jimpy mutation in mice
complemented with an autosomal transgene for myelin
proteolipid protein. Proc Natl Acad Sci USA 92:4447–4451
23. Ma YJ, Hendershot LM (2001) The unfolding tale of the
unfolded protein response. Cell 107:827–830
24. Harding HP, Zhang YH, Ron D (1999) Protein translation
and folding are coupled by an endoplasmic-reticulum-resi-
dent kinase. Nature 397:271–274
Neurochem Res (2007) 32:167–176 175
123
25. Vlug AS, Teuling E, Haasdijk ED, French P, Hoogenraad
CC, Jaarsma D (2005) ATF3 expression precedes death of
spinal motoneurons in amyotrophic lateral sclerosis-SOD1
transgenic mice and correlates with c-Jun phosphorylation,
CHOP expression, somato-dendritic ubiquitination and
Golgi fragmentation. Eur J Neurosci 22:1881–1894
26. Liu N, Kuang X, Kim HT, Stoica G, Qiang W, Scofield VL,
Wong PK (2004) Possible involvement of both endoplasmic
reticulum- and mitochondria-dependent pathways in Mo-
MuLV-ts1-induced apoptosis in astrocytes. J Neurovirol
10:189–198
27. Lin W, Harding HP, Ron D, Popko B (2005) Endoplasmic
reticulum stress modulates the response of myelinating oli-
godendrocytes to the immune cytokine interferon-gamma.
J Cell Biol 169:603–612
176 Neurochem Res (2007) 32:167–176
123
Processing of PLP in a Model of Pelizaeus-Merzbacher
Disease/SPG2 due to the rumpshaker Mutation
MARK McLAUGHLIN, JENNIFER A. BARRIE, SAADIA KARIM, PAUL MONTAGUE, JULIA M. EDGAR,
DOUGLAS KIRKHAM, CHRISTINE E. THOMSON, AND IAN R GRIFFITHS*
Applied Neurobiology Group, Institute of Comparative Medicine, University of Glasgow, Bearsden Glasgow G61 1QH, Scotland
KEY WORDS
oligodendrocyte; myelin; misfolded protein; dysmyelination;
spastic paraplegia type 2
ABSTRACT
The rumpshaker mutation of the X-linked myelin proteo-
lipid protein (PLP1) gene causes spastic paraplegia type 2
or a mild form of Pelizaeus-Merzbacher disease in man.
The identical mutation occurs spontaneously in mice. Both
human and murine diseases are associated with dysmyeli-
nation. Using the mouse model, we show that the low
steady state levels of PLP result from accelerated proteaso-
mal degradation rather than decreased synthesis. The T1/2
for degradation of rumpshaker PLP is 11 h compared with
23 h for wild type. A minority of newly synthesized PLP is
incorporated into myelin in the correct orientation but at a
reduced rate compared with wild type. However, inhibition
of proteasomal degradation does not increase the level of
PLP incorporated into myelin. As Plp null mice do not have
a similar myelin deﬁciency, it is unlikely that the reduced
PLP levels are the main cause of the dysmyelination.
Rumpshaker oligodendrocytes also have a reduced level of
other myelin proteins, such as MBP, although the mecha-
nisms are not yet deﬁned but are likely to operate at a
translational or post-translational level. VC 2006 Wiley-Liss, Inc.
INTRODUCTION
Proteolipid protein (PLP) and the smaller DM20 iso-
form constitute the major proteins of CNS myelin. The
functions of PLP/DM20 have been partly clariﬁed through
the study of PLP-deﬁcient mice and humans. Despite its
abundance, the protein is not essential for myelin forma-
tion but is required for the formation of a normal intra-
period line (IPL) and maintenance of axonal integrity
(Garbern et al., 2002; Grifﬁths et al., 1998; Klugmann
et al., 1997). Both PLP and DM20 seem necessary for
completely normal function, although each is capable,
individually, of insertion into myelin (McLaughlin et al.,
2002).
Mutations of the X-linked myelin PLP1/Plp1 gene cause
Pelizaeus-Merzbacher disease (PMD) and spastic paraple-
gia type 2 (SPG2) in man and dysmyelinating disorders in
a range of animal species (Hudson, 2003; Inoue, 2005). In
man, gene duplication is the most frequent cause of PMD,
with a range of missense mutations accounting for the
majority of the remaining cases. Typically, missense mu-
tations are associated with dysmyelination characterized
by hypomyelination, increased apoptosis of oligodendro-
cytes, and gliosis (Al-Saktawi et al., 2003; Skoff, 1995),
although the severity of each parameter varies between
different mutations. The lack of a similar phenotype in
PLP-deﬁcient mice and humans (Garbern et al., 2002;
Klugmann et al., 1997) suggests that missense mutations
cause disease through a ‘‘gain of function’’ effect.
The rumpshaker mutation of the PLP1/Plp1 gene
(Plpjp-rsh) causes disease in both man and mouse and pro-
vides an excellent model of mild forms of PMD and of
SPG2. The distinction between mild PMD and SPG2 is
blurred depending on the clinical presentation, which
may change over time and also on individual clinicians;
both syndromes have been ascribed to the rumpshaker
mutation, with spastic paraparesis as a major sign (John-
ston and McKusick, 1962; Kobayashi et al., 1994; Naidu
et al., 1997). The mutation, an amino acid substitution
(Ile186Thr), was described ﬁrst in mice of the C3H.HeH
strain, in which it causes a relatively benign phenotype
with normal longevity and fertility and is characterized
by mild to moderate dysmyelination with oligodendrocyte
numbers being maintained (Al-Saktawi et al., 2003; Grif-
ﬁths et al., 1990). Many larger axons are either naked or
surrounded by thin sheaths, whereas the smaller axons
obtain sheaths of appropriate thickness by 12 to 18
months (Edgar et al., 2004). An outstanding question is
why the surviving oligodendrocytes fail to assemble nor-
mal amounts of myelin, particularly around larger axons.
Misfolding of proteins is a common mechanism by
which mutations cause disease (Sanders and Myers,
2004), and cells have evolved the unfolded protein re-
sponse (UPR) and endoplasmic reticulum-associated deg-
radation (ERAD) to deal with this event (Ellgaard and
Helenius, 2003; Jarosch et al., 2003; Rutkowski and Kauf-
man, 2004). Evidence for a UPR is present in rumpshaker
mice (Southwood and Gow, 2001; Southwood et al., 2002),
suggesting that PLP/DM20 is misfolded. As oligoden-
drocytes generate massive amounts of membrane during
myelination and PLP accounts for 50% of protein
in myelin, the rumpshaker mutation provides an ideal
model to dissect how the cell deals with a misfolded, non-
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glycosylated, polytopic membrane protein. Very little is
known about the dynamics of PLP/DM20 encoded by mis-
sense mutations or how this may inﬂuence the processing
of other myelin components. Evidence, largely from trans-
fected heterologous cells, has implicated impaired protein
trafﬁcking in that the products are retained within the
rough endoplasmic reticulum (RER) (Gow and Lazzarini,
1996). Variations in trafﬁcking between different PLP1/
Plp1 mutations have been demonstrated in such systems
and, in general, suggest that the impairment correlates
with phenotypic severity of the natural disease (Thomson
et al., 1997). The purpose of this study was to establish
how the oligodendrocyte handles misfolded rumpshaker
PLP.
We ﬁnd that rumpshaker oligodendrocytes synthesize
PLP/DM20 as efﬁciently as their wild type counterparts
but, once formed, much of the protein is rapidly degraded,
most probably by the proteasome, with a minority insert-
ing correctly into the myelin membrane.
MATERIALS AND METHODS
Animals
The rumpshaker (Plpjp-rsh) mutation arose originally in
C3H.HeH mice and was maintained on a hybrid C3H/101
background. Mutant mice were genotyped by PCR ampli-
ﬁcation of genomic DNA and restriction digest of the
novel AccI site (Schneider et al., 1992). All animal studies
were approved by the Ethical Committee of the Univer-
sity of Glasgow and licensed by the UK Home Ofﬁce.
Quantitative Real Time PCR (qRT-PCR)
Total RNA was extracted from oligodendrocyte cultures
using RNAzol Bee reagent (Tel-Test Inc, Friendswood,
TX) following the manufacturer’s instructions. RNA was
extracted from wild type and rumpshaker cultures and
reconstituted in DEPC water. RNA quality and integrity
were determined using spectrophotometry and gel elec-
trophoresis. The ABI prism 7500 sequence detection sys-
tem (Applied Biosystems, Foster City, CA) using Taqman
technologies (PE Biosystems, Foster City, CA, USA) was
employed following the manufacturer’s instructions. Real
time PCR was preformed using the Platinum Quantita-
tive RT-PCR Thermoscript One-Step System (Invitrogen,
Carlsbad, CA). Full details of the primers, probes, and
method are in Supplementary Information. The relative
amount of rumpshaker Plp and Plp/Dm20 mRNA was
expressed as a percentage of wild type.
Antibodies and Immunostaining
Antibodies
PLP/DM20 was detected with a rabbit polyclonal antibody
recognizing the common C-terminal (gift from Prof. N.P.
Groome) or a rat monoclonal (AA3, gift from Dr. S. Pfeif-
fer). MBP was detected with a mouse monoclonal (clone
12, gift from Prof. N.P. Groome). CNP was detected with a
mouse monoclonal (Chemicon Europe, Chandlers Ford,
UK). Monoclonal and polyclonal antibodies to MAG were
obtained from Chemicon (clone 513) and as gifts from
Prof. N.P. Groome and Dr. R.H. Quarles. Aspartoacylase
(ASPA) was detected with a rabbit polyclonal (gift from
Dr. J. Garbern). Anti ubiquitin monoclonal was obtained
from Santa Cruz (sc 8017, Autogen Bioclear UK Ltd,
Calne, UK) and a rabbit polyclonal against p27kip1 from
Upstate (Lake Placid, NY). A rabbit polyclonal against
GRP78 was obtained from Stressgen (Bioquote Ltd., York,
UK) and a mouse monoclonal GM130 antibody for Golgi
membranes from Chemicon.
Immunostaining
Immunostaining of cells or tissue sections by indirect im-
munoﬂuorescence was performed as described previously
(Al-Saktawi et al., 2003; Edgar et al., 2002; Thomson
et al., 1999). Fluorescent images were obtained using an
Olympus IX70 microscope and a Photonic Sciences Colour
CoolView camera. Contrast and brightness were adjusted
using Adobe Photoshop 6.
Primary Oligodendrocyte Cultures
Oligodendrocytes were isolated and cultured from the
spinal cords of P5 mice as previously described (Montague
et al., 1998). Females homozygous for the rumpshaker
mutation were mated with hemizygous males to generate
litters in which all pups were affected. Cells from spinal
cords were pooled and plated onto two 30mm poly-L-ly-
sine coated plates per mouse. The resultant cultures con-
tained a mixed population—70–80% O41 cells together
with astrocytes, occasional neurons, and other cells.
At 7 days in culture, the medium was removed, cells
washed twice with Hank’s buffered salt (HBS), then in-
cubated for 30 min in HBS. The medium was replaced
with 0.5 ml HBS containing [35S]-Pro-Mix (Amersham) at
100 lCi/ml. For analysis of protein synthesis, dishes were
removed at the indicated times, rinsed twice in chilled
PBS, and lysed with Buffer A (10mM Tris pH 7.4, 150 mM
NaCl, 1% triton X-100, and inhibitors of protease and
phosphatase activity). For pulse chase experiments, cells
were labeled for 1.5 h and chased by replacing the HBS
with SATO medium supplemented with 2.5mM cysteine/
2.5mM methionine. At the appropriate time point, cells
were washed twice with chilled PBS, then lysed with
75 ll buffer A. The lysates were rotated at 4C for 30 min
and cell debris pelleted by centrifugation at 5,000 rpm for
5 min. Proteins were quantiﬁed using the BCA assay sys-
tem (Perbio Science UK Ltd, Tattenhall, UK).
Brain Slices, Myelin Extraction, and
Fractionation Procedures
A brain slice system was used to investigate the incor-
poration of newly synthesized, radiolabeled PLP/DM20
716 McLAUGHLIN ET AL.
GLIA DOI 10.1002/glia
into myelin. Full details of the methods are presented in
Supplementary Information.
Western Blotting and Immunoprecipitation
Western blotting and immunoprecipitation analysis were
conducted as described in detail elsewhere (McLaughlin
et al., 2002; Yool et al., 2001), except that in the present
study the immunoprecipitation reactions were conducted
with buffer A, which contains 1% triton X-100 as the
major solubilization detergent. Following SDS PAGE
separation, the proteins were transferred to PVDF and
the membrane exposed to a low energy, high sensitivity
phosphorimage screen (Amersham) for a period of 1–2
weeks and the image captured on a Storm phosphorimage
system. Quantitation was performed using ImageQuant
densitometry software. The PVDF membranes were then
processed for western blotting.
Statistical Analysis
Statistical signiﬁcance of differences between values
was assessed by ANOVA followed by Bonferonni’s post
hoc comparison test or by Student’s t-test, as appropriate,
with signiﬁcance P < 0.05. Analyses and curve ﬁtting
were performed using Graphpad Prism4 software (Graph-
Pad Software Inc., San Diego, CA). In the bar charts,
signiﬁcance is indicated as <0.05 (*), <0.01 (**), and
<0.001 (***).
RESULTS
Myelin Protein Levels Are Disproportionately
Low Compared with mRNA
In a previous study we quantiﬁed levels of representa-
tive proteins in myelin fractions from spinal cords of post-
natal day 20 (P20) mice, a time of active myelination
(Al-Saktawi et al., 2003). Levels of PLP and DM20 per
unit of myelin in mutants were 9 and 15%, respectively, of
wild type while levels of myelin basic protein (MBP), 20,30-
cyclic nucleotide 30phosphodiesterase (CNP), and myelin-
associated glycoprotein (MAG) were approximately 60,
81, and 71%. Levels of Plp mRNA in mutants were 66%
of wild type, while message for the other myelin proteins
was similar to control. Analysis of brain myelin extracts
and mRNA levels found changes comparable with those
in the spinal cord (data not shown).
In the CNS, myelin acts as the main repository of these
proteins. To determine if the mutation had a comparable
effect in the oligodendrocytes per se, we examined similar
parameters in cultured primary oligodendrocytes, which
do not elaborate a compact myelin sheath. Rumpshaker
Plp/Dm20 mRNA (combined probe) and the Plp speciﬁc
isoform levels by qRT-PCR were 89 6 0.04% and 83 6
0.08% (M 6 SEM, N 5 5), respectively, of wild type (data
not shown), whereas the PLP and DM20 protein levels
were 2 and 4%. MBP, MAG, and CNP were 16%, 54%, and
30% (Fig. 1); all MBP isoforms were reduced to a simi-
lar extent. Levels of ASPA, a speciﬁc oligodendrocyte cell
body marker (Kirmani et al., 2002) used as a control
between samples, were unchanged from wild type.
Rumpshaker Oligodendrocytes Synthesize
PLP at Normal Rate
In view of the discrepancy between message and prod-
uct, we determined if translation was proceeding efﬁ-
ciently. Primary oligodendrocyte cultures from wild type
and mutant mice were radiolabeled with Pro-Mix for
between 10 and 90 min. The overall proﬁle and signal
intensity of radiolabeled proteins present in the cell
lysates was similar for wild type and rumpshaker (data
not shown). Analysis of immunoprecipitated products
showed a similar accumulation of PLP and DM20 over
time in both groups (Figs. 2a,b). Despite the similar levels
of radiolabeled PLP and DM20, the total amount of both
proteins recovered from the immunoprecipitation was
consistently lower in the rumpshaker than wild type.
These data demonstrate that rumpshaker oligodendro-
cytes synthesize PLP and DM20 with the same efﬁciency
as wild type oligodendrocytes and indicate that other fac-
tors are responsible for the reduced steady state level of
these proteins.
The Degradation of rumpshaker
PLP Is Enhanced
The combination of normal rates of synthesis and low
protein levels suggested that the mutant protein was
being degraded rapidly. To conﬁrm this, we pulsed cul-
tured oligodendrocytes with [35S] Pro-Mix for 1.5 h and
then chased the labeled proteins for periods of up to 64 h.
The level of labeled PLP declined exponentially with a T1/2
of 23 h in wild type cells compared with 11 h in rump-
Fig. 1. Steady state levels of myelin proteins in cultured oligoden-
drocytes. a: Representative western blots from wild type (WT) and
rumpshaker (rsh) oligodendrocytes. In order to visualize the signal in
rumpshaker, some lanes were loaded with 5 (1:5) or 10 (1:10) times the
amount of wild type protein. b: Quantitation of protein levels relative
to wild type (100%) (M 6 SEM, n 5 4.) Equality in the number of oligo-
dendrocytes and of loading between samples is veriﬁed by the level
of aspartoacylase (ASPA), an oligodendrocyte-speciﬁc protein, which is
identical in wild type and mutant.
717PLP IN THE RUMPSHAKER MUTATION
GLIA DOI 10.1002/glia
shaker (Figs. 3a,b); for DM20 the equivalent times were
11.7 h and 8.4 h, respectively. The decay curves of wild
type and mutant were signiﬁcantly different (P < 0.05).
The Proteasome Is Probably Involved in the
Degradation of Wild Type and rumpshaker PLP
A common degradation pathway involves degradation
by the proteasome system, a process known as ER-asso-
ciated degradation (ERAD) (Jarosch et al., 2003). We in-
vestigated the inﬂuence of increasing doses of MG132,
a proteasome inhibitor (Lee and Goldberg, 1996), on pro-
tein degradation. We ﬁrst conﬁrmed the effectiveness of
MG132 in decreasing degradation of p27kip1 in oligoden-
drocytes (Fig. 4a), a process known to involve the protea-
some (Pasquini et al., 2000). Using the same approach,
we found that degradation of both wild type and rump-
shaker PLP/DM20 was markedly ameliorated in a dose-
dependant manner by MG132 (Figs. 4a, b). Whereas
approximately 30% of wild type PLP was degraded by the
proteasome and recovered after treatment with 50 lM
MG132, two thirds of rumpshaker PLP was lost and
restored to 90% of normal by inhibiting the proteasome
(Fig. 4b). Although MG132 treatment resulted in a
marked increase in the ubiquitination proﬁle of the cell
lysates and an increase in the level of PLP/DM20 (data
not shown), we were unable to demonstrate an interaction
of PLP and ubiquitin by co-immunoprecipitation. Co-im-
munostaining of rumpshaker oligodendrocytes for PLP/
DM20 and the ER marker GRP78 showed strong PLP/
DM20 staining in the ER but also extending through the
cytoplasm to the cell membrane, indicating that at least
some of the mutant protein was escaping ERAD (Fig. 4c).
We immunostained wild type and rumpshaker oligoden-
drocytes for PLP/DM20, ubiquitin, and HSP70 following
treatment with the proteasomal inhibitor but were unable
to demonstrate any evidence of aggresomes (data not
shown).
The rumpshaker Mutation Impairs
the Insertion of PLP into Myelin
Despite the accelerated degradation, rumpshaker PLP/
DM20 (Al-Saktawi et al., 2003) and PLP (Fig. 5a) inte-
grate into myelin. We examined the insertion of the mole-
cule into the plasma membrane by immunostaining live
cells with the O10 antibody (Jung et al., 1996) and then
detecting cytoplasmic PLP/DM20 after permeabilization.
The O10 antibody detects a conformation-sensitive epi-
tope on the extracellular ‘‘CD’’ loop of PLP/DM20, thus
indicating the molecule is inserted correctly into the
Fig. 2. Synthesis of PLP/DM20 in wild type and mutant oligoden-
drocytes. a: Cells were radiolabeled for the times shown above each
lane prior to lysis and immunoprecipitation. The upper panel is a phos-
phorimage (P) of the radiolabeled precipitates, and the lower panel a
western blot (W) using an antibody recognizing PLP/DM20. The radio-
labeled protein increases with time in both genotypes. The amount of
total protein (includes radiolabeled and non-labeled) precipitated from
the mutants is lower than from wild type. b: Quantiﬁcation of radio-
labeled PLP and DM20 at times from 10 to 90 min. The data are
expressed relative to the 10-min sample. (M 6 SEM, n 5 6.) There is
no signiﬁcant difference between mutant and wild type.
Fig. 3. Degradation of PLP/DM20 in oligodendrocytes from wild
type and rumpshaker mice. a: Representative experiment from wild
type and mutant mice showing the phosphorimage (P) and correspond-
ing western blot (W) of the immunoprecipitates. Cells were pulse la-
beled with [35S] Pro-Mix for 90 min and chased for the times shown,
prior to immunoprecipitation. The accelerated decay of newly synthe-
sized protein in the mutant is evident. The total amount of PLP/DM20
recovered over the 64-h period of chase remains constant for each geno-
type. For the western blots, a higher antibody concentration has been
used in rumpshaker than wild type (due to the lower levels of PLP/
DM20); therefore, the western blots of mutant and wild type are not
directly comparable. b: Decay proﬁles for PLP and DM20 from wild
type and mutant mice. The points represent M 6 SEM, n 5 4; the
curves show the exponential decay. The T1/2 for mutant PLP is 11 h
compared with 23 h for wild type PLP; the two DM20 proﬁles have T1/2
of 8 and 11 h, respectively.
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plasma membrane (Jung et al., 1996). After 7 days in cul-
ture, virtually 100% of wild type oligodendrocytes that
expressed PLP/DM20 were also surface stained with O10,
whereas signiﬁcantly fewer, 64 6 10% (M 6 SEM, n 5 5),
of rumpshaker cells stained in a similar manner (Fig. 5b).
The O10 staining intensity of the mutant cells showed
variability, whereas most wild type cells were intensely
stained.
We used brain slices to compare the kinetics of radiola-
beled PLP and DM20 incorporation into myelin between
the genotypes. Newly synthesized protein accumulated
progressively over the 6-h labeling period in total homoge-
nates from the brain slices. The rate of accumulation in
total homogenate was not different between wild type and
mutant (data not shown), again suggesting that the rate
of synthesis was similar in the two genotypes. Newly
synthesized PLP and DM20 were present in myelin after
a 2-h label in both wild type and mutant and increased
over the subsequent 4 h (Figs. 5c, d). The amount and rate
of incorporation of PLP into myelin was signiﬁcantly less
in rumpshaker so that at 6 h the relative intensity of
rumpshaker PLP was similar to the wild type signal
Fig. 4. Wild type and mutant PLP/DM20 are degraded via the pro-
teasome. a: Wild type (WT) or rumpshaker (rsh) cells were pulsed with
[35S] Pro-Mix for 90 min to obtain a control (C) labeling and chased
for 24 and 16 h, respectively, without (0) or with (2, 10, 50 lM) MG132.
Lysates were immunoprecipitated with p27kip1 (P27) or PLP/DM20
(PLP) antibodies. The p27kip1, a known substrate for proteasomal deg-
radation, acts as a control system, showing a dose-dependent rescue by
MG132. The decline in levels of PLP and DM20 is ameliorated by pro-
teasome inhibition, more so in the wild type cells. b: Inhibition of the
proteasome by 50 lM MG132 (a concentration with maximum effect in
the dose-response studies) reverses the decline in levels of PLP. Cells
were labeled, as above, and the intensity of the PLP band in wild type
and rumpshaker quantiﬁed at 24 or 16 h, respectively, without (0 lM)
or with (50 lM) MG132 treatment. The data (M 6 SEM, n 5 4) are
expressed relative to the control level after the 90-min pulse. The level
of wild type PLP is completely restored, while rumpshaker PLP is
86% of control. c: rumpshaker oligodendrocyte immunostained for PLP/
DM20 (red) and for the ER marker, GRP78 (green). A proportion of
PLP/DM20 has exited the ER and extends through the cytoplasm to
the plasma membrane. Bar 5 10 lm.
Fig. 5. Incorporation of wild type and mutant PLP/DM20 into myelin
membrane. a: Immunostaining of rumpshaker spinal cord with an anti-
body speciﬁc to PLP demonstrates this isoform is incorporated into mye-
lin. Bar5 400 lm. b: Oligodendrocytes from rumpshaker spinal cord were
cultured for 7 days and surface stained with the O10 antibody before
being permeabilized and immunostained for PLP/DM20. Two cells are
shown, only one of which has correctly inserted PLP/DM20 into its
plasma membrane. Bar 5 20 lm. c: Incorporation of newly synthesized
PLP/DM20 into myelin in brain slices from P20 wild type and rumpshaker
mice. Slices were radiolabeled for 2, 4, and 6 h and the proteins immuno-
precipitated from 400 lg total homogenate and 20 lg myelin fractions;
this ratio was retained for all studies. The panels show the phosphor-
image (P) of newly synthesized, radiolabeled PLP and DM20 and the cor-
responding western blots (W) of total (labeled and unlabeled) PLP and
DM20. d: Incorporation of PLP and DM20 into myelin in wild type and
rumpshaker mice. At each time point, the signal intensity of newly
synthesized PLP and DM20 in myelin is expressed relative to the signal
of the total homogenate at 2 h. The rate of incorporation of newly synthe-
sized wild type PLP into myelin is signiﬁcantly greater than in the mu-
tant (P5 0.04), whereas DM20 is not different between the two genotypes
(P 5 0.5). e: Inhibition of the proteasome does not increase incorporation
of PLP/DM20 into myelin in rumpshaker. Brain slices labeled with [35S]
Pro-Mix for 2 h were treated with MG132 or the DMSO vehicle (control)
for an additional 4 h before fractionation and immunoprecipitation.
Whereas the signal increased in the total homogenate (T) and pellet (P)
fractions with treatment, no corresponding increase occurred in the mye-
lin (M) or supernatant/cytosolic (C) fractions.
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observed after 2 h, indicating a signiﬁcant delay in incor-
poration. The rate at which rumpshaker DM20 incorpo-
rated into myelin was similar to wild type, although the
amounts were considerably lower. Western blot analysis
of the immunoprecipitated products (Fig. 5c) showed that
the ratio of PLP recovered from the homogenate com-
pared with the myelin fraction was similar for wild type
and rumpshaker. The difference in myelin incorporation
rates is not simply a reﬂection of the amount of PLP
recovered from the myelin fraction in rumpshaker.
As inhibition of ERAD resulted in a signiﬁcant eleva-
tion of the level of PLP in cultured rumpshaker cells, we
asked whether there would be a similar increase in mye-
lin incorporation. However, treatment of brain slices with
50 lM MG132 failed to increase PLP/DM20 incorporation
into the myelin fraction, although signal in both the total
homogenate and pellet fractions was elevated (Fig. 5e).
DISCUSSION
Missense mutations of the PLP1/Plp1 gene resulting in
an amino acid substitution are a cause of PMD in man
and account for the majority of spontaneous disorders in
animals. Dysmyelination is a major feature of the pathol-
ogy and probably accounts for many of the clinical signs,
yet its basis is not clear. Indeed, how the abnormal PLP/
DM20 is handled by the oligodendrocyte is only partly
resolved and is the focus of the present study. The rump-
shaker mutation encodes an isoleucine to threonine sub-
stitution in the putative extracellular CD loop of the PLP/
DM20 molecule that results in mild or lethal phenotypes
dependent on genetic background, suggesting the inﬂu-
ence of other modifying genes (Al-Saktawi et al., 2003).
Using a model of the mild form of PMD/SPG2, we show
that the reduced steady state level of PLP/DM20 is caused
principally by enhanced degradation, most probably via
the proteasome, rather than a reduced rate of translation.
The majority of rumpshaker PLP/DM20 that escapes
ERAD is targeted to the developing myelin sheath, where
it inserts correctly into the membrane, albeit more slowly
than in wild type.
Translational Efﬁciency of PLP Is Not
Affected by the rumpshaker Mutation
The level of Plp/Dm20mRNA is only minimally reduced
compared with PLP/DM20 protein, suggesting that a
translational or post-translational defect is responsible
for the low protein level. Misfolded proteins in the RER
can inhibit translation by activating PERK, leading to
phosphorylation of the eIF2a factor (Harding et al., 1999),
although this is often a transient effect and is not nec-
essarily operative. For example, in the Akita diabetic
mouse, misfolded proinsulin accumulates in the RER yet
translation proceeds normally (Izumi et al., 2003). Simi-
larly, translational efﬁciency of PLP/DM20 in rumpshaker
oligodendrocytes is comparable with wild type, indicating
that the low protein levels are due to post-translational
mechanisms.
The Fate of the rumpshaker PLP/DM20
The exit of most misfolded membrane proteins from the
RER tends to be perturbed (Ellgaard and Helenius, 2003).
Transfection and in vivo studies have shown that pro-
ducts encoded by many missense mutations of the PLP1/
Plp1 gene accumulate in the RER rather than reach the
plasma membrane (Gow and Lazzarini, 1996). The major-
ity of information has been gathered from microscopic
images, which create the impression of a static protein
mass in the RER cisternae and provide little kinetic infor-
mation. We show that rumpshaker PLP is a dynamic pro-
tein, the majority of which is degraded by an MG132-sen-
sitive pathway at twice the rate of the wild type product,
causing the low steady state levels. The rate of DM20
breakdown is also accelerated by the mutation. Only a mi-
nority of PLP/DM20 reaches its correct destination in the
myelin sheath.
The majority of proteins destined for proteasomal deg-
radation are polyubiquitinated, although there are exam-
ples of non-ubiquitinated proteins being degraded by this
pathway (Asher et al., 2002; Jarosch et al., 2003; Shrin-
garpure et al., 2003). Despite numerous attempts, we
were unable to demonstrate polyubiquitination of PLP/
DM20. We cannot exclude the possibility that the putative
pool of ubiquitin-conjugated PLP is rapidly deubiquiti-
nated by the activity of isopeptidases (Kim et al., 2003).
There are also examples of wild type or misfolded RER
proteins being degraded by non-proteasomal pathways
(Donoso et al., 2005; Schmitz and Herzog, 2004). Sensitiv-
ity to MG132 is a well-accepted indicator of proteasomal
involvement; and despite the failure to demonstrate poly-
ubiquitination, it seems most probable that the protea-
some is the main degradative pathway for rumpshaker
PLP/DM20.
Rumpshaker PLP Is Incorporated into Myelin Less
Efﬁciently than Wild Type
The amount and rate of incorporation of newly synthe-
sized PLP into myelin, relative to the total pool of labeled
PLP, were reduced in rumpshaker consistent with a delay
in the processing pathway at an earlier stage. Evidence
for the insertion of PLP and/or DM20 into the myelin
membrane was obtained by surface staining with the O10
antibody, which recognizes an epitope on the extracellular
CD loop (Jung et al., 1996), a region that also contains the
rumpshaker mutation. While the amino acid substitution
compromises the function of PLP/DM20, it does not ap-
pear sufﬁcient to prevent the membrane insertion of the
fraction that escapes ERAD.
The presence of misfolded PLP inﬂuences the structure
of myelin. In common with other Plp1 mutants (Duncan
et al., 1987), rumpshaker mice have thin myelin sheaths
with abnormal, condensed, intraperiod lines (IPL), com-
pared with the closely apposed double IPL of normal mye-
lin (Grifﬁths et al., 1990). In contrast, Plp1 null mice have
widened or absent IPL (Yool et al., 2002). Although PMD
is classed as a dysmyelinating rather than a demyelinat-
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ing disorder, it is possible that individual components,
such as misfolded PLP, have an enhanced rate of turnover
in myelin, thus making the myelin unstable and unable to
achieve the appropriate thickness.
Increasing the amount of rumpshaker PLP/DM20
potentially available to myelin by inhibiting proteasomal
degradation does not lead to an enhanced incorporation,
suggesting the system is handling the maximum amount
of mutated product or that other mechanisms of degrada-
tion also operate (Schmitz and Herzog, 2004). One candi-
date is the endosomes/lysosome system, which is involved
in clearing excess wild type PLP generated by increased
Plp1 gene dosage (Simons et al., 2002). It is possible that
this pathway also degrades a minority of the rumpshaker
PLP/DM20.
Relevance to the Dysmyelinating Phenotype
Most forms of PMD and its spontaneous animal models
are characterized by the inability of surviving oligoden-
drocytes to assemble and maintain normal amounts of
myelin. Although the level of PLP/DM20 is markedly
reduced in rumpshaker myelin, this is unlikely to be the
cause of the hypomyelination, as a similar phenotype does
not occur in Plp null mice or humans (Garbern et al.,
2002; Klugmann et al., 1997). Also, introducing wild type
PLP/DM20 into mutant myelin through transgenic com-
plementation does not rescue the phenotype (Schneider
et al., 1995). One potential mechanism is the effect of the
rumpshaker mutation on other myelin components, parti-
cularly MBP, which is critical for myelin formation (Shine
et al., 1992). Levels of MBP are markedly reduced in
rumpshaker oligodendrocytes (present study), and parti-
cularly when the mutation is expressed on the C57BL/6
background (Al-Saktawi et al., 2003). In ongoing studies
(Barrie et al., unpublished) we have complemented the
C57 rumpshaker mice with a wild type Plp transgene,
increasing their PLP/DM20 levels to normal. However,
MBP levels remain low and severe dysmyelination is still
present. It is, therefore, possible that the low levels of
MBP in rumpshaker contribute to the hypomyelination.
MbpmRNA levels are only minimally reduced, suggesting
the rumpshaker mutation operates at a translational or
post-translational level to perturb MBP, presumably
through the action of misfolded PLP/DM20 through an, as
yet, unknown mechanism.
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Hindshaker (hsh), a spontaneous, autosomal recessive mouse mutation, displays a developmentally dependent tremor of the hindquarters
due to hypomyelination in the CNS. This myelin deficit is followed by progressive, but incomplete, recovery by postnatal day 42. Herein we
describe the construction of a genomic contig spanning the interval between the markers D3Mit187 (42.4 cM) and D3Mit232 (45.2 cM) on
mouse chromosome 3, which we have previously shown to contain the hsh mutation. A physical map, covering approximately 3.5 Mb, was
constructed from a series of overlapping yeast and bacterial artificial chromosomes. A 1.2- to 1.4-Mb segment central to the contig was
compared extensively with the syntenic regions in human (chromosome 1q21–q23) and rat (chromosome 2). We present new data on 10
genes erroneously assigned to this area and on another 6 genes previously assigned elsewhere. For absent genes, our work suggests that they
are telomeric to the region encompassed in our map. Accordingly, our findings both map the area surrounding the hsh mutation and present
important corrections to the current maps in an area rich in genes related to the nervous system.
D 2003 Elsevier Inc. All rights reserved.Keywords: Hindshaker; Gene; Contig; Genomic mapThe recent completion of the human and mouse genome
sequences has contributed to the mapping of genes linked to
diseases with similar phenotypes in humans and mice [1–4].
One phenotype in mouse is hindshaker (hsh), a spontaneous
autosomal recessive mutation characterized by a tremor of
the hindquarters due to hypomyelination of the CNS. Unlike
many other CNS myelin disorders in which the brain is
predominantly affected, in hsh the spinal cord is the main
site of dysmyelination. Progressive, but incomplete, im-
provement in myelination follows after approximately post-
natal day 20 (when the hsh phenotype is most evident) [5,6].
Although myelin deficiency has serious clinical consequen-
ces in humans, the underlying molecular mechanisms in-
volved in myelin assembly are not fully understood.
Therefore, positional cloning and analysis of mouse muta-0888-7543/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2003.08.014
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E-mail address: dv2u@udcf.gla.ac.uk (D.A. Vouyiouklis).
1 Present address: Pfizer Corp., 2800 Plymouth Road, Ann Arbor, MI,
USA.
2 Present address: Yoshitomi Research Institute for Neuroscience in
Glasgow (YRING), West Medical Building Room 307, University of
Glasgow, Glasgow, G12 8QQ, UK.tions, such as hsh, can give insights into either novel or
uncharacterized genes involved in myelination. Additional-
ly, such mouse mutants may serve as models of human
myelin diseases [7,8].
The hsh mutation was previously mapped to a region
near the centromere of mouse chromosome 3 [9]. In the
present paper we report the completion of a YAC/BAC
contig spanning the interval 42.4–45.2 cM on this chromo-
some. Our map of the area includes several published genes
such as brevican (Bcan), brain link protein 1 (Bral1),
chaperonin subunit 3 (Cct3), death-associated protein 3
(Dap3), glucocerebrosidase precursor (Gba), and recombi-
nation activating gene 1 gene activation (Rga). However,
other genes placed in this region on the mouse genomic map
(http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG =
mouse&CHR= 3) are absent from our map. We report that
the bone g-carboxyglutamate protein gene 1 (Bglap1)
(which has the same sequence as Bglap-rs1), semaphorin
4 (Sema4), lamin A (LmnA), and possibly other genes
contained within an area of approximately 250 kb are absent
between 42.4 and 45.2 cM. These genes may, nevertheless,
belong on mouse chromosome 3 but nearer the telomere, as
suggested by the Identify Unknown Nucleic Sequence (NIX)
S.A. Karim et al. / Genomics 83 (2004) 225–230226analysis program (http://www.hgmp.mrc.ac.uk/Registered/
Webapp/nix/). By contrast, the genes selenium binding
protein 1 (Selenbp1), Selenbp2, proteasome (prosome, mac-
ropain) subunit h type 4 (Psmb4), and regulatory factor X5
(Rfx5) and the mouse homologues to human IQ motif-
containing GTPase activating protein 3 (IQGAP3) and
human cingulin (CGN), which have been mapped closer to
the telomere of chromosome 3 on other maps, are present in
our contig. Therefore, our new physical map both introduces
new genes in specific positions on mouse chromosome 3 that
may be related to the hsh phenotype and corrects misassign-
ments in the current databases.Results
A contig spanning a region of the mouse chromosome 3
genetic map, corresponding to 2.8 cM between the markers  
Fig. 1. Contig of area 42.4–45.2 cM in mouse chromosome 3. The region is encom
scale and the BAC clones in black or light gray, the former denoting known sizes
placed on the map by both PCR and Southern blotting, the rest by NIX analysis.
telomere of mouse chromosome 3; however, we have mapped them to this region. Y
appears to have an internal deletion, since the terminus sequence of YAC clone 44
domain 2A protein; Bcan, brevican; Bral1, brain link protein 1; Iqgap3, IQ motif
myocyte enhancer factor 2D; Psmb4, proteasome (prosome, macropain) subunit, h
Selenbp2, selenium binding protein 2; Cgn, cingulin; Dap3, death-associated pr
thrombospondin 3; Mtx1, metaxin 1; Rga, recombination activating gene 1; Ad
KIAA0144, potential phospholipid transporting ATPase; S100A4, s100calcium-binD3Mit187 (centromeric end of the hsh interval) and
D3Mit232 (telomeric end), was assembled from 5 YAC
and 11 BAC clones. Our experimental evidence (unpub-
lished) placed the hsh gene in the center of this interval;
hence we mapped the region with this central area as the
main focus. Three methods were used to screen for clones:
marker/gene PCR, BAC end-sequence (BES) screening, and
YAC library screening. A contig map representing the
positions of selected clones is shown in Fig. 1. Not all the
clones identified by each method are shown if they contrib-
uted no new or extra information to the results. Based on
clone sizes and overlaps, approximately 3.5 Mb of chromo-
somal DNA is covered by these clones.
Bioinformatics analysis and contig construction
We obtained mapping information on YAC clones con-
taining the D3Mit187 and D3Mit232 markers from thepassed by 5 YAC and 11 BAC clones. The YAC clones are in sliding gray
. Boxed area corresponds to the BAC tile. Underlined genes/markers were
Genes in larger font and bold were ascribed by others to an area nearer the
AC clone 57F5, which contains the intact Sh2d2a gene in its telomeric end,
4G3 and the nestin gene are missing. Cen, centromere; Nes, nestin; Sh2, sh2
containing GTPase activating protein 3; Cct3, chaperonin subunit 3; Mef2d,
type 4; Rfx5, regulatory factor X 5; Selenbp1, selenium binding protein 1;
otein 3; Pklr, pyruvate kinase; Gba, glucocerebrosidase precursor; Thbs3,
am15, metalloprotease-disintegrin MDC15; Lenep, lens epithelial protein;
ding protein A4; and Tel, telomere.
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cgi-bin/mouse/index) and also screened by PCR for genes
and markers. Clones 444G3 and 376E7 contained D3Mit187
and D3Mit232, respectively.
Two other YAC clones, 57F5 and 140H7, were also
positive for D3Mit187. Clone 57F5 appeared to have an
internal deletion and was missing the entire SH2 domain
protein 2A (Sh2d2a) gene; however, clone 140H7 was
positive for Sh2d2a. Using the 444G3 end sequence as
probe, BAC 377C20 was cloned from the BAC RP23 library.
NIX analysis of the sequence of 377C20 (available at http://
www.ncbi.nlm.nih.gov) revealed the presence of several
genes (Nes; Sh2d2a; Bcan; and Bral1). These were also
present in YAC 140H7, as confirmed by PCR and Southern
blotting.
Analysis of YAC clone 376E7 showed it contained the
gene S100A4 and the mouse sequence orthologous for
KIAA0144, a putative gene homologous to organic cation
transporter (OCT1) transcription factor [10]. YAC clone
371F2 was obtained by screening with a KIAA0144 probe.
This clone also contained the intact a disintegrin and
metalloproteinase domain 15 (Adam15) and recombination
activating gene 1 (Rga) genes proximally, which helped us
extend the contig farther in the upstream direction. We
were unable to detect YAC clones containing the genes
published in the gap between Bral1 and Rga. To map this
area more precisely, we decided to complete the contig with
clones isolated from the mouse BAC RP23 and RP24
libraries.
BAC clone analysis and build of an internal BAC tile
Computational analysis of BAC clone sequences, whether
full or BESs, utilized electronic PCR (http://www.ncbi.nlm.
nih.gov/ePCR) and pair-wise and standard nucleotide–nu-
cleotide BLAST. These analyses provided sufficient numbers
of unique overlaps to build a BAC tile within the final
contig. Initially, data and sequence analysis of known
clones on chromosome 3 were carried out to identify
possible overlaps. From these we identified the BAC clones
RP23-68H24, RP23-4L11, RP23-15P14, RP23-367M7,
RP23-4P7, RP23-51N3, RP24-194O6, and RP23-295A4.
However, there was no overlap between BAC clones RP23-
51N3 and RP24-194O6. For this gap, the cytoview of
chromosome 3 at Ensembl (http://www.ensembl.org/Mus_
musculus/cytoview) (version 16.30.1, May 2003) was used.
BAC clones RP23-93O5 and RP23-214B5 had not been
fully sequenced; however, our analysis showed that their
BESs were unique. Analysis revealed a single overlap
between these clones and also single (opposite end) over-
laps with clones RP23-51N3 and RP24-194O6, respectively
(Fig. 1).
Comparative analysis with supercontig NW_000191
suggested that the physical gap between Bral1 and Rga
was approximately 1.3 Mb. In agreement, estimating the
sizes of the two unsequenced clones and taking overlapsinto account, the BAC contig tile length was calculated to be
1.2–1.4 Mb.Discussion
Mapping anomalies
In the process of constructing the contig, we came
across several irregularities. As the public maps were
updated, genes such as Ctsk, Ctss, and Mcl1 were removed
from the region. However, other genes such as Bglap1
(which has the same sequence as Bglap-rs1, as verified by
BLAST analysis) are still present on the public maps
(August 2003). We found that Bglap1 is contained within
both the 0.35-Mb YAC clone 331A8 and the BAC clone
RP24-298F19; however, Bglap1 is absent from the
D3Mit187–D3Mit232 region. In addition, both PCR and
Southern blot analysis confirmed that YAC clone 331A8
does not contain several of the genes shown in public
mouse maps near Bglap1 (such as Sema4a and Lmna).
However, the 331A8 clone does contain the polyamine-
modulated factor-1 (Pmf-1)-like gene. We found that the
BAC clone RP24-298F19 also contains Pmf-1, Sema4a,
and Lmna (Table 1), and it is therefore possible that clone
331A8 is chimeric. In human, PMF-1 is located on chro-
mosome 1q12 next to tropomodulin 4 (TMOD4), the mouse
orthologue of which is present in chromosome 3 between
49 and 52 cM.
Genes present in the contig but shown elsewhere in public
databases
We have also mapped genes present in clones within the
contig, which, in public databases, are shown nearer the
telomere (Fig. 1, Table 1). Using NIX analysis of sequenced
BAC clones (NCBI) containing Iqgap3, Psmb4, Rfx5,
Selenpb1, Selenbp2, and a gene homologous to human
CGN, followed by colony PCR and Southern blotting
experiments, these genes have been assigned to BAC clones
in the center of our contig (Table 1, Fig. 1).
The genomic interval 42.4–45.2 cM and flanking areas
on mouse chromosome 3 are rich in genes that are actively
transcribed in the nervous system. Such genes are Bcan,
neurotrophic tyrosine kinase receptor type 1 (Ntrk1) at the
same map location as hepatoma-derived growth factor
(Hdgf), Bral1, and potassium channel calcium-activated
intermediate/small conductance subfamily n member 3
(Kcnn3) at 90.85 Mb. This is also true for the human
and rat syntenic regions in chromosomes 1q21–q23 and 2,
respectively (http://www.ensembl.org human version
16.33.1, July 2003, and http://www.rgd.mcw.edu rat ver-
sion 5.0_HS, August 2003). Our previous results mapped
the hsh gene to this interval [9] and due to the relatively
poor genomic maps available at that time, we undertook to
construct a contig across this region to help identify the
Table 1
Differences between the map presented in this paper and the ones presented at http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG=mouse&CHR= 3,
http://www.jax.org/resources/documents/cmdata/rhmap/3data.html, and http://www.ensembl.org/Mus_musculus/mapview?chr = 3
Genes markers Accession
No./Refseq
YAC/BAC
clone
NCBI
map
JAX
map
ENSEMBL
map
Our
map
Human/rat
syntenic region
Genes removed from area of interest
Bglap1 NM_007541 y331A8 + + +  1q21/?
(sequence identical
to that of Bglap1-rs1)
NM_013480 bRP24 298F19
Sema4a NM_013658 bRP23 93E19 + + +  1q21/2
Lmna NM_019390 bRP24 298F19 + + +  1q21.2–q21.3/2
Rab25 NM_01899 bRP23 76F18 + + +  1q21.3/2
Mapbpip NM_031248 bRP23 18J1 + + +  1q21.3/?
Ubin NM_033526 bRP23 76F18 + + +  1q21/?
Lbcl1 NM_008487 bRP23 199B2 + + +  1q/2
Rit1 NM_009069 bRP23 199B2 + + +  1q21.3/?
Syt11 NM_018804 bRP23 199B2 + + +  1q21–q23/UN
Fdps NM_134469 bRP23 318I15 + + +  1q21.3/4
Genes added to area of interest
Iqgap3 NM_178229 bRP23 68H24    + 1q22/?
Psmb4 XM_203986 bRP23 4L11
bRP23 15P14
 +  + 1q21.2/UN
Rfx5 NM_017395 bRP23 15P14  +  + 1q21/?
Selenbp1 NM_009150 bRP23 15p14
bRP23 367m7
   + 1q21–q22/2
Selenbp2 NM_019414 bRP23 15p14
bRP23 367M7
   + 1q21–q22/2
Cgn XM_194107
(human seq)
bRP23 4P7
bRP23 367M7
 +  + 1q21.3/?
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consists of approximately 3.5 Mb, with the internal BAC
tile accounting for 1.2–1.4 Mb. Since the hsh phenotype
locus was mapped approximately in the center, greater
emphasis was placed on mapping this region and therefore
additional genes were studied. Currently, we are evaluating
the expression of potential candidate genes within the CNS
of wild-type and hsh mice. Over the course of constructing
the contig, several genes such as Ctss, Ctsk, and Mcl1
were moved out of the area (42.4–45.2 cM in public
databases) and are now placed around 48 cM [1,4]. In
addition, we revealed several other differences by compar-
ison with the most recent releases of data (August 2003).
Several genes are absent from our contig, and our exper-
imental results confirmed that Bglap1, Sema4a, Lmna,
Rab25, Mapbpip, Ubin, Lbcl1, Rit1, Syt11, and Fdps are
missing from the clones representing this region (42.4–
45.2 cM). However, our analysis showed that these genes
are present in other BAC clones (Table 1), suggesting that
these genes exist toward the telomere on mouse chromo-
some 3 at 49–52 cM, adjacent to the genes Oaz3, Rorc,
Tcf1, and Tmod4.
We also discovered that six other genes are present within
the contig, four of which (Psmb4, Rfx5, Selenbp1, and
Selenbp2) were previously mapped at 50 cM on mouse
chromosome 3 (Fig. 1, Table 1) (July 2003). The fifth gene,
Iqgap3, was recently mapped to human chromosome 1q22
(April 2003); however, in the mouse there are only two
mapped Iqgap genes, Iqgap1 on chromosome 15 and Iqgap2on chromosome 7. Genscan analysis (http://genes.mit.edu/
GENSCAN.html) of mouse BAC RP23-68H24, which con-
tains the entire gene, shows that Iqgap3 is present in this clone
(bases 170905 to 130160); however, it differs from the
published human mRNA by 108 bases. The sixth gene,
Cgn, also maps on human chromosome 1. These six genes
are now mapped between 42.4 and 45.2 cM on mouse
chromosome 3.
All the genes reported in this paper are in cytogenetic
bands F1–F2 on mouse chromosome 3 in all publicly held
data (www.ncbi.nlm.nih.gov, August 2003; www.ensembl.
org, August 2003; and www.jax.org, August 2003). We
have highlighted the differences between our map and that
at NCBI, Ensembl, and the Radiation Hybrid (RH) map at
The Jackson Laboratory (Table 1). There are, however,
differences in gene location between each source of infor-
mation, with some more frequently updated than others. As
yet, this region in mouse chromosome 3 has not been
completely mapped in any of the above maps. The
Ensembl database has an incomplete BAC contig, which
contains unsequenced BACs and at least one gap between
89 and 89.9 Mb. The information at Mouse Genome
Informatics at www.jax.org appears to correlate better (than
other public maps) with our findings (Table 1). The
complete mouse, human, and eventually rat genomic se-
quence will allow researchers to speed up positioning of
genes and allow further refinement in genomic maps,
facilitating functional studies and analysis of positional
effects and modifications.
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To prepare the physical map from 42.4 to 45.2 cM on
chromosome 3, we analyzed the Jackson Mouse RH map
(June 2003) between markers D3Mit187 and D3Mit232
(http://www.jax.org/resources/documents/cmdata/rhmap/
3data.html) [11,12]. This region in the RH map contained
many ESTs expressed in the brain, suggesting that this area
might warrant further research. The polymorphic markers
identified were then checked in the Whitehead database to
match YAC clones (http://www-genome.wi.mit.edu/cgi-bin/
mouse/index). All the clones that corresponded to a specific
marker were obtained through HGMP (http://www.
hgmp.mrc.ac.uk/geneservice/reagents/products//index.
shtml). For the markers and genes that did not belong to
known YAC clones, screening by PCR with appropriate
primers was performed on the WI/MIT C57BL/6J female
mouse genomic YAC library [13,14]. PCR and Southern
blotting analysis confirmed the presence of either the gene or
the marker in the clone.
Database analysis
The mouse chromosome 3 cytogenetic map spanning
bases 88.6–90.3Mb (http://www.ensembl.org/Mus_muscu-
lus/cytoview) and the Jackson RH map permitted us to
bridge the gap between YAC clones placed at either end
of our region of interest. This also allowed us to indicate
the potential positions of genes within the area containing
hsh that were used to search the High Throughput
Genomic Sequence database (restricted to mouse) and
the NCBI Non-Redundant protein database using BLAST
(http://www.ncbi.nlm.nih.gov/blast). The results showed all
the significant overlaps in the sequences. From this,
sequences of genes that gave only two/three highly sig-
nificant and specific overlaps were used to design PCR
primers. BAC clones were selected from Ensembl (http://
www.ensembl.org/Mus_musculus/cytoview) (mouse ver-
sion 16.30.1, May 2003). Their BES (http://www.tigr.org/
tdb/humgen/bac_end_search/bac_end_search.html) was an-
alyzed using BLAST and the resulting clones using NIX.
The results confirmed our gene placements and revealed
additional genes that might belong to the region of
interest. The latter genes were examined in a similar
fashion to generate the contig. Once the overlaps within
the area were confirmed using bioinformatics, the appro-
priate clones were obtained from BACPAC Resources at
http://www.chori.org/bacpac/ [15].
NIX analysis
NIX is a free access tool to perform several analysis
programs on large (20–100 kb) DNA sequences simulta-
neously. It aids identification of regions such as promoters,
exons, CpG islands, and poly(A) tails. The output page
allows viewing of all the results and can be used to highlightareas of interest. If a consensus is found between analysis
packages, then it may warrant experimental research to
confirm. NIX analysis is carried out on all regions of interest
by entering the genomic sequence at the HGMP Web site
(www.menu.hgmp.mrc.ac.uk/menu-bin/Nix/Nix.pl). If a se-
quence is larger than 100 kb then the sequence is entered as
overlapping segments.
YAC and BAC clone culturing
YAC clones were either streaked on AHC plates (0.17%
w/v yeast nitrogen base without amino acids, 0.5% w/v
ammonium sulfate, 1% w/v casein hydrosylate acid, 0.50
mg/ml adenine hemisulfate, 2% w/v Bactoagar, and, added
after autoclaving, 2% w/v glucose) (Becton–Dickinson,
UK) or grown in AHC broth [13,14]. BAC clones were
grown either in LB medium containing 20 Ag/ml chloram-
phenicol or on agar plates. Freshly plated YAC and BAC
clones from the original stocks were routinely tested for
genes and markers by single-colony PCR [16].
PCR and Southern blotting
A general colony PCR amplification protocol was a
single cycle of 94jC for 3 min, 62jC for 1 min, 72jC for
3 min 30 s (preamplification step); 34 step cycles of 93jC
for 30 s, 63jC for 45 s, and 72jC for 25 s (amplification
steps); and 93jC for 30 s, 63jC for 1 min, and 72jC for 3
min (chain termination step). The annealing temperature and
extension time varied depending on the primer pairs. The
products were separated in 2% agarose gels and viewed by
ethidium bromide (0.5 Ag/ml) staining. In all cases only the
predicted clones yielded PCR products of the appropriate
sizes, and the results were confirmed by sequencing and/or
Southern blot analysis.
Pulsed-field gel electrophoresis
PFGE was used to calculate the size of the YAC clones.
The clones were grown in AHC broth and intact cells were
embedded in agarose [17]. The cell wall was removed by
lyticase (Sigma–Aldrich, UK) (0.13 mg/ml) in SCEM (20
mM h-mercaptoethanol, 1 M sorbitol, 100 mM sodium
citrate, 10 mM EDTA), rendering the DNA accessible.
Electrophoresis was performed on a Chef III Pulsed Field
Gel System (Bio-Rad, UK) (24-h run time, switch time 60–
120 s). After electrophoresis, the gels were stained with
ethidium bromide and photographed. Transfer to nylon
membrane for Southern blotting was in 10 SSC. The
filters were baked at 80jC for 2 h, followed by probing with
well-characterized gene-specific probes labeled with [a-32P]
dCTP. The membranes were washed to a final stringency
of 0.1 SSC at 65jC and then exposed to X-ray film.
This permitted sizing of the YAC inserts, confirmation of
the PCR results, and analysis of appropriate digestion
products.
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